{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "5STo30E4C57o"
   },
   "source": [
    "# Paper Filtering Criterias\n",
    "1. Paper must be original research article and (not a review, poster or preprint) ---**Programatically Solvable**---\n",
    "  - Include Publication Type Field in Search Query\n",
    "\n",
    "2. Paper must have an AD focus.This means: ---**Optimized Search Query + LLM Task**---\n",
    "  - Either having a population of AD patients or\n",
    "  - Looking at Alzheimer disease specific biomarkers  \n",
    "\n",
    "\n",
    "3. Human sample size must be over 50 ---**LLM Task**---\n",
    "  - Extract *Abstract* and *Methods* sections from calls to BioC API\n",
    "  - Feed extracted data into LLM that has been prompt engineered to search and filter papers based on the desired criterias.\n",
    "\n",
    "\n",
    "4. Must be looking at a protein. ---**Optimized Search Query + LLM Task**---\n",
    "  - Amyloid Î²\n",
    "  - Tau\n",
    "  - Amyloid Precursor Protein\n",
    "  - Presenilin-1 and Presenilin-2\n",
    "  - Apolipoprotein E (ApoE)\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "5. Fluid samples like CSF, blood from animal models? ---**Optimized Search Query + LLM Task**---\n",
    "  - How is this different from clinical models?\n",
    "\n",
    "\n",
    "6. \"Blood\" vs \"Blood Pressure\" ---**Optimized Search Query + LLM Task**---\n",
    "  - How is blood being used in the paper? Is the paper using blood pressure as a biomarker or are actual blood samples being taken for biomarkers.\n",
    "\n",
    "\n",
    "7. Papers from 2024 and onward. ---**Optimized Search Query**---\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "KXgAMtiTRBrd"
   },
   "source": [
    "## LLM Task\n",
    "\n",
    "One way that we can have the LLM do filtering is by extracting the abstract and maybe methodology sections through PubMed's BioC API.\n",
    "Therefore we don't have to worry about going through the downloaded articles, unzip their parent folders and parse through the PDF, we could just get the Abstract and Methodolgies returned to us in plain text format and feed it into the LLM.\n",
    "\n",
    "I'm able to get those fields returned from the API for several articles so this seems promising."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "OPa2XvpqpOWK"
   },
   "source": [
    "# Optimizing Search Queries\n",
    "**All the queries we're making are getting translated by PubMed into a different string that tries to capture our original query string that is then used to query the database.** Because of this papers that might not be relevant to the researchers is being returned.\n",
    "\n",
    "### Solutions?\n",
    "**Is there any way we can have more control over the translated string?**\n",
    "\n",
    "\n",
    "- Using MeSH Headings in the Query | [A description of the MeSH hierarchy](https://www.nlm.nih.gov/mesh/intro_trees.html)\n",
    "\n",
    "  - Automatic Explosion causes MeSH terms that are not included in the query, both original and translated, to be included in the search results. This can broaden the returned papers which might not be relevant. So a solution to this is to either select MeSH terms that when exploded still included terms that are relevant to us or by writing our query with terms that won't cause explosion, *i.e.* leaf terms that don't have any children- refer to picture below for an example.\n",
    "\n",
    "- Using MeSH **subheadings** in the Query\n",
    "\n",
    "  - Subheadings act as qualifiers for MeSH Headings [List of MeSH qualifiers](https://www.nlm.nih.gov/mesh/subhierarchy.html)\n",
    "  - Like MeSH headings, subheadings also explode\n",
    "\n",
    "- Limiting the use of Automatic Term Mapping?\n",
    "  - PubMed's search engine maps entry terms, **i.e.** terms with the field [\"All Fields\"], to a common MeSH heading depending on their similarity.\n",
    "  - We can limit this by using **Search Field** tags\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "TL3AR6p6igX8"
   },
   "source": [
    "#Recording Relevant MeSH Headings\n",
    "\n",
    "- Chemicals and Drugs Category\n",
    "  - Macromolecular Substances\n",
    "  - Amino Acids, Peptides, and Proteins\n",
    "  - Biological Factors\n",
    "    - Biomarkers\n",
    "    - Blood Coagulation Factor Inhibitors\n",
    "    - Blood Coagulation Factors\n",
    "- Diseases Category\n",
    "  - Nervous System Diseases\n",
    "- Anatomy Category\n",
    "  - Nervous System\n",
    "  - Cells\n",
    "- Psychiatry and Psychology Category\n",
    "  - Psychological Phenomena\n",
    "  - Mental Disroders\n",
    "- Pharmacological Actions Category"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "4s4R-AmQ7_4C"
   },
   "source": [
    "# Ideas\n",
    "\n",
    "- How crazy would it be to have the LLM generate the query string itslef?"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Filtering papers using Ollama at Oceanus"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "!pip install ollama\n",
    "!pip install tiktoken"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "Hs4JSjVk-jcN"
   },
   "source": [
    "## Using BioC API to return full articles from PMC in JSON format"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "66OugbJeGEM7"
   },
   "source": [
    "# Experimenting with Ollama for filtering\n",
    "\n",
    "* Design prompt for filtering\n",
    "* Pick Models\n",
    "* Test classification"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Retreiving Papers\n",
    "* Extract title or article using OCR or just type it in\n",
    "* Request BioC API to retreive full article from Pubmed Central"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "from collections import defaultdict\n",
    "\n",
    "article_info = defaultdict(str)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "import json\n",
    "import time\n",
    "\n",
    "with open(\"valid.txt\", 'r') as f1:\n",
    "    with open('valid_articles.txt', 'r') as f2:\n",
    "        for id, line in zip(f1, f2):\n",
    "            article_info[id[:-1]] = {'class': 1, \"title\": line[:-1]}\n",
    "        f2.close()\n",
    "    f1.close()\n",
    "with open(\"invalid.txt\", 'r') as f1:\n",
    "    with open('invalid_articles.txt', 'r') as f2:\n",
    "        for id, line in zip(f1, f2):\n",
    "            article_info[id[:-1]] = {'class': 0, \"title\": line[:-1]}\n",
    "        f2.close()\n",
    "    f1.close()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from urllib.parse import quote\n",
    "def search_article_ids(query, max_articles_per_query, api_key = \"5209f5d2ecb2ce377d8c20c5b5a08fd46f09\"):\n",
    "    \"\"\"\n",
    "    Search articles matching the query, return their ID\n",
    "    \"\"\"\n",
    "    search_url = \"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi\"\n",
    "    all_article_ids = []\n",
    "\n",
    "\n",
    "    for start in range(0, max_articles_per_query):\n",
    "        params = {\n",
    "            \"db\": \"pmc\",\n",
    "            \"term\": f'{query}',\n",
    "            \"retmode\": \"json\",\n",
    "            \"api_key\": api_key,\n",
    "            \"retstart\": start,\n",
    "            \"retmax\": 1\n",
    "        }\n",
    "        response = requests.get(search_url, params=params)\n",
    "        try:\n",
    "          if response.status_code == 200:\n",
    "              data = response.json()\n",
    "              article_ids = data[\"esearchresult\"][\"idlist\"]\n",
    "              if not article_ids:\n",
    "                  break  # No more articles found\n",
    "              all_article_ids.extend(article_ids)\n",
    "              time.sleep(.5)  # To respect PubMed's rate limit\n",
    "          else:\n",
    "            # While response status code is 500 then increase wait time and retry\n",
    "              print(f\"Failed to search article IDs at {start}: {response.status_code}\\n{query}\\nTrying again\")\n",
    "              time.sleep(3)\n",
    "              while response.status_code == 500:\n",
    "                params = {\n",
    "                  \"db\": \"pmc\",\n",
    "                  \"term\": query,\n",
    "                  \"retmode\": \"json\",\n",
    "                  \"api_key\": api_key,\n",
    "                  \"retstart\": start,\n",
    "                  \"retmax\": 100\n",
    "                }\n",
    "                response = requests.get(search_url, params=params)\n",
    "                if response.status_code == 200:\n",
    "                  data = response.json()\n",
    "                  article_ids = data[\"esearchresult\"][\"idlist\"]\n",
    "                if not article_ids:\n",
    "                  print(f\"No more articles found at {start}\")\n",
    "                  break  # No more articles found\n",
    "                all_article_ids.extend(article_ids)\n",
    "          all_article_ids.extend(article_ids)\n",
    "        except KeyError as e:\n",
    "          print(f\"Key Error found at {start}\")\n",
    "          continue\n",
    "        except json.decoder.JSONDecodeError as e:\n",
    "          print(f\"JSON Decode Error found at {start}\")\n",
    "          continue\n",
    "              # break\n",
    "    return all_article_ids\n",
    "\n",
    "for title in titles:\n",
    "    title['pmc_id'] = search_article_ids(title['title'], 1)[0]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "valid_ids = []\n",
    "invalid_ids = []\n",
    "\n",
    "with open('valid.txt', 'r') as f:\n",
    "    valid_ids = [line.strip() for line in f]\n",
    "\n",
    "with open('invalid.txt', 'r') as f:\n",
    "    invalid_ids = [line.strip() for line in f]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "def fetch_full_text(article_id):\n",
    "    response = requests.get(f\"https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_json/{article_id}/unicode\")\n",
    "\n",
    "    summary = {\n",
    "        'Abstract': [],\n",
    "        'Method': []\n",
    "    }\n",
    "\n",
    "    if response.text == f'No record can be found for the input: pmc{article_id[3:]}':\n",
    "        print(f\"No record found for article {article_id}.\")\n",
    "\n",
    "    else:\n",
    "        try:\n",
    "            data = json.loads(response.text[1:-1])\n",
    "            for text in data['documents'][0]['passages'][:]:\n",
    "                if text['infons']['section_type'] == 'ABSTRACT':\n",
    "                    summary['Abstract'].append(text['text'])\n",
    "                if text['infons']['section_type'] == 'METHODS':\n",
    "                    summary['Method'].append(text['text'])\n",
    "        except json.JSONDecodeError as e:\n",
    "            print(\"Json error for string: \", response.text)\n",
    "    \n",
    "    return summary"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Json error for string:  [{\"bioctype\": \"BioCCollection\", \"source\": \"PMC\", \"date\": \"20241021\", \"key\": \"pmc.key\", \"version\": \"1.0\", \"infons\": {}, \"documents\": [{\"bioctype\": \"BioCDocument\", \"id\": \"PMC11485411\", \"infons\": {\"license\": \"CC BY\"}, \"passages\": [{\"bioctype\": \"BioCPassage\", \"offset\": 0, \"infons\": {\"alt-title\": \"BLUM et\\u00a0al.\\n\", \"article-id_doi\": \"10.1002/alz.14169\", \"article-id_pmc\": \"PMC11485411\", \"article-id_pmid\": \"39099181\", \"article-id_publisher-id\": \"ALZ14169\", \"fn\": \"David Blum, Susanna Schraen\\u2010Maschke, and Olivier Hanon co\\u2010directed this work.\", \"fpage\": \"6948\", \"issue\": \"10\", \"kwd\": \"Alzheimer's disease caffeine CSF biomarkers memory mild cognitive impairment\", \"license\": \"This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\", \"lpage\": \"6959\", \"name_0\": \"surname:Blum;given-names:David\", \"name_1\": \"surname:Cailliau;given-names:Emeline\", \"name_10\": \"surname:Schraen\\u2010Maschke;given-names:Susanna\", \"name_100\": \"surname:Saulnier;given-names:Isabelle\", \"name_101\": \"surname:Mondon;given-names:Karl\", \"name_102\": \"surname:Picat;given-names:Marie\\u2010Agn\\u00e8s\", \"name_103\": \"surname:Laurent;given-names:Marie\", \"name_104\": \"surname:Godefroy;given-names:Olivier\", \"name_105\": \"surname:Daheb;given-names:Rezki\", \"name_106\": \"surname:Libercier;given-names:St\\u00e9phanie\", \"name_107\": \"surname:Krabchi;given-names:Djamila\", \"name_108\": \"surname:Chupin;given-names:Marie\", \"name_109\": \"surname:Vidal;given-names:JeanS\\u00e9bastien\", \"name_11\": \"surname:Hanon;given-names:Olivier\", \"name_110\": \"surname:Chaussade;given-names:Edouard\", \"name_111\": \"surname:Baret\\u2010Rose;given-names:Christiane\", \"name_112\": \"surname:Lehmann;given-names:Sylvain\", \"name_113\": \"surname:Allinquant;given-names:Bernadette\", \"name_114\": \"surname:Schraen\\u2010Maschke;given-names:Susanna\", \"name_12\": \"surname:Hanon;given-names:Olivier\", \"name_13\": \"surname:Blanc;given-names:Fr\\u00e9d\\u00e9ric\", \"name_14\": \"surname:Boudali;given-names:Yasmina\", \"name_15\": \"surname:Gabelle;given-names:Audrey\", \"name_16\": \"surname:Touchon;given-names:Jacques\", \"name_17\": \"surname:Seux;given-names:Marie\\u2010Laure\", \"name_18\": \"surname:Lenoir;given-names:Hermine\", \"name_19\": \"surname:Bayle;given-names:Catherine\", \"name_2\": \"surname:B\\u00e9hal;given-names:H\\u00e9l\\u00e8ne\", \"name_20\": \"surname:Bombois;given-names:St\\u00e9phanie\", \"name_21\": \"surname:Delmaire;given-names:Christine\", \"name_22\": \"surname:Delbeuck;given-names:Xavier\", \"name_23\": \"surname:Moulin;given-names:Florence\", \"name_24\": \"surname:Duron;given-names:Emmanuelle\", \"name_25\": \"surname:Latour;given-names:Florence\", \"name_26\": \"surname:Plichart;given-names:Matthieu\", \"name_27\": \"surname:Pichierri;given-names:Sophie\", \"name_28\": \"surname:Orvo\\u00ebn;given-names:Galdric\", \"name_29\": \"surname:Galbrun;given-names:Evelyne\", \"name_3\": \"surname:Vidal;given-names:Jean\\u2010S\\u00e9bastien\", \"name_30\": \"surname:Castelnovo;given-names:Giovanni\", \"name_31\": \"surname:Volpe\\u2010Gillot;given-names:Lisette\", \"name_32\": \"surname:Labour\\u00e9e;given-names:Florien\", \"name_33\": \"surname:Cassagnaud;given-names:Pascaline\", \"name_34\": \"surname:Paquet;given-names:Claire\", \"name_35\": \"surname:Lala;given-names:Fran\\u00e7oise\", \"name_36\": \"surname:Vellas;given-names:Bruno\", \"name_37\": \"surname:Dumurgier;given-names:Julien\", \"name_38\": \"surname:Rigaud;given-names:Anne\\u2010Sophie\", \"name_39\": \"surname:Perret\\u2010Guillaume;given-names:Christine\", \"name_4\": \"surname:Delaby;given-names:Constance\", \"name_40\": \"surname:Alonso;given-names:Eliana\", \"name_41\": \"surname:du Boisgueheneuc;given-names:Foucaud\", \"name_42\": \"surname:Hugonot\\u2010Diener;given-names:Laurence\", \"name_43\": \"surname:Rollin\\u2010Sillaire;given-names:Adeline\", \"name_44\": \"surname:Martinaud;given-names:Olivier\", \"name_45\": \"surname:Boully;given-names:Cl\\u00e9mence\", \"name_46\": \"surname:Spivac;given-names:Yann\", \"name_47\": \"surname:Devendeville;given-names:Agn\\u00e8s\", \"name_48\": \"surname:Belmin;given-names:Jo\\u00ebl\", \"name_49\": \"surname:Robert;given-names:Philippe\", \"name_5\": \"surname:Bu\\u00e9e;given-names:Luc\", \"name_50\": \"surname:Dantoine;given-names:Thierry\", \"name_51\": \"surname:Caillard;given-names:Laure\", \"name_52\": \"surname:Wallon;given-names:David\", \"name_53\": \"surname:Hannequin;given-names:Didier\", \"name_54\": \"surname:Sastre;given-names:Nathalie\", \"name_55\": \"surname:Haffen;given-names:Sophie\", \"name_56\": \"surname:Kearney\\u2010Schwartz;given-names:Anna\", \"name_57\": \"surname:Novella;given-names:Jean\\u2010Luc\", \"name_58\": \"surname:Deramecourt;given-names:Vincent\", \"name_59\": \"surname:Chauvire;given-names:Val\\u00e9rie\", \"name_6\": \"surname:Allinquant;given-names:Bernadette\", \"name_60\": \"surname:Abitbol;given-names:Gabiel\", \"name_61\": \"surname:Schwald;given-names:Nathalie\", \"name_62\": \"surname:Hommet;given-names:Caroline\", \"name_63\": \"surname:Sellal;given-names:Fran\\u00e7ois\", \"name_64\": \"surname:Cariot;given-names:Marie\\u2010Ange\", \"name_65\": \"surname:Abdellaoui;given-names:Mohamed\", \"name_66\": \"surname:Benisty;given-names:Sarah\", \"name_67\": \"surname:Gherabli;given-names:Salim\", \"name_68\": \"surname:Anthony;given-names:Pierre\", \"name_69\": \"surname:Bloch;given-names:Fr\\u00e9d\\u00e9ric\", \"name_7\": \"surname:Gabelle;given-names:Audrey\", \"name_70\": \"surname:Charasz;given-names:Nathalie\", \"name_71\": \"surname:Chauvelier;given-names:Sophie\", \"name_72\": \"surname:Gaubert;given-names:Jean\\u2010Yves\", \"name_73\": \"surname:Sacco;given-names:Guillaume\", \"name_74\": \"surname:Guerin;given-names:Olivier\", \"name_75\": \"surname:Boddaert;given-names:Jacques\", \"name_76\": \"surname:Paccalin;given-names:Marc\", \"name_77\": \"surname:Mackowiak;given-names:Marie\\u2010Anne\", \"name_78\": \"surname:Rabus;given-names:Marie\\u2010Th\\u00e9r\\u00e8se\", \"name_79\": \"surname:Gissot;given-names:Val\\u00e9rie\", \"name_8\": \"surname:Bombois;given-names:St\\u00e9phanie\", \"name_80\": \"surname:Benetos;given-names:Athanase\", \"name_81\": \"surname:Picard;given-names:Candice\", \"name_82\": \"surname:Guillemaud;given-names:C\\u00e9line\", \"name_83\": \"surname:Berrut;given-names:Gilles\", \"name_84\": \"surname:Gervais;given-names:Claire\", \"name_85\": \"surname:Hugon;given-names:Jacques\", \"name_86\": \"surname:Michel;given-names:Jean\\u2010Marc\", \"name_87\": \"surname:David;given-names:JeanPhilippe\", \"name_88\": \"surname:Paulin;given-names:Marion\", \"name_89\": \"surname:Ousset;given-names:Pierre\\u2010Jean\", \"name_9\": \"surname:Lehmann;given-names:Sylvain\", \"name_90\": \"surname:Vandel;given-names:Pierre\", \"name_91\": \"surname:Pariel;given-names:Sylvie\", \"name_92\": \"surname:Camus;given-names:Vincent\", \"name_93\": \"surname:Chawakilian;given-names:Anne\", \"name_94\": \"surname:Kermanac'h;given-names:L\\u00e9na\", \"name_95\": \"surname:Troussiere;given-names:Anne\\u2010C\\u00e9cile\", \"name_96\": \"surname:Adam;given-names:C\\u00e9cile\", \"name_97\": \"surname:Dupuy;given-names:Diane\", \"name_98\": \"surname:Paillaud;given-names:Elena\", \"name_99\": \"surname:Briault;given-names:H\\u00e9l\\u00e8ne\", \"notes\": \"\\n\\n, , , et\\u00a0al. . . ;:\\u2013. \\n\\n\", \"pub-id_doi\": \"10.1002/alz.14169\", \"section_type\": \"TITLE\", \"source\": \"Alzheimer's Dement\", \"type\": \"front\", \"volume\": \"20\", \"year\": \"2024\"}, \"text\": \"Association of caffeine consumption with cerebrospinal fluid biomarkers in mild cognitive impairment and Alzheimer's disease: A BALTAZAR cohort study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 150, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract_title_1\"}, \"text\": \"Abstract\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 159, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract_title_1\"}, \"text\": \"INTRODUCTION\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 172, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract\"}, \"text\": \"We investigated the link between habitual caffeine intake with memory impairments and cerebrospinal fluid (CSF) biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 369, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract_title_1\"}, \"text\": \"METHODS\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 377, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract\"}, \"text\": \"MCI (N\\u00a0=\\u00a0147) and AD (N\\u00a0=\\u00a0116) patients of the Biomarker of AmyLoid pepTide and AlZheimer's diseAse Risk (BALTAZAR) cohort reported their caffeine intake at inclusion using a dedicated survey. Associations of caffeine consumption with memory impairments and CSF biomarkers (tau, p\\u2010tau181, amyloid beta 1\\u201042 [A\\u03b21\\u201042], A\\u03b21\\u201040) were analyzed using logistic and analysis of covariance models.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 780, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract_title_1\"}, \"text\": \"RESULTS\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 788, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract\"}, \"text\": \"Adjusted on Apolipoprotein E (APOE \\u03b54), age, sex, education level, and tobacco, lower caffeine consumption was associated with higher risk to be amnestic (OR: 2.49 [95% CI: 1.13 to 5.46]; p\\u00a0=\\u00a00.023) and lower CSF A\\u03b21\\u201042 (p\\u00a0=\\u00a00.047), A\\u03b21\\u201042/A\\u03b21\\u201040 (p\\u00a0=\\u00a00.040), and A\\u03b21\\u201042/p\\u2010tau181 (p\\u00a0=\\u00a00.020) in the whole cohort.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1124, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract_title_1\"}, \"text\": \"DISCUSSION\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1135, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract\"}, \"text\": \"Data support the beneficial effect of caffeine consumption to memory impairments and CSF amyloid markers in MCI and AD patients.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1264, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract_title_1\"}, \"text\": \"Highlights\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1275, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract\"}, \"text\": \"We studied the impact of caffeine consumption in the BALTAZAR cohort.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1345, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract\"}, \"text\": \"Low caffeine intake is associated with higher risk of being amnestic in MCI/AD patients.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1434, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract\"}, \"text\": \"Caffeine intake is associated with CSF biomarkers in AD patients.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1500, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"title_1\"}, \"text\": \"BACKGROUND\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1511, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"Alzheimer's disease (AD) is characterized by a progressive cognitive decline linked to both extracellular deposits of aggregated amyloid beta (A\\u03b2) peptides into plaques and the intraneuronal aggregation of hyperphosphorylated tau proteins. Besides aging, AD risk depends on various genetic and environmental factors. \", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1832, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"Caffeine is the most widely consumed psychoactive agent worldwide via dietary intake from coffee, tea, or soda beverages. Coffee consumption has been inversely associated with total and cause\\u2010specific mortality in a large prospective cohort of participants aged 50 to 71 years at baseline (National Institutes of Health\\u2014AARP Diet and Health Study) with an 8\\u2010year follow\\u2010up. Compelling evidence supports acute caffeine's ability to increase/improve wakefulness, alertness, and memory ([6]; for a review see Cunha and van Dam et\\u00a0al.). Various longitudinal, cross\\u2010sectional, and retrospective studies support the idea that habitual coffee/caffeine consumption reduces cognitive decline in the elderly (for reviews see ref. Cunha and Yelanchezian et\\u00a0al.). Further, other works suggest that coffee/caffeine intake reduces dementia or AD risk. Caffeine consumption has also been associated with a decrease of behavioral symptoms in patients with dementia. All these observations, obtained mostly during follow\\u2010up on non\\u2010demented elderly populations, have been acknowledged in meta\\u2010analysis studies. \", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 2944, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"Although experimental works using both amyloid and tau models show the beneficial impact of caffeine on the development of AD lesions (for a review see Cunha and Yelanchezian et\\u00a0al.), it remains largely unclear whether caffeine consumption is associated with brain levels of amyloid and tau in MCI or AD individuals. Two studies support, in cognitively normal aged individuals, a significant association between lower coffee intake and a higher A\\u03b2 positivity, as seen by positron emission tomography (PET), but these data have been discussed elsewhere. Notably, the link between caffeine intake and cerebrospinal fluid (CSF) biomarkers, including amyloid peptides A\\u03b2 and tau protein, in individuals presenting with MCI and AD has been largely overlooked. Only one study could not find an association of caffeine consumption, caffeine concentration in plasma, or caffeine concentration in the CSF with the levels of the core AD CSF biomarkers, in a cohort that included 88 patients with AD or mild cognitive impairment (MCI). \", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 3976, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"In this context, the present study aimed to reinvestigate the link between habitual caffeine intake with CSF levels of amyloid A\\u03b240, A\\u03b242, tau, and p\\u2010tau in the clinically defined Biomarker of AmyLoid pepTide and AlZheimer's diseAse Risk (BALTAZAR) cohort, including non\\u2010amnestic MCI (naMCI), amnestic MCI (aMCI), and AD patients.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 4313, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_1\"}, \"text\": \"METHODS\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 4321, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_2\"}, \"text\": \"Study population\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 4338, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"This study is ancillary to BALTAZAR, a multicenter (23 memory centers) prospective cohort study (ClinicalTrials.gov, Identifier #NCT01315639) including participants with MCI and AD at baseline from September 2010 to April 2015 and with an ongoing 3\\u2010year follow\\u2010up. All participants or their legal guardians gave written informed consent. The study was approved by the Paris Ethics Committee (CPP Ile de France IV Saint Louis Hospital). All participants were Caucasian community dwellers and had caregivers. Inclusion criteria for AD participants were age \\u226545 years, probable AD based on the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM IV\\u2010TR), and the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association criteria and from mild to moderate stage (Mini\\u2010Mental State Examination [MMSE] score \\u226515). Inclusion criteria for MCI participants were age \\u226570 years with MCI diagnostic criteria according to Petersen. Exclusion criteria were non\\u2010AD dementia (ie, vascular dementia, Lewy body or Parkinson's disease dementia, and frontotemporal dementia); genetic forms of AD; major depression according to DSM IV\\u2010TR or geriatric depression scale >\\u00a020/30; other diseases that could interfere with cognitive evaluation; diseases with short\\u2010term survival; use of cholinesterase inhibitors or methyl\\u2010D\\u2010aspartate receptor partial antagonists before inclusion (for participants with MCI); and illiterateness or less than 4 years of education.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 5910, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"At baseline, all the participants underwent clinical, neuropsychological, and biological assessments, and participants without contraindications underwent magnetic resonance imaging (MRI) brain examinations. Cognitive evaluations were performed by neuropsychologists after training programs to harmonize the evaluation. At inclusion, MCI and AD participants underwent a neuropsychological test battery that included global cognitive assessment with the MMSE (normal score 30/30), Clinical Dementia Rating (CDR) scale (CDR sum of boxes: normal score 0/18). Functional disability was assessed using instrumental activities of daily living (IADL, normal score 14/14) (for the description of all tests performed in the cohort see Hanon et\\u00a0al.). MCI participants were then categorized as aMCI or naMCI according to the presence of memory impairment on the free and cued selective recall reminding test related to age, sex, and educational level. Conversion to dementia in the naMCI group was very low (2.5%) compared to the aMCI group (22.4%).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 6950, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_2\"}, \"text\": \"Habitual caffeine consumption\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 6980, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"This study enrolled 263 patients (see flowchart in Figure S1) in which habitual caffeine intake was assessed using an in\\u2010house validated self\\u2010survey, completed together by the patients and their caregivers. At inclusion, the daily intake of caffeine\\u2010containing items (coffee, tea, chocolate, sodas) was reported. The daily caffeine intake at inclusion was then calculated as milligrams per day. Participants were dichotomized according to their median caffeine consumption (216\\u00a0mg/day), defining \\u201clow caffeine consumption\\u201d (\\u2264216\\u00a0mg/day) and \\u201chigh caffeine consumption\\u201d (>216\\u00a0mg/day) groups.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 7590, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_2\"}, \"text\": \"CSF and plasma biomarker measurements\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 7628, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Blood and CSF samples were collected at the same time. Investigators involved in the biological analysis were blinded to other assessments. A standard protocol was established beforehand and used throughout the study. CSF samples (>4\\u00a0mL) were centrifuged (1000\\u00a0\\u00d7 g, +4 C, 10\\u00a0min) less than 4\\u00a0h after collection using the same 10\\u2010mL polypropylene tube (Catalogue No. #62.610.201; Sarstedt, Germany), aliquoted into polypropylene protein low\\u2010binding tubes (LoBind microtube\\u2010ref 022431064; Eppendorf), and stored at \\u221280\\u00b0C. CSF tau, p\\u2010tau181, A\\u03b240, and A\\u03b242 were measured in duplicate using the same aliquot in a single centralized laboratory (IRMB, Montpellier, France) using commercially available ELISA kits (Euroimmun A\\u03b21\\u201040 and A\\u03b21\\u201042, Innotest htau and Innotest p\\u2010tau181). It is noteworthy that about half of patients did not accept lumbar puncture, which explains the missing data on CSF biomarkers.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 8557, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Regarding plasma, all centers used the same 10\\u00a0mL collection tube with EDTA (BD Vacutainer K2E Catalogue No. 367,525, Becton Dickinson, Rungis, France). After centrifugation (2500\\u00a0\\u00d7 g, 10\\u00a0min), the supernatants were aliquoted into polypropylene protein low\\u2010binding tubes (LoBind\\u2010microtube, Ref #022431064; Eppendorf, Hamburg, Germany) and stored at \\u221280\\u00b0C. Plasma A\\u03b240 and A\\u03b242 peptide assay was performed in a single centralized laboratory (Inserm UMRS1172, Lille) using the INNO\\u2010BIA kit (Fujirebio Europe NV, formerly Innogenetics NV, Belgium), based on a multiplex xMAP technique with a LABScan\\u2010200 system (Luminex BV). Plasma p\\u2010tau181 was determined using a commercial Simoa plasma p\\u2010tau181 Advantage V1 kit, and plasma neurofilament light (NfL) using a commercial Simoa NF\\u2010light Advantage Kit (Quanterix, Billerica, MA, USA) in a single centralized laboratory (IRMB, Montpellier, France). Internal quality controls (IQCs) represented by serum pool aliquots were used to monitor the accuracy of Simoa. All samples were measured after a single thaw.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 9632, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_3\"}, \"text\": \"RESEARCH IN CONTEXT\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 9652, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \" Systematic review: The authors reviewed the literature using traditional (eg, PubMed) sources, meeting abstracts, and presentations. While the impact of habitual caffeine consumption on age\\u2010related cognitive decline has been addressed in longitudinal studies and meta\\u2010analyses, its impact in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients remains ill defined, in particular regarding cerebrospinal fluid (CSF) biomarkers.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 10102, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \" Interpretation: Our data support an association of lower caffeine consumption with a higher risk of being amnestic as well as with deleterious changes in CSF biomarkers of MCI and AD patients.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 10296, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \" Future directions: The article proposes a framework for future interventional clinical studies aimed at evaluating the effect of caffeine on clinical progression and biomarker changes during the course of AD and at better understanding the associated biological mechanisms.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 10571, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_2\"}, \"text\": \"Statistical analysis\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 10592, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Categorical variables are reported as frequency (percentage). Continuous variables are reported as mean (standard deviation [SD]) in the case of normal distribution or median (interquartile range [IQR]) otherwise. Normality of distributions was assessed using histograms and the Shapiro\\u2013Wilk test.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 10892, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Patient characteristics and CSF biomarkers were compared between the three diagnostic groups (naMCI, aMCI, and AD) using chi\\u2010squared test (or Fisher's exact test in the case of an expected value\\u00a0<5) for categorical variables and using analysis of variance or Kruskal\\u2013Wallis test for quantitative variables. CSF data were not imputed as the proportion of missing data was too important and not random. For MCI patients, association between biomarkers and conversion to AD were evaluated using a Cox proportional hazards model. The proportional hazards assumption and the log\\u2010linearity assumption for quantitative variables were assessed by examining the scaled Schoenfeld residuals plots and the Martingale residual plots. Hazard ratios were estimated with their 95% confidence interval (CI).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 11691, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"The impact of low or high caffeine consumption on the diagnostic group was evaluated using a multinomial logistic regression model adjusted on predefined confounding factors (Apolipoprotein E [APOE \\u03b54], age, sex, education level, and tobacco consumption). Odds ratios (ORs) were derived from models with their 95% CIs. The same analysis was performed by regrouping aMCI and DA groups using a logistic regression model adjusted on predefined confounding factors.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 12159, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"The impact of low or high caffeine consumption on biomarkers was evaluated using an analysis of covariance (ANCOVA) adjusted on predefined confounding factors and after applying a log transformation of the CSF biomarkers and plasma NfL levels. Mean difference was derived from models with their 95% CIs.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 12463, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"All statistical tests were done at the two\\u2010tailed \\u03b1\\u2010level of 0.05 using SAS software version 9.4 (SAS Institute, Cary, NC, USA).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 12597, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"title_1\"}, \"text\": \"RESULTS\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 12605, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"title_2\"}, \"text\": \"Demographic and clinical characteristics at baseline\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 12658, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"Two hundred and sixty\\u2010three participants of the BALTAZAR cohort with available caffeine data were included (40 naMCI, 107 aMCI, and 116 AD; Table\\u00a01). At baseline, among the 263 participants, 38.0% (N\\u00a0=\\u00a0100) were males, 40.8% (N\\u00a0=\\u00a0106) had at least a high school diploma, and 74.8% (N\\u00a0=\\u00a0193) never smoked. The median MMSE score was 26 (IQR: 23 to 28) and 47.7% (N\\u00a0=\\u00a0114) were APOE \\u03b54 carriers. The median caffeine consumption was 216 (IQR: 84 to 374) mg/day. During the clinical follow\\u2010up period (6 to 36 months), 24 MCI participants developed dementia and converted to probable AD. Analysis of CSF biomarkers at inclusion showed, as expected, higher CSF total tau (tau) and phospho\\u2010tau (p\\u2010tau181) levels and lower amyloid A\\u03b242 levels, A\\u03b242/A\\u03b240, and A\\u03b242/p\\u2010tau181 ratios in AD patients compared to naMCI and aMCI individuals. As shown in Table S1, we also described CSF and plasma biomarker changes in the MCI patients converting to dementia (mainly AD) versus non\\u2010converters: as in the whole BALTAZAR MCI cohort, we found higher CSF tau and p\\u2010tau181 levels; lower CSF A\\u03b242 levels and A\\u03b242/A\\u03b240 and A\\u03b242/p\\u2010tau181 ratios, and lower plasma A\\u03b242/A\\u03b240. Similarly, hippocampal volume, MMSE, and IADL were significantly lower, while CDR was higher in AD versus aMCI and naMCI (Table\\u00a01).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 13976, \"infons\": {\"file\": \"alz14169-tbl-0001.xml\", \"id\": \"alz14169-tbl-0001\", \"section_type\": \"TABLE\", \"type\": \"table_caption\"}, \"text\": \"General characteristics, global cognitive assessment, and CSF biomarkers at baseline.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 14062, \"infons\": {\"file\": \"alz14169-tbl-0001.xml\", \"id\": \"alz14169-tbl-0001\", \"section_type\": \"TABLE\", \"type\": \"table\", \"xml\": \"<?xml version=\\\"1.0\\\" encoding=\\\"UTF-8\\\"?>\\n<table frame=\\\"hsides\\\" rules=\\\"groups\\\"><col align=\\\"left\\\" span=\\\"1\\\"/><col align=\\\"left\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\".\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\".\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\".\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\".\\\" span=\\\"1\\\"/><thead><tr style=\\\"border-bottom:solid 1px #000000\\\"><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">N</italic>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<p>Overall</p>\\n<p>\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 263</p>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">N</italic>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<p>naMCI</p>\\n<p>\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 40</p>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">N</italic>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<p>aMCI</p>\\n<p>\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 107</p>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">N</italic>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<p>AD</p>\\n<p>\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 116</p>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">p</italic>\\u2010value</th></tr></thead><tbody><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>Age (years)</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">263</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">77\\u00a0\\u00b1 6</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">76\\u00a0\\u00b1 5</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">77\\u00a0\\u00b1 5</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">78\\u00a0\\u00b1 7</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.11</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>Male (<italic toggle=\\\"yes\\\">N</italic>, %)</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">263</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">100 (38.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">9 (22.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">50 (46.7)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">41 (35.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.019</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>Education level (<italic toggle=\\\"yes\\\">N</italic>, %)</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">260</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">38</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">106</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.038</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Primary</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">47 (18.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">8 (21.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">13 (12.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">26 (22.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Secondary</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107 (41.2)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">10 (26.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">45 (42.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">52 (45.2)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">High school diploma or above</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">106 (40.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">20 (52.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">49 (45.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">37 (32.2)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>Tobacco (<italic toggle=\\\"yes\\\">N</italic>, %)</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">258</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">38</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">105</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">115</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">NA</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Never</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">193 (74.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">29 (76.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">73 (69.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">91 (79.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Current</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">7 (2.7)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2 (5.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">3 (2.9)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2 (1.7)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Former</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">58 (22.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">7 (18.4)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">29 (27.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">22 (19.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>BMI (kg/m<sup>2</sup>)</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">262</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">25.2\\u00a0\\u00b1 3.6</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">24.5\\u00a0\\u00b1 3.2</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">106</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">24.9\\u00a0\\u00b1 3.3</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">25.8\\u00a0\\u00b1 3.9</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.058</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>Caffeine (mg/day)</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">263</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">216 (84 to 374)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">266 (182 to 427)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">197 (79 to 332)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">216 (76 to 385)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.16</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Low\\u2010caffeine group (\\u2264216\\u00a0mg/day)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">132 (50.2)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">15 (37.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">59 (55.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">58 (50.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">High\\u2010caffeine group (&gt;216\\u00a0mg/day)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">131 (49.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">25 (62.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">48 (44.9)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">58 (50.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>Comorbidity (<italic toggle=\\\"yes\\\">N</italic>, %)</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Hypertension</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">261</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">190 (72.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">38</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">28 (70.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">82 (76.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">80 (70.2)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.51</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Mellitus diabetes</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">238</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">35 (14.7)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">38</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">4 (10.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">99</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">14 (14.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">101</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">17 (16.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.63</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Dyslipidemia</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">260</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">106 (40.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">39</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">20 (50.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">105</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">45 (42.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">41 (36.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.27</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">History of stroke or TIA</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">262</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">18 (6.9)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">39</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0 (0.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">9 (8.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">9 (7.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.16</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">History of depression</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">261</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">59 (22.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">38</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">11 (27.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">25 (23.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">23 (19.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.56</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>Relative hippocampal volume</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">229</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.33\\u00a0\\u00b1 0.09</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">35</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.40\\u00a0\\u00b1 0.05</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">91</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.35\\u00a0\\u00b1 0.08</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">103</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.29\\u00a0\\u00b1 0.09</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">APOE</italic> \\u03b54 carrier (<bold>\\n<italic toggle=\\\"yes\\\">N</italic>, %)</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">239</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">114 (47.7)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">12 (30.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">105</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">50 (47.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">94</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">52 (55.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.027</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>Global cognitive assessment</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">CDR sum of boxes (/18)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">263</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2.0 (0.5 to 4.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.5 (0.5 to 0.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1.0 (0.5 to 2.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">4.3 (2.5 to 5.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">MMSE (/30)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">252</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">26 (23 to 28)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">37</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">28 (27 to 30)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">105</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">27 (25 to 28)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">110</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">23 (20 to 25)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">IADL score (/14)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">257</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">13 (11 to 14)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">39</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">14 (14 to 14)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">105</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">14 (12 to 14)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">113</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">11 (7 to 13)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>CSF biomarkers</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">A\\u03b240 (pg/mL)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">6963 (5925 to 8647)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">18</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">6801 (6293.0 to 9547)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">49</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">7350 (5925 to 9023)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">6799 (58278 to 8182)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.48</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">A\\u03b242 (pg/mL)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">589 (411 to 956)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">18</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">853 (673 to 1030)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">49</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">667 (431 to 1183)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">471 (403 to 624)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">A\\u03b242/A\\u03b240 (%)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">8.2 (6.7 to 13.2)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">18</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">11.2 (8.3 to 14.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">49</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">9.3 (6.7 to 15.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">7.3 (6.1 to 8.7)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">tau (pg/mL)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">118</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">399 (309 to 625)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">18</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">311 (214 to 410)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">56</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">371 (280 to 600)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">44</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">596 (392 to 710)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">p\\u2010tau181 (pg/mL)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">120</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">61 (48 to 82)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">18</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">52 (45 to 60)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">57</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">56 (48 to 77)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">45</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">69 (63 to 98)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">A\\u03b242/p\\u2010tau</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">103</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">9.2 (5.7 to 19.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">18</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">15.5 (11.6 to 22.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">47</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">11.5 (6.5 to 21.9)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">38</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">7.0 (4.8 to 9.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr></tbody></table>\\n\"}, \"text\": \"\\tN\\tOverallN\\u00a0= 263\\tN\\tnaMCIN\\u00a0= 40\\tN\\taMCIN\\u00a0= 107\\tN\\tADN\\u00a0= 116\\tp\\u2010value\\t \\tAge (years)\\t263\\t77\\u00a0\\u00b1 6\\t40\\t76\\u00a0\\u00b1 5\\t107\\t77\\u00a0\\u00b1 5\\t116\\t78\\u00a0\\u00b1 7\\t0.11\\t \\tMale (N, %)\\t263\\t100 (38.0)\\t40\\t9 (22.5)\\t107\\t50 (46.7)\\t116\\t41 (35.3)\\t0.019\\t \\tEducation level (N, %)\\t260\\t\\t38\\t\\t106\\t\\t116\\t\\t0.038\\t \\tPrimary\\t\\t47 (18.1)\\t\\t8 (21.1)\\t\\t13 (12.1)\\t\\t26 (22.6)\\t\\t \\tSecondary\\t\\t107 (41.2)\\t\\t10 (26.3)\\t\\t45 (42.1)\\t\\t52 (45.2)\\t\\t \\tHigh school diploma or above\\t\\t106 (40.8)\\t\\t20 (52.6)\\t\\t49 (45.8)\\t\\t37 (32.2)\\t\\t \\tTobacco (N, %)\\t258\\t\\t38\\t\\t105\\t\\t115\\t\\tNA\\t \\tNever\\t\\t193 (74.8)\\t\\t29 (76.3)\\t\\t73 (69.5)\\t\\t91 (79.1)\\t\\t \\tCurrent\\t\\t7 (2.7)\\t\\t2 (5.3)\\t\\t3 (2.9)\\t\\t2 (1.7)\\t\\t \\tFormer\\t\\t58 (22.5)\\t\\t7 (18.4)\\t\\t29 (27.6)\\t\\t22 (19.1)\\t\\t \\tBMI (kg/m2)\\t262\\t25.2\\u00a0\\u00b1 3.6\\t40\\t24.5\\u00a0\\u00b1 3.2\\t106\\t24.9\\u00a0\\u00b1 3.3\\t116\\t25.8\\u00a0\\u00b1 3.9\\t0.058\\t \\tCaffeine (mg/day)\\t263\\t216 (84 to 374)\\t40\\t266 (182 to 427)\\t107\\t197 (79 to 332)\\t116\\t216 (76 to 385)\\t0.16\\t \\tLow\\u2010caffeine group (\\u2264216\\u00a0mg/day)\\t\\t132 (50.2)\\t\\t15 (37.5)\\t\\t59 (55.1)\\t\\t58 (50.0)\\t\\t \\tHigh\\u2010caffeine group (>216\\u00a0mg/day)\\t\\t131 (49.8)\\t\\t25 (62.5)\\t\\t48 (44.9)\\t\\t58 (50.0)\\t\\t \\tComorbidity (N, %)\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t \\tHypertension\\t261\\t190 (72.8)\\t38\\t28 (70.0)\\t107\\t82 (76.6)\\t116\\t80 (70.2)\\t0.51\\t \\tMellitus diabetes\\t238\\t35 (14.7)\\t38\\t4 (10.5)\\t99\\t14 (14.1)\\t101\\t17 (16.8)\\t0.63\\t \\tDyslipidemia\\t260\\t106 (40.8)\\t39\\t20 (50.0)\\t105\\t45 (42.5)\\t116\\t41 (36.0)\\t0.27\\t \\tHistory of stroke or TIA\\t262\\t18 (6.9)\\t39\\t0 (0.0)\\t107\\t9 (8.5)\\t116\\t9 (7.8)\\t0.16\\t \\tHistory of depression\\t261\\t59 (22.6)\\t38\\t11 (27.5)\\t107\\t25 (23.8)\\t116\\t23 (19.8)\\t0.56\\t \\tRelative hippocampal volume\\t229\\t0.33\\u00a0\\u00b1 0.09\\t35\\t0.40\\u00a0\\u00b1 0.05\\t91\\t0.35\\u00a0\\u00b1 0.08\\t103\\t0.29\\u00a0\\u00b1 0.09\\t<0.001\\t \\tAPOE \\u03b54 carrier (N, %)\\t239\\t114 (47.7)\\t40\\t12 (30.0)\\t105\\t50 (47.6)\\t94\\t52 (55.3)\\t0.027\\t \\tGlobal cognitive assessment\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t \\tCDR sum of boxes (/18)\\t263\\t2.0 (0.5 to 4.0)\\t40\\t0.5 (0.5 to 0.6)\\t107\\t1.0 (0.5 to 2.0)\\t116\\t4.3 (2.5 to 5.6)\\t<0.001\\t \\tMMSE (/30)\\t252\\t26 (23 to 28)\\t37\\t28 (27 to 30)\\t105\\t27 (25 to 28)\\t110\\t23 (20 to 25)\\t<0.001\\t \\tIADL score (/14)\\t257\\t13 (11 to 14)\\t39\\t14 (14 to 14)\\t105\\t14 (12 to 14)\\t113\\t11 (7 to 13)\\t<0.001\\t \\tCSF biomarkers\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t \\tA\\u03b240 (pg/mL)\\t107\\t6963 (5925 to 8647)\\t18\\t6801 (6293.0 to 9547)\\t49\\t7350 (5925 to 9023)\\t40\\t6799 (58278 to 8182)\\t0.48\\t \\tA\\u03b242 (pg/mL)\\t107\\t589 (411 to 956)\\t18\\t853 (673 to 1030)\\t49\\t667 (431 to 1183)\\t40\\t471 (403 to 624)\\t<0.001\\t \\tA\\u03b242/A\\u03b240 (%)\\t107\\t8.2 (6.7 to 13.2)\\t18\\t11.2 (8.3 to 14.3)\\t49\\t9.3 (6.7 to 15.6)\\t40\\t7.3 (6.1 to 8.7)\\t<0.001\\t \\ttau (pg/mL)\\t118\\t399 (309 to 625)\\t18\\t311 (214 to 410)\\t56\\t371 (280 to 600)\\t44\\t596 (392 to 710)\\t<0.001\\t \\tp\\u2010tau181 (pg/mL)\\t120\\t61 (48 to 82)\\t18\\t52 (45 to 60)\\t57\\t56 (48 to 77)\\t45\\t69 (63 to 98)\\t<0.001\\t \\tA\\u03b242/p\\u2010tau\\t103\\t9.2 (5.7 to 19.3)\\t18\\t15.5 (11.6 to 22.8)\\t47\\t11.5 (6.5 to 21.9)\\t38\\t7.0 (4.8 to 9.5)\\t<0.001\\t \\t\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 16704, \"infons\": {\"file\": \"alz14169-tbl-0001.xml\", \"id\": \"alz14169-tbl-0001\", \"section_type\": \"TABLE\", \"type\": \"table_footnote\"}, \"text\": \"\\nNote: Values are presented as mean\\u00a0\\u00b1\\u00a0SD or median (interquartile range) for quantitative variables and as frequency (percentage) for categorical variables.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 16864, \"infons\": {\"file\": \"alz14169-tbl-0001.xml\", \"id\": \"alz14169-tbl-0001\", \"section_type\": \"TABLE\", \"type\": \"table_footnote\"}, \"text\": \"Abbreviations: AD, Alzheimer's disease; aMCI: amnestic mild cognitive impairment; BMI, body mass index; CDR SOB, Clinical Dementia Rating Sum of Boxes; CSF, cerebrospinal fluid; IADL, instrumental activities of daily living; MMSE, Mini\\u2010Mental State Examination; naMCI, non\\u2010amnestic mild cognitive impairment; N, number of available observations; TIA, transient ischemic attack.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 17246, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"title_2\"}, \"text\": \"Association of caffeine consumption with the diagnostic groups at baseline according to the cognitive status (AD, aMCI, naMCI)\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 17373, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"Participants were dichotomized according to their median caffeine consumption (216\\u00a0mg/day) in the overall cohort as well as in each subgroup (AD, aMCI, naMCI). Body mass index (BMI) was not significantly different between low and high caffeine consumers (mean BMI: 25.3\\u00a0\\u00b1\\u00a03.8 in the low vs 25.2\\u00a0\\u00b1\\u00a03.5 in the high consumer group; p\\u00a0=\\u00a0.93, Student's t test). At baseline, we did not find a statistical difference in caffeine intake between naMCI, aMCI, and AD patients (Table\\u00a01), suggesting that the development of AD is not associated with a change in consumption, at least versus MCI patients. Also, the median caffeine consumption calculated for MCI patient that convert (199.5\\u00a0mg/day) or not (217.7\\u00a0mg/day) was not found significantly different (p\\u00a0=\\u00a00.88). However, after adjustment on APOE \\u03b54, age, sex, education level, and tobacco consumption, and using the naMCI group as reference, we found a significant association of a lower caffeine consumption with a higher risk to be aMCI (OR: 2.72 [95% CI: 1.17 to 6.30]) and a similar effect size, even non\\u2010significant, for higher risk of being AD (OR:2.31 [95% CI: 0.98 to 5.40]; Table\\u00a02). When aMCI and AD groups were combined, the association of a lower caffeine consumption with higher risk of being amnestic was significant (OR: 2.49 [95% CI: 1.13 to 5.46]; p\\u00a0=\\u00a00.023) (Table\\u00a02). Nevertheless, a Kaplan\\u2013Meyer analysis indicated that the rate of MCI conversion to AD was not modified regarding the caffeine consumption class (p\\u00a0=\\u00a00.94; not shown).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 18899, \"infons\": {\"file\": \"alz14169-tbl-0002.xml\", \"id\": \"alz14169-tbl-0002\", \"section_type\": \"TABLE\", \"type\": \"table_caption\"}, \"text\": \"Association of caffeine consumption according to cognitive status (naMCI, aMCI, AD).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 18984, \"infons\": {\"file\": \"alz14169-tbl-0002.xml\", \"id\": \"alz14169-tbl-0002\", \"section_type\": \"TABLE\", \"type\": \"table\", \"xml\": \"<?xml version=\\\"1.0\\\" encoding=\\\"UTF-8\\\"?>\\n<table frame=\\\"hsides\\\" rules=\\\"groups\\\"><col align=\\\"left\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\".\\\" span=\\\"1\\\"/><thead><tr style=\\\"border-bottom:solid 1px #000000\\\"><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Overall</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 263</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<p>Low caffeine consumption</p>\\n<p>\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 132</p>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<p>High caffeine consumption</p>\\n<p>\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 131</p>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Odds ratio (95% CI)</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">p</italic>\\u2010value</th></tr></thead><tbody><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>naMCI_aMCI_AD (<italic toggle=\\\"yes\\\">N</italic>, %)</bold>\\n</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.062</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">naMCI</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40 (15.2)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">15 (11.4)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">25 (19.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1.00 (r\\u00e9f.)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\u2013</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">aMCI</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107 (40.7)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">59 (44.7)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">48 (36.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2.72 (1.17 to 6.30)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>0.019</bold>\\n</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">AD</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116 (44.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">58 (43.9)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">58 (44.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2.31 (0.98 to 5.40)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.054</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>naMCI_aMCI+AD (<italic toggle=\\\"yes\\\">N</italic>, %)</bold>\\n</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">naMCI</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40 (15.2)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">15 (11.4)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">25 (19.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1.00 (r\\u00e9f.)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\u2013</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">aMCI+AD</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">223 (84.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">117 (88.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">106 (80.9)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2.49 (1.13 to 5.46)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>0.023</bold>\\n</td></tr></tbody></table>\\n\"}, \"text\": \"Overall\\tN\\u00a0= 263\\tLow caffeine consumptionN\\u00a0= 132\\tHigh caffeine consumptionN\\u00a0= 131\\tOdds ratio (95% CI)\\tp\\u2010value\\t \\tnaMCI_aMCI_AD (N, %)\\t\\t\\t\\t\\t0.062\\t \\tnaMCI\\t40 (15.2)\\t15 (11.4)\\t25 (19.1)\\t1.00 (r\\u00e9f.)\\t\\u2013\\t \\taMCI\\t107 (40.7)\\t59 (44.7)\\t48 (36.6)\\t2.72 (1.17 to 6.30)\\t0.019\\t \\tAD\\t116 (44.1)\\t58 (43.9)\\t58 (44.3)\\t2.31 (0.98 to 5.40)\\t0.054\\t \\tnaMCI_aMCI+AD (N, %)\\t\\t\\t\\t\\t\\t \\tnaMCI\\t40 (15.2)\\t15 (11.4)\\t25 (19.1)\\t1.00 (r\\u00e9f.)\\t\\u2013\\t \\taMCI+AD\\t223 (84.8)\\t117 (88.6)\\t106 (80.9)\\t2.49 (1.13 to 5.46)\\t0.023\\t \\t\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 19467, \"infons\": {\"file\": \"alz14169-tbl-0002.xml\", \"id\": \"alz14169-tbl-0002\", \"section_type\": \"TABLE\", \"type\": \"table_footnote\"}, \"text\": \"\\nNote: Values are presented as frequency (percentage). Odds ratios and p values were adjusted for APOE \\u03b54, age, sex, education level, and tobacco consumption.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 19632, \"infons\": {\"file\": \"alz14169-tbl-0002.xml\", \"id\": \"alz14169-tbl-0002\", \"section_type\": \"TABLE\", \"type\": \"table_footnote\"}, \"text\": \"Abbreviations: AD, Alzheimer's disease; aMCI, amnestic mild cognitive impairment; CI, confidence interval; naMCI, non\\u2010amnestic mild cognitive impairment; N, number of available observations.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 19825, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"title_2\"}, \"text\": \"Association of caffeine consumption with CSF and plasma biomarkers at baseline\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 19904, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"Among the whole cohort, after adjustment on APOE \\u03b54, age, sex, education level, and tobacco consumption, lower caffeine consumption was found to be associated with lower CSF A\\u03b242 levels (p\\u00a0=\\u00a00.047) as well as lower A\\u03b242/A\\u03b240 (p\\u00a0=\\u00a00.040) and A\\u03b242/p\\u2010tau181 ratio (p\\u00a0=\\u00a00.020; Table\\u00a03). No significant difference was observed regarding CSF total tau and p\\u2010tau181 levels based on caffeine consumption (Table\\u00a03). We also evaluated plasma biomarkers (p\\u2010tau181, A\\u03b242, A\\u03b240, and NfL) but did not observe significant differences per the caffeine consumption group (Table S2).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 20494, \"infons\": {\"file\": \"alz14169-tbl-0003.xml\", \"id\": \"alz14169-tbl-0003\", \"section_type\": \"TABLE\", \"type\": \"table_caption\"}, \"text\": \"Association of caffeine consumption with CSF biomarkers at baseline.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 20563, \"infons\": {\"file\": \"alz14169-tbl-0003.xml\", \"id\": \"alz14169-tbl-0003\", \"section_type\": \"TABLE\", \"type\": \"table\", \"xml\": \"<?xml version=\\\"1.0\\\" encoding=\\\"UTF-8\\\"?>\\n<table frame=\\\"hsides\\\" rules=\\\"groups\\\"><col align=\\\"left\\\" span=\\\"1\\\"/><col align=\\\"left\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"left\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"left\\\" span=\\\"1\\\"/><thead><tr style=\\\"border-bottom:solid 1px #000000\\\"><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">CSF biomarkers</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">N</italic>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<p>Low caffeine consumption</p>\\n<p>\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 132</p>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">N</italic>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<p>High caffeine consumption</p>\\n<p>\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 131</p>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Mean difference (95% CI)</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">p</italic>\\u2010value</th></tr></thead><tbody><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">tau (pg/mL)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">55</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">400 (311 to 627)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">63</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">385 (287 to 622)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.14 (\\u22120.06 to 0.35)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.17</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">p\\u2010tau181 (pg/mL)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">56</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">62 (49 to 84)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">64</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">60 (47 to 80)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.13 (\\u22120.03 to 0.30)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.11</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">A\\u03b242 (pg/mL)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">50</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">577 (411 to 953)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">57</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">658 (431 to 956)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\u22120.21 (\\u22120.41 to 0.00)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>0.040</bold>\\n</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">A\\u03b240 (pg/mL)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">50</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">7075 (5934 to 8647)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">57</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">6795 (5874 to 9007)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\u22120.05 (\\u22120.18 to 0.09)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.47</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">A\\u03b242/A\\u03b240 (%)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">50</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">8.1 (6.7 to 14.0)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">57</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">8.4 (6.8 to 12.9)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\u22120.17 (\\u22120.32 to \\u22120.01)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>0.047</bold>\\n</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">CSF A\\u03b242/p\\u2010tau</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">49</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">8.5 (5.7 to 17.2)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">54</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">10.5 (6.5 to 21.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\u22120.34 (\\u22120.61 to \\u22120.06)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>0.020</bold>\\n</td></tr></tbody></table>\\n\"}, \"text\": \"CSF biomarkers\\tN\\tLow caffeine consumptionN\\u00a0= 132\\tN\\tHigh caffeine consumptionN\\u00a0= 131\\tMean difference (95% CI)\\tp\\u2010value\\t \\ttau (pg/mL)\\t55\\t400 (311 to 627)\\t63\\t385 (287 to 622)\\t0.14 (\\u22120.06 to 0.35)\\t0.17\\t \\tp\\u2010tau181 (pg/mL)\\t56\\t62 (49 to 84)\\t64\\t60 (47 to 80)\\t0.13 (\\u22120.03 to 0.30)\\t0.11\\t \\tA\\u03b242 (pg/mL)\\t50\\t577 (411 to 953)\\t57\\t658 (431 to 956)\\t\\u22120.21 (\\u22120.41 to 0.00)\\t0.040\\t \\tA\\u03b240 (pg/mL)\\t50\\t7075 (5934 to 8647)\\t57\\t6795 (5874 to 9007)\\t\\u22120.05 (\\u22120.18 to 0.09)\\t0.47\\t \\tA\\u03b242/A\\u03b240 (%)\\t50\\t8.1 (6.7 to 14.0)\\t57\\t8.4 (6.8 to 12.9)\\t\\u22120.17 (\\u22120.32 to \\u22120.01)\\t0.047\\t \\tCSF A\\u03b242/p\\u2010tau\\t49\\t8.5 (5.7 to 17.2)\\t54\\t10.5 (6.5 to 21.3)\\t\\u22120.34 (\\u22120.61 to \\u22120.06)\\t0.020\\t \\t\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 21226, \"infons\": {\"file\": \"alz14169-tbl-0003.xml\", \"id\": \"alz14169-tbl-0003\", \"section_type\": \"TABLE\", \"type\": \"table_footnote\"}, \"text\": \"\\nNote: Values are presented as median (IQR). Mean differences and p values were calculated on log transformed data and were adjusted for APOE \\u03b54, age, sex, education level, and tobacco consumption, using high caffeine consumption as reference.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 21476, \"infons\": {\"file\": \"alz14169-tbl-0003.xml\", \"id\": \"alz14169-tbl-0003\", \"section_type\": \"TABLE\", \"type\": \"table_footnote\"}, \"text\": \"Abbreviations: CI, confidence interval; CSF, cerebrospinal fluid; N, number of available observations.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 21579, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"title_1\"}, \"text\": \"DISCUSSION\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 21590, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"In this study, we evaluated the impact of caffeine consumption on clinical outcomes and biomarkers at baseline in the BALTAZAR cohort, including MCI and AD patients. Our data show an association of a lower caffeine consumption with memory disorders related to AD and aMCI at inclusion. Importantly, our data also demonstrate that caffeine is associated with changes in CSF biomarkers of AD patients, particularly with regard to the amyloid component.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 22041, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"The association fits well with few, and potentially underpowered, previous retrospective studies investigating the impact of caffeine consumption on populations of patients presenting with MCI or AD. Maia and de Mendon\\u00e7a showed a significantly lower average consumption of caffeine (74\\u00a0mg/day, N\\u00a0=\\u00a054) during the 20 years preceding AD development in subjects as compared with age\\u2010matched non\\u2010demented subjects (approximately 200\\u00a0mg/day, N\\u00a0=\\u00a054). In the same way, Cao et\\u00a0al. suggested that plasma caffeine concentrations were approximately 50% lower in subjects converting to dementia (N\\u00a0=\\u00a015) (presumably comparable to our aMCI group at high risk of converting to dementia) versus subjects that did not convert (N\\u00a0=\\u00a09) (presumably comparable to our naMCI group). Interestingly, one study, in line with experimental data, found that higher caffeine intake was associated with better function in overall cognition, encompassing episodic memory, executive function, semantic categorization, and working memory, in a cohort of approximately 600 subjects presenting with diabetes, known to be a significant risk factor for dementia, as are aMCI individuals. These data support a benefit of habitual caffeine consumption in at\\u2010risk individuals that would warrant extending more broadly cognitive endophenotypes at MCI inclusion and follow\\u2010up regarding caffeine consumption. Besides an impact on brain lesions (see following discussion), association between caffeine consumption and memory might primarily relate to the ability of caffeine to act on synaptic plasticity. Indeed, in rodents, caffeine's effect on hippocampal slices is to enhance basal synaptic transmission, long\\u2010term potentiation (LTP), and sharp wave\\u2013ripple complexes, which underlie memory consolidation. Caffeine also controls neuronal excitability and LTP\\u2010like effects in the human cortex. More recently, we also demonstrated that regular caffeine intake acted on epigenomic and transcriptional processes that would improve the signal\\u2010to\\u2010noise ratio during information encoding, favoring the functioning of circuits involved in learning. The beneficial effect of caffeine on synaptic plasticity during MCI and AD would be particularly ascribed to its ability to block adenosine receptors, particularly the A2AR subtypes. \", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 24357, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Importantly, we showed a significant association across the BALTAZAR cohort between lower caffeine intake and lower CSF levels of A\\u03b242 as well as A\\u03b242/A\\u03b240 and A\\u03b242/p\\u2010tau181 ratios. To our knowledge, this is the first study to report an association between caffeine and CSF AD biomarkers. Only one previous study addressed, unsuccessfully, such an association in another population. However, this study included a more limited number of subjects (37 MCI and 51 AD), the biomarker assay techniques were different, and, for an unclear reason, the median caffeine consumption was two times lower (around 100\\u00a0mg/day) than in our population. Using our in\\u2010house survey \\u2013 developed to obtain more precise information on consumption habits than caffeine unit or mugs \\u2013 and considering all types of caffeine consumption and volume ingested, we estimated the median consumption of our population to be 216\\u00a0mg/day. This amount was in line with previous studies in cohorts of a similar age and the average consumption in French population as shown by Fredholm et\\u00a0al. Our CSF data point to a particular impact of caffeine on amyloid burden. This is in accordance with a Korean study that included elderly subjects (mean age 71 years old) without dementia (282 cognitively normal and 129 with MCI), showing an association between coffee consumption greater than two cups/day (ie, about 200\\u00a0mg) with amyloid Pittsburgh compound B (PIB)\\u2010PET positivity. Another recent study involving only cognitively normal subjects (mean age 71 years) also found a significant association between higher caffeine consumption and slower accumulation of cerebral amyloid load measured by PIB\\u2010PET during a 126\\u2010month follow\\u2010up. \", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 26075, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"We also evaluated plasma biomarkers, except plasma total tau (t\\u2010tau) levels, as it has been acknowledged that they do not provide valuable information regarding tau brain levels. Indeed, plasma t\\u2010tau concentrations do not to correlate with CSF t\\u2010tau or PET and neuropathological evidence of AD. Evaluation of plasma p\\u2010tau181 and A\\u03b2 did not reveal differences in connection with caffeine consumption. Such a lack of a difference could be explained by the smaller variations observed in amyloid and p\\u2010tau levels in plasma compared to CSF. Indeed, in the BALTAZAR cohort, we previously observed an association between CSF biomarkers and plasma amyloid levels as well as plasma p\\u2010tau. However, the difference or lack thereof in mean levels between MCI converters was respectively for plasma and CSF: \\u22122.1 and \\u2212283 pg/mL for A\\u03b21\\u201042 and +0.9 and + 21.7 pg/mL for p\\u2010tau181. Therefore, the lack of difference in the present study could be simply due to a lack of statistical power linked to an insufficient number of patients with known caffeine consumption. Alternatively, this could also suggest that caffeine mainly has a direct central effect on brain processes rather an indirect effect through peripheral inflammation, amyloid clearance, or metabolism. Regarding plasma NfL levels, also not associated with caffeine consumption, we previously showed in the BALTAZAR cohort that they were not linked to conversion to dementia. Therefore, the observed variations of CSF amyloid levels based on caffeine consumption in our study are compatible with the lack of plasma NfL variations. NfL is well known as a non\\u2010specific biomarker for neurodegeneration. The lack of difference observed for plasma NfL also therefore suggests a lack of caffeine protection on a terminal neurodegenerative process but an upstream effect on amyloidogenic pathway and/or neuronal plasticity.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 27964, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Several mechanisms might indeed explain the effect of caffeine on amyloid pathology revealed by our CSF biomarker results. In vitro data by Sharma et\\u00a0al. showed that the hydrophobic core\\u2010recognition motif of amyloid formation was physically blocked by caffeine, thereby abolishing self\\u2010assembly formation. Also, Janitschke et\\u00a0al. showed that caffeine was able to decrease A\\u03b2 levels by shifting the amyloid precursor protein (APP) processing from the A\\u03b2\\u2010producing amyloidogenic to the non\\u2010amyloidogenic pathway. Accordingly, several studies showed that amyloid mice treated with chronic caffeine administration had lower hippocampal A\\u03b2 levels associated with a reduced presenilin 1 (PS1) and \\u03b2\\u2010secretase (BACE1) levels. These observations are likely in line with the ability of the A2A receptor, an important pharmacological target of caffeine, to modulate A\\u03b2 production in vitro and in vivo. Further, in addition to acting on processes driving amyloid peptide formation and/or aggregation, caffeine could also enhance brain amyloid clearance in C57Bl6/J mice. In agreement with this, as hypothesized, caffeine would be likely to increase the production of CSF, enhancing CSF turnover and, subsequently, presumably improving A\\u03b2 brain clearance (for a review see Mehta and Mehta). This attractive hypothesis, however, awaits definitive verification. Non\\u2010mutually exclusively, the effect of caffeine on amyloid load might also rely on its ability to restrain neuroinflammatory processes, which are known to impair the clearance of amyloid lesions by glial cells (see Launay et\\u00a0al. and Hansen et\\u00a0al. for reviews).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 29596, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Puzzlingly, caffeine does not seem to impact CSF tau and p\\u2010tau. The underlying reasons remain unclear. Actually, in sharp contrast to amyloid model studies, only a few works tried to link caffeine to tau. In a previous in vitro study, caffeine was shown to block the cell cycle at the G1 phase in neuroblastoma cells and lead to a decrease in tau phosphorylation. But the model used might not be relevant to AD. Only one study by our team demonstrated the beneficial impact of caffeine in a mouse model of AD\\u2010like tauopathy. In that work, we showed that caffeine improved memory, slightly decreasing hippocampal p\\u2010tau, without any effect on tau aggregation, but showing rather a strong impact on tau truncation. However, another study performed in a diabetes model showing increased p\\u2010tau supported the notion that caffeine exacerbates tau hyperphosphorylation by promoting hypothermia. Therefore, the link between caffeine and tau remains unclear and warrants further investigation.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 30588, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Overall, the strength of the present study is that it allows for the possibility of addressing the impact of habitual caffeine consumption in a cohort including only MCI and AD patients very well described at the clinical, neuropsychological, MRI, and CSF biomarker levels, as well as for the possibility of adjusting statistical analyses of known confounding factors for AD (APOE \\u03b54, age, sex, education level) and caffeine intake (smoking). However, our study had several limitations. First, we used a survey previously used in patients with Huntington's disease (HD). As indicated in our initial paper, the reliability of the survey was assessed by a retest and found to be excellent. However, that survey was not re\\u2010validated in the present population of MCI and AD patients. Nevertheless, it is particularly noteworthy that the survey was completed by both patients and caregivers, minimizing the risk of error. We are therefore confident of the reliability of our survey, since coffee intake is less prone to being misreported due to its long\\u2010term habitual nature.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31665, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Notably, the median consumption measured in the BALTAZAR cohort (216\\u00a0mg/day) is very close to what we that measured in our previous HD study (median 190\\u00a0mg/day) as well as in another ongoing yet unpublished study on patients diagnosed with amyotrophic lateral sclerosis (median 250\\u00a0mg/day; not shown). One limit of the present study is, however, that we only estimated the intake at inclusion and did not determine consumption of the previous 10 or 20 years, but our consumption data fit with the reported habitual caffeine consumption in the overall French population by Fredholm et\\u00a0al. (239\\u00a0mg/day). This supports the idea that, despite our survey being only used to quantify caffeine consumption at inclusion, the values may very well reflect long\\u2010lasting habitual caffeine consumption. This question is, however, relevant since patients may radically change their lifestyles with the diagnosis of life\\u2010threatening diseases but also because caffeine\\u2010associated neuroprotection may result from long\\u2010term caffeine intake rather than from the actual caffeine intake. In a retrospective case\\u2010control study by Maia and Mendonca in Portuguese individuals, daily caffeine consumption was calculated for the period from early adulthood (age 25 years old) to 20 years before diagnosis of AD, but also for the period after the diagnosis of AD up to the time of the survey at inclusion. In this study, patients with AD had an average daily caffeine intake during the 20 years that preceded diagnosis of AD of 73.9\\u00a0\\u00b1\\u00a097.9\\u00a0mg, whereas the controls had an average daily caffeine intake of 198.7\\u00a0\\u00b1\\u00a0135.7\\u00a0mg during the corresponding 20 years of their lifetime, the latter amount being actually comparable to our patients\\u2019 consumption levels. During the period from young adulthood (25 years old) to 20 years before diagnosis, in Maia's study, AD patients already had a lower average daily caffeine intake. The average daily caffeine intake further declined in AD patients after the diagnosis, reaching a value of 36.3\\u00a0\\u00b1\\u00a064.1\\u00a0mg, while matched controls remained stable.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33750, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"In another study by Cao et\\u00a0al., MCI patients converting to AD exhibited lower plasma caffeine levels compared with non\\u2010converter MCI patients. Therefore, differences in caffeine consumption before the onset of any memory decline may in fact exist. Nevertheless, our current data do not fit at all with these observations. Indeed, at baseline, we did not find a statistical difference in caffeine intake between naMCI, aMCI, and AD patients, suggesting that the development of AD is not associated with a change in consumption, at least when compared with MCI patients. Further, the median caffeine consumption calculated for MCI patients that convert to AD (199.5\\u00a0mg/day) or not (217.7\\u00a0mg/day) was similar (p\\u00a0=\\u00a00.88). Therefore, in our cohort, it seems that we did not observe a drop in caffeine consumption linked to the development of memory deficits or AD. Our results are rather in line with the study of Solfrizzi and al., where no significant variations of caffeine consumption could be observed in MCI patients during a mean follow\\u2010up of 3 years.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34813, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"The BALTAZAR cohort is a prospective study, and although the existing literature mostly evaluates the impact of caffeine at baseline, evaluating cognition over 3 years from inclusion of MCI and AD patients would have been essential to estimate the potential consumption changes versus cognitive decline as suggested by Solfrizzi et\\u00a0al. The lack of consumption data during follow\\u2010up visits in the present multicentric study precludes performing an association study between caffeine intake and decline without bias. This is another limit, and prospective studies on cognition, biomarkers, and pathological evolution in MCI and AD patients should be carefully paired with a longitudinal evaluation of caffeine consumption. Finally, while in our study the sample size was larger than in the previous study of Travasos et\\u00a0al., it remained limited, in particular regarding the naMCI group. Another limitation of our cross\\u2010sectional study is that the associations observed did not allow us to establish with certainty a cause\\u2010and\\u2010effect relationship between caffeine consumption and the effects observed. Causality can only be demonstrated by a randomized double\\u2010blind interventional trial comparing patients treated with a caffeine arm or a placebo. This is the reason why we set up the interventional Effect of CAFfeine on Cognition in Alzheimer's Disease clinical phase 3 trial (NCT04570085), which is currently recruiting.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36246, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Paris, EA 4468, APHP, Hopital Broca, Memory Resource and Research Centre of de Paris\\u2010Broca\\u2010Ile de France, F\\u201075013 Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36396, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Strasbourg, H\\u00f4pitaux Universitaires de Strasbourg, CM2R, p\\u00f4le de G\\u00e9riatrie, Laboratoire ICube, FMTS, CNRS, \\u00e9quipe IMIS, F\\u201067000 Strasbourg, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36565, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Montpellier, CHU Montpellier, Memory Research and Resources center of Montpellier, department of Neurology, Inserm INM NeuroPEPs team, excellence center of neurodegenerative disorders, F\\u201034000 Montpellier, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36796, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Univ. Lille, Inserm, CHU Lille, U1172\\u2010LilNCog, LiCEND, LabEx DISTALZ, F\\u201059000 Lille, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36893, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Univ. Lille, Inserm U1171 Degenerative and Vascular Cognitive Disorders, F\\u201059000 Lille, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36991, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 Paris\\u2010Saclay, APHP, H\\u00f4pital Paul Brousse, d\\u00e9partement de g\\u00e9riatrie, \\u00c9quipe MOODS, Inserm 1178, F\\u201094800 Villejuif, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37133, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Centre Hospitalier de la C\\u00f4te Basque, Department of Gerontology, F\\u201064100 Bayonne, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37226, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Nantes, EA 4334 Movement\\u2010Interactions\\u2010Performance, CHU Nantes, Memory Research Resource Center of Nantes, Department of clinical gerontology, F\\u201044000 Nantes, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37413, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Sorbonne Universit\\u00e9, APHP, Centre Hospitalier Dupuytren, Department of G\\u00e9rontology 2, F\\u201091210 Draveil, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37528, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHU de Nimes, H\\u00f4pital Caremeau, Neurology Department, F\\u201030029 Nimes, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37608, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"H\\u00f4pital L\\u00e9opold Bellan, Service de Neuro\\u2010Psycho\\u2010G\\u00e9riatrie, Memory Clinic, F\\u201075014 Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37714, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Univ. Lille, CHU de Lille, Memory Resource and Research Centre of Lille, Department of Neurology, F\\u201059000 Lille, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37837, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Paris, APHP, Groupe Hospitalier Saint Louis\\u2010Lariboisi\\u00e8reFernand Widal, Center of Cognitive Neurology, F\\u201075010 Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37982, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Toulouse III, CHU La Grave\\u2010Casselardit, Memory Resource and Research Centre of Midi\\u2010Pyr\\u00e9n\\u00e9es, F\\u201031300 Toulouse, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38125, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Lorraine, CHRU de Nancy, Memory Resource and Research Centre of Lorraine, F\\u201054500 Vandoeuvre\\u2010l\\u00e8s\\u2010Nancy, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38259, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Paris, APHP, H\\u00f4pital europeen Georges Pompidou, Service de G\\u00e9riatrie, F\\u201075015, Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38372, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHU de Poitiers, Memory Resource and Research Centre of Poitiers, F\\u201086000 Poitiers, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38466, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHU Charles Nicolle, Memory Resource and Research Centre of HauteNormandie, F\\u201076000 Rouen, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38567, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"APHP, Centre Hospitalier \\u00c9mile\\u2010Roux, Department of G\\u00e9rontology 1, F\\u201094450 Limeil\\u2010Br\\u00e9vannes, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38676, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHU d'Amiens\\u2010Picardie, Memory Resource and Research Centre of AmiensPicardie, F\\u201080000 Amiens, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38782, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Sorbonne Universit\\u00e9, APHP, H\\u00f4pitaux Universitaires Pitie\\u2010Salp\\u00eatri\\u00e8re\\u2010Charles\\u2010Foix, Service de G\\u00e9riatrie Ambulatoire, F\\u201075013 Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38935, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 C\\u00f4te d'Azur, CHU de Nice, Memory Research Resource Center of Nice, CoBTek lab, F\\u201006100 Nice, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39051, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHU de Limoges, Memory Research Resource Center of Limoges, F\\u201087000 Limoges, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39138, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Normandie Univ, UNIROUEN, Inserm U1245, CHU de Rouen, Department of Neurology and CNR\\u2010MAJ, Normandy Center for Genomic and Personalized Medicine, CIC\\u2010CRB1404, F\\u201076000, Rouen, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39327, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHU de Besan\\u00e7on, Memory Resource and Research Centre of Besan\\u00e7on Franche\\u2010Comt\\u00e9, F\\u201025000 Besan\\u00e7on, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39441, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Reims Champagne\\u2010Ardenne, EA 3797, CHU de Reims, Memory Resource and Research Centre of Champagne\\u2010Ardenne, F\\u201051100 Reims, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39591, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHU d'Angers, Memory Resource and Research Centre of Angers, F\\u201049000 Angers, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39678, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHRU de Tours, Memory Resource and Research Centre of Tours, F\\u201037000 Tours, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39764, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Strasbourg, CHRU de Strasbourg, Memory Resource and Research Centre of Strasbourg/Colmar, Inserm U\\u2010118, F\\u201067000 Strasbourg, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39915, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Univ Paris Est Creteil, EA 4391 Excitabilit\\u00e9 Nerveuse et Th\\u00e9rapeutique, CHU Henri Mondor, Department of Neurology, F\\u201094000 Cr\\u00e9teil, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 40060, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"H\\u00f4pital Fondation Rothschild, Department of Neurology, F\\u201075019 Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 40141, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHU d'Amiens\\u2010Picardie, Department of Gerontology, F\\u201080000 Amiens, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 40219, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Sorbonne Universit\\u00e9, APHP, H\\u00f4pitaux Universitaires Pitie\\u2010Salp\\u00eatri\\u00e8re\\u2010Charles Foix, Memory Resource and Research Centre, Centre des Maladies Cognitives et Comportementales IM2A, Inserm UMR 8256, F\\u201075013 Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 40446, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 Fran\\u00e7ois\\u2010Rabelais de Tours, CHRU de Tours, Memory Resource and Research Centre of Tours, Inserm CIC 1415, F\\u201037000 Tours, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 40592, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Sorbonne Universit\\u00e9, APHP, H\\u00f4pitaux Universitaires Pitie\\u2010Salp\\u00eatri\\u00e8re\\u2010Charles Foix, Memory Resource and Research Centre, Centre des Maladies Cognitives et Comportementales IM2A, F\\u201075013 Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 40802, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 Bourgogne Franche\\u2010Comt\\u00e9, Laboratoire de Recherches Int\\u00e9gratives en Neurosciences et Psychologie Cognitive, CHU de Besan\\u00e7on, Memory Resource and Research Centre of Besan\\u00e7on Franche\\u2010Comt\\u00e9, F\\u201025000 Besan\\u00e7on, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 41039, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 Fran\\u00e7ois\\u2010Rabelais de Tours, CHRU de Tours, UMR Inserm U1253, F\\u201037000 Tours, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 41140, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Limoges, EA 6310 HAVAE, CHU de Limoges, Memory Research Resource Center of Limoges, F\\u201087000 Limoges, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 41266, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 Paris\\u2010Saclay, Neurospin, CEA, CNRS, cati\\u2010neuroimaging.com, CATI Multicenter Neuroimaging Platform, F\\u201091190 Gif\\u2010sur\\u2010Yvette, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 41419, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Paris, Institute of Psychiatric and Neurosciences, Inserm UMR\\u2010S 1266, F\\u201075014 Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 41531, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Montpellier, CHU Montpellier, LBPC, Inserm, F\\u201034000 Montpellier, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 41621, \"infons\": {\"section_type\": \"COMP_INT\", \"type\": \"title_1\"}, \"text\": \"CONFLICT OF INTEREST STATEMENT\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 41652, \"infons\": {\"section_type\": \"COMP_INT\", \"type\": \"paragraph\"}, \"text\": \"David Blum DB is a (non\\u2010appointed) member of the scientific advisory board of Marvel Biosciences Corp. developing an A2AR antagonist but has no conflict of interest regarding the present work. Olivier Hanon received personal payment from Bayer, Servier, AstraZeneca, Boston Scientific, Vifor, BMS, Boehringer\\u2010Ingelheim, and Pfizer for lectures and/or consulting services. Jean Sebastien Vidal received payment from Bayer for lectures made to a non\\u2010profit medical association. Sylvain Lehmann received for his institution support from the following: H2020 MARIE SK\\u0141ODOWSKA\\u2010CURIE \\u201cMIRIADE Multi\\u2010omics Interdisciplinary Research Integration to Address DEmentia diagnosis,\\u201d ANR Flash Covid: \\u201cProteoCOVID: Clinical proteomic characterization of the SARS\\u2010CoV\\u20102 Spike protein to optimize its detection and the development of serological assays,\\u201d ANR \\u201cSilk_road: The Stable Isotope Labeling Kinetics (SILK) road to investigate human protein turnover in blood and cerebrospinal fluid,\\u201d EUROMET EMPIR \\u201cNeuroMet2 project: Metrology and Innovation for early diagnosis and accurate stratification of patients with neurodegenerative diseases.\\u201d During the past 36 months, he had a patent issued for \\u201cProc\\u00e9d\\u00e9 de pr\\u00e9paration d'un \\u00e9chantillon peptidique\\u201d Brevet INPI n\\u00b01905247 du 20/05/2019 du CHU DE MONTPELLIER, UNIVERSIT\\u00c9 DE MONTPELLIER and SPOT TO LAB. He received personal payment for participating on the Roche Diagnostic board on CSF biomarkers. St\\u00e9phanie Bombois, Bernadette Allinquant, Christiane Baret\\u2010Rose, Jean\\u2010Marc Tr\\u00e9luyer, Hendy Abdoul, Patrick Gel\\u00e9, Christine Delmaire, Jean\\u2010Fran\\u00e7ois Mangin, and Evelyne Galbrun have no conflicts of interest. Fred\\u00e9ric Blanc received honoraria from Roche and Biogen for presentations. He received payment to his institution as the national coordinator for the clinical trial DELPHIA for patients with dementia with Lewy bodies (Eisai). He received payment to his institution as the national coordinator for the clinical trial GRADUATE for patients with AD. Luc Bu\\u00e9e received support for the present manuscript from LabEx DISTALZ. He received grants or contracts from the French National Research Agency (ANR) Fondation pour la Recherche M\\u00e9dicale (FRM). In the past 36 months, he had a patent on anti\\u2010tau therapy issued. Jacques Touchon received payment or honoraria as chairman of CTAD. He received contracts from Regenlife and consulting fees from Regenlife. He is chairman of JT Conseil society. Jacques Hugon received grants or contracts from Protekt Therapeutics and consulting fees from Protekt Therapeutics. He is principal investigator of RECAGE project European Union H20/20 program and he is member of the scientific board of Fondation Philippe Chatrier, Paris, France. Bruno Vellas received grants or contracts from Biogen, Roche, and Lilly; consulting fees from Roche, Lily, Biogen, and Cerellis; and is part of WHO's ICOPE program (unpaid position). AthanBase Benetos is the president of the European Geriatric Medicine Society (unpaid position). He received support for attending meetings and/or travel from Fukuda company, for the Congress of the European Society of Hypertension, and received royalties or licenses from Cambridge University Editions. Gilles Berrut received a grant from Boehringer Ingelheim and consulting fees from Boehringer Ingelheim, Smart macadam Institut, bien vieillir Korian. Elena Paillaud has no conflicts of interest. David Wallon, Giovanni Castelnovo, Lisette Volpe\\u2010Gillot, Marc Paccalin, Philippe Robert, and Vincent Camus have no conflicts of interest. Olivier Godefroy received support to his institution for attending meetings and/or travel from BRISTOL\\u2010MYERS SQUIBB, ROCHE SAS, BIOGEN FRANCE SAS. Jo\\u00ebl Belmin received consulting fees from Pfizer and honoraria from Novartis Pharmaceuticals. Pierre Vandel is president of the \\u201cSoci\\u00e9t\\u00e9 Francophone de Psychog\\u00e9riatrie et Psychiatrie de la Personne Ag\\u00e9e\\u201d (SF3PA) and received consulting fees from Eisai. Jean\\u2010Luc Novella, Emmanuelle Duron, Anne\\u2010Sophie Rigaud, Susanna Schraen\\u2010Maschke, Bernard Sablonni\\u00e8re, and Audrey Gabelle have no conflicts of interest. Author disclosures are available in the supporting information.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 45874, \"infons\": {\"section_type\": \"COMP_INT\", \"type\": \"title_1\"}, \"text\": \"CONSENT STATEMENT\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 45892, \"infons\": {\"section_type\": \"COMP_INT\", \"type\": \"paragraph\"}, \"text\": \"All participants or their legal guardians gave written informed consent.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 45965, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"title_1\"}, \"text\": \"Supporting information\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 45988, \"infons\": {\"section_type\": \"REF\", \"type\": \"title\"}, \"text\": \"REFERENCES\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 45999, \"infons\": {\"fpage\": \"603\", \"lpage\": \"615\", \"pub-id_doi\": \"10.1016/j.cell.2015.12.056\", \"pub-id_pmid\": \"26871627\", \"section_type\": \"REF\", \"source\": \"Cell\", \"type\": \"ref\", \"volume\": \"164\", \"year\": \"2016\"}, \"text\": \"The cellular phase of Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46041, \"infons\": {\"fpage\": \"2716\", \"lpage\": \"2727\", \"pub-id_doi\": \"10.1038/s41380-023-02076-1\", \"pub-id_pmid\": \"37131074\", \"section_type\": \"REF\", \"source\": \"Mol Psychiatry\", \"type\": \"ref\", \"volume\": \"28\", \"year\": \"2023\"}, \"text\": \"Step by step: towards a better understanding of the genetic architecture of Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46137, \"infons\": {\"fpage\": \"137\", \"lpage\": \"152\", \"pub-id_doi\": \"10.1038/nrneurol.2011.2\", \"pub-id_pmid\": \"21304480\", \"section_type\": \"REF\", \"source\": \"Nat Rev Neurol\", \"type\": \"ref\", \"volume\": \"7\", \"year\": \"2011\"}, \"text\": \"Epidemiology of Alzheimer disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46171, \"infons\": {\"fpage\": \"83\", \"lpage\": \"133\", \"pub-id_pmid\": \"10049999\", \"section_type\": \"REF\", \"source\": \"Pharmacol Rev\", \"type\": \"ref\", \"volume\": \"51\", \"year\": \"1999\"}, \"text\": \"Actions of caffeine in the brain with special reference to factors that contribute to its widespread use\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46276, \"infons\": {\"fpage\": \"1891\", \"lpage\": \"1904\", \"pub-id_doi\": \"10.1056/NEJMoa1112010\", \"pub-id_pmid\": \"22591295\", \"section_type\": \"REF\", \"source\": \"N Engl J Med\", \"type\": \"ref\", \"volume\": \"366\", \"year\": \"2012\"}, \"text\": \"Association of coffee drinking with total and cause\\u2010specific mortality\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46349, \"infons\": {\"fpage\": \"201\", \"lpage\": \"203\", \"pub-id_doi\": \"10.1038/nn.3623\", \"pub-id_pmid\": \"24413697\", \"section_type\": \"REF\", \"source\": \"Nat Neurosci\", \"type\": \"ref\", \"volume\": \"17\", \"year\": \"2014\"}, \"text\": \"Post\\u2010study caffeine administration enhances memory consolidation in humans\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46426, \"infons\": {\"fpage\": \"1019\", \"lpage\": \"1055\", \"pub-id_doi\": \"10.1111/jnc.13724\", \"pub-id_pmid\": \"27365148\", \"section_type\": \"REF\", \"source\": \"J Neurochem\", \"type\": \"ref\", \"volume\": \"139\", \"year\": \"2016\"}, \"text\": \"How does adenosine control neuronal dysfunction and neurodegeneration?\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46497, \"infons\": {\"fpage\": \"369\", \"lpage\": \"378\", \"pub-id_doi\": \"10.1056/NEJMra1816604\", \"pub-id_pmid\": \"32706535\", \"section_type\": \"REF\", \"source\": \"N Engl J Med\", \"type\": \"ref\", \"volume\": \"383\", \"year\": \"2020\"}, \"text\": \"Coffee, Caffeine, and Health\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46526, \"infons\": {\"fpage\": \"536\", \"lpage\": \"545\", \"pub-id_doi\": \"10.1212/01.wnl.0000266670.35219.0c\", \"pub-id_pmid\": \"17679672\", \"section_type\": \"REF\", \"source\": \"Neurology\", \"type\": \"ref\", \"volume\": \"69\", \"year\": \"2007\"}, \"text\": \"The neuroprotective effects of caffeine: a prospective population study (the Three City Study)\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46621, \"infons\": {\"fpage\": \"226\", \"lpage\": \"232\", \"pub-id_doi\": \"10.1038/sj.ejcn.1602495\", \"pub-id_pmid\": \"16929246\", \"section_type\": \"REF\", \"source\": \"Eur J Clin Nutr\", \"type\": \"ref\", \"volume\": \"61\", \"year\": \"2007\"}, \"text\": \"Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46727, \"infons\": {\"fpage\": \"S175\", \"issue\": \"1\", \"lpage\": \"185\", \"pub-id_doi\": \"10.3233/JAD-2010-091303\", \"pub-id_pmid\": \"20182036\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"20\", \"year\": \"2010\"}, \"text\": \"Caffeine intake is associated with a lower risk of cognitive decline: a cohort study from Portugal\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46826, \"infons\": {\"fpage\": \"553\", \"lpage\": \"566\", \"pub-id_doi\": \"10.3233/JAD-2011-110431\", \"pub-id_pmid\": \"21841254\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"27\", \"year\": \"2011\"}, \"text\": \"Gender differences in tea, coffee, and cognitive decline in the elderly: the Cardiovascular Health Study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46931, \"infons\": {\"fpage\": \"413\", \"lpage\": \"421\", \"pub-id_doi\": \"10.3233/JAD-122371\", \"pub-id_pmid\": \"23422357\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"35\", \"year\": \"2013\"}, \"text\": \"Caffeine and cognitive decline in elderly women at high vascular risk\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47001, \"infons\": {\"fpage\": \"889\", \"lpage\": \"899\", \"pub-id_doi\": \"10.3233/JAD-150333\", \"pub-id_pmid\": \"26401769\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"47\", \"year\": \"2015\"}, \"text\": \"Coffee consumption habits and the risk of mild cognitive impairment: the Italian Longitudinal Study on Aging\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47110, \"infons\": {\"fpage\": \"491\", \"lpage\": \"500\", \"pub-id_doi\": \"10.3233/JAD-150693\", \"pub-id_pmid\": \"26682686\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"50\", \"year\": \"2016\"}, \"text\": \"Association between coffee consumption and incident risk of disabling dementia in elderly Japanese: the Ohsaki Cohort 2006 Study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47239, \"infons\": {\"fpage\": \"387\", \"lpage\": \"395\", \"pub-id_doi\": \"10.1007/s00234-017-1803-5\", \"pub-id_pmid\": \"28289811\", \"section_type\": \"REF\", \"source\": \"Neuroradiology\", \"type\": \"ref\", \"volume\": \"59\", \"year\": \"2017\"}, \"text\": \"Caffeine impact on working memory\\u2010related network activation patterns in early stages of cognitive decline\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47348, \"infons\": {\"fpage\": \"2158\", \"lpage\": \"2168\", \"pub-id_doi\": \"10.1016/j.clnu.2019.09.003\", \"pub-id_pmid\": \"31582197\", \"section_type\": \"REF\", \"source\": \"Clin Nutr\", \"type\": \"ref\", \"volume\": \"39\", \"year\": \"2020\"}, \"text\": \"Association between caffeine intake and cognitive function in adults; effect modification by sex: data from National Health and Nutrition Examination Survey (NHANES) 2013\\u20102014\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47526, \"infons\": {\"fpage\": \"840\", \"pub-id_doi\": \"10.3390/nu12030840\", \"pub-id_pmid\": \"32245123\", \"section_type\": \"REF\", \"source\": \"Nutrients\", \"type\": \"ref\", \"volume\": \"12\", \"year\": \"2020\"}, \"text\": \"Association of coffee, decaffeinated coffee and caffeine intake from coffee with cognitive performance in older adults: National Health and Nutrition Examination Survey (NHANES) 2011\\u20102014\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47716, \"infons\": {\"fpage\": \"3737\", \"pub-id_doi\": \"10.3390/molecules27123737\", \"pub-id_pmid\": \"35744865\", \"section_type\": \"REF\", \"source\": \"Molecules\", \"type\": \"ref\", \"volume\": \"27\", \"year\": \"2022\"}, \"text\": \"Neuroprotective effect of caffeine in Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47774, \"infons\": {\"fpage\": \"445\", \"lpage\": \"453\", \"pub-id_doi\": \"10.1093/aje/kwf074\", \"pub-id_pmid\": \"12196314\", \"section_type\": \"REF\", \"source\": \"Am J Epidemiol\", \"type\": \"ref\", \"volume\": \"156\", \"year\": \"2002\"}, \"text\": \"Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47879, \"infons\": {\"fpage\": \"377\", \"lpage\": \"382\", \"pub-id_doi\": \"10.1046/j.1468-1331.2002.00421.x\", \"pub-id_pmid\": \"12099922\", \"section_type\": \"REF\", \"source\": \"Eur J Neurol\", \"type\": \"ref\", \"volume\": \"9\", \"year\": \"2002\"}, \"text\": \"Does caffeine intake protect from Alzheimer's disease?\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47934, \"infons\": {\"fpage\": \"85\", \"lpage\": \"91\", \"pub-id_doi\": \"10.3233/JAD-2009-0920\", \"pub-id_pmid\": \"19158424\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"16\", \"year\": \"2009\"}, \"text\": \"Midlife coffee and tea drinking and the risk of late\\u2010life dementia: a population\\u2010based CAIDE study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48037, \"infons\": {\"fpage\": \"21\", \"lpage\": \"26\", \"pub-id_doi\": \"10.1097/WAD.0000000000000087\", \"pub-id_pmid\": \"25710250\", \"section_type\": \"REF\", \"source\": \"Alzheimer Dis Assoc Disord\", \"type\": \"ref\", \"volume\": \"30\", \"year\": \"2016\"}, \"text\": \"Lifestyle factors and dementia in the oldest\\u2010old: the 90+ Study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48103, \"infons\": {\"fpage\": \"100\", \"lpage\": \"107\", \"pub-id_doi\": \"10.1007/s12603-020-1436-y\", \"pub-id_pmid\": \"33367469\", \"section_type\": \"REF\", \"source\": \"J Nutr Health Aging\", \"type\": \"ref\", \"volume\": \"25\", \"year\": \"2021\"}, \"text\": \"Caffeine consumption and behavioral symptoms in nursing home residents: a cross\\u2010sectional analysis\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48204, \"infons\": {\"fpage\": \"S151\", \"issue\": \"1\", \"lpage\": \"159\", \"pub-id_doi\": \"10.3233/JAD-2010-1409\", \"pub-id_pmid\": \"20182052\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"20\", \"year\": \"2010\"}, \"text\": \"Caffeine, cognition, and socioeconomic status\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48250, \"infons\": {\"fpage\": \"451\", \"lpage\": \"461\", \"pub-id_doi\": \"10.3233/JAD-160116\", \"pub-id_pmid\": \"27163820\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"53\", \"year\": \"2016\"}, \"text\": \"Association of coffee consumption with MRI markers and cognitive function: a population\\u2010based study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48352, \"infons\": {\"fpage\": \"834\", \"lpage\": \"846\", \"pub-id_doi\": \"10.1002/ana.26349\", \"pub-id_pmid\": \"35288978\", \"section_type\": \"REF\", \"source\": \"Ann Neurol\", \"type\": \"ref\", \"volume\": \"91\", \"year\": \"2022\"}, \"text\": \"Caffeine consumption and dementia: are Lewy bodies the link?\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48413, \"infons\": {\"fpage\": \"852\", \"pub-id_doi\": \"10.3390/nu10070852\", \"pub-id_pmid\": \"29966314\", \"section_type\": \"REF\", \"source\": \"Nutrients\", \"type\": \"ref\", \"volume\": \"10\", \"year\": \"2018\"}, \"text\": \"Prospective associations between single foods, Alzheimer's dementia and memory decline in the elderly\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48515, \"infons\": {\"fpage\": \"941\", \"lpage\": \"952\", \"pub-id_doi\": \"10.1016/j.neuroscience.2006.07.021\", \"pub-id_pmid\": \"16938404\", \"section_type\": \"REF\", \"source\": \"Neuroscience\", \"type\": \"ref\", \"volume\": \"142\", \"year\": \"2006\"}, \"text\": \"Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta\\u2010amyloid production\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48623, \"infons\": {\"fpage\": \"661\", \"lpage\": \"680\", \"pub-id_doi\": \"10.3233/JAD-2009-1087\", \"pub-id_pmid\": \"19581722\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"17\", \"year\": \"2009\"}, \"text\": \"Caffeine reverses cognitive impairment and decreases brain amyloid\\u2010beta levels in aged Alzheimer's disease mice\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48737, \"infons\": {\"fpage\": \"2079\", \"lpage\": \"2090\", \"pub-id_doi\": \"10.1016/j.neurobiolaging.2014.03.027\", \"pub-id_pmid\": \"24780254\", \"section_type\": \"REF\", \"source\": \"Neurobiol Aging\", \"type\": \"ref\", \"volume\": \"35\", \"year\": \"2014\"}, \"text\": \"Beneficial effects of caffeine in a transgenic model of Alzheimer's disease\\u2010like tau pathology\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48834, \"infons\": {\"elocation-id\": \"744872\", \"pub-id_doi\": \"10.3389/fnagi.2021.744872\", \"pub-id_pmid\": \"34867277\", \"section_type\": \"REF\", \"source\": \"Front Aging Neurosci\", \"type\": \"ref\", \"volume\": \"13\", \"year\": \"2021\"}, \"text\": \"Higher coffee consumption is associated with slower cognitive decline and less cerebral A\\u03b2\\u2010amyloid accumulation over 126 months: data from the Australian imaging, biomarkers, and lifestyle study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49032, \"infons\": {\"fpage\": \"270\", \"pub-id_doi\": \"10.1038/s41398-019-0604-5\", \"pub-id_pmid\": \"31641100\", \"section_type\": \"REF\", \"source\": \"Transl Psychiatry\", \"type\": \"ref\", \"volume\": \"9\", \"year\": \"2019\"}, \"text\": \"Coffee intake and decreased amyloid pathology in human brain\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49093, \"infons\": {\"fpage\": \"483\", \"lpage\": \"493\", \"pub-id_doi\": \"10.3233/JAD-220591\", \"pub-id_pmid\": \"37038808\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"93\", \"year\": \"2023\"}, \"text\": \"Association of caffeine consumption and brain amyloid positivity in cognitively normal older adults\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49193, \"infons\": {\"fpage\": \"1069\", \"lpage\": \"1078\", \"pub-id_doi\": \"10.3233/JAD-150374\", \"pub-id_pmid\": \"26401784\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"47\", \"year\": \"2015\"}, \"text\": \"Does caffeine consumption modify cerebrospinal fluid amyloid\\u2010\\u03b2 levels in patients with Alzheimer's disease?\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49304, \"infons\": {\"fpage\": \"939\", \"lpage\": \"939\", \"pub-id_doi\": \"10.1212/WNL.34.7.939\", \"pub-id_pmid\": \"6610841\", \"section_type\": \"REF\", \"source\": \"Neurology\", \"type\": \"ref\", \"volume\": \"34\", \"year\": \"1984\"}, \"text\": \"Clinical diagnosis of Alzheimer's disease: report of the NINCDS\\u2010ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49484, \"infons\": {\"fpage\": \"303\", \"lpage\": \"308\", \"pub-id_doi\": \"10.1001/archneur.56.3.303\", \"pub-id_pmid\": \"10190820\", \"section_type\": \"REF\", \"source\": \"Arch Neurol\", \"type\": \"ref\", \"volume\": \"56\", \"year\": \"1999\"}, \"text\": \"Mild cognitive impairment: clinical characterization and outcome\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49549, \"infons\": {\"fpage\": \"858\", \"lpage\": \"868\", \"pub-id_doi\": \"10.1016/j.jalz.2018.01.004\", \"pub-id_pmid\": \"29458036\", \"section_type\": \"REF\", \"source\": \"Alzheimers Dement\", \"type\": \"ref\", \"volume\": \"14\", \"year\": \"2018\"}, \"text\": \"Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49643, \"infons\": {\"fpage\": \"183\", \"lpage\": \"194\", \"pub-id_doi\": \"10.1111/j.1365-2796.2004.01388.x\", \"pub-id_pmid\": \"15324362\", \"section_type\": \"REF\", \"source\": \"J Intern Med\", \"type\": \"ref\", \"volume\": \"256\", \"year\": \"2004\"}, \"text\": \"Mild cognitive impairment as a diagnostic entity\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49692, \"infons\": {\"fpage\": \"179\", \"lpage\": \"182\", \"pub-id_doi\": \"10.1016/j.nbd.2013.05.013\", \"pub-id_pmid\": \"23732677\", \"section_type\": \"REF\", \"source\": \"Neurobiol Dis\", \"type\": \"ref\", \"volume\": \"58\", \"year\": \"2013\"}, \"text\": \"Association between caffeine intake and age at onset in Huntington's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49769, \"infons\": {\"fpage\": \"2537\", \"lpage\": \"2550\", \"pub-id_doi\": \"10.1002/alz.12613\", \"pub-id_pmid\": \"35187794\", \"section_type\": \"REF\", \"source\": \"Alzheimers Dement\", \"type\": \"ref\", \"volume\": \"18\", \"year\": \"2022\"}, \"text\": \"Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: the BALTAZAR study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49884, \"infons\": {\"fpage\": \"559\", \"lpage\": \"572\", \"pub-id_doi\": \"10.3233/JAD-2012-111781\", \"pub-id_pmid\": \"22430531\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"30\", \"year\": \"2012\"}, \"text\": \"High blood caffeine levels in MCI linked to lack of progression to dementia\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49960, \"infons\": {\"fpage\": \"683\", \"lpage\": \"688\", \"pub-id_doi\": \"10.1093/gerona/gly090\", \"pub-id_pmid\": \"29982422\", \"section_type\": \"REF\", \"source\": \"J Gerontol A Biol Sci Med Sci\", \"type\": \"ref\", \"volume\": \"74\", \"year\": \"2019\"}, \"text\": \"Age modulates the association of caffeine intake with cognition and with Gray matter in elderly diabetics\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50066, \"infons\": {\"fpage\": \"1015\", \"pub-id_doi\": \"10.3389/fnins.2018.01015\", \"pub-id_pmid\": \"30686981\", \"section_type\": \"REF\", \"source\": \"Front Neurosci\", \"type\": \"ref\", \"volume\": \"12\", \"year\": \"2019\"}, \"text\": \"Impact of caffeine consumption on type 2 diabetes\\u2010induced spatial memory impairment and neurochemical alterations in the hippocampus\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50201, \"infons\": {\"fpage\": \"S143\", \"issue\": \"1\", \"lpage\": \"150\", \"pub-id_doi\": \"10.3233/JAD-2010-091228\", \"pub-id_pmid\": \"20182038\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"20\", \"year\": \"2010\"}, \"text\": \"Caffeine, diabetes, cognition, and dementia\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50245, \"infons\": {\"fpage\": \"1859\", \"lpage\": \"1867\", \"pub-id_doi\": \"10.1212/01.wnl.0000279336.36610.f7\", \"pub-id_pmid\": \"17984454\", \"section_type\": \"REF\", \"source\": \"Neurology\", \"type\": \"ref\", \"volume\": \"69\", \"year\": \"2007\"}, \"text\": \"Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50337, \"infons\": {\"fpage\": \"313\", \"lpage\": \"321\", \"pub-id_doi\": \"10.1016/j.bcp.2019.06.008\", \"pub-id_pmid\": \"31199895\", \"section_type\": \"REF\", \"source\": \"Biochem Pharmacol\", \"type\": \"ref\", \"volume\": \"166\", \"year\": \"2019\"}, \"text\": \"The physiological effects of caffeine on synaptic transmission and plasticity in the mouse hippocampus selectively depend on adenosine A1 and A2A receptors\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50493, \"infons\": {\"fpage\": \"S25\", \"lpage\": \"34\", \"pub-id_doi\": \"10.3233/JAD-2010-091384\", \"pub-id_pmid\": \"20182030\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"20\", \"year\": \"2010\"}, \"text\": \"Caffeine, adenosine receptors, and synaptic plasticity\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50548, \"infons\": {\"fpage\": \"23\", \"lpage\": \"25\", \"pub-id_doi\": \"10.1038/nn.2962\", \"section_type\": \"REF\", \"source\": \"Nat Neurosci\", \"type\": \"ref\", \"volume\": \"15\", \"year\": \"2012\"}, \"text\": \"Caffeine\\u2010induced synaptic potentiation in hippocampal CA2 neurons\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50616, \"infons\": {\"fpage\": \"1111\", \"lpage\": \"1115\", \"pub-id_doi\": \"10.1248/bpb.b17-00101\", \"pub-id_pmid\": \"28674254\", \"section_type\": \"REF\", \"source\": \"Biol Pharm Bull\", \"type\": \"ref\", \"volume\": \"40\", \"year\": \"2017\"}, \"text\": \"Caffeine increases hippocampal sharp waves in vitro\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50668, \"infons\": {\"fpage\": \"647\", \"lpage\": \"651\", \"pub-id_doi\": \"10.1007/s00221-018-5450-9\", \"pub-id_pmid\": \"30535949\", \"section_type\": \"REF\", \"source\": \"Exp Brain Res\", \"type\": \"ref\", \"volume\": \"237\", \"year\": \"2019\"}, \"text\": \"Effect of caffeine on long\\u2010term potentiation\\u2010like effects induced by quadripulse transcranial magnetic stimulation\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50787, \"infons\": {\"fpage\": \"899\", \"pub-id_doi\": \"10.3389/fphar.2017.00899\", \"pub-id_pmid\": \"29354052\", \"section_type\": \"REF\", \"source\": \"Front Pharmacol\", \"type\": \"ref\", \"volume\": \"8\", \"year\": \"2018\"}, \"text\": \"Caffeine controls glutamatergic synaptic transmission and pyramidal neuron excitability in human neocortex\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50894, \"infons\": {\"elocation-id\": \"e149371\", \"pub-id_doi\": \"10.1172/JCI149371\", \"pub-id_pmid\": \"35536645\", \"section_type\": \"REF\", \"source\": \"J Clin Invest\", \"type\": \"ref\", \"volume\": \"132\", \"year\": \"2022\"}, \"text\": \"Caffeine intake exerts dual genome\\u2010wide effects on hippocampal metabolism and learning\\u2010dependent transcription\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51009, \"infons\": {\"fpage\": \"1876\", \"lpage\": \"1900\", \"pub-id_doi\": \"10.1038/s41380-018-0110-9\", \"pub-id_pmid\": \"29950682\", \"section_type\": \"REF\", \"source\": \"Mol Psychiatry\", \"type\": \"ref\", \"volume\": \"25\", \"year\": \"2020\"}, \"text\": \"Age\\u2010related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51126, \"infons\": {\"elocation-id\": \"e20200861\", \"pub-id_doi\": \"10.1084/jem.20200861\", \"pub-id_pmid\": \"32725127\", \"section_type\": \"REF\", \"source\": \"J Exp Med\", \"type\": \"ref\", \"volume\": \"217\", \"year\": \"2020\"}, \"text\": \"Blood plasma phosphorylated\\u2010tau isoforms track CNS change in Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51209, \"infons\": {\"pub-id_doi\": \"10.1212/WNL.0000000000012513\", \"section_type\": \"REF\", \"source\": \"Neurology\", \"type\": \"ref\", \"volume\": \"97\", \"year\": \"2021\"}, \"text\": \"Associations of fully automated CSF and novel plasma biomarkers with Alzheimer disease neuropathology at autopsy\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51322, \"infons\": {\"fpage\": \"1827\", \"lpage\": \"1835\", \"pub-id_doi\": \"10.1212/WNL.0000000000003246\", \"pub-id_pmid\": \"27694257\", \"section_type\": \"REF\", \"source\": \"Neurology\", \"type\": \"ref\", \"volume\": \"87\", \"year\": \"2016\"}, \"text\": \"Plasma tau in Alzheimer disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51354, \"infons\": {\"fpage\": \"9\", \"pub-id_doi\": \"10.1186/alzrt163\", \"pub-id_pmid\": \"23551972\", \"section_type\": \"REF\", \"source\": \"Alzheimers Res Ther\", \"type\": \"ref\", \"volume\": \"5\", \"year\": \"2013\"}, \"text\": \"Plasma tau levels in Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51395, \"infons\": {\"fpage\": \"411\", \"lpage\": \"419\", \"pub-id_doi\": \"10.1136/jnnp-2022-330540\", \"pub-id_pmid\": \"37012068\", \"section_type\": \"REF\", \"source\": \"J Neurol Neurosurg Psychiatry\", \"type\": \"ref\", \"volume\": \"94\", \"year\": \"2023\"}, \"text\": \"Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51510, \"infons\": {\"elocation-id\": \"17361\", \"pub-id_doi\": \"10.3390/ijms242417361\", \"pub-id_pmid\": \"38139190\", \"section_type\": \"REF\", \"source\": \"Int J Mol Sci\", \"type\": \"ref\", \"volume\": \"24\", \"year\": \"2023\"}, \"text\": \"Blood neurofilament levels predict cognitive decline across the Alzheimer's disease continuum\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51604, \"infons\": {\"elocation-id\": \"1034684\", \"pub-id_doi\": \"10.3389/fnagi.2022.1034684\", \"pub-id_pmid\": \"36389064\", \"section_type\": \"REF\", \"source\": \"Front Aging Neurosci\", \"type\": \"ref\", \"volume\": \"14\", \"year\": \"2022\"}, \"text\": \"Neurofilaments contribution in clinic: state of the art\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51660, \"infons\": {\"fpage\": \"9019\", \"lpage\": \"9033\", \"pub-id_doi\": \"10.1021/acs.jpcb.6b03892\", \"pub-id_pmid\": \"27487451\", \"section_type\": \"REF\", \"source\": \"J Phys Chem B\", \"type\": \"ref\", \"volume\": \"120\", \"year\": \"2016\"}, \"text\": \"Action of caffeine as an amyloid inhibitor in the aggregation of A\\u03b2 16\\u201022 peptides\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51746, \"infons\": {\"fpage\": \"689\", \"pub-id_doi\": \"10.3390/biom9110689\", \"pub-id_pmid\": \"31684105\", \"section_type\": \"REF\", \"source\": \"Biomolecules\", \"type\": \"ref\", \"volume\": \"9\", \"year\": \"2019\"}, \"text\": \"Effect of caffeine and other methylxanthines on A\\u03b2\\u2010homeostasis in SH\\u2010SY5Y cells\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51831, \"infons\": {\"fpage\": \"681\", \"lpage\": \"697\", \"pub-id_doi\": \"10.3233/JAD-2009-1071\", \"pub-id_pmid\": \"19581723\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"17\", \"year\": \"2009\"}, \"text\": \"Caffeine suppresses amyloid\\u2010\\u03b2 levels in plasma and brain of Alzheimer's disease transgenic mice\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51930, \"infons\": {\"elocation-id\": \"e88508\", \"pub-id_doi\": \"10.1371/journal.pone.0088508\", \"pub-id_pmid\": \"24523906\", \"section_type\": \"REF\", \"source\": \"PLoS One\", \"type\": \"ref\", \"volume\": \"9\", \"year\": \"2014\"}, \"text\": \"Hydrogen sulfide inhibits A2A adenosine receptor agonist induced \\u03b2\\u2010Amyloid production in SH\\u2010SY5Y neuroblastoma cells via a cAMP dependent pathway\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 52081, \"infons\": {\"fpage\": \"235\", \"pub-id_doi\": \"10.3389/fnmol.2018.00235\", \"pub-id_pmid\": \"30050407\", \"section_type\": \"REF\", \"source\": \"Front Mol Neurosci\", \"type\": \"ref\", \"volume\": \"11\", \"year\": \"2018\"}, \"text\": \"Beneficial effect of a selective adenosine A2A receptor antagonist in the APPswe/PS1dE9 mouse model of Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 52204, \"infons\": {\"fpage\": \"151\", \"lpage\": \"165\", \"pub-id_doi\": \"10.3233/JAD-2012-120319\", \"pub-id_pmid\": \"22504320\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"31\", \"year\": \"2012\"}, \"text\": \"Enhanced brain amyloid\\u2010\\u03b2 clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 52332, \"infons\": {\"elocation-id\": \"617420\", \"pub-id_doi\": \"10.4061/2011/617420\", \"pub-id_pmid\": \"21660211\", \"section_type\": \"REF\", \"source\": \"Int J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"2011\", \"year\": \"2011\"}, \"text\": \"Increased cerebrospinal fluid production as a possible mechanism underlying caffeine's protective effect against Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 52465, \"infons\": {\"fpage\": \"408\", \"pub-id_doi\": \"10.3390/biomedicines11020408\", \"pub-id_pmid\": \"36830944\", \"section_type\": \"REF\", \"source\": \"Biomedicines\", \"type\": \"ref\", \"volume\": \"11\", \"year\": \"2023\"}, \"text\": \"The vascular\\u2010immune hypothesis of Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 52521, \"infons\": {\"elocation-id\": \"109379\", \"pub-id_doi\": \"10.1016/j.neuropharm.2022.109379\", \"pub-id_pmid\": \"36572177\", \"section_type\": \"REF\", \"source\": \"Neuropharmacology\", \"type\": \"ref\", \"volume\": \"226\", \"year\": \"2023\"}, \"text\": \"The role of adenosine A2A receptors in Alzheimer's disease and tauopathies\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 52596, \"infons\": {\"fpage\": \"459\", \"lpage\": \"472\", \"pub-id_doi\": \"10.1083/jcb.201709069\", \"pub-id_pmid\": \"29196460\", \"section_type\": \"REF\", \"source\": \"J Cell Biol\", \"type\": \"ref\", \"volume\": \"217\", \"year\": \"2018\"}, \"text\": \"Microglia in Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 52629, \"infons\": {\"fpage\": \"326\", \"lpage\": \"332\", \"pub-id_doi\": \"10.1007/s12031-010-9444-8\", \"pub-id_pmid\": \"20838929\", \"section_type\": \"REF\", \"source\": \"J Mol Neurosci\", \"type\": \"ref\", \"volume\": \"43\", \"year\": \"2011\"}, \"text\": \"Caffeine modulates tau phosphorylation and affects Akt signaling in postmitotic neurons\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 52717, \"infons\": {\"fpage\": \"1\", \"lpage\": \"8\", \"pub-id_doi\": \"10.1016/j.nbd.2016.10.004\", \"pub-id_pmid\": \"27793638\", \"section_type\": \"REF\", \"source\": \"Neurobiol Dis\", \"type\": \"ref\", \"volume\": \"98\", \"year\": \"2017\"}, \"text\": \"Tau hyperphosphorylation in the brain of ob/ob mice is due to hypothermia: importance of thermoregulation in linking diabetes and Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}], \"annotations\": [], \"relations\": []}]}, {\"bioctype\": \"BioCCollection\", \"source\": \"PMC\", \"date\": \"20241022\", \"key\": \"pmc.key\", \"version\": \"1.0\", \"infons\": {}, \"documents\": [{\"bioctype\": \"BioCDocument\", \"id\": \"11485411\", \"infons\": {\"license\": \"CC BY\"}, \"passages\": [{\"bioctype\": \"BioCPassage\", \"offset\": 0, \"infons\": {\"alt-title\": \"BLUM et\\u00a0al.\\n\", \"article-id_doi\": \"10.1002/alz.14169\", \"article-id_pmc\": \"11485411\", \"article-id_pmid\": \"39099181\", \"article-id_publisher-id\": \"ALZ14169\", \"fn\": \"David Blum, Susanna Schraen\\u2010Maschke, and Olivier Hanon co\\u2010directed this work.\", \"fpage\": \"6948\", \"issue\": \"10\", \"kwd\": \"Alzheimer's disease caffeine CSF biomarkers memory mild cognitive impairment\", \"license\": \"This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\", \"lpage\": \"6959\", \"name_0\": \"surname:Blum;given-names:David\", \"name_1\": \"surname:Cailliau;given-names:Emeline\", \"name_10\": \"surname:Schraen\\u2010Maschke;given-names:Susanna\", \"name_100\": \"surname:Saulnier;given-names:Isabelle\", \"name_101\": \"surname:Mondon;given-names:Karl\", \"name_102\": \"surname:Picat;given-names:Marie\\u2010Agn\\u00e8s\", \"name_103\": \"surname:Laurent;given-names:Marie\", \"name_104\": \"surname:Godefroy;given-names:Olivier\", \"name_105\": \"surname:Daheb;given-names:Rezki\", \"name_106\": \"surname:Libercier;given-names:St\\u00e9phanie\", \"name_107\": \"surname:Krabchi;given-names:Djamila\", \"name_108\": \"surname:Chupin;given-names:Marie\", \"name_109\": \"surname:Vidal;given-names:JeanS\\u00e9bastien\", \"name_11\": \"surname:Hanon;given-names:Olivier\", \"name_110\": \"surname:Chaussade;given-names:Edouard\", \"name_111\": \"surname:Baret\\u2010Rose;given-names:Christiane\", \"name_112\": \"surname:Lehmann;given-names:Sylvain\", \"name_113\": \"surname:Allinquant;given-names:Bernadette\", \"name_114\": \"surname:Schraen\\u2010Maschke;given-names:Susanna\", \"name_12\": \"surname:Hanon;given-names:Olivier\", \"name_13\": \"surname:Blanc;given-names:Fr\\u00e9d\\u00e9ric\", \"name_14\": \"surname:Boudali;given-names:Yasmina\", \"name_15\": \"surname:Gabelle;given-names:Audrey\", \"name_16\": \"surname:Touchon;given-names:Jacques\", \"name_17\": \"surname:Seux;given-names:Marie\\u2010Laure\", \"name_18\": \"surname:Lenoir;given-names:Hermine\", \"name_19\": \"surname:Bayle;given-names:Catherine\", \"name_2\": \"surname:B\\u00e9hal;given-names:H\\u00e9l\\u00e8ne\", \"name_20\": \"surname:Bombois;given-names:St\\u00e9phanie\", \"name_21\": \"surname:Delmaire;given-names:Christine\", \"name_22\": \"surname:Delbeuck;given-names:Xavier\", \"name_23\": \"surname:Moulin;given-names:Florence\", \"name_24\": \"surname:Duron;given-names:Emmanuelle\", \"name_25\": \"surname:Latour;given-names:Florence\", \"name_26\": \"surname:Plichart;given-names:Matthieu\", \"name_27\": \"surname:Pichierri;given-names:Sophie\", \"name_28\": \"surname:Orvo\\u00ebn;given-names:Galdric\", \"name_29\": \"surname:Galbrun;given-names:Evelyne\", \"name_3\": \"surname:Vidal;given-names:Jean\\u2010S\\u00e9bastien\", \"name_30\": \"surname:Castelnovo;given-names:Giovanni\", \"name_31\": \"surname:Volpe\\u2010Gillot;given-names:Lisette\", \"name_32\": \"surname:Labour\\u00e9e;given-names:Florien\", \"name_33\": \"surname:Cassagnaud;given-names:Pascaline\", \"name_34\": \"surname:Paquet;given-names:Claire\", \"name_35\": \"surname:Lala;given-names:Fran\\u00e7oise\", \"name_36\": \"surname:Vellas;given-names:Bruno\", \"name_37\": \"surname:Dumurgier;given-names:Julien\", \"name_38\": \"surname:Rigaud;given-names:Anne\\u2010Sophie\", \"name_39\": \"surname:Perret\\u2010Guillaume;given-names:Christine\", \"name_4\": \"surname:Delaby;given-names:Constance\", \"name_40\": \"surname:Alonso;given-names:Eliana\", \"name_41\": \"surname:du Boisgueheneuc;given-names:Foucaud\", \"name_42\": \"surname:Hugonot\\u2010Diener;given-names:Laurence\", \"name_43\": \"surname:Rollin\\u2010Sillaire;given-names:Adeline\", \"name_44\": \"surname:Martinaud;given-names:Olivier\", \"name_45\": \"surname:Boully;given-names:Cl\\u00e9mence\", \"name_46\": \"surname:Spivac;given-names:Yann\", \"name_47\": \"surname:Devendeville;given-names:Agn\\u00e8s\", \"name_48\": \"surname:Belmin;given-names:Jo\\u00ebl\", \"name_49\": \"surname:Robert;given-names:Philippe\", \"name_5\": \"surname:Bu\\u00e9e;given-names:Luc\", \"name_50\": \"surname:Dantoine;given-names:Thierry\", \"name_51\": \"surname:Caillard;given-names:Laure\", \"name_52\": \"surname:Wallon;given-names:David\", \"name_53\": \"surname:Hannequin;given-names:Didier\", \"name_54\": \"surname:Sastre;given-names:Nathalie\", \"name_55\": \"surname:Haffen;given-names:Sophie\", \"name_56\": \"surname:Kearney\\u2010Schwartz;given-names:Anna\", \"name_57\": \"surname:Novella;given-names:Jean\\u2010Luc\", \"name_58\": \"surname:Deramecourt;given-names:Vincent\", \"name_59\": \"surname:Chauvire;given-names:Val\\u00e9rie\", \"name_6\": \"surname:Allinquant;given-names:Bernadette\", \"name_60\": \"surname:Abitbol;given-names:Gabiel\", \"name_61\": \"surname:Schwald;given-names:Nathalie\", \"name_62\": \"surname:Hommet;given-names:Caroline\", \"name_63\": \"surname:Sellal;given-names:Fran\\u00e7ois\", \"name_64\": \"surname:Cariot;given-names:Marie\\u2010Ange\", \"name_65\": \"surname:Abdellaoui;given-names:Mohamed\", \"name_66\": \"surname:Benisty;given-names:Sarah\", \"name_67\": \"surname:Gherabli;given-names:Salim\", \"name_68\": \"surname:Anthony;given-names:Pierre\", \"name_69\": \"surname:Bloch;given-names:Fr\\u00e9d\\u00e9ric\", \"name_7\": \"surname:Gabelle;given-names:Audrey\", \"name_70\": \"surname:Charasz;given-names:Nathalie\", \"name_71\": \"surname:Chauvelier;given-names:Sophie\", \"name_72\": \"surname:Gaubert;given-names:Jean\\u2010Yves\", \"name_73\": \"surname:Sacco;given-names:Guillaume\", \"name_74\": \"surname:Guerin;given-names:Olivier\", \"name_75\": \"surname:Boddaert;given-names:Jacques\", \"name_76\": \"surname:Paccalin;given-names:Marc\", \"name_77\": \"surname:Mackowiak;given-names:Marie\\u2010Anne\", \"name_78\": \"surname:Rabus;given-names:Marie\\u2010Th\\u00e9r\\u00e8se\", \"name_79\": \"surname:Gissot;given-names:Val\\u00e9rie\", \"name_8\": \"surname:Bombois;given-names:St\\u00e9phanie\", \"name_80\": \"surname:Benetos;given-names:Athanase\", \"name_81\": \"surname:Picard;given-names:Candice\", \"name_82\": \"surname:Guillemaud;given-names:C\\u00e9line\", \"name_83\": \"surname:Berrut;given-names:Gilles\", \"name_84\": \"surname:Gervais;given-names:Claire\", \"name_85\": \"surname:Hugon;given-names:Jacques\", \"name_86\": \"surname:Michel;given-names:Jean\\u2010Marc\", \"name_87\": \"surname:David;given-names:JeanPhilippe\", \"name_88\": \"surname:Paulin;given-names:Marion\", \"name_89\": \"surname:Ousset;given-names:Pierre\\u2010Jean\", \"name_9\": \"surname:Lehmann;given-names:Sylvain\", \"name_90\": \"surname:Vandel;given-names:Pierre\", \"name_91\": \"surname:Pariel;given-names:Sylvie\", \"name_92\": \"surname:Camus;given-names:Vincent\", \"name_93\": \"surname:Chawakilian;given-names:Anne\", \"name_94\": \"surname:Kermanac'h;given-names:L\\u00e9na\", \"name_95\": \"surname:Troussiere;given-names:Anne\\u2010C\\u00e9cile\", \"name_96\": \"surname:Adam;given-names:C\\u00e9cile\", \"name_97\": \"surname:Dupuy;given-names:Diane\", \"name_98\": \"surname:Paillaud;given-names:Elena\", \"name_99\": \"surname:Briault;given-names:H\\u00e9l\\u00e8ne\", \"notes\": \"\\n\\n, , , et\\u00a0al. . . ;:\\u2013. \\n\\n\", \"pub-id_doi\": \"10.1002/alz.14169\", \"section_type\": \"TITLE\", \"source\": \"Alzheimer's Dement\", \"type\": \"front\", \"volume\": \"20\", \"year\": \"2024\"}, \"text\": \"Association of caffeine consumption with cerebrospinal fluid biomarkers in mild cognitive impairment and Alzheimer's disease: A BALTAZAR cohort study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 150, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract_title_1\"}, \"text\": \"Abstract\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 159, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract_title_1\"}, \"text\": \"INTRODUCTION\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 172, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract\"}, \"text\": \"We investigated the link between habitual caffeine intake with memory impairments and cerebrospinal fluid (CSF) biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 369, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract_title_1\"}, \"text\": \"METHODS\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 377, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract\"}, \"text\": \"MCI (N\\u00a0=\\u00a0147) and AD (N\\u00a0=\\u00a0116) patients of the Biomarker of AmyLoid pepTide and AlZheimer's diseAse Risk (BALTAZAR) cohort reported their caffeine intake at inclusion using a dedicated survey. Associations of caffeine consumption with memory impairments and CSF biomarkers (tau, p\\u2010tau181, amyloid beta 1\\u201042 [A\\u03b21\\u201042], A\\u03b21\\u201040) were analyzed using logistic and analysis of covariance models.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 780, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract_title_1\"}, \"text\": \"RESULTS\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 788, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract\"}, \"text\": \"Adjusted on Apolipoprotein E (APOE \\u03b54), age, sex, education level, and tobacco, lower caffeine consumption was associated with higher risk to be amnestic (OR: 2.49 [95% CI: 1.13 to 5.46]; p\\u00a0=\\u00a00.023) and lower CSF A\\u03b21\\u201042 (p\\u00a0=\\u00a00.047), A\\u03b21\\u201042/A\\u03b21\\u201040 (p\\u00a0=\\u00a00.040), and A\\u03b21\\u201042/p\\u2010tau181 (p\\u00a0=\\u00a00.020) in the whole cohort.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1124, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract_title_1\"}, \"text\": \"DISCUSSION\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1135, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract\"}, \"text\": \"Data support the beneficial effect of caffeine consumption to memory impairments and CSF amyloid markers in MCI and AD patients.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1264, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract_title_1\"}, \"text\": \"Highlights\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1275, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract\"}, \"text\": \"We studied the impact of caffeine consumption in the BALTAZAR cohort.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1345, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract\"}, \"text\": \"Low caffeine intake is associated with higher risk of being amnestic in MCI/AD patients.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1434, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract\"}, \"text\": \"Caffeine intake is associated with CSF biomarkers in AD patients.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1500, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"title_1\"}, \"text\": \"BACKGROUND\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1511, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"Alzheimer's disease (AD) is characterized by a progressive cognitive decline linked to both extracellular deposits of aggregated amyloid beta (A\\u03b2) peptides into plaques and the intraneuronal aggregation of hyperphosphorylated tau proteins. Besides aging, AD risk depends on various genetic and environmental factors. \", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 1832, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"Caffeine is the most widely consumed psychoactive agent worldwide via dietary intake from coffee, tea, or soda beverages. Coffee consumption has been inversely associated with total and cause\\u2010specific mortality in a large prospective cohort of participants aged 50 to 71 years at baseline (National Institutes of Health\\u2014AARP Diet and Health Study) with an 8\\u2010year follow\\u2010up. Compelling evidence supports acute caffeine's ability to increase/improve wakefulness, alertness, and memory ([6]; for a review see Cunha and van Dam et\\u00a0al.). Various longitudinal, cross\\u2010sectional, and retrospective studies support the idea that habitual coffee/caffeine consumption reduces cognitive decline in the elderly (for reviews see ref. Cunha and Yelanchezian et\\u00a0al.). Further, other works suggest that coffee/caffeine intake reduces dementia or AD risk. Caffeine consumption has also been associated with a decrease of behavioral symptoms in patients with dementia. All these observations, obtained mostly during follow\\u2010up on non\\u2010demented elderly populations, have been acknowledged in meta\\u2010analysis studies. \", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 2944, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"Although experimental works using both amyloid and tau models show the beneficial impact of caffeine on the development of AD lesions (for a review see Cunha and Yelanchezian et\\u00a0al.), it remains largely unclear whether caffeine consumption is associated with brain levels of amyloid and tau in MCI or AD individuals. Two studies support, in cognitively normal aged individuals, a significant association between lower coffee intake and a higher A\\u03b2 positivity, as seen by positron emission tomography (PET), but these data have been discussed elsewhere. Notably, the link between caffeine intake and cerebrospinal fluid (CSF) biomarkers, including amyloid peptides A\\u03b2 and tau protein, in individuals presenting with MCI and AD has been largely overlooked. Only one study could not find an association of caffeine consumption, caffeine concentration in plasma, or caffeine concentration in the CSF with the levels of the core AD CSF biomarkers, in a cohort that included 88 patients with AD or mild cognitive impairment (MCI). \", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 3976, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"In this context, the present study aimed to reinvestigate the link between habitual caffeine intake with CSF levels of amyloid A\\u03b240, A\\u03b242, tau, and p\\u2010tau in the clinically defined Biomarker of AmyLoid pepTide and AlZheimer's diseAse Risk (BALTAZAR) cohort, including non\\u2010amnestic MCI (naMCI), amnestic MCI (aMCI), and AD patients.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 4313, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_1\"}, \"text\": \"METHODS\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 4321, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_2\"}, \"text\": \"Study population\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 4338, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"This study is ancillary to BALTAZAR, a multicenter (23 memory centers) prospective cohort study (ClinicalTrials.gov, Identifier #NCT01315639) including participants with MCI and AD at baseline from September 2010 to April 2015 and with an ongoing 3\\u2010year follow\\u2010up. All participants or their legal guardians gave written informed consent. The study was approved by the Paris Ethics Committee (CPP Ile de France IV Saint Louis Hospital). All participants were Caucasian community dwellers and had caregivers. Inclusion criteria for AD participants were age \\u226545 years, probable AD based on the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM IV\\u2010TR), and the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association criteria and from mild to moderate stage (Mini\\u2010Mental State Examination [MMSE] score \\u226515). Inclusion criteria for MCI participants were age \\u226570 years with MCI diagnostic criteria according to Petersen. Exclusion criteria were non\\u2010AD dementia (ie, vascular dementia, Lewy body or Parkinson's disease dementia, and frontotemporal dementia); genetic forms of AD; major depression according to DSM IV\\u2010TR or geriatric depression scale >\\u00a020/30; other diseases that could interfere with cognitive evaluation; diseases with short\\u2010term survival; use of cholinesterase inhibitors or methyl\\u2010D\\u2010aspartate receptor partial antagonists before inclusion (for participants with MCI); and illiterateness or less than 4 years of education.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 5910, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"At baseline, all the participants underwent clinical, neuropsychological, and biological assessments, and participants without contraindications underwent magnetic resonance imaging (MRI) brain examinations. Cognitive evaluations were performed by neuropsychologists after training programs to harmonize the evaluation. At inclusion, MCI and AD participants underwent a neuropsychological test battery that included global cognitive assessment with the MMSE (normal score 30/30), Clinical Dementia Rating (CDR) scale (CDR sum of boxes: normal score 0/18). Functional disability was assessed using instrumental activities of daily living (IADL, normal score 14/14) (for the description of all tests performed in the cohort see Hanon et\\u00a0al.). MCI participants were then categorized as aMCI or naMCI according to the presence of memory impairment on the free and cued selective recall reminding test related to age, sex, and educational level. Conversion to dementia in the naMCI group was very low (2.5%) compared to the aMCI group (22.4%).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 6950, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_2\"}, \"text\": \"Habitual caffeine consumption\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 6980, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"This study enrolled 263 patients (see flowchart in Figure S1) in which habitual caffeine intake was assessed using an in\\u2010house validated self\\u2010survey, completed together by the patients and their caregivers. At inclusion, the daily intake of caffeine\\u2010containing items (coffee, tea, chocolate, sodas) was reported. The daily caffeine intake at inclusion was then calculated as milligrams per day. Participants were dichotomized according to their median caffeine consumption (216\\u00a0mg/day), defining \\u201clow caffeine consumption\\u201d (\\u2264216\\u00a0mg/day) and \\u201chigh caffeine consumption\\u201d (>216\\u00a0mg/day) groups.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 7590, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_2\"}, \"text\": \"CSF and plasma biomarker measurements\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 7628, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Blood and CSF samples were collected at the same time. Investigators involved in the biological analysis were blinded to other assessments. A standard protocol was established beforehand and used throughout the study. CSF samples (>4\\u00a0mL) were centrifuged (1000\\u00a0\\u00d7 g, +4 C, 10\\u00a0min) less than 4\\u00a0h after collection using the same 10\\u2010mL polypropylene tube (Catalogue No. #62.610.201; Sarstedt, Germany), aliquoted into polypropylene protein low\\u2010binding tubes (LoBind microtube\\u2010ref 022431064; Eppendorf), and stored at \\u221280\\u00b0C. CSF tau, p\\u2010tau181, A\\u03b240, and A\\u03b242 were measured in duplicate using the same aliquot in a single centralized laboratory (IRMB, Montpellier, France) using commercially available ELISA kits (Euroimmun A\\u03b21\\u201040 and A\\u03b21\\u201042, Innotest htau and Innotest p\\u2010tau181). It is noteworthy that about half of patients did not accept lumbar puncture, which explains the missing data on CSF biomarkers.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 8557, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Regarding plasma, all centers used the same 10\\u00a0mL collection tube with EDTA (BD Vacutainer K2E Catalogue No. 367,525, Becton Dickinson, Rungis, France). After centrifugation (2500\\u00a0\\u00d7 g, 10\\u00a0min), the supernatants were aliquoted into polypropylene protein low\\u2010binding tubes (LoBind\\u2010microtube, Ref #022431064; Eppendorf, Hamburg, Germany) and stored at \\u221280\\u00b0C. Plasma A\\u03b240 and A\\u03b242 peptide assay was performed in a single centralized laboratory (Inserm UMRS1172, Lille) using the INNO\\u2010BIA kit (Fujirebio Europe NV, formerly Innogenetics NV, Belgium), based on a multiplex xMAP technique with a LABScan\\u2010200 system (Luminex BV). Plasma p\\u2010tau181 was determined using a commercial Simoa plasma p\\u2010tau181 Advantage V1 kit, and plasma neurofilament light (NfL) using a commercial Simoa NF\\u2010light Advantage Kit (Quanterix, Billerica, MA, USA) in a single centralized laboratory (IRMB, Montpellier, France). Internal quality controls (IQCs) represented by serum pool aliquots were used to monitor the accuracy of Simoa. All samples were measured after a single thaw.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 9632, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_3\"}, \"text\": \"RESEARCH IN CONTEXT\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 9652, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \" Systematic review: The authors reviewed the literature using traditional (eg, PubMed) sources, meeting abstracts, and presentations. While the impact of habitual caffeine consumption on age\\u2010related cognitive decline has been addressed in longitudinal studies and meta\\u2010analyses, its impact in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients remains ill defined, in particular regarding cerebrospinal fluid (CSF) biomarkers.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 10102, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \" Interpretation: Our data support an association of lower caffeine consumption with a higher risk of being amnestic as well as with deleterious changes in CSF biomarkers of MCI and AD patients.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 10296, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \" Future directions: The article proposes a framework for future interventional clinical studies aimed at evaluating the effect of caffeine on clinical progression and biomarker changes during the course of AD and at better understanding the associated biological mechanisms.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 10571, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_2\"}, \"text\": \"Statistical analysis\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 10592, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Categorical variables are reported as frequency (percentage). Continuous variables are reported as mean (standard deviation [SD]) in the case of normal distribution or median (interquartile range [IQR]) otherwise. Normality of distributions was assessed using histograms and the Shapiro\\u2013Wilk test.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 10892, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Patient characteristics and CSF biomarkers were compared between the three diagnostic groups (naMCI, aMCI, and AD) using chi\\u2010squared test (or Fisher's exact test in the case of an expected value\\u00a0<5) for categorical variables and using analysis of variance or Kruskal\\u2013Wallis test for quantitative variables. CSF data were not imputed as the proportion of missing data was too important and not random. For MCI patients, association between biomarkers and conversion to AD were evaluated using a Cox proportional hazards model. The proportional hazards assumption and the log\\u2010linearity assumption for quantitative variables were assessed by examining the scaled Schoenfeld residuals plots and the Martingale residual plots. Hazard ratios were estimated with their 95% confidence interval (CI).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 11691, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"The impact of low or high caffeine consumption on the diagnostic group was evaluated using a multinomial logistic regression model adjusted on predefined confounding factors (Apolipoprotein E [APOE \\u03b54], age, sex, education level, and tobacco consumption). Odds ratios (ORs) were derived from models with their 95% CIs. The same analysis was performed by regrouping aMCI and DA groups using a logistic regression model adjusted on predefined confounding factors.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 12159, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"The impact of low or high caffeine consumption on biomarkers was evaluated using an analysis of covariance (ANCOVA) adjusted on predefined confounding factors and after applying a log transformation of the CSF biomarkers and plasma NfL levels. Mean difference was derived from models with their 95% CIs.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 12463, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"All statistical tests were done at the two\\u2010tailed \\u03b1\\u2010level of 0.05 using SAS software version 9.4 (SAS Institute, Cary, NC, USA).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 12597, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"title_1\"}, \"text\": \"RESULTS\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 12605, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"title_2\"}, \"text\": \"Demographic and clinical characteristics at baseline\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 12658, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"Two hundred and sixty\\u2010three participants of the BALTAZAR cohort with available caffeine data were included (40 naMCI, 107 aMCI, and 116 AD; Table\\u00a01). At baseline, among the 263 participants, 38.0% (N\\u00a0=\\u00a0100) were males, 40.8% (N\\u00a0=\\u00a0106) had at least a high school diploma, and 74.8% (N\\u00a0=\\u00a0193) never smoked. The median MMSE score was 26 (IQR: 23 to 28) and 47.7% (N\\u00a0=\\u00a0114) were APOE \\u03b54 carriers. The median caffeine consumption was 216 (IQR: 84 to 374) mg/day. During the clinical follow\\u2010up period (6 to 36 months), 24 MCI participants developed dementia and converted to probable AD. Analysis of CSF biomarkers at inclusion showed, as expected, higher CSF total tau (tau) and phospho\\u2010tau (p\\u2010tau181) levels and lower amyloid A\\u03b242 levels, A\\u03b242/A\\u03b240, and A\\u03b242/p\\u2010tau181 ratios in AD patients compared to naMCI and aMCI individuals. As shown in Table S1, we also described CSF and plasma biomarker changes in the MCI patients converting to dementia (mainly AD) versus non\\u2010converters: as in the whole BALTAZAR MCI cohort, we found higher CSF tau and p\\u2010tau181 levels; lower CSF A\\u03b242 levels and A\\u03b242/A\\u03b240 and A\\u03b242/p\\u2010tau181 ratios, and lower plasma A\\u03b242/A\\u03b240. Similarly, hippocampal volume, MMSE, and IADL were significantly lower, while CDR was higher in AD versus aMCI and naMCI (Table\\u00a01).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 13976, \"infons\": {\"file\": \"alz14169-tbl-0001.xml\", \"id\": \"alz14169-tbl-0001\", \"section_type\": \"TABLE\", \"type\": \"table_caption\"}, \"text\": \"General characteristics, global cognitive assessment, and CSF biomarkers at baseline.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 14062, \"infons\": {\"file\": \"alz14169-tbl-0001.xml\", \"id\": \"alz14169-tbl-0001\", \"section_type\": \"TABLE\", \"type\": \"table\", \"xml\": \"<?xml version=\\\"1.0\\\" encoding=\\\"UTF-8\\\"?>\\n<table frame=\\\"hsides\\\" rules=\\\"groups\\\"><col align=\\\"left\\\" span=\\\"1\\\"/><col align=\\\"left\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\".\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\".\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\".\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\".\\\" span=\\\"1\\\"/><thead><tr style=\\\"border-bottom:solid 1px #000000\\\"><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">N</italic>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<p>Overall</p>\\n<p>\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 263</p>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">N</italic>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<p>naMCI</p>\\n<p>\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 40</p>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">N</italic>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<p>aMCI</p>\\n<p>\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 107</p>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">N</italic>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<p>AD</p>\\n<p>\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 116</p>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">p</italic>\\u2010value</th></tr></thead><tbody><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>Age (years)</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">263</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">77\\u00a0\\u00b1 6</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">76\\u00a0\\u00b1 5</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">77\\u00a0\\u00b1 5</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">78\\u00a0\\u00b1 7</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.11</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>Male (<italic toggle=\\\"yes\\\">N</italic>, %)</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">263</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">100 (38.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">9 (22.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">50 (46.7)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">41 (35.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.019</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>Education level (<italic toggle=\\\"yes\\\">N</italic>, %)</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">260</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">38</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">106</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.038</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Primary</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">47 (18.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">8 (21.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">13 (12.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">26 (22.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Secondary</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107 (41.2)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">10 (26.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">45 (42.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">52 (45.2)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">High school diploma or above</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">106 (40.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">20 (52.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">49 (45.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">37 (32.2)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>Tobacco (<italic toggle=\\\"yes\\\">N</italic>, %)</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">258</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">38</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">105</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">115</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">NA</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Never</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">193 (74.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">29 (76.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">73 (69.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">91 (79.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Current</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">7 (2.7)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2 (5.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">3 (2.9)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2 (1.7)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Former</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">58 (22.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">7 (18.4)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">29 (27.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">22 (19.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>BMI (kg/m<sup>2</sup>)</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">262</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">25.2\\u00a0\\u00b1 3.6</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">24.5\\u00a0\\u00b1 3.2</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">106</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">24.9\\u00a0\\u00b1 3.3</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">25.8\\u00a0\\u00b1 3.9</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.058</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>Caffeine (mg/day)</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">263</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">216 (84 to 374)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">266 (182 to 427)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">197 (79 to 332)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">216 (76 to 385)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.16</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Low\\u2010caffeine group (\\u2264216\\u00a0mg/day)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">132 (50.2)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">15 (37.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">59 (55.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">58 (50.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">High\\u2010caffeine group (&gt;216\\u00a0mg/day)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">131 (49.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">25 (62.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">48 (44.9)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">58 (50.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>Comorbidity (<italic toggle=\\\"yes\\\">N</italic>, %)</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Hypertension</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">261</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">190 (72.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">38</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">28 (70.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">82 (76.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">80 (70.2)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.51</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Mellitus diabetes</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">238</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">35 (14.7)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">38</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">4 (10.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">99</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">14 (14.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">101</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">17 (16.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.63</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Dyslipidemia</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">260</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">106 (40.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">39</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">20 (50.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">105</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">45 (42.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">41 (36.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.27</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">History of stroke or TIA</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">262</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">18 (6.9)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">39</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0 (0.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">9 (8.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">9 (7.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.16</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">History of depression</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">261</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">59 (22.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">38</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">11 (27.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">25 (23.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">23 (19.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.56</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>Relative hippocampal volume</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">229</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.33\\u00a0\\u00b1 0.09</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">35</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.40\\u00a0\\u00b1 0.05</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">91</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.35\\u00a0\\u00b1 0.08</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">103</td><td align=\\\"char\\\" char=\\\"plusmn\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.29\\u00a0\\u00b1 0.09</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">APOE</italic> \\u03b54 carrier (<bold>\\n<italic toggle=\\\"yes\\\">N</italic>, %)</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">239</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">114 (47.7)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">12 (30.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">105</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">50 (47.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">94</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">52 (55.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.027</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>Global cognitive assessment</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">CDR sum of boxes (/18)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">263</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2.0 (0.5 to 4.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.5 (0.5 to 0.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1.0 (0.5 to 2.0)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">4.3 (2.5 to 5.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">MMSE (/30)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">252</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">26 (23 to 28)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">37</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">28 (27 to 30)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">105</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">27 (25 to 28)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">110</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">23 (20 to 25)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">IADL score (/14)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">257</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">13 (11 to 14)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">39</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">14 (14 to 14)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">105</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">14 (12 to 14)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">113</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">11 (7 to 13)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>CSF biomarkers</bold>\\n</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">A\\u03b240 (pg/mL)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">6963 (5925 to 8647)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">18</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">6801 (6293.0 to 9547)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">49</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">7350 (5925 to 9023)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">6799 (58278 to 8182)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.48</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">A\\u03b242 (pg/mL)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">589 (411 to 956)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">18</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">853 (673 to 1030)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">49</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">667 (431 to 1183)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">471 (403 to 624)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">A\\u03b242/A\\u03b240 (%)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">8.2 (6.7 to 13.2)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">18</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">11.2 (8.3 to 14.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">49</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">9.3 (6.7 to 15.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">7.3 (6.1 to 8.7)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">tau (pg/mL)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">118</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">399 (309 to 625)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">18</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">311 (214 to 410)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">56</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">371 (280 to 600)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">44</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">596 (392 to 710)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">p\\u2010tau181 (pg/mL)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">120</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">61 (48 to 82)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">18</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">52 (45 to 60)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">57</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">56 (48 to 77)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">45</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">69 (63 to 98)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">A\\u03b242/p\\u2010tau</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">103</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">9.2 (5.7 to 19.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">18</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">15.5 (11.6 to 22.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">47</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">11.5 (6.5 to 21.9)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">38</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">7.0 (4.8 to 9.5)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">&lt;0.001</td></tr></tbody></table>\\n\"}, \"text\": \"\\tN\\tOverallN\\u00a0= 263\\tN\\tnaMCIN\\u00a0= 40\\tN\\taMCIN\\u00a0= 107\\tN\\tADN\\u00a0= 116\\tp\\u2010value\\t \\tAge (years)\\t263\\t77\\u00a0\\u00b1 6\\t40\\t76\\u00a0\\u00b1 5\\t107\\t77\\u00a0\\u00b1 5\\t116\\t78\\u00a0\\u00b1 7\\t0.11\\t \\tMale (N, %)\\t263\\t100 (38.0)\\t40\\t9 (22.5)\\t107\\t50 (46.7)\\t116\\t41 (35.3)\\t0.019\\t \\tEducation level (N, %)\\t260\\t\\t38\\t\\t106\\t\\t116\\t\\t0.038\\t \\tPrimary\\t\\t47 (18.1)\\t\\t8 (21.1)\\t\\t13 (12.1)\\t\\t26 (22.6)\\t\\t \\tSecondary\\t\\t107 (41.2)\\t\\t10 (26.3)\\t\\t45 (42.1)\\t\\t52 (45.2)\\t\\t \\tHigh school diploma or above\\t\\t106 (40.8)\\t\\t20 (52.6)\\t\\t49 (45.8)\\t\\t37 (32.2)\\t\\t \\tTobacco (N, %)\\t258\\t\\t38\\t\\t105\\t\\t115\\t\\tNA\\t \\tNever\\t\\t193 (74.8)\\t\\t29 (76.3)\\t\\t73 (69.5)\\t\\t91 (79.1)\\t\\t \\tCurrent\\t\\t7 (2.7)\\t\\t2 (5.3)\\t\\t3 (2.9)\\t\\t2 (1.7)\\t\\t \\tFormer\\t\\t58 (22.5)\\t\\t7 (18.4)\\t\\t29 (27.6)\\t\\t22 (19.1)\\t\\t \\tBMI (kg/m2)\\t262\\t25.2\\u00a0\\u00b1 3.6\\t40\\t24.5\\u00a0\\u00b1 3.2\\t106\\t24.9\\u00a0\\u00b1 3.3\\t116\\t25.8\\u00a0\\u00b1 3.9\\t0.058\\t \\tCaffeine (mg/day)\\t263\\t216 (84 to 374)\\t40\\t266 (182 to 427)\\t107\\t197 (79 to 332)\\t116\\t216 (76 to 385)\\t0.16\\t \\tLow\\u2010caffeine group (\\u2264216\\u00a0mg/day)\\t\\t132 (50.2)\\t\\t15 (37.5)\\t\\t59 (55.1)\\t\\t58 (50.0)\\t\\t \\tHigh\\u2010caffeine group (>216\\u00a0mg/day)\\t\\t131 (49.8)\\t\\t25 (62.5)\\t\\t48 (44.9)\\t\\t58 (50.0)\\t\\t \\tComorbidity (N, %)\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t \\tHypertension\\t261\\t190 (72.8)\\t38\\t28 (70.0)\\t107\\t82 (76.6)\\t116\\t80 (70.2)\\t0.51\\t \\tMellitus diabetes\\t238\\t35 (14.7)\\t38\\t4 (10.5)\\t99\\t14 (14.1)\\t101\\t17 (16.8)\\t0.63\\t \\tDyslipidemia\\t260\\t106 (40.8)\\t39\\t20 (50.0)\\t105\\t45 (42.5)\\t116\\t41 (36.0)\\t0.27\\t \\tHistory of stroke or TIA\\t262\\t18 (6.9)\\t39\\t0 (0.0)\\t107\\t9 (8.5)\\t116\\t9 (7.8)\\t0.16\\t \\tHistory of depression\\t261\\t59 (22.6)\\t38\\t11 (27.5)\\t107\\t25 (23.8)\\t116\\t23 (19.8)\\t0.56\\t \\tRelative hippocampal volume\\t229\\t0.33\\u00a0\\u00b1 0.09\\t35\\t0.40\\u00a0\\u00b1 0.05\\t91\\t0.35\\u00a0\\u00b1 0.08\\t103\\t0.29\\u00a0\\u00b1 0.09\\t<0.001\\t \\tAPOE \\u03b54 carrier (N, %)\\t239\\t114 (47.7)\\t40\\t12 (30.0)\\t105\\t50 (47.6)\\t94\\t52 (55.3)\\t0.027\\t \\tGlobal cognitive assessment\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t \\tCDR sum of boxes (/18)\\t263\\t2.0 (0.5 to 4.0)\\t40\\t0.5 (0.5 to 0.6)\\t107\\t1.0 (0.5 to 2.0)\\t116\\t4.3 (2.5 to 5.6)\\t<0.001\\t \\tMMSE (/30)\\t252\\t26 (23 to 28)\\t37\\t28 (27 to 30)\\t105\\t27 (25 to 28)\\t110\\t23 (20 to 25)\\t<0.001\\t \\tIADL score (/14)\\t257\\t13 (11 to 14)\\t39\\t14 (14 to 14)\\t105\\t14 (12 to 14)\\t113\\t11 (7 to 13)\\t<0.001\\t \\tCSF biomarkers\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t \\tA\\u03b240 (pg/mL)\\t107\\t6963 (5925 to 8647)\\t18\\t6801 (6293.0 to 9547)\\t49\\t7350 (5925 to 9023)\\t40\\t6799 (58278 to 8182)\\t0.48\\t \\tA\\u03b242 (pg/mL)\\t107\\t589 (411 to 956)\\t18\\t853 (673 to 1030)\\t49\\t667 (431 to 1183)\\t40\\t471 (403 to 624)\\t<0.001\\t \\tA\\u03b242/A\\u03b240 (%)\\t107\\t8.2 (6.7 to 13.2)\\t18\\t11.2 (8.3 to 14.3)\\t49\\t9.3 (6.7 to 15.6)\\t40\\t7.3 (6.1 to 8.7)\\t<0.001\\t \\ttau (pg/mL)\\t118\\t399 (309 to 625)\\t18\\t311 (214 to 410)\\t56\\t371 (280 to 600)\\t44\\t596 (392 to 710)\\t<0.001\\t \\tp\\u2010tau181 (pg/mL)\\t120\\t61 (48 to 82)\\t18\\t52 (45 to 60)\\t57\\t56 (48 to 77)\\t45\\t69 (63 to 98)\\t<0.001\\t \\tA\\u03b242/p\\u2010tau\\t103\\t9.2 (5.7 to 19.3)\\t18\\t15.5 (11.6 to 22.8)\\t47\\t11.5 (6.5 to 21.9)\\t38\\t7.0 (4.8 to 9.5)\\t<0.001\\t \\t\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 16704, \"infons\": {\"file\": \"alz14169-tbl-0001.xml\", \"id\": \"alz14169-tbl-0001\", \"section_type\": \"TABLE\", \"type\": \"table_footnote\"}, \"text\": \"\\nNote: Values are presented as mean\\u00a0\\u00b1\\u00a0SD or median (interquartile range) for quantitative variables and as frequency (percentage) for categorical variables.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 16864, \"infons\": {\"file\": \"alz14169-tbl-0001.xml\", \"id\": \"alz14169-tbl-0001\", \"section_type\": \"TABLE\", \"type\": \"table_footnote\"}, \"text\": \"Abbreviations: AD, Alzheimer's disease; aMCI: amnestic mild cognitive impairment; BMI, body mass index; CDR SOB, Clinical Dementia Rating Sum of Boxes; CSF, cerebrospinal fluid; IADL, instrumental activities of daily living; MMSE, Mini\\u2010Mental State Examination; naMCI, non\\u2010amnestic mild cognitive impairment; N, number of available observations; TIA, transient ischemic attack.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 17246, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"title_2\"}, \"text\": \"Association of caffeine consumption with the diagnostic groups at baseline according to the cognitive status (AD, aMCI, naMCI)\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 17373, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"Participants were dichotomized according to their median caffeine consumption (216\\u00a0mg/day) in the overall cohort as well as in each subgroup (AD, aMCI, naMCI). Body mass index (BMI) was not significantly different between low and high caffeine consumers (mean BMI: 25.3\\u00a0\\u00b1\\u00a03.8 in the low vs 25.2\\u00a0\\u00b1\\u00a03.5 in the high consumer group; p\\u00a0=\\u00a0.93, Student's t test). At baseline, we did not find a statistical difference in caffeine intake between naMCI, aMCI, and AD patients (Table\\u00a01), suggesting that the development of AD is not associated with a change in consumption, at least versus MCI patients. Also, the median caffeine consumption calculated for MCI patient that convert (199.5\\u00a0mg/day) or not (217.7\\u00a0mg/day) was not found significantly different (p\\u00a0=\\u00a00.88). However, after adjustment on APOE \\u03b54, age, sex, education level, and tobacco consumption, and using the naMCI group as reference, we found a significant association of a lower caffeine consumption with a higher risk to be aMCI (OR: 2.72 [95% CI: 1.17 to 6.30]) and a similar effect size, even non\\u2010significant, for higher risk of being AD (OR:2.31 [95% CI: 0.98 to 5.40]; Table\\u00a02). When aMCI and AD groups were combined, the association of a lower caffeine consumption with higher risk of being amnestic was significant (OR: 2.49 [95% CI: 1.13 to 5.46]; p\\u00a0=\\u00a00.023) (Table\\u00a02). Nevertheless, a Kaplan\\u2013Meyer analysis indicated that the rate of MCI conversion to AD was not modified regarding the caffeine consumption class (p\\u00a0=\\u00a00.94; not shown).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 18899, \"infons\": {\"file\": \"alz14169-tbl-0002.xml\", \"id\": \"alz14169-tbl-0002\", \"section_type\": \"TABLE\", \"type\": \"table_caption\"}, \"text\": \"Association of caffeine consumption according to cognitive status (naMCI, aMCI, AD).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 18984, \"infons\": {\"file\": \"alz14169-tbl-0002.xml\", \"id\": \"alz14169-tbl-0002\", \"section_type\": \"TABLE\", \"type\": \"table\", \"xml\": \"<?xml version=\\\"1.0\\\" encoding=\\\"UTF-8\\\"?>\\n<table frame=\\\"hsides\\\" rules=\\\"groups\\\"><col align=\\\"left\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\".\\\" span=\\\"1\\\"/><thead><tr style=\\\"border-bottom:solid 1px #000000\\\"><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Overall</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 263</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<p>Low caffeine consumption</p>\\n<p>\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 132</p>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<p>High caffeine consumption</p>\\n<p>\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 131</p>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Odds ratio (95% CI)</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">p</italic>\\u2010value</th></tr></thead><tbody><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>naMCI_aMCI_AD (<italic toggle=\\\"yes\\\">N</italic>, %)</bold>\\n</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.062</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">naMCI</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40 (15.2)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">15 (11.4)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">25 (19.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1.00 (r\\u00e9f.)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\u2013</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">aMCI</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">107 (40.7)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">59 (44.7)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">48 (36.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2.72 (1.17 to 6.30)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>0.019</bold>\\n</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">AD</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">116 (44.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">58 (43.9)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">58 (44.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2.31 (0.98 to 5.40)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.054</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>naMCI_aMCI+AD (<italic toggle=\\\"yes\\\">N</italic>, %)</bold>\\n</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">naMCI</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">40 (15.2)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">15 (11.4)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">25 (19.1)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1.00 (r\\u00e9f.)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\u2013</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">aMCI+AD</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">223 (84.8)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">117 (88.6)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">106 (80.9)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2.49 (1.13 to 5.46)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>0.023</bold>\\n</td></tr></tbody></table>\\n\"}, \"text\": \"Overall\\tN\\u00a0= 263\\tLow caffeine consumptionN\\u00a0= 132\\tHigh caffeine consumptionN\\u00a0= 131\\tOdds ratio (95% CI)\\tp\\u2010value\\t \\tnaMCI_aMCI_AD (N, %)\\t\\t\\t\\t\\t0.062\\t \\tnaMCI\\t40 (15.2)\\t15 (11.4)\\t25 (19.1)\\t1.00 (r\\u00e9f.)\\t\\u2013\\t \\taMCI\\t107 (40.7)\\t59 (44.7)\\t48 (36.6)\\t2.72 (1.17 to 6.30)\\t0.019\\t \\tAD\\t116 (44.1)\\t58 (43.9)\\t58 (44.3)\\t2.31 (0.98 to 5.40)\\t0.054\\t \\tnaMCI_aMCI+AD (N, %)\\t\\t\\t\\t\\t\\t \\tnaMCI\\t40 (15.2)\\t15 (11.4)\\t25 (19.1)\\t1.00 (r\\u00e9f.)\\t\\u2013\\t \\taMCI+AD\\t223 (84.8)\\t117 (88.6)\\t106 (80.9)\\t2.49 (1.13 to 5.46)\\t0.023\\t \\t\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 19467, \"infons\": {\"file\": \"alz14169-tbl-0002.xml\", \"id\": \"alz14169-tbl-0002\", \"section_type\": \"TABLE\", \"type\": \"table_footnote\"}, \"text\": \"\\nNote: Values are presented as frequency (percentage). Odds ratios and p values were adjusted for APOE \\u03b54, age, sex, education level, and tobacco consumption.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 19632, \"infons\": {\"file\": \"alz14169-tbl-0002.xml\", \"id\": \"alz14169-tbl-0002\", \"section_type\": \"TABLE\", \"type\": \"table_footnote\"}, \"text\": \"Abbreviations: AD, Alzheimer's disease; aMCI, amnestic mild cognitive impairment; CI, confidence interval; naMCI, non\\u2010amnestic mild cognitive impairment; N, number of available observations.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 19825, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"title_2\"}, \"text\": \"Association of caffeine consumption with CSF and plasma biomarkers at baseline\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 19904, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"Among the whole cohort, after adjustment on APOE \\u03b54, age, sex, education level, and tobacco consumption, lower caffeine consumption was found to be associated with lower CSF A\\u03b242 levels (p\\u00a0=\\u00a00.047) as well as lower A\\u03b242/A\\u03b240 (p\\u00a0=\\u00a00.040) and A\\u03b242/p\\u2010tau181 ratio (p\\u00a0=\\u00a00.020; Table\\u00a03). No significant difference was observed regarding CSF total tau and p\\u2010tau181 levels based on caffeine consumption (Table\\u00a03). We also evaluated plasma biomarkers (p\\u2010tau181, A\\u03b242, A\\u03b240, and NfL) but did not observe significant differences per the caffeine consumption group (Table S2).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 20494, \"infons\": {\"file\": \"alz14169-tbl-0003.xml\", \"id\": \"alz14169-tbl-0003\", \"section_type\": \"TABLE\", \"type\": \"table_caption\"}, \"text\": \"Association of caffeine consumption with CSF biomarkers at baseline.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 20563, \"infons\": {\"file\": \"alz14169-tbl-0003.xml\", \"id\": \"alz14169-tbl-0003\", \"section_type\": \"TABLE\", \"type\": \"table\", \"xml\": \"<?xml version=\\\"1.0\\\" encoding=\\\"UTF-8\\\"?>\\n<table frame=\\\"hsides\\\" rules=\\\"groups\\\"><col align=\\\"left\\\" span=\\\"1\\\"/><col align=\\\"left\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"left\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"char\\\" char=\\\"(\\\" span=\\\"1\\\"/><col align=\\\"left\\\" span=\\\"1\\\"/><thead><tr style=\\\"border-bottom:solid 1px #000000\\\"><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">CSF biomarkers</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">N</italic>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<p>Low caffeine consumption</p>\\n<p>\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 132</p>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">N</italic>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<p>High caffeine consumption</p>\\n<p>\\n<italic toggle=\\\"yes\\\">N</italic>\\u00a0= 131</p>\\n</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Mean difference (95% CI)</th><th align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<italic toggle=\\\"yes\\\">p</italic>\\u2010value</th></tr></thead><tbody><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">tau (pg/mL)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">55</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">400 (311 to 627)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">63</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">385 (287 to 622)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.14 (\\u22120.06 to 0.35)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.17</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">p\\u2010tau181 (pg/mL)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">56</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">62 (49 to 84)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">64</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">60 (47 to 80)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.13 (\\u22120.03 to 0.30)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.11</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">A\\u03b242 (pg/mL)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">50</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">577 (411 to 953)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">57</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">658 (431 to 956)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\u22120.21 (\\u22120.41 to 0.00)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>0.040</bold>\\n</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">A\\u03b240 (pg/mL)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">50</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">7075 (5934 to 8647)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">57</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">6795 (5874 to 9007)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\u22120.05 (\\u22120.18 to 0.09)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.47</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">A\\u03b242/A\\u03b240 (%)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">50</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">8.1 (6.7 to 14.0)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">57</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">8.4 (6.8 to 12.9)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\u22120.17 (\\u22120.32 to \\u22120.01)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>0.047</bold>\\n</td></tr><tr><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">CSF A\\u03b242/p\\u2010tau</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">49</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">8.5 (5.7 to 17.2)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">54</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">10.5 (6.5 to 21.3)</td><td align=\\\"char\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\u22120.34 (\\u22120.61 to \\u22120.06)</td><td align=\\\"left\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\n<bold>0.020</bold>\\n</td></tr></tbody></table>\\n\"}, \"text\": \"CSF biomarkers\\tN\\tLow caffeine consumptionN\\u00a0= 132\\tN\\tHigh caffeine consumptionN\\u00a0= 131\\tMean difference (95% CI)\\tp\\u2010value\\t \\ttau (pg/mL)\\t55\\t400 (311 to 627)\\t63\\t385 (287 to 622)\\t0.14 (\\u22120.06 to 0.35)\\t0.17\\t \\tp\\u2010tau181 (pg/mL)\\t56\\t62 (49 to 84)\\t64\\t60 (47 to 80)\\t0.13 (\\u22120.03 to 0.30)\\t0.11\\t \\tA\\u03b242 (pg/mL)\\t50\\t577 (411 to 953)\\t57\\t658 (431 to 956)\\t\\u22120.21 (\\u22120.41 to 0.00)\\t0.040\\t \\tA\\u03b240 (pg/mL)\\t50\\t7075 (5934 to 8647)\\t57\\t6795 (5874 to 9007)\\t\\u22120.05 (\\u22120.18 to 0.09)\\t0.47\\t \\tA\\u03b242/A\\u03b240 (%)\\t50\\t8.1 (6.7 to 14.0)\\t57\\t8.4 (6.8 to 12.9)\\t\\u22120.17 (\\u22120.32 to \\u22120.01)\\t0.047\\t \\tCSF A\\u03b242/p\\u2010tau\\t49\\t8.5 (5.7 to 17.2)\\t54\\t10.5 (6.5 to 21.3)\\t\\u22120.34 (\\u22120.61 to \\u22120.06)\\t0.020\\t \\t\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 21226, \"infons\": {\"file\": \"alz14169-tbl-0003.xml\", \"id\": \"alz14169-tbl-0003\", \"section_type\": \"TABLE\", \"type\": \"table_footnote\"}, \"text\": \"\\nNote: Values are presented as median (IQR). Mean differences and p values were calculated on log transformed data and were adjusted for APOE \\u03b54, age, sex, education level, and tobacco consumption, using high caffeine consumption as reference.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 21476, \"infons\": {\"file\": \"alz14169-tbl-0003.xml\", \"id\": \"alz14169-tbl-0003\", \"section_type\": \"TABLE\", \"type\": \"table_footnote\"}, \"text\": \"Abbreviations: CI, confidence interval; CSF, cerebrospinal fluid; N, number of available observations.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 21579, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"title_1\"}, \"text\": \"DISCUSSION\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 21590, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"In this study, we evaluated the impact of caffeine consumption on clinical outcomes and biomarkers at baseline in the BALTAZAR cohort, including MCI and AD patients. Our data show an association of a lower caffeine consumption with memory disorders related to AD and aMCI at inclusion. Importantly, our data also demonstrate that caffeine is associated with changes in CSF biomarkers of AD patients, particularly with regard to the amyloid component.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 22041, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"The association fits well with few, and potentially underpowered, previous retrospective studies investigating the impact of caffeine consumption on populations of patients presenting with MCI or AD. Maia and de Mendon\\u00e7a showed a significantly lower average consumption of caffeine (74\\u00a0mg/day, N\\u00a0=\\u00a054) during the 20 years preceding AD development in subjects as compared with age\\u2010matched non\\u2010demented subjects (approximately 200\\u00a0mg/day, N\\u00a0=\\u00a054). In the same way, Cao et\\u00a0al. suggested that plasma caffeine concentrations were approximately 50% lower in subjects converting to dementia (N\\u00a0=\\u00a015) (presumably comparable to our aMCI group at high risk of converting to dementia) versus subjects that did not convert (N\\u00a0=\\u00a09) (presumably comparable to our naMCI group). Interestingly, one study, in line with experimental data, found that higher caffeine intake was associated with better function in overall cognition, encompassing episodic memory, executive function, semantic categorization, and working memory, in a cohort of approximately 600 subjects presenting with diabetes, known to be a significant risk factor for dementia, as are aMCI individuals. These data support a benefit of habitual caffeine consumption in at\\u2010risk individuals that would warrant extending more broadly cognitive endophenotypes at MCI inclusion and follow\\u2010up regarding caffeine consumption. Besides an impact on brain lesions (see following discussion), association between caffeine consumption and memory might primarily relate to the ability of caffeine to act on synaptic plasticity. Indeed, in rodents, caffeine's effect on hippocampal slices is to enhance basal synaptic transmission, long\\u2010term potentiation (LTP), and sharp wave\\u2013ripple complexes, which underlie memory consolidation. Caffeine also controls neuronal excitability and LTP\\u2010like effects in the human cortex. More recently, we also demonstrated that regular caffeine intake acted on epigenomic and transcriptional processes that would improve the signal\\u2010to\\u2010noise ratio during information encoding, favoring the functioning of circuits involved in learning. The beneficial effect of caffeine on synaptic plasticity during MCI and AD would be particularly ascribed to its ability to block adenosine receptors, particularly the A2AR subtypes. \", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 24357, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Importantly, we showed a significant association across the BALTAZAR cohort between lower caffeine intake and lower CSF levels of A\\u03b242 as well as A\\u03b242/A\\u03b240 and A\\u03b242/p\\u2010tau181 ratios. To our knowledge, this is the first study to report an association between caffeine and CSF AD biomarkers. Only one previous study addressed, unsuccessfully, such an association in another population. However, this study included a more limited number of subjects (37 MCI and 51 AD), the biomarker assay techniques were different, and, for an unclear reason, the median caffeine consumption was two times lower (around 100\\u00a0mg/day) than in our population. Using our in\\u2010house survey \\u2013 developed to obtain more precise information on consumption habits than caffeine unit or mugs \\u2013 and considering all types of caffeine consumption and volume ingested, we estimated the median consumption of our population to be 216\\u00a0mg/day. This amount was in line with previous studies in cohorts of a similar age and the average consumption in French population as shown by Fredholm et\\u00a0al. Our CSF data point to a particular impact of caffeine on amyloid burden. This is in accordance with a Korean study that included elderly subjects (mean age 71 years old) without dementia (282 cognitively normal and 129 with MCI), showing an association between coffee consumption greater than two cups/day (ie, about 200\\u00a0mg) with amyloid Pittsburgh compound B (PIB)\\u2010PET positivity. Another recent study involving only cognitively normal subjects (mean age 71 years) also found a significant association between higher caffeine consumption and slower accumulation of cerebral amyloid load measured by PIB\\u2010PET during a 126\\u2010month follow\\u2010up. \", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 26075, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"We also evaluated plasma biomarkers, except plasma total tau (t\\u2010tau) levels, as it has been acknowledged that they do not provide valuable information regarding tau brain levels. Indeed, plasma t\\u2010tau concentrations do not to correlate with CSF t\\u2010tau or PET and neuropathological evidence of AD. Evaluation of plasma p\\u2010tau181 and A\\u03b2 did not reveal differences in connection with caffeine consumption. Such a lack of a difference could be explained by the smaller variations observed in amyloid and p\\u2010tau levels in plasma compared to CSF. Indeed, in the BALTAZAR cohort, we previously observed an association between CSF biomarkers and plasma amyloid levels as well as plasma p\\u2010tau. However, the difference or lack thereof in mean levels between MCI converters was respectively for plasma and CSF: \\u22122.1 and \\u2212283 pg/mL for A\\u03b21\\u201042 and +0.9 and + 21.7 pg/mL for p\\u2010tau181. Therefore, the lack of difference in the present study could be simply due to a lack of statistical power linked to an insufficient number of patients with known caffeine consumption. Alternatively, this could also suggest that caffeine mainly has a direct central effect on brain processes rather an indirect effect through peripheral inflammation, amyloid clearance, or metabolism. Regarding plasma NfL levels, also not associated with caffeine consumption, we previously showed in the BALTAZAR cohort that they were not linked to conversion to dementia. Therefore, the observed variations of CSF amyloid levels based on caffeine consumption in our study are compatible with the lack of plasma NfL variations. NfL is well known as a non\\u2010specific biomarker for neurodegeneration. The lack of difference observed for plasma NfL also therefore suggests a lack of caffeine protection on a terminal neurodegenerative process but an upstream effect on amyloidogenic pathway and/or neuronal plasticity.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 27964, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Several mechanisms might indeed explain the effect of caffeine on amyloid pathology revealed by our CSF biomarker results. In vitro data by Sharma et\\u00a0al. showed that the hydrophobic core\\u2010recognition motif of amyloid formation was physically blocked by caffeine, thereby abolishing self\\u2010assembly formation. Also, Janitschke et\\u00a0al. showed that caffeine was able to decrease A\\u03b2 levels by shifting the amyloid precursor protein (APP) processing from the A\\u03b2\\u2010producing amyloidogenic to the non\\u2010amyloidogenic pathway. Accordingly, several studies showed that amyloid mice treated with chronic caffeine administration had lower hippocampal A\\u03b2 levels associated with a reduced presenilin 1 (PS1) and \\u03b2\\u2010secretase (BACE1) levels. These observations are likely in line with the ability of the A2A receptor, an important pharmacological target of caffeine, to modulate A\\u03b2 production in vitro and in vivo. Further, in addition to acting on processes driving amyloid peptide formation and/or aggregation, caffeine could also enhance brain amyloid clearance in C57Bl6/J mice. In agreement with this, as hypothesized, caffeine would be likely to increase the production of CSF, enhancing CSF turnover and, subsequently, presumably improving A\\u03b2 brain clearance (for a review see Mehta and Mehta). This attractive hypothesis, however, awaits definitive verification. Non\\u2010mutually exclusively, the effect of caffeine on amyloid load might also rely on its ability to restrain neuroinflammatory processes, which are known to impair the clearance of amyloid lesions by glial cells (see Launay et\\u00a0al. and Hansen et\\u00a0al. for reviews).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 29596, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Puzzlingly, caffeine does not seem to impact CSF tau and p\\u2010tau. The underlying reasons remain unclear. Actually, in sharp contrast to amyloid model studies, only a few works tried to link caffeine to tau. In a previous in vitro study, caffeine was shown to block the cell cycle at the G1 phase in neuroblastoma cells and lead to a decrease in tau phosphorylation. But the model used might not be relevant to AD. Only one study by our team demonstrated the beneficial impact of caffeine in a mouse model of AD\\u2010like tauopathy. In that work, we showed that caffeine improved memory, slightly decreasing hippocampal p\\u2010tau, without any effect on tau aggregation, but showing rather a strong impact on tau truncation. However, another study performed in a diabetes model showing increased p\\u2010tau supported the notion that caffeine exacerbates tau hyperphosphorylation by promoting hypothermia. Therefore, the link between caffeine and tau remains unclear and warrants further investigation.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 30588, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Overall, the strength of the present study is that it allows for the possibility of addressing the impact of habitual caffeine consumption in a cohort including only MCI and AD patients very well described at the clinical, neuropsychological, MRI, and CSF biomarker levels, as well as for the possibility of adjusting statistical analyses of known confounding factors for AD (APOE \\u03b54, age, sex, education level) and caffeine intake (smoking). However, our study had several limitations. First, we used a survey previously used in patients with Huntington's disease (HD). As indicated in our initial paper, the reliability of the survey was assessed by a retest and found to be excellent. However, that survey was not re\\u2010validated in the present population of MCI and AD patients. Nevertheless, it is particularly noteworthy that the survey was completed by both patients and caregivers, minimizing the risk of error. We are therefore confident of the reliability of our survey, since coffee intake is less prone to being misreported due to its long\\u2010term habitual nature.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31665, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Notably, the median consumption measured in the BALTAZAR cohort (216\\u00a0mg/day) is very close to what we that measured in our previous HD study (median 190\\u00a0mg/day) as well as in another ongoing yet unpublished study on patients diagnosed with amyotrophic lateral sclerosis (median 250\\u00a0mg/day; not shown). One limit of the present study is, however, that we only estimated the intake at inclusion and did not determine consumption of the previous 10 or 20 years, but our consumption data fit with the reported habitual caffeine consumption in the overall French population by Fredholm et\\u00a0al. (239\\u00a0mg/day). This supports the idea that, despite our survey being only used to quantify caffeine consumption at inclusion, the values may very well reflect long\\u2010lasting habitual caffeine consumption. This question is, however, relevant since patients may radically change their lifestyles with the diagnosis of life\\u2010threatening diseases but also because caffeine\\u2010associated neuroprotection may result from long\\u2010term caffeine intake rather than from the actual caffeine intake. In a retrospective case\\u2010control study by Maia and Mendonca in Portuguese individuals, daily caffeine consumption was calculated for the period from early adulthood (age 25 years old) to 20 years before diagnosis of AD, but also for the period after the diagnosis of AD up to the time of the survey at inclusion. In this study, patients with AD had an average daily caffeine intake during the 20 years that preceded diagnosis of AD of 73.9\\u00a0\\u00b1\\u00a097.9\\u00a0mg, whereas the controls had an average daily caffeine intake of 198.7\\u00a0\\u00b1\\u00a0135.7\\u00a0mg during the corresponding 20 years of their lifetime, the latter amount being actually comparable to our patients\\u2019 consumption levels. During the period from young adulthood (25 years old) to 20 years before diagnosis, in Maia's study, AD patients already had a lower average daily caffeine intake. The average daily caffeine intake further declined in AD patients after the diagnosis, reaching a value of 36.3\\u00a0\\u00b1\\u00a064.1\\u00a0mg, while matched controls remained stable.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33750, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"In another study by Cao et\\u00a0al., MCI patients converting to AD exhibited lower plasma caffeine levels compared with non\\u2010converter MCI patients. Therefore, differences in caffeine consumption before the onset of any memory decline may in fact exist. Nevertheless, our current data do not fit at all with these observations. Indeed, at baseline, we did not find a statistical difference in caffeine intake between naMCI, aMCI, and AD patients, suggesting that the development of AD is not associated with a change in consumption, at least when compared with MCI patients. Further, the median caffeine consumption calculated for MCI patients that convert to AD (199.5\\u00a0mg/day) or not (217.7\\u00a0mg/day) was similar (p\\u00a0=\\u00a00.88). Therefore, in our cohort, it seems that we did not observe a drop in caffeine consumption linked to the development of memory deficits or AD. Our results are rather in line with the study of Solfrizzi and al., where no significant variations of caffeine consumption could be observed in MCI patients during a mean follow\\u2010up of 3 years.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34813, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"The BALTAZAR cohort is a prospective study, and although the existing literature mostly evaluates the impact of caffeine at baseline, evaluating cognition over 3 years from inclusion of MCI and AD patients would have been essential to estimate the potential consumption changes versus cognitive decline as suggested by Solfrizzi et\\u00a0al. The lack of consumption data during follow\\u2010up visits in the present multicentric study precludes performing an association study between caffeine intake and decline without bias. This is another limit, and prospective studies on cognition, biomarkers, and pathological evolution in MCI and AD patients should be carefully paired with a longitudinal evaluation of caffeine consumption. Finally, while in our study the sample size was larger than in the previous study of Travasos et\\u00a0al., it remained limited, in particular regarding the naMCI group. Another limitation of our cross\\u2010sectional study is that the associations observed did not allow us to establish with certainty a cause\\u2010and\\u2010effect relationship between caffeine consumption and the effects observed. Causality can only be demonstrated by a randomized double\\u2010blind interventional trial comparing patients treated with a caffeine arm or a placebo. This is the reason why we set up the interventional Effect of CAFfeine on Cognition in Alzheimer's Disease clinical phase 3 trial (NCT04570085), which is currently recruiting.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36246, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Paris, EA 4468, APHP, Hopital Broca, Memory Resource and Research Centre of de Paris\\u2010Broca\\u2010Ile de France, F\\u201075013 Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36396, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Strasbourg, H\\u00f4pitaux Universitaires de Strasbourg, CM2R, p\\u00f4le de G\\u00e9riatrie, Laboratoire ICube, FMTS, CNRS, \\u00e9quipe IMIS, F\\u201067000 Strasbourg, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36565, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Montpellier, CHU Montpellier, Memory Research and Resources center of Montpellier, department of Neurology, Inserm INM NeuroPEPs team, excellence center of neurodegenerative disorders, F\\u201034000 Montpellier, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36796, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Univ. Lille, Inserm, CHU Lille, U1172\\u2010LilNCog, LiCEND, LabEx DISTALZ, F\\u201059000 Lille, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36893, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Univ. Lille, Inserm U1171 Degenerative and Vascular Cognitive Disorders, F\\u201059000 Lille, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36991, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 Paris\\u2010Saclay, APHP, H\\u00f4pital Paul Brousse, d\\u00e9partement de g\\u00e9riatrie, \\u00c9quipe MOODS, Inserm 1178, F\\u201094800 Villejuif, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37133, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Centre Hospitalier de la C\\u00f4te Basque, Department of Gerontology, F\\u201064100 Bayonne, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37226, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Nantes, EA 4334 Movement\\u2010Interactions\\u2010Performance, CHU Nantes, Memory Research Resource Center of Nantes, Department of clinical gerontology, F\\u201044000 Nantes, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37413, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Sorbonne Universit\\u00e9, APHP, Centre Hospitalier Dupuytren, Department of G\\u00e9rontology 2, F\\u201091210 Draveil, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37528, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHU de Nimes, H\\u00f4pital Caremeau, Neurology Department, F\\u201030029 Nimes, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37608, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"H\\u00f4pital L\\u00e9opold Bellan, Service de Neuro\\u2010Psycho\\u2010G\\u00e9riatrie, Memory Clinic, F\\u201075014 Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37714, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Univ. Lille, CHU de Lille, Memory Resource and Research Centre of Lille, Department of Neurology, F\\u201059000 Lille, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37837, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Paris, APHP, Groupe Hospitalier Saint Louis\\u2010Lariboisi\\u00e8reFernand Widal, Center of Cognitive Neurology, F\\u201075010 Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37982, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Toulouse III, CHU La Grave\\u2010Casselardit, Memory Resource and Research Centre of Midi\\u2010Pyr\\u00e9n\\u00e9es, F\\u201031300 Toulouse, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38125, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Lorraine, CHRU de Nancy, Memory Resource and Research Centre of Lorraine, F\\u201054500 Vandoeuvre\\u2010l\\u00e8s\\u2010Nancy, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38259, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Paris, APHP, H\\u00f4pital europeen Georges Pompidou, Service de G\\u00e9riatrie, F\\u201075015, Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38372, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHU de Poitiers, Memory Resource and Research Centre of Poitiers, F\\u201086000 Poitiers, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38466, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHU Charles Nicolle, Memory Resource and Research Centre of HauteNormandie, F\\u201076000 Rouen, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38567, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"APHP, Centre Hospitalier \\u00c9mile\\u2010Roux, Department of G\\u00e9rontology 1, F\\u201094450 Limeil\\u2010Br\\u00e9vannes, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38676, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHU d'Amiens\\u2010Picardie, Memory Resource and Research Centre of AmiensPicardie, F\\u201080000 Amiens, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38782, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Sorbonne Universit\\u00e9, APHP, H\\u00f4pitaux Universitaires Pitie\\u2010Salp\\u00eatri\\u00e8re\\u2010Charles\\u2010Foix, Service de G\\u00e9riatrie Ambulatoire, F\\u201075013 Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38935, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 C\\u00f4te d'Azur, CHU de Nice, Memory Research Resource Center of Nice, CoBTek lab, F\\u201006100 Nice, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39051, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHU de Limoges, Memory Research Resource Center of Limoges, F\\u201087000 Limoges, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39138, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Normandie Univ, UNIROUEN, Inserm U1245, CHU de Rouen, Department of Neurology and CNR\\u2010MAJ, Normandy Center for Genomic and Personalized Medicine, CIC\\u2010CRB1404, F\\u201076000, Rouen, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39327, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHU de Besan\\u00e7on, Memory Resource and Research Centre of Besan\\u00e7on Franche\\u2010Comt\\u00e9, F\\u201025000 Besan\\u00e7on, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39441, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Reims Champagne\\u2010Ardenne, EA 3797, CHU de Reims, Memory Resource and Research Centre of Champagne\\u2010Ardenne, F\\u201051100 Reims, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39591, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHU d'Angers, Memory Resource and Research Centre of Angers, F\\u201049000 Angers, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39678, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHRU de Tours, Memory Resource and Research Centre of Tours, F\\u201037000 Tours, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39764, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Strasbourg, CHRU de Strasbourg, Memory Resource and Research Centre of Strasbourg/Colmar, Inserm U\\u2010118, F\\u201067000 Strasbourg, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39915, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Univ Paris Est Creteil, EA 4391 Excitabilit\\u00e9 Nerveuse et Th\\u00e9rapeutique, CHU Henri Mondor, Department of Neurology, F\\u201094000 Cr\\u00e9teil, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 40060, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"H\\u00f4pital Fondation Rothschild, Department of Neurology, F\\u201075019 Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 40141, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"CHU d'Amiens\\u2010Picardie, Department of Gerontology, F\\u201080000 Amiens, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 40219, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Sorbonne Universit\\u00e9, APHP, H\\u00f4pitaux Universitaires Pitie\\u2010Salp\\u00eatri\\u00e8re\\u2010Charles Foix, Memory Resource and Research Centre, Centre des Maladies Cognitives et Comportementales IM2A, Inserm UMR 8256, F\\u201075013 Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 40446, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 Fran\\u00e7ois\\u2010Rabelais de Tours, CHRU de Tours, Memory Resource and Research Centre of Tours, Inserm CIC 1415, F\\u201037000 Tours, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 40592, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Sorbonne Universit\\u00e9, APHP, H\\u00f4pitaux Universitaires Pitie\\u2010Salp\\u00eatri\\u00e8re\\u2010Charles Foix, Memory Resource and Research Centre, Centre des Maladies Cognitives et Comportementales IM2A, F\\u201075013 Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 40802, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 Bourgogne Franche\\u2010Comt\\u00e9, Laboratoire de Recherches Int\\u00e9gratives en Neurosciences et Psychologie Cognitive, CHU de Besan\\u00e7on, Memory Resource and Research Centre of Besan\\u00e7on Franche\\u2010Comt\\u00e9, F\\u201025000 Besan\\u00e7on, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 41039, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 Fran\\u00e7ois\\u2010Rabelais de Tours, CHRU de Tours, UMR Inserm U1253, F\\u201037000 Tours, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 41140, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Limoges, EA 6310 HAVAE, CHU de Limoges, Memory Research Resource Center of Limoges, F\\u201087000 Limoges, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 41266, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 Paris\\u2010Saclay, Neurospin, CEA, CNRS, cati\\u2010neuroimaging.com, CATI Multicenter Neuroimaging Platform, F\\u201091190 Gif\\u2010sur\\u2010Yvette, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 41419, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Paris, Institute of Psychiatric and Neurosciences, Inserm UMR\\u2010S 1266, F\\u201075014 Paris, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 41531, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Universit\\u00e9 de Montpellier, CHU Montpellier, LBPC, Inserm, F\\u201034000 Montpellier, France.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 41621, \"infons\": {\"section_type\": \"COMP_INT\", \"type\": \"title_1\"}, \"text\": \"CONFLICT OF INTEREST STATEMENT\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 41652, \"infons\": {\"section_type\": \"COMP_INT\", \"type\": \"paragraph\"}, \"text\": \"David Blum DB is a (non\\u2010appointed) member of the scientific advisory board of Marvel Biosciences Corp. developing an A2AR antagonist but has no conflict of interest regarding the present work. Olivier Hanon received personal payment from Bayer, Servier, AstraZeneca, Boston Scientific, Vifor, BMS, Boehringer\\u2010Ingelheim, and Pfizer for lectures and/or consulting services. Jean Sebastien Vidal received payment from Bayer for lectures made to a non\\u2010profit medical association. Sylvain Lehmann received for his institution support from the following: H2020 MARIE SK\\u0141ODOWSKA\\u2010CURIE \\u201cMIRIADE Multi\\u2010omics Interdisciplinary Research Integration to Address DEmentia diagnosis,\\u201d ANR Flash Covid: \\u201cProteoCOVID: Clinical proteomic characterization of the SARS\\u2010CoV\\u20102 Spike protein to optimize its detection and the development of serological assays,\\u201d ANR \\u201cSilk_road: The Stable Isotope Labeling Kinetics (SILK) road to investigate human protein turnover in blood and cerebrospinal fluid,\\u201d EUROMET EMPIR \\u201cNeuroMet2 project: Metrology and Innovation for early diagnosis and accurate stratification of patients with neurodegenerative diseases.\\u201d During the past 36 months, he had a patent issued for \\u201cProc\\u00e9d\\u00e9 de pr\\u00e9paration d'un \\u00e9chantillon peptidique\\u201d Brevet INPI n\\u00b01905247 du 20/05/2019 du CHU DE MONTPELLIER, UNIVERSIT\\u00c9 DE MONTPELLIER and SPOT TO LAB. He received personal payment for participating on the Roche Diagnostic board on CSF biomarkers. St\\u00e9phanie Bombois, Bernadette Allinquant, Christiane Baret\\u2010Rose, Jean\\u2010Marc Tr\\u00e9luyer, Hendy Abdoul, Patrick Gel\\u00e9, Christine Delmaire, Jean\\u2010Fran\\u00e7ois Mangin, and Evelyne Galbrun have no conflicts of interest. Fred\\u00e9ric Blanc received honoraria from Roche and Biogen for presentations. He received payment to his institution as the national coordinator for the clinical trial DELPHIA for patients with dementia with Lewy bodies (Eisai). He received payment to his institution as the national coordinator for the clinical trial GRADUATE for patients with AD. Luc Bu\\u00e9e received support for the present manuscript from LabEx DISTALZ. He received grants or contracts from the French National Research Agency (ANR) Fondation pour la Recherche M\\u00e9dicale (FRM). In the past 36 months, he had a patent on anti\\u2010tau therapy issued. Jacques Touchon received payment or honoraria as chairman of CTAD. He received contracts from Regenlife and consulting fees from Regenlife. He is chairman of JT Conseil society. Jacques Hugon received grants or contracts from Protekt Therapeutics and consulting fees from Protekt Therapeutics. He is principal investigator of RECAGE project European Union H20/20 program and he is member of the scientific board of Fondation Philippe Chatrier, Paris, France. Bruno Vellas received grants or contracts from Biogen, Roche, and Lilly; consulting fees from Roche, Lily, Biogen, and Cerellis; and is part of WHO's ICOPE program (unpaid position). AthanBase Benetos is the president of the European Geriatric Medicine Society (unpaid position). He received support for attending meetings and/or travel from Fukuda company, for the Congress of the European Society of Hypertension, and received royalties or licenses from Cambridge University Editions. Gilles Berrut received a grant from Boehringer Ingelheim and consulting fees from Boehringer Ingelheim, Smart macadam Institut, bien vieillir Korian. Elena Paillaud has no conflicts of interest. David Wallon, Giovanni Castelnovo, Lisette Volpe\\u2010Gillot, Marc Paccalin, Philippe Robert, and Vincent Camus have no conflicts of interest. Olivier Godefroy received support to his institution for attending meetings and/or travel from BRISTOL\\u2010MYERS SQUIBB, ROCHE SAS, BIOGEN FRANCE SAS. Jo\\u00ebl Belmin received consulting fees from Pfizer and honoraria from Novartis Pharmaceuticals. Pierre Vandel is president of the \\u201cSoci\\u00e9t\\u00e9 Francophone de Psychog\\u00e9riatrie et Psychiatrie de la Personne Ag\\u00e9e\\u201d (SF3PA) and received consulting fees from Eisai. Jean\\u2010Luc Novella, Emmanuelle Duron, Anne\\u2010Sophie Rigaud, Susanna Schraen\\u2010Maschke, Bernard Sablonni\\u00e8re, and Audrey Gabelle have no conflicts of interest. Author disclosures are available in the supporting information.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 45874, \"infons\": {\"section_type\": \"COMP_INT\", \"type\": \"title_1\"}, \"text\": \"CONSENT STATEMENT\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 45892, \"infons\": {\"section_type\": \"COMP_INT\", \"type\": \"paragraph\"}, \"text\": \"All participants or their legal guardians gave written informed consent.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 45965, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"title_1\"}, \"text\": \"Supporting information\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 45988, \"infons\": {\"section_type\": \"REF\", \"type\": \"title\"}, \"text\": \"REFERENCES\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 45999, \"infons\": {\"fpage\": \"603\", \"lpage\": \"615\", \"pub-id_doi\": \"10.1016/j.cell.2015.12.056\", \"pub-id_pmid\": \"26871627\", \"section_type\": \"REF\", \"source\": \"Cell\", \"type\": \"ref\", \"volume\": \"164\", \"year\": \"2016\"}, \"text\": \"The cellular phase of Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46041, \"infons\": {\"fpage\": \"2716\", \"lpage\": \"2727\", \"pub-id_doi\": \"10.1038/s41380-023-02076-1\", \"pub-id_pmid\": \"37131074\", \"section_type\": \"REF\", \"source\": \"Mol Psychiatry\", \"type\": \"ref\", \"volume\": \"28\", \"year\": \"2023\"}, \"text\": \"Step by step: towards a better understanding of the genetic architecture of Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46137, \"infons\": {\"fpage\": \"137\", \"lpage\": \"152\", \"pub-id_doi\": \"10.1038/nrneurol.2011.2\", \"pub-id_pmid\": \"21304480\", \"section_type\": \"REF\", \"source\": \"Nat Rev Neurol\", \"type\": \"ref\", \"volume\": \"7\", \"year\": \"2011\"}, \"text\": \"Epidemiology of Alzheimer disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46171, \"infons\": {\"fpage\": \"83\", \"lpage\": \"133\", \"pub-id_pmid\": \"10049999\", \"section_type\": \"REF\", \"source\": \"Pharmacol Rev\", \"type\": \"ref\", \"volume\": \"51\", \"year\": \"1999\"}, \"text\": \"Actions of caffeine in the brain with special reference to factors that contribute to its widespread use\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46276, \"infons\": {\"fpage\": \"1891\", \"lpage\": \"1904\", \"pub-id_doi\": \"10.1056/NEJMoa1112010\", \"pub-id_pmid\": \"22591295\", \"section_type\": \"REF\", \"source\": \"N Engl J Med\", \"type\": \"ref\", \"volume\": \"366\", \"year\": \"2012\"}, \"text\": \"Association of coffee drinking with total and cause\\u2010specific mortality\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46349, \"infons\": {\"fpage\": \"201\", \"lpage\": \"203\", \"pub-id_doi\": \"10.1038/nn.3623\", \"pub-id_pmid\": \"24413697\", \"section_type\": \"REF\", \"source\": \"Nat Neurosci\", \"type\": \"ref\", \"volume\": \"17\", \"year\": \"2014\"}, \"text\": \"Post\\u2010study caffeine administration enhances memory consolidation in humans\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46426, \"infons\": {\"fpage\": \"1019\", \"lpage\": \"1055\", \"pub-id_doi\": \"10.1111/jnc.13724\", \"pub-id_pmid\": \"27365148\", \"section_type\": \"REF\", \"source\": \"J Neurochem\", \"type\": \"ref\", \"volume\": \"139\", \"year\": \"2016\"}, \"text\": \"How does adenosine control neuronal dysfunction and neurodegeneration?\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46497, \"infons\": {\"fpage\": \"369\", \"lpage\": \"378\", \"pub-id_doi\": \"10.1056/NEJMra1816604\", \"pub-id_pmid\": \"32706535\", \"section_type\": \"REF\", \"source\": \"N Engl J Med\", \"type\": \"ref\", \"volume\": \"383\", \"year\": \"2020\"}, \"text\": \"Coffee, Caffeine, and Health\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46526, \"infons\": {\"fpage\": \"536\", \"lpage\": \"545\", \"pub-id_doi\": \"10.1212/01.wnl.0000266670.35219.0c\", \"pub-id_pmid\": \"17679672\", \"section_type\": \"REF\", \"source\": \"Neurology\", \"type\": \"ref\", \"volume\": \"69\", \"year\": \"2007\"}, \"text\": \"The neuroprotective effects of caffeine: a prospective population study (the Three City Study)\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46621, \"infons\": {\"fpage\": \"226\", \"lpage\": \"232\", \"pub-id_doi\": \"10.1038/sj.ejcn.1602495\", \"pub-id_pmid\": \"16929246\", \"section_type\": \"REF\", \"source\": \"Eur J Clin Nutr\", \"type\": \"ref\", \"volume\": \"61\", \"year\": \"2007\"}, \"text\": \"Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46727, \"infons\": {\"fpage\": \"S175\", \"issue\": \"1\", \"lpage\": \"185\", \"pub-id_doi\": \"10.3233/JAD-2010-091303\", \"pub-id_pmid\": \"20182036\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"20\", \"year\": \"2010\"}, \"text\": \"Caffeine intake is associated with a lower risk of cognitive decline: a cohort study from Portugal\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46826, \"infons\": {\"fpage\": \"553\", \"lpage\": \"566\", \"pub-id_doi\": \"10.3233/JAD-2011-110431\", \"pub-id_pmid\": \"21841254\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"27\", \"year\": \"2011\"}, \"text\": \"Gender differences in tea, coffee, and cognitive decline in the elderly: the Cardiovascular Health Study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 46931, \"infons\": {\"fpage\": \"413\", \"lpage\": \"421\", \"pub-id_doi\": \"10.3233/JAD-122371\", \"pub-id_pmid\": \"23422357\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"35\", \"year\": \"2013\"}, \"text\": \"Caffeine and cognitive decline in elderly women at high vascular risk\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47001, \"infons\": {\"fpage\": \"889\", \"lpage\": \"899\", \"pub-id_doi\": \"10.3233/JAD-150333\", \"pub-id_pmid\": \"26401769\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"47\", \"year\": \"2015\"}, \"text\": \"Coffee consumption habits and the risk of mild cognitive impairment: the Italian Longitudinal Study on Aging\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47110, \"infons\": {\"fpage\": \"491\", \"lpage\": \"500\", \"pub-id_doi\": \"10.3233/JAD-150693\", \"pub-id_pmid\": \"26682686\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"50\", \"year\": \"2016\"}, \"text\": \"Association between coffee consumption and incident risk of disabling dementia in elderly Japanese: the Ohsaki Cohort 2006 Study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47239, \"infons\": {\"fpage\": \"387\", \"lpage\": \"395\", \"pub-id_doi\": \"10.1007/s00234-017-1803-5\", \"pub-id_pmid\": \"28289811\", \"section_type\": \"REF\", \"source\": \"Neuroradiology\", \"type\": \"ref\", \"volume\": \"59\", \"year\": \"2017\"}, \"text\": \"Caffeine impact on working memory\\u2010related network activation patterns in early stages of cognitive decline\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47348, \"infons\": {\"fpage\": \"2158\", \"lpage\": \"2168\", \"pub-id_doi\": \"10.1016/j.clnu.2019.09.003\", \"pub-id_pmid\": \"31582197\", \"section_type\": \"REF\", \"source\": \"Clin Nutr\", \"type\": \"ref\", \"volume\": \"39\", \"year\": \"2020\"}, \"text\": \"Association between caffeine intake and cognitive function in adults; effect modification by sex: data from National Health and Nutrition Examination Survey (NHANES) 2013\\u20102014\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47526, \"infons\": {\"fpage\": \"840\", \"pub-id_doi\": \"10.3390/nu12030840\", \"pub-id_pmid\": \"32245123\", \"section_type\": \"REF\", \"source\": \"Nutrients\", \"type\": \"ref\", \"volume\": \"12\", \"year\": \"2020\"}, \"text\": \"Association of coffee, decaffeinated coffee and caffeine intake from coffee with cognitive performance in older adults: National Health and Nutrition Examination Survey (NHANES) 2011\\u20102014\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47716, \"infons\": {\"fpage\": \"3737\", \"pub-id_doi\": \"10.3390/molecules27123737\", \"pub-id_pmid\": \"35744865\", \"section_type\": \"REF\", \"source\": \"Molecules\", \"type\": \"ref\", \"volume\": \"27\", \"year\": \"2022\"}, \"text\": \"Neuroprotective effect of caffeine in Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47774, \"infons\": {\"fpage\": \"445\", \"lpage\": \"453\", \"pub-id_doi\": \"10.1093/aje/kwf074\", \"pub-id_pmid\": \"12196314\", \"section_type\": \"REF\", \"source\": \"Am J Epidemiol\", \"type\": \"ref\", \"volume\": \"156\", \"year\": \"2002\"}, \"text\": \"Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47879, \"infons\": {\"fpage\": \"377\", \"lpage\": \"382\", \"pub-id_doi\": \"10.1046/j.1468-1331.2002.00421.x\", \"pub-id_pmid\": \"12099922\", \"section_type\": \"REF\", \"source\": \"Eur J Neurol\", \"type\": \"ref\", \"volume\": \"9\", \"year\": \"2002\"}, \"text\": \"Does caffeine intake protect from Alzheimer's disease?\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 47934, \"infons\": {\"fpage\": \"85\", \"lpage\": \"91\", \"pub-id_doi\": \"10.3233/JAD-2009-0920\", \"pub-id_pmid\": \"19158424\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"16\", \"year\": \"2009\"}, \"text\": \"Midlife coffee and tea drinking and the risk of late\\u2010life dementia: a population\\u2010based CAIDE study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48037, \"infons\": {\"fpage\": \"21\", \"lpage\": \"26\", \"pub-id_doi\": \"10.1097/WAD.0000000000000087\", \"pub-id_pmid\": \"25710250\", \"section_type\": \"REF\", \"source\": \"Alzheimer Dis Assoc Disord\", \"type\": \"ref\", \"volume\": \"30\", \"year\": \"2016\"}, \"text\": \"Lifestyle factors and dementia in the oldest\\u2010old: the 90+ Study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48103, \"infons\": {\"fpage\": \"100\", \"lpage\": \"107\", \"pub-id_doi\": \"10.1007/s12603-020-1436-y\", \"pub-id_pmid\": \"33367469\", \"section_type\": \"REF\", \"source\": \"J Nutr Health Aging\", \"type\": \"ref\", \"volume\": \"25\", \"year\": \"2021\"}, \"text\": \"Caffeine consumption and behavioral symptoms in nursing home residents: a cross\\u2010sectional analysis\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48204, \"infons\": {\"fpage\": \"S151\", \"issue\": \"1\", \"lpage\": \"159\", \"pub-id_doi\": \"10.3233/JAD-2010-1409\", \"pub-id_pmid\": \"20182052\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"20\", \"year\": \"2010\"}, \"text\": \"Caffeine, cognition, and socioeconomic status\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48250, \"infons\": {\"fpage\": \"451\", \"lpage\": \"461\", \"pub-id_doi\": \"10.3233/JAD-160116\", \"pub-id_pmid\": \"27163820\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"53\", \"year\": \"2016\"}, \"text\": \"Association of coffee consumption with MRI markers and cognitive function: a population\\u2010based study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48352, \"infons\": {\"fpage\": \"834\", \"lpage\": \"846\", \"pub-id_doi\": \"10.1002/ana.26349\", \"pub-id_pmid\": \"35288978\", \"section_type\": \"REF\", \"source\": \"Ann Neurol\", \"type\": \"ref\", \"volume\": \"91\", \"year\": \"2022\"}, \"text\": \"Caffeine consumption and dementia: are Lewy bodies the link?\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48413, \"infons\": {\"fpage\": \"852\", \"pub-id_doi\": \"10.3390/nu10070852\", \"pub-id_pmid\": \"29966314\", \"section_type\": \"REF\", \"source\": \"Nutrients\", \"type\": \"ref\", \"volume\": \"10\", \"year\": \"2018\"}, \"text\": \"Prospective associations between single foods, Alzheimer's dementia and memory decline in the elderly\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48515, \"infons\": {\"fpage\": \"941\", \"lpage\": \"952\", \"pub-id_doi\": \"10.1016/j.neuroscience.2006.07.021\", \"pub-id_pmid\": \"16938404\", \"section_type\": \"REF\", \"source\": \"Neuroscience\", \"type\": \"ref\", \"volume\": \"142\", \"year\": \"2006\"}, \"text\": \"Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta\\u2010amyloid production\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48623, \"infons\": {\"fpage\": \"661\", \"lpage\": \"680\", \"pub-id_doi\": \"10.3233/JAD-2009-1087\", \"pub-id_pmid\": \"19581722\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"17\", \"year\": \"2009\"}, \"text\": \"Caffeine reverses cognitive impairment and decreases brain amyloid\\u2010beta levels in aged Alzheimer's disease mice\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48737, \"infons\": {\"fpage\": \"2079\", \"lpage\": \"2090\", \"pub-id_doi\": \"10.1016/j.neurobiolaging.2014.03.027\", \"pub-id_pmid\": \"24780254\", \"section_type\": \"REF\", \"source\": \"Neurobiol Aging\", \"type\": \"ref\", \"volume\": \"35\", \"year\": \"2014\"}, \"text\": \"Beneficial effects of caffeine in a transgenic model of Alzheimer's disease\\u2010like tau pathology\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 48834, \"infons\": {\"elocation-id\": \"744872\", \"pub-id_doi\": \"10.3389/fnagi.2021.744872\", \"pub-id_pmid\": \"34867277\", \"section_type\": \"REF\", \"source\": \"Front Aging Neurosci\", \"type\": \"ref\", \"volume\": \"13\", \"year\": \"2021\"}, \"text\": \"Higher coffee consumption is associated with slower cognitive decline and less cerebral A\\u03b2\\u2010amyloid accumulation over 126 months: data from the Australian imaging, biomarkers, and lifestyle study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49032, \"infons\": {\"fpage\": \"270\", \"pub-id_doi\": \"10.1038/s41398-019-0604-5\", \"pub-id_pmid\": \"31641100\", \"section_type\": \"REF\", \"source\": \"Transl Psychiatry\", \"type\": \"ref\", \"volume\": \"9\", \"year\": \"2019\"}, \"text\": \"Coffee intake and decreased amyloid pathology in human brain\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49093, \"infons\": {\"fpage\": \"483\", \"lpage\": \"493\", \"pub-id_doi\": \"10.3233/JAD-220591\", \"pub-id_pmid\": \"37038808\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"93\", \"year\": \"2023\"}, \"text\": \"Association of caffeine consumption and brain amyloid positivity in cognitively normal older adults\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49193, \"infons\": {\"fpage\": \"1069\", \"lpage\": \"1078\", \"pub-id_doi\": \"10.3233/JAD-150374\", \"pub-id_pmid\": \"26401784\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"47\", \"year\": \"2015\"}, \"text\": \"Does caffeine consumption modify cerebrospinal fluid amyloid\\u2010\\u03b2 levels in patients with Alzheimer's disease?\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49304, \"infons\": {\"fpage\": \"939\", \"lpage\": \"939\", \"pub-id_doi\": \"10.1212/WNL.34.7.939\", \"pub-id_pmid\": \"6610841\", \"section_type\": \"REF\", \"source\": \"Neurology\", \"type\": \"ref\", \"volume\": \"34\", \"year\": \"1984\"}, \"text\": \"Clinical diagnosis of Alzheimer's disease: report of the NINCDS\\u2010ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49484, \"infons\": {\"fpage\": \"303\", \"lpage\": \"308\", \"pub-id_doi\": \"10.1001/archneur.56.3.303\", \"pub-id_pmid\": \"10190820\", \"section_type\": \"REF\", \"source\": \"Arch Neurol\", \"type\": \"ref\", \"volume\": \"56\", \"year\": \"1999\"}, \"text\": \"Mild cognitive impairment: clinical characterization and outcome\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49549, \"infons\": {\"fpage\": \"858\", \"lpage\": \"868\", \"pub-id_doi\": \"10.1016/j.jalz.2018.01.004\", \"pub-id_pmid\": \"29458036\", \"section_type\": \"REF\", \"source\": \"Alzheimers Dement\", \"type\": \"ref\", \"volume\": \"14\", \"year\": \"2018\"}, \"text\": \"Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49643, \"infons\": {\"fpage\": \"183\", \"lpage\": \"194\", \"pub-id_doi\": \"10.1111/j.1365-2796.2004.01388.x\", \"pub-id_pmid\": \"15324362\", \"section_type\": \"REF\", \"source\": \"J Intern Med\", \"type\": \"ref\", \"volume\": \"256\", \"year\": \"2004\"}, \"text\": \"Mild cognitive impairment as a diagnostic entity\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49692, \"infons\": {\"fpage\": \"179\", \"lpage\": \"182\", \"pub-id_doi\": \"10.1016/j.nbd.2013.05.013\", \"pub-id_pmid\": \"23732677\", \"section_type\": \"REF\", \"source\": \"Neurobiol Dis\", \"type\": \"ref\", \"volume\": \"58\", \"year\": \"2013\"}, \"text\": \"Association between caffeine intake and age at onset in Huntington's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49769, \"infons\": {\"fpage\": \"2537\", \"lpage\": \"2550\", \"pub-id_doi\": \"10.1002/alz.12613\", \"pub-id_pmid\": \"35187794\", \"section_type\": \"REF\", \"source\": \"Alzheimers Dement\", \"type\": \"ref\", \"volume\": \"18\", \"year\": \"2022\"}, \"text\": \"Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: the BALTAZAR study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49884, \"infons\": {\"fpage\": \"559\", \"lpage\": \"572\", \"pub-id_doi\": \"10.3233/JAD-2012-111781\", \"pub-id_pmid\": \"22430531\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"30\", \"year\": \"2012\"}, \"text\": \"High blood caffeine levels in MCI linked to lack of progression to dementia\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 49960, \"infons\": {\"fpage\": \"683\", \"lpage\": \"688\", \"pub-id_doi\": \"10.1093/gerona/gly090\", \"pub-id_pmid\": \"29982422\", \"section_type\": \"REF\", \"source\": \"J Gerontol A Biol Sci Med Sci\", \"type\": \"ref\", \"volume\": \"74\", \"year\": \"2019\"}, \"text\": \"Age modulates the association of caffeine intake with cognition and with Gray matter in elderly diabetics\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50066, \"infons\": {\"fpage\": \"1015\", \"pub-id_doi\": \"10.3389/fnins.2018.01015\", \"pub-id_pmid\": \"30686981\", \"section_type\": \"REF\", \"source\": \"Front Neurosci\", \"type\": \"ref\", \"volume\": \"12\", \"year\": \"2019\"}, \"text\": \"Impact of caffeine consumption on type 2 diabetes\\u2010induced spatial memory impairment and neurochemical alterations in the hippocampus\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50201, \"infons\": {\"fpage\": \"S143\", \"issue\": \"1\", \"lpage\": \"150\", \"pub-id_doi\": \"10.3233/JAD-2010-091228\", \"pub-id_pmid\": \"20182038\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"20\", \"year\": \"2010\"}, \"text\": \"Caffeine, diabetes, cognition, and dementia\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50245, \"infons\": {\"fpage\": \"1859\", \"lpage\": \"1867\", \"pub-id_doi\": \"10.1212/01.wnl.0000279336.36610.f7\", \"pub-id_pmid\": \"17984454\", \"section_type\": \"REF\", \"source\": \"Neurology\", \"type\": \"ref\", \"volume\": \"69\", \"year\": \"2007\"}, \"text\": \"Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50337, \"infons\": {\"fpage\": \"313\", \"lpage\": \"321\", \"pub-id_doi\": \"10.1016/j.bcp.2019.06.008\", \"pub-id_pmid\": \"31199895\", \"section_type\": \"REF\", \"source\": \"Biochem Pharmacol\", \"type\": \"ref\", \"volume\": \"166\", \"year\": \"2019\"}, \"text\": \"The physiological effects of caffeine on synaptic transmission and plasticity in the mouse hippocampus selectively depend on adenosine A1 and A2A receptors\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50493, \"infons\": {\"fpage\": \"S25\", \"lpage\": \"34\", \"pub-id_doi\": \"10.3233/JAD-2010-091384\", \"pub-id_pmid\": \"20182030\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"20\", \"year\": \"2010\"}, \"text\": \"Caffeine, adenosine receptors, and synaptic plasticity\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50548, \"infons\": {\"fpage\": \"23\", \"lpage\": \"25\", \"pub-id_doi\": \"10.1038/nn.2962\", \"section_type\": \"REF\", \"source\": \"Nat Neurosci\", \"type\": \"ref\", \"volume\": \"15\", \"year\": \"2012\"}, \"text\": \"Caffeine\\u2010induced synaptic potentiation in hippocampal CA2 neurons\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50616, \"infons\": {\"fpage\": \"1111\", \"lpage\": \"1115\", \"pub-id_doi\": \"10.1248/bpb.b17-00101\", \"pub-id_pmid\": \"28674254\", \"section_type\": \"REF\", \"source\": \"Biol Pharm Bull\", \"type\": \"ref\", \"volume\": \"40\", \"year\": \"2017\"}, \"text\": \"Caffeine increases hippocampal sharp waves in vitro\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50668, \"infons\": {\"fpage\": \"647\", \"lpage\": \"651\", \"pub-id_doi\": \"10.1007/s00221-018-5450-9\", \"pub-id_pmid\": \"30535949\", \"section_type\": \"REF\", \"source\": \"Exp Brain Res\", \"type\": \"ref\", \"volume\": \"237\", \"year\": \"2019\"}, \"text\": \"Effect of caffeine on long\\u2010term potentiation\\u2010like effects induced by quadripulse transcranial magnetic stimulation\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50787, \"infons\": {\"fpage\": \"899\", \"pub-id_doi\": \"10.3389/fphar.2017.00899\", \"pub-id_pmid\": \"29354052\", \"section_type\": \"REF\", \"source\": \"Front Pharmacol\", \"type\": \"ref\", \"volume\": \"8\", \"year\": \"2018\"}, \"text\": \"Caffeine controls glutamatergic synaptic transmission and pyramidal neuron excitability in human neocortex\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 50894, \"infons\": {\"elocation-id\": \"e149371\", \"pub-id_doi\": \"10.1172/JCI149371\", \"pub-id_pmid\": \"35536645\", \"section_type\": \"REF\", \"source\": \"J Clin Invest\", \"type\": \"ref\", \"volume\": \"132\", \"year\": \"2022\"}, \"text\": \"Caffeine intake exerts dual genome\\u2010wide effects on hippocampal metabolism and learning\\u2010dependent transcription\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51009, \"infons\": {\"fpage\": \"1876\", \"lpage\": \"1900\", \"pub-id_doi\": \"10.1038/s41380-018-0110-9\", \"pub-id_pmid\": \"29950682\", \"section_type\": \"REF\", \"source\": \"Mol Psychiatry\", \"type\": \"ref\", \"volume\": \"25\", \"year\": \"2020\"}, \"text\": \"Age\\u2010related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51126, \"infons\": {\"elocation-id\": \"e20200861\", \"pub-id_doi\": \"10.1084/jem.20200861\", \"pub-id_pmid\": \"32725127\", \"section_type\": \"REF\", \"source\": \"J Exp Med\", \"type\": \"ref\", \"volume\": \"217\", \"year\": \"2020\"}, \"text\": \"Blood plasma phosphorylated\\u2010tau isoforms track CNS change in Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51209, \"infons\": {\"pub-id_doi\": \"10.1212/WNL.0000000000012513\", \"section_type\": \"REF\", \"source\": \"Neurology\", \"type\": \"ref\", \"volume\": \"97\", \"year\": \"2021\"}, \"text\": \"Associations of fully automated CSF and novel plasma biomarkers with Alzheimer disease neuropathology at autopsy\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51322, \"infons\": {\"fpage\": \"1827\", \"lpage\": \"1835\", \"pub-id_doi\": \"10.1212/WNL.0000000000003246\", \"pub-id_pmid\": \"27694257\", \"section_type\": \"REF\", \"source\": \"Neurology\", \"type\": \"ref\", \"volume\": \"87\", \"year\": \"2016\"}, \"text\": \"Plasma tau in Alzheimer disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51354, \"infons\": {\"fpage\": \"9\", \"pub-id_doi\": \"10.1186/alzrt163\", \"pub-id_pmid\": \"23551972\", \"section_type\": \"REF\", \"source\": \"Alzheimers Res Ther\", \"type\": \"ref\", \"volume\": \"5\", \"year\": \"2013\"}, \"text\": \"Plasma tau levels in Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51395, \"infons\": {\"fpage\": \"411\", \"lpage\": \"419\", \"pub-id_doi\": \"10.1136/jnnp-2022-330540\", \"pub-id_pmid\": \"37012068\", \"section_type\": \"REF\", \"source\": \"J Neurol Neurosurg Psychiatry\", \"type\": \"ref\", \"volume\": \"94\", \"year\": \"2023\"}, \"text\": \"Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51510, \"infons\": {\"elocation-id\": \"17361\", \"pub-id_doi\": \"10.3390/ijms242417361\", \"pub-id_pmid\": \"38139190\", \"section_type\": \"REF\", \"source\": \"Int J Mol Sci\", \"type\": \"ref\", \"volume\": \"24\", \"year\": \"2023\"}, \"text\": \"Blood neurofilament levels predict cognitive decline across the Alzheimer's disease continuum\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51604, \"infons\": {\"elocation-id\": \"1034684\", \"pub-id_doi\": \"10.3389/fnagi.2022.1034684\", \"pub-id_pmid\": \"36389064\", \"section_type\": \"REF\", \"source\": \"Front Aging Neurosci\", \"type\": \"ref\", \"volume\": \"14\", \"year\": \"2022\"}, \"text\": \"Neurofilaments contribution in clinic: state of the art\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51660, \"infons\": {\"fpage\": \"9019\", \"lpage\": \"9033\", \"pub-id_doi\": \"10.1021/acs.jpcb.6b03892\", \"pub-id_pmid\": \"27487451\", \"section_type\": \"REF\", \"source\": \"J Phys Chem B\", \"type\": \"ref\", \"volume\": \"120\", \"year\": \"2016\"}, \"text\": \"Action of caffeine as an amyloid inhibitor in the aggregation of A\\u03b2 16\\u201022 peptides\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51746, \"infons\": {\"fpage\": \"689\", \"pub-id_doi\": \"10.3390/biom9110689\", \"pub-id_pmid\": \"31684105\", \"section_type\": \"REF\", \"source\": \"Biomolecules\", \"type\": \"ref\", \"volume\": \"9\", \"year\": \"2019\"}, \"text\": \"Effect of caffeine and other methylxanthines on A\\u03b2\\u2010homeostasis in SH\\u2010SY5Y cells\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51831, \"infons\": {\"fpage\": \"681\", \"lpage\": \"697\", \"pub-id_doi\": \"10.3233/JAD-2009-1071\", \"pub-id_pmid\": \"19581723\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"17\", \"year\": \"2009\"}, \"text\": \"Caffeine suppresses amyloid\\u2010\\u03b2 levels in plasma and brain of Alzheimer's disease transgenic mice\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 51930, \"infons\": {\"elocation-id\": \"e88508\", \"pub-id_doi\": \"10.1371/journal.pone.0088508\", \"pub-id_pmid\": \"24523906\", \"section_type\": \"REF\", \"source\": \"PLoS One\", \"type\": \"ref\", \"volume\": \"9\", \"year\": \"2014\"}, \"text\": \"Hydrogen sulfide inhibits A2A adenosine receptor agonist induced \\u03b2\\u2010Amyloid production in SH\\u2010SY5Y neuroblastoma cells via a cAMP dependent pathway\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 52081, \"infons\": {\"fpage\": \"235\", \"pub-id_doi\": \"10.3389/fnmol.2018.00235\", \"pub-id_pmid\": \"30050407\", \"section_type\": \"REF\", \"source\": \"Front Mol Neurosci\", \"type\": \"ref\", \"volume\": \"11\", \"year\": \"2018\"}, \"text\": \"Beneficial effect of a selective adenosine A2A receptor antagonist in the APPswe/PS1dE9 mouse model of Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 52204, \"infons\": {\"fpage\": \"151\", \"lpage\": \"165\", \"pub-id_doi\": \"10.3233/JAD-2012-120319\", \"pub-id_pmid\": \"22504320\", \"section_type\": \"REF\", \"source\": \"J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"31\", \"year\": \"2012\"}, \"text\": \"Enhanced brain amyloid\\u2010\\u03b2 clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 52332, \"infons\": {\"elocation-id\": \"617420\", \"pub-id_doi\": \"10.4061/2011/617420\", \"pub-id_pmid\": \"21660211\", \"section_type\": \"REF\", \"source\": \"Int J Alzheimers Dis\", \"type\": \"ref\", \"volume\": \"2011\", \"year\": \"2011\"}, \"text\": \"Increased cerebrospinal fluid production as a possible mechanism underlying caffeine's protective effect against Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 52465, \"infons\": {\"fpage\": \"408\", \"pub-id_doi\": \"10.3390/biomedicines11020408\", \"pub-id_pmid\": \"36830944\", \"section_type\": \"REF\", \"source\": \"Biomedicines\", \"type\": \"ref\", \"volume\": \"11\", \"year\": \"2023\"}, \"text\": \"The vascular\\u2010immune hypothesis of Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 52521, \"infons\": {\"elocation-id\": \"109379\", \"pub-id_doi\": \"10.1016/j.neuropharm.2022.109379\", \"pub-id_pmid\": \"36572177\", \"section_type\": \"REF\", \"source\": \"Neuropharmacology\", \"type\": \"ref\", \"volume\": \"226\", \"year\": \"2023\"}, \"text\": \"The role of adenosine A2A receptors in Alzheimer's disease and tauopathies\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 52596, \"infons\": {\"fpage\": \"459\", \"lpage\": \"472\", \"pub-id_doi\": \"10.1083/jcb.201709069\", \"pub-id_pmid\": \"29196460\", \"section_type\": \"REF\", \"source\": \"J Cell Biol\", \"type\": \"ref\", \"volume\": \"217\", \"year\": \"2018\"}, \"text\": \"Microglia in Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 52629, \"infons\": {\"fpage\": \"326\", \"lpage\": \"332\", \"pub-id_doi\": \"10.1007/s12031-010-9444-8\", \"pub-id_pmid\": \"20838929\", \"section_type\": \"REF\", \"source\": \"J Mol Neurosci\", \"type\": \"ref\", \"volume\": \"43\", \"year\": \"2011\"}, \"text\": \"Caffeine modulates tau phosphorylation and affects Akt signaling in postmitotic neurons\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 52717, \"infons\": {\"fpage\": \"1\", \"lpage\": \"8\", \"pub-id_doi\": \"10.1016/j.nbd.2016.10.004\", \"pub-id_pmid\": \"27793638\", \"section_type\": \"REF\", \"source\": \"Neurobiol Dis\", \"type\": \"ref\", \"volume\": \"98\", \"year\": \"2017\"}, \"text\": \"Tau hyperphosphorylation in the brain of ob/ob mice is due to hypothermia: importance of thermoregulation in linking diabetes and Alzheimer's disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}], \"annotations\": [], \"relations\": []}]}]\n",
      "Json error for string:  [{\"bioctype\": \"BioCCollection\", \"source\": \"PMC\", \"date\": \"20240911\", \"key\": \"pmc.key\", \"version\": \"1.0\", \"infons\": {}, \"documents\": [{\"bioctype\": \"BioCDocument\", \"id\": \"PMC9974914\", \"infons\": {\"license\": \"CC BY-NC-ND\"}, \"passages\": [{\"bioctype\": \"BioCPassage\", \"offset\": 0, \"infons\": {\"article-id_doi\": \"10.1016/j.envint.2023.107800\", \"article-id_manuscript\": \"NIHMS1876059\", \"article-id_pmc\": \"PMC9974914\", \"article-id_pmid\": \"36773564\", \"fpage\": \"107800\", \"kwd\": \"Air pollution Alzheimer\\u2019s disease Dementia Biomarkers Amyloid beta Aging\", \"license\": \"This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).\", \"lpage\": \"107800\", \"name_0\": \"surname:Hajat;given-names:Anjum\", \"name_1\": \"surname:Park;given-names:Christina\", \"name_2\": \"surname:Adam;given-names:Claire\", \"name_3\": \"surname:Fitzpatrick;given-names:Annette L.\", \"name_4\": \"surname:Ilango;given-names:Sindana D.\", \"name_5\": \"surname:Leary;given-names:Cindy\", \"name_6\": \"surname:Libby;given-names:Tanya\", \"name_7\": \"surname:Lopez;given-names:Oscar\", \"name_8\": \"surname:Semmens;given-names:Erin O.\", \"name_9\": \"surname:Kaufman;given-names:Joel D.\", \"section_type\": \"TITLE\", \"type\": \"front\", \"volume\": \"172\", \"year\": \"2023\"}, \"text\": \"Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 119, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract\"}, \"text\": \"Air pollution has been linked to Alzheimer\\u2019s disease and related dementias (ADRD), but the mechanisms connecting air pollution to ADRD have not been firmly established. Air pollution may cause oxidative stress and neuroinflammation and contribute to the deposition of amyloid beta (A\\u03b2) in the brain. We examined the association between fine particulate matter<2.5 \\u03bcm in diameter (PM2.5), particulate matter<10 \\u03bcm in diameter (PM10), nitrogen dioxide (NO2), and plasma based measures of A\\u03b21\\u201340, A\\u03b21\\u201342 and A\\u03b21\\u201342/A\\u03b21\\u201340 using data from 3044 dementia-free participants of the Ginkgo Evaluation of Memory Study (GEMS). Air pollution exposures were estimated at residential addresses that incorporated address histories dating back to 1980, resulting in one-, five-, 10- and 20- year exposure averages. A\\u03b2 was measured at baseline (2000\\u20132002) and then again at the end of the study (2007\\u20132008) allowing for linear regression models to assess cross-sectional associations and linear random effects models to evaluate repeated measures. After adjustment for socio-demographic and behavioral covariates, we found small positive associations between each air pollutant and A\\u03b21\\u201340 but no association with A\\u03b21\\u201342 or the ratio measures in cross sectional analysis. In repeat measures analysis, we found larger positive associations between each air pollutant and all three outcomes. We observed a 4.43% (95% CI 3.26%, 5.60%) higher A\\u03b21\\u201340 level, 9.73% (6.20%, 13.38%) higher A\\u03b21\\u201342 and 1.57% (95% CI: 0.94%, 2.20%) higher A\\u03b21\\u201342/A\\u03b21\\u201340 ratio associated with a 2 \\u03bcg/m3 higher 20-year average PM2.5. Associations with other air pollutants were similar. Our study contributes to the broader evidence base on air pollution and ADRD biomarkers by evaluating longer air pollution exposure averaging periods to better mimic disease progression and provides a modifiable target for ADRD prevention.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 2040, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"title_1\"}, \"text\": \"Introduction\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 2053, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"The global population is rapidly aging. Globally, the percentage of people age 65 and older is expected to increase from 8% in 2010 to 16% by 2050. With the aging population, cases of dementia are also anticipated to rise, resulting in an estimated 152.8 million cases, a tripling, by 2050. Treatments for Alzheimer\\u2019s Disease and related dementias (ADRD) remain elusive, but several modifiable risk factors have been identified. In addition to lifestyle factors such as exercise and diet, environmental hazards such as air pollution have also been linked to ADRD.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 2619, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"The mechanism by which air pollution causes dementia has not yet been firmly established. Several animal studies suggest that air pollution through its impacts on the central nervous system (CNS) causes neuroinflammation and oxidative stress, which are critical to the development of ADRD. In addition, by altering the activity of key enzymes, air pollution may increase deposition of amyloid beta (A\\u03b2) in the brain, a hallmark of Alzheimer\\u2019s disease (AD). Animal studies have found that long-term exposure to traffic-related air pollution (TRAP) resulted in more A\\u03b2 plaques in animals exposed to TRAP compared to those exposed to filtered air.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 3270, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"Although the utility of treatments that reduce A\\u03b2 plaques as a means to improve cognitive function have been debated, understanding the mechanism by which air pollution impacts brain health remains an important endeavor. A\\u03b21\\u201340, a peptide with a chain of 40 amino acids, has proinflammatory and atherosclerotic properties and has been associated with cardiovascular disease and diabetes; studying A\\u03b21\\u201340 and air pollution can also shed light on other disease processes. A\\u03b21\\u201342, on the other hand, is a key component of A\\u03b2 plaques found in the brain.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 3835, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"Unlike A\\u03b2 plaques in the brain, the presence of A\\u03b2 in plasma is expected. Plasma A\\u03b2 biomarkers are dynamic over time, can be impacted by various factors and have different trajectories for cognitively intact individuals compared to those that go on to develop dementia. For the cognitively intact, plasma A\\u03b2 levels increase with age while for those who transition from intact to MCI to AD, a decline in plasma A\\u03b2 biomarkers is seen over time. A\\u03b2 from the brain can be transported to the blood via the blood brain barrier (and vice versa). In disease-free individuals, soluble A\\u03b2 found in the brain could clear into the blood resulting in higher plasma levels, while in diseased persons, the soluble A\\u03b2 turns into insoluble A\\u03b2 plaques in the brain, which the body is unable to clear, resulting in lower plasma levels.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 4679, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"Given that higher air pollution has been shown to result in worse outcomes (greater cognitive decline and more dementia), we would expect that higher air pollution levels would be associated with lower plasma A\\u03b2 levels among those who go on to develop dementia but higher among those who remain disease free. Higher plasma A\\u03b2 levels may signify air pollution\\u2019s role in accelerating plasma A\\u03b2 levels that could then result in worse cognitive health.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 5137, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"Only a few studies have explored the association between air pollution and A\\u03b2 in humans, some using positron emission tomography (PET) scans or magnetic resonance imaging (MRI) to identify A\\u03b2, others using cerebrospinal fluid (CSF) or autopsy data. Overall the research finds a positive association between air pollution and A\\u03b2; studies using imaging data show a more consistent association. These approaches, although effective at identifying A\\u03b2, have disadvantages in terms of ease, cost and participant burden relative to blood biomarkers of AD. To our knowledge, no study has examined the effect of air pollution on plasma-based A\\u03b2 biomarkers.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 5800, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"Researchers continue to search for highly sensitive approaches to measuring A\\u03b2 in the blood in hopes of developing a diagnostic test to more easily identify ADRD. Once identified, these approaches will allow for a better understanding of the mechanisms underlying demonstrated associations between air pollution and dementia. In this study we examined the associations between air pollution and plasma based biomarkers of A\\u03b2 both cross-sectionally and in repeated measures in a cohort of dementia-free older adults.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 6322, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_1\"}, \"text\": \"Materials and methods\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 6344, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"This study consisted of 3,069 adults aged 75 years or older who were free of dementia at baseline and enrolled in the Ginkgo Evaluation of Memory Study (GEMS), a randomized double-blind controlled trial originally designed to evaluate the efficacy of Ginkgo biloba on AD and dementia. Participants were recruited from four US study sites (Winston-Salem, North Carolina; Hagerstown, Maryland; Sacramento, California; and Pittsburgh, Pennsylvania) between 2000 and 2002 and followed through 2008. Participants were censored upon death, the development of ADRD or loss to follow-up. This study was approved by the Institutional Review Board at the University of Washington and all institutions affiliated with the trial.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 7062, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_2\"}, \"text\": \"Exposure ascertainment\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 7085, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Primary exposures of interest were long-term residential concentrations of fine particulate matter<2.5 \\u03bcm in diameter (PM2.5), particulate matter<10 \\u03bcm in diameter (PM10) and nitrogen dioxide (NO2) estimated at participant residential addresses. Address histories dating back to 1980 (20 years prior to study entry) were reconstructed using data from LexisNexis (LN), a data analytics corporation that applies a proprietary algorithm to publicly available real estate, driver\\u2019s license, voting and court records to identify residential history. LN has been used by a few previous epidemiologic studies to create residential histories. For individuals missing historical residential address data, we used air pollution estimates from last known residential address. More information on the reconstruction of residential histories can be found in the supplement of.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 7953, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"A previously-described spatiotemporal model was then applied to individual addresses to predict air pollution concentrations at participant\\u2019s address. Briefly, the model uses inputs from EPA monitoring data and over 300 geographic covariates to predict air pollution. External validation statistics show good performance of the air pollution prediction models, with R2 ranging from 0.84 to 0.91 for PM2.5 and 0.78 to 0.88 for NO2. Several exposure metrics reflecting different averaging periods were created to better understand when during the life course exposure to air pollution was most strongly associated with A\\u03b2 and to better reflect the development of ADRD. Exposure to PM2.5 was estimated by averaging one, five, ten, and 20 years of modeled PM2.5 prior to the date of blood draw. Estimates of PM10 and NO2 were based only on one-, five- and ten-year exposure metrics because data were not available to create a 20-year prediction.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 8898, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_2\"}, \"text\": \"Outcome ascertainment\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 8920, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Primary outcomes of interest were levels of plasma A\\u03b21\\u201340, A\\u03b21\\u201342 and A\\u03b21\\u201342/A\\u03b21\\u201340 ratio. The ratio of A\\u03b21\\u201342/A\\u03b21\\u201340, both in plasma and CSF, has been found to improve diagnosis of AD relative to A\\u03b21\\u201342 alone and is used frequently in research. A\\u03b2 levels were measured from stored blood samples collected in 2000\\u20132002 and 2007\\u20132008 using a sandwich ELISA initially developed by Eli Lilly and implemented at the University of Vermont Laboratory for Clinical Biochemistry. Interassay coefficients of variation ranged from 3.1% to 7.9% for A\\u03b21\\u201340 and 12.0% to 20.0% for A\\u03b21\\u201342.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 9528, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_2\"}, \"text\": \"Covariates\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 9539, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Covariates included basic socio-demographic characteristics: continuous age, sex (male or female), race (white or person of color), education (high school or less, some college, college graduate or postgraduate), and study site (Winston-Salem, NC; Sacramento, CA; Hagerstown, MD; and Pittsburgh, PA). Although the GEMS clinical trial was negative, treatment assignment (Ginkgo biloba vs placebo) was included to account for potential differences between the two arms of the original study. Cystatin C (from plasma collected at the same time as A\\u03b2) was an additional covariate given its role in binding to soluble A\\u03b2 and inhibiting A\\u03b2 deposition in the brain.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 10207, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"A neighborhood deprivation index (NDI) was created for all GEMS participants because of the lack of data on individual income and to account for its potential role as a confounder between air pollution and A\\u03b2. Annual NDI values for each participant were based on the census tract of residence and were created from decennial Census data from 1980, 1990, 2000 and American Community Survey (ACS) 2005\\u20132009. Previous research used over 30 Census variables to conduct a principal components analysis (PCA) to identify the variables that most strongly represented the latent construct of neighborhood disadvantage. Seven variables were identified from the PCA (% of adults age 25 or older with at least a high school education; % of adults age 25 or older with at least a Bachelor\\u2019s degree; % of persons age 16 and older with executive, managerial, or professional occupation; median value of owner occupied housing units; median household income; % of households with income of at least $50,000; and % of households with interest, dividend, or net rental income) and weighted according to factor loadings (see supplementary material for more information).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 11365, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Covariates to account for behavioral factors were smoking status (current, former, never), pack-years smoking, percentage of life exposed to secondhand smoke (created by dividing the number of years exposed to secondhand smoke by age at baseline), alcohol consumption (yes/no), and physical activity. We created a physical activity score based on responses to questions from the GEMS questionnaires that are adapted from components of the validated Physical Activity Scale for the Elderly (PASE) questionnaire designed to assess physical activity in adults aged 65 years and older. The total physical activity score was calculated from answers to questions about the frequency of engaging in seven activities: gardening and yard work, walking, volunteering, assisting family or friends, hunting, fishing or camping, babysitting and shopping. Response options were \\u201cnever or less than once a month\\u201d, \\u201conce a month\\u201d, \\u201cfew (2\\u20133) times a month\\u201d, \\u201conce a week\\u201d, \\u201cfew (2\\u20133) times a week\\u201d and \\u201cevery day\\u201d. Responses were assigned a score of 0\\u20135 and then summed to a total score ranging from 0 to 35 (potential maximum total score) with higher scores indicating greater physical activity. Missing values were imputed by taking the average of the non-missing responses within each participant if at least 3 of the questions had complete data. In the present study, we used physical activity data collected one year after baseline (nearest the blood sample collection in 2000\\u20132002) and carried forward to missing measurements at the 2007\\u20132008 visit in participants with non-missing data.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 12977, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Apolipoprotein E (APOE \\u03b54) carrier status (yes/no), hypertension (defined as anti-hypertensive medication use or systolic blood pressure \\u2265 140 mmHg or diastolic blood pressure \\u2265 90 mmHg and recorded one year after baseline) and body mass index (BMI) created from measured height and weight were also included as covariates. Mild cognitive impairment (MCI) was defined using guidelines from the International Working group on mild cognitive impairment and provided for descriptive purposes as was participant\\u2019s average score on the Modified Mini-Mental State Examination (3MSE).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 13563, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_2\"}, \"text\": \"Statistical analyses\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 13584, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Descriptive statistics were calculated for all variables. Due to the skewed nature of A\\u03b2, a one percent Winsorization was performed, i.e., values less than or equal to the first percentile of the distribution were set to the minimum value. For A\\u03b21\\u201340 these values corresponded to 56.75 and 28.73 pg/mL in 2000\\u201302 or 2007\\u201308 respectively and for A\\u03b21\\u201342 they were 0.75 and 0.77 pg/mL respectively. Winsorized values were then log transformed (Fig. 1). To create A\\u03b21\\u201342/A\\u03b21\\u201340 ratio, we first log-transformed the numerator and denominator before dividing the values. Given the continuous nature of the outcomes, cross-sectional associations were examined using ordinary least squares regression. Repeated measures analyses were evaluated using linear random effects models with a random intercept for participant. Results were reported as percent differences with their corresponding 95% confidence intervals (CIs).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 14514, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"A staged modeling approach was used to assess the impact of adding increasingly more covariates. Model 1 included basic socio-demographic characteristics (continuous age, sex, race, education, study site, treatment assignment, Cystatin C and NDI). Model 2 included Model 1 covariates plus smoking history, alcohol consumption, pack-years smoking, percentage of life exposed to secondhand smoke and physical activity. Model 3 included Model 2 covariates plus APOE \\u03b54, and Model 4 included Model 3 covariates plus hypertension and BMI. As these variables are potentially on the causal pathway between air pollution and A\\u03b2, they were included at the last stage. We considered model 3 as the primary model of interest. Age, Cystatin C, NDI, BMI and hypertension were treated as time-varying in the random effects models.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 15340, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Data in 2000\\u201302 were carried forward for two individuals missing data on non-time-varying covariates in 2007\\u201308. Most covariates had \\u2264 8% missing data with the exception of APOE \\u03b54 which had about 20% missingness. We implemented multiple imputation using chained equations (MICE) to handle missing continuous and categorical covariates. Separate MICE procedures were implemented for each combination of air pollution metric and A\\u03b2 outcome at baseline and repeat measures. Logistic or multinomial regression models were specified to impute missing categorical variables. Predictive mean matching was used to impute missing continuous variables. All covariates were included as predictors in the imputation models, but we also included time-varying 3MSE scores as they are potentially informative variables. Ten imputed datasets were constructed using 50 iterations per imputation. Final models were evaluated on all ten imputed datasets and parameter estimates and standard errors were pooled according to Rubin\\u2019s rules.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 16370, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"In addition to our main analysis, we conducted a secondary analysis to explore the association between air pollution and A\\u03b2 outcomes among those with and without MCI. This analysis assessed whether or not plasma A\\u03b2 biomarkers show different trajectories for cognitively intact individuals versus those exhibiting some cognitive impairment irrespective of if they go on to develop ADRD. We ran stratified models for both cross-sectional and repeated measures analysis using only Model 3 covariates and the longer-term averaging periods for air pollutants.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 16931, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Two sensitivity analyses are also presented. First, to explore the impact of our approach to handling outliers we constructed models using a) the original distribution of values and b) excluding those that were less than or equal to the first percentile. Second, to account for potential selection bias among participants who remained in the study until the end of follow-up (those with repeated A\\u03b2 measurements), we ran separate OLS models with baseline and follow-up A\\u03b2 as the outcome among only those participants with repeated A\\u03b2 measurements (i.e., we did not include those who only had baseline values of A\\u03b2).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 17559, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Analyses were performed with SAS version 9.4 (SAS Institute Inc., Cary, NC). MICE was performed using PROC MI/PROC MIANALYZE in SAS, and plots were generated using R version 4.0.4 (R Foundation for Statistical Computing). All statistical tests were two-sided and considered significant at p-value < 0.05.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 17864, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"title_1\"}, \"text\": \"Results\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 17872, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"We excluded 25 individuals who did not have data on at least one baseline A\\u03b2 measurement; 23 of these individuals were also missing address data so did not have air pollution exposure estimates. Our final analytic cohort consisted of 3,044 participants, among whom 1,669 participants had A\\u03b21\\u201340 or A\\u03b21\\u201342 measurements from blood samples drawn between 2007 and 2008. Specifically, 1375 censored participants did not have a blood sample available for testing at follow-up, of these 379 died, 469 developed ADRD, and 527 were lost to follow-up. Exact sample sizes vary depending on the specific outcome (Supplemental Fig. 1). Baseline A\\u03b21\\u201340 ranged from 56.75 pg/mL to 473.95 pg/mL and A\\u03b21\\u201342 from 0.75 pg/mL to 140.23 pg/mL (Fig. 1). At baseline, average age was 78.6 years, participants were mostly non-Hispanic White (95%), were 46% female, and 64% had at least a college degree (Table 1). Seventeen percent were considered to have mild cognitive impairment at baseline and the average score on the 3MSE for all participants was 93.4 out of 100. Distributions of air pollutants showed higher levels of PM2.5 and NO2 at the Pittsburgh site, higher concentrations for longer averaging periods (e.g., 20 year vs one year averages) and declines in air pollution between baseline and follow-up (Fig. 2). Model results are reported per interquartile range (IQR) increase which corresponded to 2 \\u03bcg/m3 for PM2.5, 3 \\u03bcg/ m3 for PM10 and 6 ppb for NO2. IQR for each air pollutant was obtained by taking the mean IQR across all averaging periods at baseline.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 19437, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"Characteristics that are updated at follow-up visit include age, neighborhood deprivation index, body mass index, hypertension, Cystatin C, mild cognitive impairment status and Mini-Mental State Exam Score.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 19644, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"Number and percent missing are presented for the following characteristics that were missing data at baseline and follow-up visits, respectively: alcohol consumption, n = 48 (2%) and n = 26 (2%); smoking history, n = 58 (2%) and n = 32 (2%); pack-years smoking, n = 230 (8%) and n = 132 (8%); percentage of life exposed to SHS, n = 63 (2%) and n = 33 (2%); neighborhood deprivation index, n = 15 (<1%) and n = 10 (<1%); body mass index, n = 13 (<1%) and n = 4 (<1%); hypertension, n = 2 (<1%) and n = 11 (<1%); physical activity score, n = 185 (6%) and n = 21 (1%); Cystatin C, n = 3 (<1%) and n = 2 (<1%); APOE \\u03b54 carrier status, n = 624 (20%) and n = 305 (18%); and Mini-Mental State Exam score, n = 0 (0%) and n = 18 (1%).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 20376, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"In cross-sectional analysis using baseline A\\u03b2 measurements, we observed small positive associations between A\\u03b21\\u201340 and each air pollutant in Model 3, our primary model. A 2 \\u03bcg/m3 higher one-year PM2.5 level was associated with a 1.69% higher A\\u03b21\\u201340 concentration (95% CI: 0.52%,2.87%). The estimates were attenuated and much closer to zero for longer PM2.5 averaging periods. All PM10 averaging periods showed a similar association with A\\u03b21\\u201340, where a 3 \\u03bcg/m3 higher PM10 was associated with 2% (95% CI: 0.82%, 3.19%), 2.19% (95% CI: 0.92%, 3.48%) and 1.89% (95% CI: 0.74%, 3.05%) higher A\\u03b21\\u201340 for the one-, five- and ten-year averages respectively. Associations between the one, five and ten-year NO2 metrics and A\\u03b21\\u201340 were similar in magnitude but had slightly worse precision. For the other two outcomes, A\\u03b21\\u201342 and the ratio measure, Model 3 showed null associations between our three air pollutants at differing averaging periods (Fig. 3a \\u2013 3c and Supplemental Table 1).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 21378, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"The repeated measures analysis showed stronger magnitudes of effect for all pollutant-outcome combinations in Model 3 (Fig. 3d \\u2013 3f and Supplemental Table 2). We observed a 4.43% (95% CI 3.26%, 5.60%), 5.01% (95% CI 3.93%, 6.10%) and 7.20% (95% CI 5.45%, 8.97%) higher A\\u03b21\\u201340 level associated with an IQR higher 20-year average PM2.5, ten-year PM10 and ten-year NO2 respectively. A\\u03b21\\u201342 had even higher magnitudes of association with each of the air pollutants: 20-year PM2.5 was associated with 9.73% (6.20%, 13.38%) higher A\\u03b21\\u201342; ten-year PM10 was associated with 7.34% (95% CI 4.19%, 10.60%) higher A\\u03b21\\u201342; and ten-year NO2 was associated with 13.28% (95% CI: 7.95%, 18.86%) higher A\\u03b21\\u201342. The A\\u03b21\\u201342/A\\u03b21\\u201340 ratio showed the smallest associations with all three pollutants: 1.57% (95% CI: 0.94%, 2.20%) with 20-year PM2.5, 1.13% (95% CI: 0.56%, 1.71%) with ten-year PM10 and 2.09% (95% CI: 1.16%, 3.03%) with ten-year NO2.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 22328, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"Our MCI-stratified models showed little difference between those with and without MCI both in cross-sectional (Supplemental Table 3) and repeated measures analysis (Supplemental Table 4). For example, a 2 \\u03bcg/m3 higher 20-year average PM2.5 was associated with a 3.55% higher A\\u03b21\\u201340 among those with MCI and 4.37% higher A\\u03b21\\u201340 among those without MCI. Slightly larger differences between those with and without MCI were seen in the A\\u03b21\\u201342 results, however, the confidence limits were wide and overlapping.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 22844, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"In sensitivity analyses, we explored alternative methods to ensure normality of the outcome residuals, specifically trimming (i.e., excluding) the extreme outliers and making no change to the distribution. This did not change the results in any substantive way but did result in a slight attenuation of parameter estimates when outliers were excluded specifically in the repeat measures analysis (Supplemental Table 5 for cross sectional analysis and Supplemental Table 6 for repeat measures analysis).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 23347, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"Furthermore, we investigated the potential impact of selection bias by examining only those participants who contributed samples to both baseline and the 2007 \\u2013 2008 visit (i.e., those who were not censored or lost to follow-up). We found stronger associations for both PM2.5 and NO2 with all outcomes measured at follow-up relative to baseline (Supplemental Table 7). There was little change in PM10 results. This suggests that findings from our repeated measures analysis were driven by participants who remained in the study until the end of follow-up.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 23905, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"title_1\"}, \"text\": \"Discussion\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 23916, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Our study examined the association between air pollutants and biomarkers of A\\u03b2 in plasma samples of dementia-free older adults. Findings suggest strong positive associations in the repeat measures analysis for all pollutant-outcome combinations, confirming our initial hypothesis, but largely null associations (with the exception of A\\u03b21\\u201340) in the cross-sectional ones. Our study contributes to the broader evidence base on air pollution and ADRD biomarkers by evaluating longer air pollution exposure averaging periods relative to many existing studies and improved exposure assessment relative to others. Given that ADRD develops over the course of many years, evaluating air pollution at longer averaging periods more closely mimics disease development.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 24680, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"There are several potential reasons that our repeated measures analysis produced stronger associations compared to the cross-sectional results. First, we have more power to detect an effect in the repeated measures analysis given its larger sample size. In addition, those in our repeated measures analysis may have less misclassification of exposure because we are more certain about residential histories during follow up and the several years prior to GEMS enrollment (e.g., approximately 1998\\u20132008 for the 10 year averaging period) relative to residential histories prior to GEMS enrollment (approximately 1990\\u20132000 for the 10 year averaging period). Furthermore, exposure assessment further back in time relies on historical models which are based on less monitoring data and are thus more prone to measurement error. Both improved power and less exposure measurement error could be producing estimates with larger magnitudes in the repeat measures analysis.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 25648, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"We opted to perform a repeat measures analysis as opposed to one that evaluates change in A\\u03b2 over time because plasma biomarker data fluctuates significantly, with some disease-free participants seeing decreases in A\\u03b2 over the period of follow up. Given the dynamic nature of plasma A\\u03b2 (described above), this is to be expected. Furthermore, given the loss to follow up in our sample the repeat measures approach allows us to have a more generalizable sample with more power.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 26133, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"In terms of our MCI stratified results, we did not observe lower A\\u03b2 levels among those with MCI. It has been well documented that some with MCI revert back to normal cognition over time; one study estimates an over 50% reversion rate from MCI to normal. Alternatively, those with stable MCI may not be far enough along in their disease progression to show declines in A\\u03b2. Furthermore, the number of people with MCI in our study was relatively small and our analysis may have been underpowered to see an effect.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 26650, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Our findings are not directly comparable to existing research as ours was the first to examine plasma A\\u03b2; other studies examined A\\u03b2 via PET scans, CSF and autopsy data. Studies in cognitively normal or mildly impaired populations found five-year average PM10 and annual average NO2 to be associated with higher odds of A\\u03b2 positivity measured via PET scan (i.e., those with indication of A\\u03b2 deposits in their brain). Although these studies were cross-sectional in nature, for these mildly impaired groups the association with air pollution was in the expected direction and corroborates our findings.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 27262, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Another study found that biennial PM2.5 concentrations were associated with higher odds of A\\u03b2 positivity, also measured with PET scans, in a population composed of participants with either MCI or dementia. One might expect to see different associations with air pollution between the two groups; air pollution would be associated with higher odds of A\\u03b2 positivity in the MCI group, but lower A\\u03b2 positivity in those with dementia. To better evaluate the Iaccarino et al. findings, stratification by dementia and MCI would be needed.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 27803, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Limited research has explored the association between air pollution and A\\u03b2 measured in CSF. One recent study found no association between several air pollutants and A\\u03b2 ratio, but others have seen lower concentrations of A\\u03b21\\u201342 among children living in more polluted areas. Substantial research finds that those with AD have lower concentrations of A\\u03b21\\u201342 in CSF compared to those with MCI and normal cognition. Thus future air pollution studies should stratify by disease stage in order to better evaluate the relation between air pollution and CSF A\\u03b2.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 28371, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"It is difficult to compare our results to autopsy studies because the GEMS population at the end of follow-up is likely a mix of those who have ADRD pathology and those who do not and because we do not know who went on to develop ADRD after the GEMS study ended.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 28634, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Many studies of dementia do not find A\\u03b21\\u201340 to be highly predictive of dementia status. In our study the strong associations with A\\u03b21\\u201340, which as noted above has inflammatory and atherosclerotic properties, could reflect the well-established relation between air pollution and cardiovascular disease. These results help validate our findings and suggest that future research on air pollution and dementia should explore A\\u03b21\\u201340 as it may be playing an important role in vascular dementia.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 29132, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Our study has several strengths. GEMS provides a large sample size of standardized data, thorough adjustment for potential confounders, and state-of-the-art exposure assessment approaches at the individual residential address level. In terms of limitations, we recognize that our study uses an older biomarker assay. In recent years the scientific community has made significant advances in identifying A\\u03b2 in plasma; we hope to utilize new biomarker technology for future air pollution studies. Furthermore, GEMS is a cohort of primarily White participants who were more educated relative to the US population. At the end of GEMS follow up we were left with a healthier and more resilient population. These features limit our ability to generalize to the broader population. Lastly, we did not adjust for multiple comparisons, which could increase the possibility that findings are due to chance alone, because we set out to test a priori hypotheses about the importance of evaluating longer air pollution averaging periods and because the multiple averaging periods (5-, 10- and 20 year) are nested exposures so may not be considered separate exposures.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 30290, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"A better understanding of the relationship between air pollution and plasma biomarkers of ADRD will help shed light on the mechanisms by which air pollution may be impacting cognitive health. Air pollution is modifiable through policy and regulation thus providing another realistic target for ADRD prevention.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 30601, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"title_1\"}, \"text\": \"Supplementary Material\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 30624, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"footnote\"}, \"text\": \"CRediT authorship contribution statement\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 30665, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"footnote\"}, \"text\": \"Anjum Hajat: Conceptualization, Funding acquisition, Methodology, Project administration, Supervision, Writing \\u2013 original draft, Writing \\u2013 review & editing. Christina Park: Data curation, Formal analysis, Methodology, Software, Validation, Visualization, Writing \\u2013 original draft, Writing \\u2013 review & editing. Claire Adam: Methodology, Writing \\u2013 review & editing. Annette L. Fitzpatrick: Conceptualization, Funding acquisition, Writing \\u2013 review & editing. Sindana D. Ilango: Writing \\u2013 review & editing. Cindy Leary: Validation, Visualization, Writing \\u2013 review & editing. Tanya Libby: Validation, Visualization, Writing \\u2013 review & editing. Oscar Lopez: Writing \\u2013 review & editing. Erin O. Semmens: Conceptualization, Funding acquisition, Writing \\u2013 review & editing. Joel D. Kaufman: Conceptualization, Funding acquisition, Writing \\u2013 review & editing.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31538, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"footnote\"}, \"text\": \"Declaration of Competing Interest\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31572, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"footnote\"}, \"text\": \"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31743, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"footnote\"}, \"text\": \"Appendix A. Supplementary data\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31774, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"footnote\"}, \"text\": \"Supplementary data to this article can be found online at https://doi.org/10.1016/j.envint.2023.107800.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31878, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"title_1\"}, \"text\": \"Data availability\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31896, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"paragraph\"}, \"text\": \"The authors do not have permission to share data.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31946, \"infons\": {\"section_type\": \"REF\", \"type\": \"title\"}, \"text\": \"References\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31957, \"infons\": {\"name_0\": \"surname:Ackley;given-names:SF\", \"name_1\": \"surname:Zimmerman;given-names:SC\", \"name_10\": \"surname:Brickman;given-names:AM\", \"name_11\": \"surname:Glymour;given-names:MM\", \"name_2\": \"surname:Brenowitz;given-names:WD\", \"name_3\": \"surname:Tchetgen Tchetgen;given-names:EJ\", \"name_4\": \"surname:Gold;given-names:AL\", \"name_5\": \"surname:Manly;given-names:JJ\", \"name_6\": \"surname:Mayeda;given-names:ER\", \"name_7\": \"surname:Filshtein;given-names:TJ\", \"name_8\": \"surname:Power;given-names:MC\", \"name_9\": \"surname:Elahi;given-names:FM\", \"pub-id_doi\": \"10.1136/bmj.n156\", \"section_type\": \"REF\", \"source\": \"BMJ\", \"type\": \"ref\", \"volume\": \"372\", \"year\": \"2021\"}, \"text\": \"Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 32074, \"infons\": {\"fpage\": \"106864\", \"name_0\": \"surname:Alemany;given-names:S\", \"name_1\": \"surname:Crous-Bou;given-names:M\", \"name_10\": \"surname:Minguillon;given-names:C\", \"name_11\": \"surname:Fauria;given-names:K\", \"name_12\": \"surname:Kollmorgen;given-names:G\", \"name_13\": \"surname:Domingo Gispert;given-names:J\", \"name_14\": \"surname:Gasc\\u00f3n;given-names:M\", \"name_15\": \"surname:Nieuwenhuijsen;given-names:M\", \"name_16\": \"surname:Zetterberg;given-names:H\", \"name_17\": \"surname:Blennow;given-names:K\", \"name_18\": \"surname:Sunyer;given-names:J\", \"name_19\": \"surname:Luis Molinuevo;given-names:J\", \"name_2\": \"surname:Vilor-Tejedor;given-names:N\", \"name_3\": \"surname:Mila-Alom\\u00e1;given-names:M\", \"name_4\": \"surname:Su\\u00e1rez-Calvet;given-names:M\", \"name_5\": \"surname:Salvad\\u00f3;given-names:G\", \"name_6\": \"surname:Cirach;given-names:M\", \"name_7\": \"surname:Arenaza-Urquijo;given-names:EM\", \"name_8\": \"surname:Sanchez-Benavides;given-names:G\", \"name_9\": \"surname:Grau-Rivera;given-names:O\", \"pub-id_doi\": \"10.1016/j.envint.2021.106864\", \"pub-id_pmid\": \"34537521\", \"section_type\": \"REF\", \"source\": \"Environ. Int\", \"type\": \"ref\", \"volume\": \"157\", \"year\": \"2021\"}, \"text\": \"Associations between air pollution and biomarkers of Alzheimer\\u2019s disease in cognitively unimpaired individuals\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 32187, \"infons\": {\"fpage\": \"795\", \"lpage\": \"804\", \"name_0\": \"surname:Bateman;given-names:RJ\", \"name_1\": \"surname:Xiong;given-names:C\", \"name_10\": \"surname:Holtzman;given-names:DM\", \"name_11\": \"surname:Santacruz;given-names:A\", \"name_12\": \"surname:Buckles;given-names:V\", \"name_13\": \"surname:Oliver;given-names:A\", \"name_14\": \"surname:Moulder;given-names:K\", \"name_15\": \"surname:Aisen;given-names:PS\", \"name_16\": \"surname:Ghetti;given-names:B\", \"name_17\": \"surname:Klunk;given-names:WE\", \"name_18\": \"surname:McDade;given-names:E\", \"name_19\": \"surname:Martins;given-names:RN\", \"name_2\": \"surname:Benzinger;given-names:TLS\", \"name_20\": \"surname:Masters;given-names:CL\", \"name_21\": \"surname:Mayeux;given-names:R\", \"name_22\": \"surname:Ringman;given-names:JM\", \"name_23\": \"surname:Rossor;given-names:MN\", \"name_24\": \"surname:Schofield;given-names:PR\", \"name_25\": \"surname:Sperling;given-names:RA\", \"name_26\": \"surname:Salloway;given-names:S\", \"name_27\": \"surname:Morris;given-names:JC\", \"name_28\": \"surname:Network;given-names:DIA\", \"name_3\": \"surname:Fagan;given-names:AM\", \"name_4\": \"surname:Goate;given-names:A\", \"name_5\": \"surname:Fox;given-names:NC\", \"name_6\": \"surname:Marcus;given-names:DS\", \"name_7\": \"surname:Cairns;given-names:NJ\", \"name_8\": \"surname:Xie;given-names:X\", \"name_9\": \"surname:Blazey;given-names:TM\", \"pub-id_doi\": \"10.1056/NEJMoa1202753\", \"pub-id_pmid\": \"22784036\", \"section_type\": \"REF\", \"source\": \"N. Engl. J. Med\", \"type\": \"ref\", \"volume\": \"367\", \"year\": \"2012\"}, \"text\": \"Clinical and biomarker changes in dominantly inherited Alzheimer\\u2019s disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 32264, \"infons\": {\"name_0\": \"surname:Bhatt;given-names:DP\", \"name_1\": \"surname:Puig;given-names:KL\", \"name_2\": \"surname:Gorr;given-names:MW\", \"name_3\": \"surname:Wold;given-names:LE\", \"name_4\": \"surname:Combs;given-names:CK\", \"pub-id_doi\": \"10.1371/journal.pone.0127102\", \"section_type\": \"REF\", \"source\": \"PLoS One\", \"type\": \"ref\", \"volume\": \"10\", \"year\": \"2015\"}, \"text\": \"A pilot study to assess effects of long-term inhalation of airborne particulate matter on early Alzheimer-like changes in the mouse brain\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 32402, \"infons\": {\"fpage\": \"369\", \"name_0\": \"surname:Bhatti;given-names:GK\", \"name_1\": \"surname:Reddy;given-names:AP\", \"name_2\": \"surname:Reddy;given-names:PH\", \"name_3\": \"surname:Bhatti;given-names:JS\", \"pub-id_doi\": \"10.3389/fnagi.2019.00369\", \"pub-id_pmid\": \"31998117\", \"section_type\": \"REF\", \"source\": \"Front. Aging Neurosci\", \"type\": \"ref\", \"volume\": \"11\", \"year\": \"2019\"}, \"text\": \"Lifestyle Modifications and Nutritional Interventions in Aging-Associated Cognitive Decline and Alzheimer\\u2019s Disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 32520, \"infons\": {\"fpage\": \"2331\", \"lpage\": \"2378\", \"name_0\": \"surname:Brook;given-names:RD\", \"name_1\": \"surname:Rajagopalan;given-names:S\", \"name_10\": \"surname:Peters;given-names:A\", \"name_11\": \"surname:Siscovick;given-names:D\", \"name_12\": \"surname:Smith;given-names:SC\", \"name_13\": \"surname:Whitsel;given-names:L\", \"name_14\": \"surname:Kaufman;given-names:JD\", \"name_2\": \"surname:Pope;given-names:CA\", \"name_3\": \"surname:Brook;given-names:JR\", \"name_4\": \"surname:Bhatnagar;given-names:A\", \"name_5\": \"surname:Diez-Roux;given-names:AV\", \"name_6\": \"surname:Holguin;given-names:F\", \"name_7\": \"surname:Hong;given-names:Y\", \"name_8\": \"surname:Luepker;given-names:RV\", \"name_9\": \"surname:Mittleman;given-names:MA\", \"pub-id_doi\": \"10.1161/CIR.0b013e3181dbece1\", \"pub-id_pmid\": \"20458016\", \"section_type\": \"REF\", \"source\": \"Circulation\", \"type\": \"ref\", \"volume\": \"121\", \"year\": \"2010\"}, \"text\": \"Particulate Matter Air Pollution and Cardiovascular Disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 32580, \"infons\": {\"name_0\": \"surname:Calderon-Garcidueas;given-names:L\", \"name_1\": \"surname:Kavanaugh;given-names:M\", \"name_10\": \"surname:Guo;given-names:R\", \"name_11\": \"surname:Hua;given-names:Z\", \"name_12\": \"surname:Zhu;given-names:H\", \"name_13\": \"surname:Perry;given-names:G\", \"name_14\": \"surname:Diaz;given-names:P\", \"name_2\": \"surname:Block;given-names:M\", \"name_3\": \"surname:D\\u2019Angiulli;given-names:A\", \"name_4\": \"surname:Delgado-Ch\\u00e1vez;given-names:R\", \"name_5\": \"surname:Torres-Jardon;given-names:R\", \"name_6\": \"surname:Gon\\u017aalez-Maciel;given-names:A\", \"name_7\": \"surname:Reynoso-Robles;given-names:R\", \"name_8\": \"surname:Osnaya;given-names:N\", \"name_9\": \"surname:Villarreal-Calderon;given-names:R\", \"pub-id_doi\": \"10.3233/JAD-2011-110722\", \"section_type\": \"REF\", \"source\": \"J. Alzheimer\\u2019s Dis\", \"type\": \"ref\", \"volume\": \"28\", \"year\": \"2012\"}, \"text\": \"Neuroinflammation, hyperphosphorylated tau, diffuse amyloid plaques, and down-regulation of the cellular prion protein in air pollution exposed children and young adults\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 32750, \"infons\": {\"fpage\": \"289\", \"lpage\": \"310\", \"name_0\": \"surname:Calder\\u00f3n-Garcidue\\u00f1as;given-names:L\", \"name_1\": \"surname:Solt;given-names:AC\", \"name_10\": \"surname:Brooks;given-names:DM\", \"name_11\": \"surname:Gonz\\u00e1lez-Maciel;given-names:A\", \"name_12\": \"surname:Reynoso-Robles;given-names:R\", \"name_13\": \"surname:Delgado-Ch\\u00e1vez;given-names:R\", \"name_14\": \"surname:Reed;given-names:W\", \"name_2\": \"surname:Henr\\u00edquez-Rold\\u00e1n;given-names:C\", \"name_3\": \"surname:Torres-Jard\\u00f3n;given-names:R\", \"name_4\": \"surname:Nuse;given-names:B\", \"name_5\": \"surname:Herritt;given-names:L\", \"name_6\": \"surname:Villarreal-Calder\\u00f3n;given-names:R\", \"name_7\": \"surname:Osnaya;given-names:N\", \"name_8\": \"surname:Stone;given-names:I\", \"name_9\": \"surname:Garc\\u00eda;given-names:R\", \"pub-id_doi\": \"10.1177/0192623307313011\", \"pub-id_pmid\": \"18349428\", \"section_type\": \"REF\", \"source\": \"Toxicol. Pathol\", \"type\": \"ref\", \"volume\": \"36\", \"year\": \"2008\"}, \"text\": \"Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid \\u03b2\\u221242 and \\u03b1-synuclein in children and young adults\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33014, \"infons\": {\"fpage\": \"597\", \"lpage\": \"613\", \"name_0\": \"surname:Calder\\u00f3n-Garcidue\\u00f1as;given-names:L\", \"name_1\": \"surname:Avila-Ram\\u00edrez;given-names:J\", \"name_10\": \"surname:Garc\\u00eda-P\\u00e9rez;given-names:MA\", \"name_11\": \"surname:Reis;given-names:J\", \"name_12\": \"surname:Mukherjee;given-names:PS\", \"name_13\": \"surname:Torres-Jard\\u00f3n;given-names:R\", \"name_14\": \"surname:Lachmann;given-names:I\", \"name_2\": \"surname:Calder\\u00e1n-Garcidue\\u00f1as;given-names:A\", \"name_3\": \"surname:Gonz\\u00e1lez-Heredia;given-names:T\", \"name_4\": \"surname:Acu\\u00f1a-Ayala;given-names:H\", \"name_5\": \"surname:Chao;given-names:C-K\", \"name_6\": \"surname:Thompson;given-names:C\", \"name_7\": \"surname:Ruiz-Ramos;given-names:R\", \"name_8\": \"surname:Cort\\u00e9s-Gonz\\u00e1lez;given-names:V\", \"name_9\": \"surname:Mart\\u00ednez-Mart\\u00ednez;given-names:L\", \"pub-id_doi\": \"10.3233/JAD-160472\", \"pub-id_pmid\": \"27567860\", \"section_type\": \"REF\", \"source\": \"J. Alzheimers. Dis\", \"type\": \"ref\", \"volume\": \"54\", \"year\": \"2016\"}, \"text\": \"Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer\\u2019s and Parkinson\\u2019s Diseases in Young Mexico City Residents\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33164, \"infons\": {\"fpage\": \"1437\", \"lpage\": \"1451\", \"name_0\": \"surname:Calder\\u00f3n-Garcidue\\u00f1as;given-names:L\", \"name_1\": \"surname:Mukherjee;given-names:PS\", \"name_10\": \"surname:G\\u00f3nzalez-Maciel;given-names:A\", \"name_11\": \"surname:Lachmann;given-names:I\", \"name_2\": \"surname:Waniek;given-names:K\", \"name_3\": \"surname:Holzer;given-names:M\", \"name_4\": \"surname:Chao;given-names:C-K\", \"name_5\": \"surname:Thompson;given-names:C\", \"name_6\": \"surname:Ruiz-Ramos;given-names:R\", \"name_7\": \"surname:Calder\\u00f3n-Garcidue\\u00f1as;given-names:A\", \"name_8\": \"surname:Franco-Lira;given-names:M\", \"name_9\": \"surname:Reynoso-Robles;given-names:R\", \"pub-id_doi\": \"10.3233/JAD-180853\", \"pub-id_pmid\": \"30412505\", \"section_type\": \"REF\", \"source\": \"J. Alzheimers. Dis\", \"type\": \"ref\", \"volume\": \"66\", \"year\": \"2018\"}, \"text\": \"Non-Phosphorylated Tau in Cerebrospinal Fluid is a Marker of Alzheimer\\u2019s Disease Continuum in Young Urbanites Exposed to Air Pollution\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33301, \"infons\": {\"fpage\": \"943\", \"lpage\": \"948\", \"name_0\": \"surname:Canevelli;given-names:M\", \"name_1\": \"surname:Grande;given-names:G\", \"name_2\": \"surname:Lacorte;given-names:E\", \"name_3\": \"surname:Quarchioni;given-names:E\", \"name_4\": \"surname:Cesari;given-names:M\", \"name_5\": \"surname:Mariani;given-names:C\", \"name_6\": \"surname:Bruno;given-names:G\", \"name_7\": \"surname:Vanacore;given-names:N\", \"pub-id_doi\": \"10.1016/j.jamda.2016.06.020\", \"pub-id_pmid\": \"27502450\", \"section_type\": \"REF\", \"source\": \"J. Am. Med. Dir. Assoc\", \"type\": \"ref\", \"volume\": \"17\", \"year\": \"2016\"}, \"text\": \"Spontaneous Reversion of Mild Cognitive Impairment to Normal Cognition: A Systematic Review of Literature and Meta-Analysis\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33425, \"infons\": {\"name_0\": \"surname:Chen;given-names:GF\", \"name_1\": \"surname:Xu;given-names:TH\", \"name_2\": \"surname:Yan;given-names:Y\", \"name_3\": \"surname:Zhou;given-names:YR\", \"name_4\": \"surname:Jiang;given-names:Y\", \"name_5\": \"surname:Melcher;given-names:K\", \"name_6\": \"surname:Xu;given-names:HE\", \"pub-id_doi\": \"10.1038/aps.2017.28\", \"section_type\": \"REF\", \"source\": \"Acta Pharmacol. Sin\", \"type\": \"ref\", \"volume\": \"38\", \"year\": \"2017\"}, \"text\": \"Amyloid beta: Structure, biology and structure-based therapeutic development\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33502, \"infons\": {\"fpage\": \"1311\", \"lpage\": \"1320\", \"name_0\": \"surname:Christine;given-names:PJ\", \"name_1\": \"surname:Auchincloss;given-names:AH\", \"name_2\": \"surname:Bertoni;given-names:AG\", \"name_3\": \"surname:Carnethon;given-names:MR\", \"name_4\": \"surname:Sanchez;given-names:BN\", \"name_5\": \"surname:Moore;given-names:K\", \"name_6\": \"surname:Adar;given-names:SD\", \"name_7\": \"surname:Horwich;given-names:TB\", \"name_8\": \"surname:Watson;given-names:KE\", \"name_9\": \"surname:Diez Roux;given-names:AV\", \"pub-id_doi\": \"10.1001/jamainternmed.2015.2691\", \"pub-id_pmid\": \"26121402\", \"section_type\": \"REF\", \"source\": \"JAMA Intern Med\", \"type\": \"ref\", \"volume\": \"175\", \"year\": \"2015\"}, \"text\": \"Longitudinal Associations Between Neighborhood Physical and Social Environments and Incident Type 2 Diabetes Mellitus: The Multi-Ethnic Study of Atherosclerosis (MESA)\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33670, \"infons\": {\"fpage\": \"627\", \"lpage\": \"642\", \"name_0\": \"surname:Cosselman;given-names:KE\", \"name_1\": \"surname:Navas-Acien;given-names:A\", \"name_2\": \"surname:Kaufman;given-names:JD\", \"pub-id_doi\": \"10.1038/nrcardio.2015.152\", \"pub-id_pmid\": \"26461967\", \"section_type\": \"REF\", \"source\": \"Nat. Rev. Cardiol\", \"type\": \"ref\", \"volume\": \"12\", \"year\": \"2015\"}, \"text\": \"Environmental factors in cardiovascular disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33718, \"infons\": {\"fpage\": \"238\", \"lpage\": \"253\", \"name_0\": \"surname:DeKosky;given-names:ST\", \"name_1\": \"surname:Fitzpatrick;given-names:A\", \"name_10\": \"surname:Tracy;given-names:R\", \"name_11\": \"surname:Woolard;given-names:N\", \"name_12\": \"surname:Dunn;given-names:L\", \"name_13\": \"surname:Kronmal;given-names:R\", \"name_14\": \"surname:Nahin;given-names:R\", \"name_15\": \"surname:Furberg;given-names:C\", \"name_2\": \"surname:Ives;given-names:DG\", \"name_3\": \"surname:Saxton;given-names:J\", \"name_4\": \"surname:Williamson;given-names:J\", \"name_5\": \"surname:Lopez;given-names:OL\", \"name_6\": \"surname:Burke;given-names:G\", \"name_7\": \"surname:Fried;given-names:L\", \"name_8\": \"surname:Kuller;given-names:LH\", \"name_9\": \"surname:Robbins;given-names:J\", \"pub-id_doi\": \"10.1016/j.cct.2006.02.007\", \"pub-id_pmid\": \"16627007\", \"section_type\": \"REF\", \"source\": \"Contemp. Clin. Trials\", \"type\": \"ref\", \"volume\": \"27\", \"year\": \"2006\"}, \"text\": \"The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33861, \"infons\": {\"fpage\": \"2253\", \"lpage\": \"2262\", \"name_0\": \"surname:DeKosky;given-names:ST\", \"name_1\": \"surname:Williamson;given-names:JD\", \"name_10\": \"surname:Kuller;given-names:LH\", \"name_11\": \"surname:Robbins;given-names:JA\", \"name_12\": \"surname:Tracy;given-names:RP\", \"name_13\": \"surname:Woolard;given-names:NF\", \"name_14\": \"surname:Dunn;given-names:L\", \"name_15\": \"surname:Snitz;given-names:BE\", \"name_16\": \"surname:Nahin;given-names:RL\", \"name_17\": \"surname:Furberg;given-names:CD\", \"name_2\": \"surname:Fitzpatrick;given-names:AL\", \"name_3\": \"surname:Kronmal;given-names:RA\", \"name_4\": \"surname:Ives;given-names:DG\", \"name_5\": \"surname:Saxton;given-names:JA\", \"name_6\": \"surname:Lopez;given-names:OL\", \"name_7\": \"surname:Burke;given-names:G\", \"name_8\": \"surname:Carlson;given-names:MC\", \"name_9\": \"surname:Fried;given-names:LP\", \"pub-id_doi\": \"10.1001/jama.2008.683\", \"pub-id_pmid\": \"19017911\", \"section_type\": \"REF\", \"source\": \"JAMA\", \"type\": \"ref\", \"volume\": \"300\", \"year\": \"2008\"}, \"text\": \"Ginkgo biloba for prevention of dementia: a randomized controlled trial\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33933, \"infons\": {\"fpage\": \"30\", \"name_0\": \"surname:Dumurgier;given-names:J\", \"name_1\": \"surname:Schraen;given-names:S\", \"name_10\": \"surname:Pasquier;given-names:F\", \"name_11\": \"surname:Touchon;given-names:J\", \"name_12\": \"surname:Hugon;given-names:J\", \"name_13\": \"surname:Paquet;given-names:C\", \"name_14\": \"surname:Lehmann;given-names:S\", \"name_2\": \"surname:Gabelle;given-names:A\", \"name_3\": \"surname:Vercruysse;given-names:O\", \"name_4\": \"surname:Bombois;given-names:S\", \"name_5\": \"surname:Laplanche;given-names:J-L\", \"name_6\": \"surname:Peoc\\u2019h;given-names:K\", \"name_7\": \"surname:Sablonni\\u00e8re;given-names:B\", \"name_8\": \"surname:Kastanenka;given-names:KV\", \"name_9\": \"surname:Delaby;given-names:C\", \"pub-id_doi\": \"10.1186/s13195-015-0114-5\", \"pub-id_pmid\": \"26034513\", \"section_type\": \"REF\", \"source\": \"Alzheimers. Res. Ther\", \"type\": \"ref\", \"volume\": \"7\", \"year\": \"2015\"}, \"text\": \"Cerebrospinal fluid amyloid-\\u03b2 42/40 ratio in clinical setting of memory centers: a multicentric study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34038, \"infons\": {\"fpage\": \"541\", \"lpage\": \"53\", \"name_0\": \"surname:Fitzpatrick;given-names:AL\", \"name_1\": \"surname:Fried;given-names:LP\", \"name_10\": \"surname:Furberg;given-names:CD\", \"name_11\": \"surname:DeKosky;given-names:ST\", \"name_2\": \"surname:Williamson;given-names:J\", \"name_3\": \"surname:Crowley;given-names:P\", \"name_4\": \"surname:Posey;given-names:D\", \"name_5\": \"surname:Kwong;given-names:L\", \"name_6\": \"surname:Bonk;given-names:J\", \"name_7\": \"surname:Moyer;given-names:R\", \"name_8\": \"surname:Chabot;given-names:J\", \"name_9\": \"surname:Kidoguchi;given-names:L\", \"pub-id_doi\": \"10.1016/j.cct.2006.06.007\", \"pub-id_pmid\": \"16949348\", \"section_type\": \"REF\", \"source\": \"Contemp. Clin. Trials\", \"type\": \"ref\", \"volume\": \"27\", \"year\": \"2006\"}, \"text\": \"Recruitment of the elderly into a pharmacologic prevention trial: the Ginkgo Evaluation of Memory Study experience\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34153, \"infons\": {\"name_0\": \"surname:Gouras;given-names:GK\", \"name_1\": \"surname:Olsson;given-names:TT\", \"name_2\": \"surname:Hansson;given-names:O\", \"pub-id_doi\": \"10.1007/s13311-014-0313-y\", \"section_type\": \"REF\", \"source\": \"Neurotherapeutics\", \"type\": \"ref\", \"volume\": \"12\", \"year\": \"2015\"}, \"text\": \"\\u03b2-amyloid Peptides and Amyloid Plaques in Alzheimer\\u2019s Disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34218, \"infons\": {\"fpage\": \"954\", \"lpage\": \"963\", \"name_0\": \"surname:Hansson;given-names:O\", \"pub-id_doi\": \"10.1038/s41591-021-01382-x\", \"pub-id_pmid\": \"34083813\", \"section_type\": \"REF\", \"source\": \"Nat. Med\", \"type\": \"ref\", \"volume\": \"27\", \"year\": \"2021\"}, \"text\": \"Biomarkers for neurodegenerative diseases\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34260, \"infons\": {\"name_0\": \"surname:Hurley;given-names:S\", \"name_1\": \"surname:Hertz;given-names:A\", \"name_2\": \"surname:Nelson;given-names:DO\", \"name_3\": \"surname:Layefsky;given-names:M\", \"name_4\": \"surname:Von Behren;given-names:J\", \"name_5\": \"surname:Bernstein;given-names:L\", \"name_6\": \"surname:Deapen;given-names:D\", \"name_7\": \"surname:Reynolds;given-names:P\", \"pub-id_doi\": \"10.1093/aje/kww108\", \"section_type\": \"REF\", \"source\": \"Am. J. Epidemiol\", \"type\": \"ref\", \"year\": \"2017\"}, \"text\": \"Tracing a Path to the Past: Exploring the Use of Commercial Credit Reporting Data to Construct Residential Histories for Epidemiologic Studies of Environmental Exposures\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34430, \"infons\": {\"fpage\": \"197\", \"lpage\": \"207\", \"name_0\": \"surname:Iaccarino;given-names:L\", \"name_1\": \"surname:La Joie;given-names:R\", \"name_10\": \"surname:Gatsonis;given-names:C\", \"name_11\": \"surname:Rabinovici;given-names:GD\", \"name_2\": \"surname:Lesman-Segev;given-names:OH\", \"name_3\": \"surname:Lee;given-names:E\", \"name_4\": \"surname:Hanna;given-names:L\", \"name_5\": \"surname:Allen;given-names:IE\", \"name_6\": \"surname:Hillner;given-names:BE\", \"name_7\": \"surname:Siegel;given-names:BA\", \"name_8\": \"surname:Whitmer;given-names:RA\", \"name_9\": \"surname:Carrillo;given-names:MC\", \"pub-id_doi\": \"10.1001/jamaneurol.2020.3962\", \"pub-id_pmid\": \"33252608\", \"section_type\": \"REF\", \"source\": \"JAMA Neurol\", \"type\": \"ref\", \"volume\": \"78\", \"year\": \"2021\"}, \"text\": \"Association between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults with Cognitive Impairment\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34566, \"infons\": {\"fpage\": \"207\", \"lpage\": \"216\", \"name_0\": \"surname:Jack;given-names:CR\", \"name_1\": \"surname:Knopman;given-names:DS\", \"name_10\": \"surname:Lesnick;given-names:TG\", \"name_11\": \"surname:Pankratz;given-names:VS\", \"name_12\": \"surname:Donohue;given-names:MC\", \"name_13\": \"surname:Trojanowski;given-names:JQ\", \"name_2\": \"surname:Jagust;given-names:WJ\", \"name_3\": \"surname:Petersen;given-names:RC\", \"name_4\": \"surname:Weiner;given-names:MW\", \"name_5\": \"surname:Aisen;given-names:PS\", \"name_6\": \"surname:Shaw;given-names:LM\", \"name_7\": \"surname:Vemuri;given-names:P\", \"name_8\": \"surname:Wiste;given-names:HJ\", \"name_9\": \"surname:Weigand;given-names:SD\", \"pub-id_doi\": \"10.1016/S1474-4422(12)70291-0\", \"pub-id_pmid\": \"23332364\", \"section_type\": \"REF\", \"source\": \"Lancet. Neurol\", \"type\": \"ref\", \"volume\": \"12\", \"year\": \"2013\"}, \"text\": \"Tracking pathophysiological processes in Alzheimer\\u2019s disease: an updated hypothetical model of dynamic biomarkers\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34682, \"infons\": {\"fpage\": \"1924\", \"lpage\": \"38\", \"name_0\": \"surname:Jansen;given-names:WJ\", \"name_1\": \"surname:Ossenkoppele;given-names:R\", \"name_10\": \"surname:Alexander;given-names:M\", \"name_100\": \"surname:Roe;given-names:CM\", \"name_101\": \"surname:Rot;given-names:U\", \"name_102\": \"surname:Rowe;given-names:CC\", \"name_103\": \"surname:R\\u00fcther;given-names:E\", \"name_104\": \"surname:Sabri;given-names:O\", \"name_105\": \"surname:Sanchez-Juan;given-names:P\", \"name_106\": \"surname:Santana;given-names:I\", \"name_107\": \"surname:Sarazin;given-names:M\", \"name_108\": \"surname:Schr\\u00f6der;given-names:J\", \"name_109\": \"surname:Sch\\u00fctte;given-names:C\", \"name_11\": \"surname:Almdahl;given-names:IS\", \"name_110\": \"surname:Seo;given-names:SW\", \"name_111\": \"surname:Soetewey;given-names:F\", \"name_112\": \"surname:Soininen;given-names:H\", \"name_113\": \"surname:Spiru;given-names:L\", \"name_114\": \"surname:Struyfs;given-names:H\", \"name_115\": \"surname:Teunissen;given-names:CE\", \"name_116\": \"surname:Tsolaki;given-names:M\", \"name_117\": \"surname:Vandenberghe;given-names:R\", \"name_118\": \"surname:Verbeek;given-names:MM\", \"name_119\": \"surname:Villemagne;given-names:VL\", \"name_12\": \"surname:Arnold;given-names:SE\", \"name_120\": \"surname:Vos;given-names:SJB\", \"name_121\": \"surname:van Waalwijk van Doorn;given-names:LJC\", \"name_122\": \"surname:Waldemar;given-names:G\", \"name_123\": \"surname:Wallin;given-names:A\", \"name_124\": \"surname:Wallin;given-names:\\u00c5K\", \"name_125\": \"surname:Wiltfang;given-names:J\", \"name_126\": \"surname:Wolk;given-names:DA\", \"name_127\": \"surname:Zboch;given-names:M\", \"name_128\": \"surname:Zetterberg;given-names:H\", \"name_13\": \"surname:Baldeiras;given-names:I\", \"name_14\": \"surname:Barthel;given-names:H\", \"name_15\": \"surname:van Berckel;given-names:BNM\", \"name_16\": \"surname:Bibeau;given-names:K\", \"name_17\": \"surname:Blennow;given-names:K\", \"name_18\": \"surname:Brooks;given-names:DJ\", \"name_19\": \"surname:van Buchem;given-names:MA\", \"name_2\": \"surname:Knol;given-names:DL\", \"name_20\": \"surname:Camus;given-names:V\", \"name_21\": \"surname:Cavedo;given-names:E\", \"name_22\": \"surname:Chen;given-names:K\", \"name_23\": \"surname:Chetelat;given-names:G\", \"name_24\": \"surname:Cohen;given-names:AD\", \"name_25\": \"surname:Drzezga;given-names:A\", \"name_26\": \"surname:Engelborghs;given-names:S\", \"name_27\": \"surname:Fagan;given-names:AM\", \"name_28\": \"surname:Fladby;given-names:T\", \"name_29\": \"surname:Fleisher;given-names:AS\", \"name_3\": \"surname:Tijms;given-names:BM\", \"name_30\": \"surname:van der Flier;given-names:WM\", \"name_31\": \"surname:Ford;given-names:L\", \"name_32\": \"surname:F\\u00f6rster;given-names:S\", \"name_33\": \"surname:Fortea;given-names:J\", \"name_34\": \"surname:Foskett;given-names:N\", \"name_35\": \"surname:Frederiksen;given-names:KS\", \"name_36\": \"surname:Freund-Levi;given-names:Y\", \"name_37\": \"surname:Frisoni;given-names:GB\", \"name_38\": \"surname:Froelich;given-names:L\", \"name_39\": \"surname:Gabryelewicz;given-names:T\", \"name_4\": \"surname:Scheltens;given-names:P\", \"name_40\": \"surname:Gill;given-names:KD\", \"name_41\": \"surname:Gkatzima;given-names:O\", \"name_42\": \"surname:G\\u00f3mez-Tortosa;given-names:E\", \"name_43\": \"surname:Gordon;given-names:MF\", \"name_44\": \"surname:Grimmer;given-names:T\", \"name_45\": \"surname:Hampel;given-names:H\", \"name_46\": \"surname:Hausner;given-names:L\", \"name_47\": \"surname:Hellwig;given-names:S\", \"name_48\": \"surname:Herukka;given-names:S-K\", \"name_49\": \"surname:Hildebrandt;given-names:H\", \"name_5\": \"surname:Verhey;given-names:FRJ\", \"name_50\": \"surname:Ishihara;given-names:L\", \"name_51\": \"surname:Ivanoiu;given-names:A\", \"name_52\": \"surname:Jagust;given-names:WJ\", \"name_53\": \"surname:Johannsen;given-names:P\", \"name_54\": \"surname:Kandimalla;given-names:R\", \"name_55\": \"surname:Kapaki;given-names:E\", \"name_56\": \"surname:Klimkowicz-Mrowiec;given-names:A\", \"name_57\": \"surname:Klunk;given-names:WE\", \"name_58\": \"surname:K\\u00f6hler;given-names:S\", \"name_59\": \"surname:Koglin;given-names:N\", \"name_6\": \"surname:Visser;given-names:PJ\", \"name_60\": \"surname:Kornhuber;given-names:J\", \"name_61\": \"surname:Kramberger;given-names:MG\", \"name_62\": \"surname:Van Laere;given-names:K\", \"name_63\": \"surname:Landau;given-names:SM\", \"name_64\": \"surname:Lee;given-names:DY\", \"name_65\": \"surname:de Leon;given-names:M\", \"name_66\": \"surname:Lisetti;given-names:V\", \"name_67\": \"surname:Lle\\u00f3;given-names:A\", \"name_68\": \"surname:Madsen;given-names:K\", \"name_69\": \"surname:Maier;given-names:W\", \"name_7\": \"surname:Aalten;given-names:P\", \"name_70\": \"surname:Marcusson;given-names:J\", \"name_71\": \"surname:Mattsson;given-names:N\", \"name_72\": \"surname:de Mendon\\u00e7a;given-names:A\", \"name_73\": \"surname:Meulenbroek;given-names:O\", \"name_74\": \"surname:Meyer;given-names:PT\", \"name_75\": \"surname:Mintun;given-names:MA\", \"name_76\": \"surname:Mok;given-names:V\", \"name_77\": \"surname:Molinuevo;given-names:JL\", \"name_78\": \"surname:M\\u00f8llerg\\u00e5rd;given-names:HM\", \"name_79\": \"surname:Morris;given-names:JC\", \"name_8\": \"surname:Aarsland;given-names:D\", \"name_80\": \"surname:Mroczko;given-names:B\", \"name_81\": \"surname:Van der Mussele;given-names:S\", \"name_82\": \"surname:Na;given-names:DL\", \"name_83\": \"surname:Newberg;given-names:A\", \"name_84\": \"surname:Nordberg;given-names:A\", \"name_85\": \"surname:Nordlund;given-names:A\", \"name_86\": \"surname:Novak;given-names:GP\", \"name_87\": \"surname:Paraskevas;given-names:GP\", \"name_88\": \"surname:Parnetti;given-names:L\", \"name_89\": \"surname:Perera;given-names:G\", \"name_9\": \"surname:Alcolea;given-names:D\", \"name_90\": \"surname:Peters;given-names:O\", \"name_91\": \"surname:Popp;given-names:J\", \"name_92\": \"surname:Prabhakar;given-names:S\", \"name_93\": \"surname:Rabinovici;given-names:GD\", \"name_94\": \"surname:Ramakers;given-names:IHGB\", \"name_95\": \"surname:Rami;given-names:L\", \"name_96\": \"surname:Resende de Oliveira;given-names:C\", \"name_97\": \"surname:Rinne;given-names:JO\", \"name_98\": \"surname:Rodrigue;given-names:KM\", \"name_99\": \"surname:Rodr\\u00edguez-Rodr\\u00edguez;given-names:E\", \"pub-id_doi\": \"10.1001/jama.2015.4668\", \"pub-id_pmid\": \"25988462\", \"section_type\": \"REF\", \"source\": \"JAMA\", \"type\": \"ref\", \"volume\": \"313\", \"year\": \"2015\"}, \"text\": \"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34768, \"infons\": {\"fpage\": \"38\", \"lpage\": \"46\", \"name_0\": \"surname:Kim;given-names:S-Y\", \"name_1\": \"surname:Olives;given-names:C\", \"name_2\": \"surname:Sheppard;given-names:L\", \"name_3\": \"surname:Sampson;given-names:PD\", \"name_4\": \"surname:Larson;given-names:TV\", \"name_5\": \"surname:Keller;given-names:JP\", \"name_6\": \"surname:Kaufman;given-names:JD\", \"pub-id_doi\": \"10.1289/EHP131\", \"pub-id_pmid\": \"27340825\", \"section_type\": \"REF\", \"source\": \"Environ. Health Perspect\", \"type\": \"ref\", \"volume\": \"125\", \"year\": \"2017\"}, \"text\": \"Historical Prediction Modeling Approach for Estimating Long-Term Concentrations of PM2.5 in Cohort Studies before the 1999 Implementation of Widespread Monitoring\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34931, \"infons\": {\"name_0\": \"surname:Kivim\\u00e4ki;given-names:M\", \"name_1\": \"surname:Singh-Manoux;given-names:A\", \"pub-id_doi\": \"10.1016/S0140-6736(18)30578-6\", \"section_type\": \"REF\", \"source\": \"Lancet (London, England)\", \"type\": \"ref\", \"year\": \"2018\"}, \"text\": \"Prevention of dementia by targeting risk factors\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34980, \"infons\": {\"name_0\": \"surname:Lee;given-names:JH\", \"name_1\": \"surname:Byun;given-names:MS\", \"name_2\": \"surname:Yi;given-names:D\", \"name_3\": \"surname:Ko;given-names:K\", \"name_4\": \"surname:Jeon;given-names:SY\", \"name_5\": \"surname:Sohn;given-names:BK\", \"name_6\": \"surname:Lee;given-names:JY\", \"name_7\": \"surname:Lee;given-names:Y\", \"name_8\": \"surname:Joung;given-names:H\", \"name_9\": \"surname:Lee;given-names:DY\", \"pub-id_doi\": \"10.3233/JAD-200694\", \"section_type\": \"REF\", \"source\": \"J. Alzheimer\\u2019s Dis\", \"type\": \"ref\", \"volume\": \"78\", \"year\": \"2020\"}, \"text\": \"Long-Term Exposure to PM10 and in vivo Alzheimer\\u2019s Disease Pathologies\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35053, \"infons\": {\"fpage\": \"687\", \"lpage\": \"689\", \"name_0\": \"surname:Levy;given-names:E\", \"pub-id_doi\": \"10.1586/14737175.8.5.687\", \"pub-id_pmid\": \"18457524\", \"section_type\": \"REF\", \"source\": \"Expert Rev.Neurother\", \"type\": \"ref\", \"volume\": \"8\", \"year\": \"2008\"}, \"text\": \"Cystatin C: a potential target for Alzheimer\\u2019s treatment\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35112, \"infons\": {\"name_0\": \"surname:Lopez;given-names:OL\", \"name_1\": \"surname:Klunk;given-names:WE\", \"name_2\": \"surname:Mathis;given-names:CA\", \"name_3\": \"surname:Snitz;given-names:BE\", \"name_4\": \"surname:Chang;given-names:Y\", \"name_5\": \"surname:Tracy;given-names:RP\", \"name_6\": \"surname:Kuller;given-names:LH\", \"pub-id_doi\": \"10.1093/braincomms/fcz038\", \"section_type\": \"REF\", \"source\": \"Brain Commun\", \"type\": \"ref\", \"volume\": \"2\", \"year\": \"2020\"}, \"text\": \"Relationship of amyloid-\\u03b21\\u201342 in blood and brain amyloid: Ginkgo Evaluation of Memory Study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35207, \"infons\": {\"name_0\": \"surname:Ma;given-names:Y\", \"name_1\": \"surname:Brettschneider;given-names:J\", \"name_2\": \"surname:Collingwood;given-names:JF\", \"pub-id_doi\": \"10.3390/biomedicines10071713\", \"section_type\": \"REF\", \"source\": \"Biomedicines\", \"type\": \"ref\", \"volume\": \"10\", \"year\": \"2022\"}, \"text\": \"A Systematic Review and Meta-Analysis of Cerebrospinal Fluid Amyloid and Tau Levels Identifies Mild Cognitive Impairment Patients Progressing to Alzheimer\\u2019s Disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35374, \"infons\": {\"name_0\": \"surname:Nakamura;given-names:A\", \"name_1\": \"surname:Kaneko;given-names:N\", \"name_10\": \"surname:Tomita;given-names:T\", \"name_11\": \"surname:Matsuzaki;given-names:K\", \"name_12\": \"surname:Ishii;given-names:K\", \"name_13\": \"surname:Ishii;given-names:K\", \"name_14\": \"surname:Arahata;given-names:Y\", \"name_15\": \"surname:Iwamoto;given-names:S\", \"name_16\": \"surname:Ito;given-names:K\", \"name_17\": \"surname:Tanaka;given-names:K\", \"name_18\": \"surname:Masters;given-names:CL\", \"name_19\": \"surname:Yanagisawa;given-names:K\", \"name_2\": \"surname:Villemagne;given-names:VL\", \"name_3\": \"surname:Kato;given-names:T\", \"name_4\": \"surname:Doecke;given-names:J\", \"name_5\": \"surname:Dor\\u00e9;given-names:V\", \"name_6\": \"surname:Fowler;given-names:C\", \"name_7\": \"surname:Li;given-names:QX\", \"name_8\": \"surname:Martins;given-names:R\", \"name_9\": \"surname:Rowe;given-names:C\", \"pub-id_doi\": \"10.1038/nature25456\", \"section_type\": \"REF\", \"source\": \"Nature\", \"type\": \"ref\", \"volume\": \"554\", \"year\": \"2018\"}, \"text\": \"High performance plasma amyloid-\\u03b2 biomarkers for Alzheimer\\u2019s disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35446, \"infons\": {\"fpage\": \"e105\", \"lpage\": \"e125\", \"name_0\": \"surname:Nichols;given-names:E\", \"name_1\": \"surname:Steinmetz;given-names:JD\", \"name_10\": \"surname:Al Hamad;given-names:H\", \"name_100\": \"surname:Hay;given-names:SI\", \"name_101\": \"surname:Hayat;given-names:K\", \"name_102\": \"surname:Hegazy;given-names:MI\", \"name_103\": \"surname:Heidari;given-names:G\", \"name_104\": \"surname:Heidari-Soureshjani;given-names:R\", \"name_105\": \"surname:Herteliu;given-names:C\", \"name_106\": \"surname:Househ;given-names:M\", \"name_107\": \"surname:Hussain;given-names:R\", \"name_108\": \"surname:Hwang;given-names:B-F\", \"name_109\": \"surname:Iacoviello;given-names:L\", \"name_11\": \"surname:Alahdab;given-names:F\", \"name_110\": \"surname:Iavicoli;given-names:I\", \"name_111\": \"surname:Ilesanmi;given-names:OS\", \"name_112\": \"surname:Ilic;given-names:IM\", \"name_113\": \"surname:Ilic;given-names:MD\", \"name_114\": \"surname:Irvani;given-names:SSN\", \"name_115\": \"surname:Iso;given-names:H\", \"name_116\": \"surname:Iwagami;given-names:M\", \"name_117\": \"surname:Jabbarinejad;given-names:R\", \"name_118\": \"surname:Jacob;given-names:L\", \"name_119\": \"surname:Jain;given-names:V\", \"name_12\": \"surname:Alanezi;given-names:FM\", \"name_120\": \"surname:Jayapal;given-names:SK\", \"name_121\": \"surname:Jayawardena;given-names:R\", \"name_122\": \"surname:Jha;given-names:RP\", \"name_123\": \"surname:Jonas;given-names:JB\", \"name_124\": \"surname:Joseph;given-names:N\", \"name_125\": \"surname:Kalani;given-names:R\", \"name_126\": \"surname:Kandel;given-names:A\", \"name_127\": \"surname:Kandel;given-names:H\", \"name_128\": \"surname:Karch;given-names:A\", \"name_129\": \"surname:Kasa;given-names:AS\", \"name_13\": \"surname:Alipour;given-names:V\", \"name_130\": \"surname:Kassie;given-names:GM\", \"name_131\": \"surname:Keshavarz;given-names:P\", \"name_132\": \"surname:Khan;given-names:MAB\", \"name_133\": \"surname:Khatib;given-names:MN\", \"name_134\": \"surname:Khoja;given-names:TAM\", \"name_135\": \"surname:Khubchandani;given-names:J\", \"name_136\": \"surname:Kim;given-names:MS\", \"name_137\": \"surname:Kim;given-names:YJ\", \"name_138\": \"surname:Kisa;given-names:A\", \"name_139\": \"surname:Kisa;given-names:S\", \"name_14\": \"surname:Almustanyir;given-names:S\", \"name_140\": \"surname:Kivim\\u00e4ki;given-names:M\", \"name_141\": \"surname:Koroshetz;given-names:WJ\", \"name_142\": \"surname:Koyanagi;given-names:A\", \"name_143\": \"surname:Kumar;given-names:GA\", \"name_144\": \"surname:Kumar;given-names:M\", \"name_145\": \"surname:Lak;given-names:HM\", \"name_146\": \"surname:Leonardi;given-names:M\", \"name_147\": \"surname:Li;given-names:B\", \"name_148\": \"surname:Lim;given-names:SS\", \"name_149\": \"surname:Liu;given-names:X\", \"name_15\": \"surname:Amu;given-names:H\", \"name_150\": \"surname:Liu;given-names:Y\", \"name_151\": \"surname:Logroscino;given-names:G\", \"name_152\": \"surname:Lorkowski;given-names:S\", \"name_153\": \"surname:Lucchetti;given-names:G\", \"name_154\": \"surname:Lutzky Saute;given-names:R\", \"name_155\": \"surname:Magnani;given-names:FG\", \"name_156\": \"surname:Malik;given-names:AA\", \"name_157\": \"surname:Massano;given-names:J\", \"name_158\": \"surname:Mehndiratta;given-names:MM\", \"name_159\": \"surname:Menezes;given-names:RG\", \"name_16\": \"surname:Ansari;given-names:I\", \"name_160\": \"surname:Meretoja;given-names:A\", \"name_161\": \"surname:Mohajer;given-names:B\", \"name_162\": \"surname:Mohamed Ibrahim;given-names:N\", \"name_163\": \"surname:Mohammad;given-names:Y\", \"name_164\": \"surname:Mohammed;given-names:A\", \"name_165\": \"surname:Mokdad;given-names:AH\", \"name_166\": \"surname:Mondello;given-names:S\", \"name_167\": \"surname:Moni;given-names:MAA\", \"name_168\": \"surname:Moniruzzaman;given-names:M\", \"name_169\": \"surname:Mossie;given-names:TB\", \"name_17\": \"surname:Arabloo;given-names:J\", \"name_170\": \"surname:Nagel;given-names:G\", \"name_171\": \"surname:Naveed;given-names:M\", \"name_172\": \"surname:Nayak;given-names:VC\", \"name_173\": \"surname:Neupane Kandel;given-names:S\", \"name_174\": \"surname:Nguyen;given-names:TH\", \"name_175\": \"surname:Oancea;given-names:B\", \"name_176\": \"surname:Otstavnov;given-names:N\", \"name_177\": \"surname:Otstavnov;given-names:SS\", \"name_178\": \"surname:Owolabi;given-names:MO\", \"name_179\": \"surname:Panda-Jonas;given-names:S\", \"name_18\": \"surname:Ashraf;given-names:T\", \"name_180\": \"surname:Pashazadeh Kan;given-names:F\", \"name_181\": \"surname:Pasovic;given-names:M\", \"name_182\": \"surname:Patel;given-names:UK\", \"name_183\": \"surname:Pathak;given-names:M\", \"name_184\": \"surname:Peres;given-names:MFP\", \"name_185\": \"surname:Perianayagam;given-names:A\", \"name_186\": \"surname:Peterson;given-names:CB\", \"name_187\": \"surname:Phillips;given-names:MR\", \"name_188\": \"surname:Pinheiro;given-names:M\", \"name_189\": \"surname:Piradov;given-names:MA\", \"name_19\": \"surname:Astell-Burt;given-names:T\", \"name_190\": \"surname:Pond;given-names:CD\", \"name_191\": \"surname:Potashman;given-names:MH\", \"name_192\": \"surname:Pottoo;given-names:FH\", \"name_193\": \"surname:Prada;given-names:SI\", \"name_194\": \"surname:Radfar;given-names:A\", \"name_195\": \"surname:Raggi;given-names:A\", \"name_196\": \"surname:Rahim;given-names:F\", \"name_197\": \"surname:Rahman;given-names:M\", \"name_198\": \"surname:Ram;given-names:P\", \"name_199\": \"surname:Ranasinghe;given-names:P\", \"name_2\": \"surname:Vollset;given-names:SE\", \"name_20\": \"surname:Ayano;given-names:G\", \"name_200\": \"surname:Rawaf;given-names:DL\", \"name_201\": \"surname:Rawaf;given-names:S\", \"name_202\": \"surname:Rezaei;given-names:N\", \"name_203\": \"surname:Rezapour;given-names:A\", \"name_204\": \"surname:Robinson;given-names:SR\", \"name_205\": \"surname:Romoli;given-names:M\", \"name_206\": \"surname:Roshandel;given-names:G\", \"name_207\": \"surname:Sahathevan;given-names:R\", \"name_208\": \"surname:Sahebkar;given-names:A\", \"name_209\": \"surname:Sahraian;given-names:MA\", \"name_21\": \"surname:Ayuso-Mateos;given-names:JL\", \"name_210\": \"surname:Sathian;given-names:B\", \"name_211\": \"surname:Sattin;given-names:D\", \"name_212\": \"surname:Sawhney;given-names:M\", \"name_213\": \"surname:Saylan;given-names:M\", \"name_214\": \"surname:Schiavolin;given-names:S\", \"name_215\": \"surname:Seylani;given-names:A\", \"name_216\": \"surname:Sha;given-names:F\", \"name_217\": \"surname:Shaikh;given-names:MA\", \"name_218\": \"surname:Shaji;given-names:KS\", \"name_219\": \"surname:Shannawaz;given-names:M\", \"name_22\": \"surname:Baig;given-names:AA\", \"name_220\": \"surname:Shetty;given-names:JK\", \"name_221\": \"surname:Shigematsu;given-names:M\", \"name_222\": \"surname:Shin;given-names:JI\", \"name_223\": \"surname:Shiri;given-names:R\", \"name_224\": \"surname:Silva;given-names:DAS\", \"name_225\": \"surname:Silva;given-names:JP\", \"name_226\": \"surname:Silva;given-names:R\", \"name_227\": \"surname:Singh;given-names:JA\", \"name_228\": \"surname:Skryabin;given-names:VY\", \"name_229\": \"surname:Skryabina;given-names:AA\", \"name_23\": \"surname:Barnett;given-names:A\", \"name_230\": \"surname:Smith;given-names:AE\", \"name_231\": \"surname:Soshnikov;given-names:S\", \"name_232\": \"surname:Spurlock;given-names:EE\", \"name_233\": \"surname:Stein;given-names:DJ\", \"name_234\": \"surname:Sun;given-names:J\", \"name_235\": \"surname:Tabar\\u00e9s-Seisdedos;given-names:R\", \"name_236\": \"surname:Thakur;given-names:B\", \"name_237\": \"surname:Timalsina;given-names:B\", \"name_238\": \"surname:Tovani-Palone;given-names:MR\", \"name_239\": \"surname:Tran;given-names:BX\", \"name_24\": \"surname:Barrow;given-names:A\", \"name_240\": \"surname:Tsegaye;given-names:GW\", \"name_241\": \"surname:Valadan Tahbaz;given-names:S\", \"name_242\": \"surname:Valdez;given-names:PR\", \"name_243\": \"surname:Venketasubramanian;given-names:N\", \"name_244\": \"surname:Vlassov;given-names:V\", \"name_245\": \"surname:Vu;given-names:GT\", \"name_246\": \"surname:Vu;given-names:LG\", \"name_247\": \"surname:Wang;given-names:Y-P\", \"name_248\": \"surname:Wimo;given-names:A\", \"name_249\": \"surname:Winkler;given-names:AS\", \"name_25\": \"surname:Baune;given-names:BT\", \"name_250\": \"surname:Yadav;given-names:L\", \"name_251\": \"surname:Yahyazadeh Jabbari;given-names:SH\", \"name_252\": \"surname:Yamagishi;given-names:K\", \"name_253\": \"surname:Yang;given-names:L\", \"name_254\": \"surname:Yano;given-names:Y\", \"name_255\": \"surname:Yonemoto;given-names:N\", \"name_256\": \"surname:Yu;given-names:C\", \"name_257\": \"surname:Yunusa;given-names:I\", \"name_258\": \"surname:Zadey;given-names:S\", \"name_259\": \"surname:Zastrozhin;given-names:MS\", \"name_26\": \"surname:B\\u00e9jot;given-names:Y\", \"name_260\": \"surname:Zastrozhina;given-names:A\", \"name_261\": \"surname:Zhang;given-names:Z-J\", \"name_262\": \"surname:Murray;given-names:CJL\", \"name_263\": \"surname:Vos;given-names:T\", \"name_27\": \"surname:Bezabhe;given-names:WMM\", \"name_28\": \"surname:Bezabih;given-names:YM\", \"name_29\": \"surname:Bhagavathula;given-names:AS\", \"name_3\": \"surname:Fukutaki;given-names:K\", \"name_30\": \"surname:Bhaskar;given-names:S\", \"name_31\": \"surname:Bhattacharyya;given-names:K\", \"name_32\": \"surname:Bijani;given-names:A\", \"name_33\": \"surname:Biswas;given-names:A\", \"name_34\": \"surname:Bolla;given-names:SR\", \"name_35\": \"surname:Boloor;given-names:A\", \"name_36\": \"surname:Brayne;given-names:C\", \"name_37\": \"surname:Brenner;given-names:H\", \"name_38\": \"surname:Burkart;given-names:K\", \"name_39\": \"surname:Burns;given-names:RA\", \"name_4\": \"surname:Chalek;given-names:J\", \"name_40\": \"surname:C\\u00e1mera;given-names:LA\", \"name_41\": \"surname:Cao;given-names:C\", \"name_42\": \"surname:Carvalho;given-names:F\", \"name_43\": \"surname:Castro-de-Araujo;given-names:LFS\", \"name_44\": \"surname:Catal\\u00e1-L\\u00f3pez;given-names:F\", \"name_45\": \"surname:Cerin;given-names:E\", \"name_46\": \"surname:Chavan;given-names:PP\", \"name_47\": \"surname:Cherbuin;given-names:N\", \"name_48\": \"surname:Chu;given-names:D-T\", \"name_49\": \"surname:Costa;given-names:VM\", \"name_5\": \"surname:Abd-Allah;given-names:F\", \"name_50\": \"surname:Couto;given-names:RAS\", \"name_51\": \"surname:Dadras;given-names:O\", \"name_52\": \"surname:Dai;given-names:X\", \"name_53\": \"surname:Dandona;given-names:L\", \"name_54\": \"surname:Dandona;given-names:R\", \"name_55\": \"surname:De la Cruz-G\\u00f3ngora;given-names:V\", \"name_56\": \"surname:Dhamnetiya;given-names:D\", \"name_57\": \"surname:Dias da Silva;given-names:D\", \"name_58\": \"surname:Diaz;given-names:D\", \"name_59\": \"surname:Douiri;given-names:A\", \"name_6\": \"surname:Abdoli;given-names:A\", \"name_60\": \"surname:Edvardsson;given-names:D\", \"name_61\": \"surname:Ekholuenetale;given-names:M\", \"name_62\": \"surname:El Sayed;given-names:I\", \"name_63\": \"surname:El-Jaafary;given-names:SI\", \"name_64\": \"surname:Eskandari;given-names:K\", \"name_65\": \"surname:Eskandarieh;given-names:S\", \"name_66\": \"surname:Esmaeilnejad;given-names:S\", \"name_67\": \"surname:Fares;given-names:J\", \"name_68\": \"surname:Faro;given-names:A\", \"name_69\": \"surname:Farooque;given-names:U\", \"name_7\": \"surname:Abualhasan;given-names:A\", \"name_70\": \"surname:Feigin;given-names:VL\", \"name_71\": \"surname:Feng;given-names:X\", \"name_72\": \"surname:Fereshtehnejad;given-names:S-M\", \"name_73\": \"surname:Fernandes;given-names:E\", \"name_74\": \"surname:Ferrara;given-names:P\", \"name_75\": \"surname:Filip;given-names:I\", \"name_76\": \"surname:Fillit;given-names:H\", \"name_77\": \"surname:Fischer;given-names:F\", \"name_78\": \"surname:Gaidhane;given-names:S\", \"name_79\": \"surname:Galluzzo;given-names:L\", \"name_8\": \"surname:Abu-Gharbieh;given-names:E\", \"name_80\": \"surname:Ghashghaee;given-names:A\", \"name_81\": \"surname:Ghith;given-names:N\", \"name_82\": \"surname:Gialluisi;given-names:A\", \"name_83\": \"surname:Gilani;given-names:SA\", \"name_84\": \"surname:Glavan;given-names:I-R\", \"name_85\": \"surname:Gnedovskaya;given-names:EV\", \"name_86\": \"surname:Golechha;given-names:M\", \"name_87\": \"surname:Gupta;given-names:R\", \"name_88\": \"surname:Gupta;given-names:VB\", \"name_89\": \"surname:Gupta;given-names:VK\", \"name_9\": \"surname:Akram;given-names:TT\", \"name_90\": \"surname:Haider;given-names:MR\", \"name_91\": \"surname:Hall;given-names:BJ\", \"name_92\": \"surname:Hamidi;given-names:S\", \"name_93\": \"surname:Hanif;given-names:A\", \"name_94\": \"surname:Hankey;given-names:GJ\", \"name_95\": \"surname:Haque;given-names:S\", \"name_96\": \"surname:Hartono;given-names:RK\", \"name_97\": \"surname:Hasaballah;given-names:AI\", \"name_98\": \"surname:Hasan;given-names:MT\", \"name_99\": \"surname:Hassan;given-names:A\", \"pub-id_doi\": \"10.1016/S2468-2667(21)00249-8\", \"section_type\": \"REF\", \"source\": \"Lancet Public Heal\", \"type\": \"ref\", \"volume\": \"7\", \"year\": \"2022\"}, \"text\": \"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35593, \"infons\": {\"fpage\": \"1939\", \"lpage\": \"49\", \"name_0\": \"surname:Ossenkoppele;given-names:R\", \"name_1\": \"surname:Jansen;given-names:WJ\", \"name_10\": \"surname:Adriaanse;given-names:SM\", \"name_11\": \"surname:Lammertsma;given-names:AA\", \"name_12\": \"surname:Barkhof;given-names:F\", \"name_13\": \"surname:Jagust;given-names:WJ\", \"name_14\": \"surname:Miller;given-names:BL\", \"name_15\": \"surname:Rosen;given-names:HJ\", \"name_16\": \"surname:Landau;given-names:SM\", \"name_17\": \"surname:Villemagne;given-names:VL\", \"name_18\": \"surname:Rowe;given-names:CC\", \"name_19\": \"surname:Lee;given-names:DY\", \"name_2\": \"surname:Rabinovici;given-names:GD\", \"name_20\": \"surname:Na;given-names:DL\", \"name_21\": \"surname:Seo;given-names:SW\", \"name_22\": \"surname:Sarazin;given-names:M\", \"name_23\": \"surname:Roe;given-names:CM\", \"name_24\": \"surname:Sabri;given-names:O\", \"name_25\": \"surname:Barthel;given-names:H\", \"name_26\": \"surname:Koglin;given-names:N\", \"name_27\": \"surname:Hodges;given-names:J\", \"name_28\": \"surname:Leyton;given-names:CE\", \"name_29\": \"surname:Vandenberghe;given-names:R\", \"name_3\": \"surname:Knol;given-names:DL\", \"name_30\": \"surname:van Laere;given-names:K\", \"name_31\": \"surname:Drzezga;given-names:A\", \"name_32\": \"surname:Forster;given-names:S\", \"name_33\": \"surname:Grimmer;given-names:T\", \"name_34\": \"surname:S\\u00e1nchez-Juan;given-names:P\", \"name_35\": \"surname:Carril;given-names:JM\", \"name_36\": \"surname:Mok;given-names:V\", \"name_37\": \"surname:Camus;given-names:V\", \"name_38\": \"surname:Klunk;given-names:WE\", \"name_39\": \"surname:Cohen;given-names:AD\", \"name_4\": \"surname:van der Flier;given-names:WM\", \"name_40\": \"surname:Meyer;given-names:PT\", \"name_41\": \"surname:Hellwig;given-names:S\", \"name_42\": \"surname:Newberg;given-names:A\", \"name_43\": \"surname:Frederiksen;given-names:KS\", \"name_44\": \"surname:Fleisher;given-names:AS\", \"name_45\": \"surname:Mintun;given-names:MA\", \"name_46\": \"surname:Wolk;given-names:DA\", \"name_47\": \"surname:Nordberg;given-names:A\", \"name_48\": \"surname:Rinne;given-names:JO\", \"name_49\": \"surname:Ch\\u00e9telat;given-names:G\", \"name_5\": \"surname:van Berckel;given-names:BNM\", \"name_50\": \"surname:Lleo;given-names:A\", \"name_51\": \"surname:Blesa;given-names:R\", \"name_52\": \"surname:Fortea;given-names:J\", \"name_53\": \"surname:Madsen;given-names:K\", \"name_54\": \"surname:Rodrigue;given-names:KM\", \"name_55\": \"surname:Brooks;given-names:DJ\", \"name_6\": \"surname:Scheltens;given-names:P\", \"name_7\": \"surname:Visser;given-names:PJ\", \"name_8\": \"surname:Verfaillie;given-names:SCJ\", \"name_9\": \"surname:Zwan;given-names:MD\", \"pub-id_doi\": \"10.1001/jama.2015.4669\", \"pub-id_pmid\": \"25988463\", \"section_type\": \"REF\", \"source\": \"JAMA\", \"type\": \"ref\", \"volume\": \"313\", \"year\": \"2015\"}, \"text\": \"Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35669, \"infons\": {\"fpage\": \"317\", \"lpage\": \"329\", \"name_0\": \"surname:Overton;given-names:M\", \"name_1\": \"surname:Pihlsg\\u00e5rd;given-names:M\", \"name_2\": \"surname:Elmst\\u00e5hl;given-names:S\", \"pub-id_doi\": \"10.1159/000506255\", \"pub-id_pmid\": \"32224608\", \"section_type\": \"REF\", \"source\": \"Dement. Geriatr. Cogn. Disord\", \"type\": \"ref\", \"volume\": \"48\", \"year\": \"2019\"}, \"text\": \"Diagnostic Stability of Mild Cognitive Impairment, and Predictors of Reversion to Normal Cognitive Functioning\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35780, \"infons\": {\"name_0\": \"surname:Patten;given-names:KT\", \"name_1\": \"surname:Valenzuela;given-names:AE\", \"name_2\": \"surname:Wallis;given-names:C\", \"name_3\": \"surname:Berg;given-names:EL\", \"name_4\": \"surname:Silverman;given-names:JL\", \"name_5\": \"surname:Bein;given-names:KJ\", \"name_6\": \"surname:Wexler;given-names:AS\", \"name_7\": \"surname:Lein;given-names:PJ\", \"pub-id_doi\": \"10.1289/EHP8905\", \"section_type\": \"REF\", \"source\": \"Environ. Health Perspect\", \"type\": \"ref\", \"volume\": \"129\", \"year\": \"2021\"}, \"text\": \"The effects of chronic exposure to ambient traffic-related air pollution on alzheimer\\u2019s disease phenotypes in wildtype and genetically predisposed male and female rats\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35950, \"infons\": {\"fpage\": \"1127\", \"lpage\": \"1133\", \"name_0\": \"surname:Peters;given-names:KE\", \"name_1\": \"surname:Davis;given-names:WA\", \"name_2\": \"surname:Taddei;given-names:K\", \"name_3\": \"surname:Martins;given-names:RN\", \"name_4\": \"surname:Masters;given-names:CL\", \"name_5\": \"surname:Davis;given-names:TME\", \"name_6\": \"surname:Bruce;given-names:DG\", \"pub-id_doi\": \"10.3233/JAD-161050\", \"pub-id_pmid\": \"28106562\", \"section_type\": \"REF\", \"source\": \"J. Alzheimer\\u2019s Dis\", \"type\": \"ref\", \"volume\": \"56\", \"year\": \"2017\"}, \"text\": \"Plasma Amyloid-\\u03b2 Peptides in Type 2 Diabetes: A Matched Case-Control Study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36028, \"infons\": {\"fpage\": \"161\", \"lpage\": \"169\", \"name_0\": \"surname:Roeben;given-names:B\", \"name_1\": \"surname:Maetzler;given-names:W\", \"name_10\": \"surname:Gaenslen;given-names:A\", \"name_11\": \"surname:Gr\\u00fcner;given-names:E\", \"name_12\": \"surname:Niebler;given-names:R\", \"name_13\": \"surname:Eschweiler;given-names:GW\", \"name_14\": \"surname:Berg;given-names:D\", \"name_2\": \"surname:Vanmechelen;given-names:E\", \"name_3\": \"surname:Schulte;given-names:C\", \"name_4\": \"surname:Heinzel;given-names:S\", \"name_5\": \"surname:Stellos;given-names:K\", \"name_6\": \"surname:Godau;given-names:J\", \"name_7\": \"surname:Huber;given-names:H\", \"name_8\": \"surname:Brockmann;given-names:K\", \"name_9\": \"surname:Wurster;given-names:I\", \"pub-id_doi\": \"10.3233/JAD-150575\", \"pub-id_pmid\": \"27003209\", \"section_type\": \"REF\", \"source\": \"J. Alzheimer\\u2019s Dis\", \"type\": \"ref\", \"volume\": \"52\", \"year\": \"2016\"}, \"text\": \"Association of Plasma A\\u03b240 Peptides, but Not A\\u03b242, with Coronary Artery Disease and Diabetes Mellitus\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36136, \"infons\": {\"name_0\": \"surname:Rubin;given-names:DB\", \"section_type\": \"REF\", \"source\": \"Multiple imputation for nonresponse in surveys\", \"type\": \"ref\", \"year\": \"2004\"}, \"text\": \"\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36137, \"infons\": {\"name_0\": \"surname:Sahu;given-names:B\", \"name_1\": \"surname:Mackos;given-names:AR\", \"name_2\": \"surname:Floden;given-names:AM\", \"name_3\": \"surname:Wold;given-names:LE\", \"name_4\": \"surname:Combs;given-names:CK\", \"pub-id_doi\": \"10.3233/JAD-200919\", \"section_type\": \"REF\", \"source\": \"J. Alzheimer\\u2019s Dis\", \"type\": \"ref\", \"volume\": \"80\", \"year\": \"2021\"}, \"text\": \"Particulate Matter Exposure Exacerbates Amyloid-\\u03b2 Plaque Deposition and Gliosis in APP/PS1 Mice\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36236, \"infons\": {\"name_0\": \"surname:Semmens;given-names:EO\", \"name_1\": \"surname:Leary;given-names:CS\", \"name_2\": \"surname:Fitzpatrick;given-names:AL\", \"name_3\": \"surname:Ilango;given-names:SD\", \"name_4\": \"surname:Park;given-names:C\", \"name_5\": \"surname:Adam;given-names:CE\", \"name_6\": \"surname:DeKosky;given-names:ST\", \"name_7\": \"surname:Lopez;given-names:O\", \"name_8\": \"surname:Hajat;given-names:A\", \"name_9\": \"surname:Kaufman;given-names:JD\", \"pub-id_doi\": \"10.1002/alz.12654\", \"section_type\": \"REF\", \"source\": \"Alzheimers. Dement\", \"type\": \"ref\", \"year\": \"2022\"}, \"text\": \"Air pollution and dementia in older adults in the Ginkgo Evaluation of Memory Study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36320, \"infons\": {\"fpage\": \"1761\", \"lpage\": \"1773\", \"name_0\": \"surname:Shaffer;given-names:RM\", \"name_1\": \"surname:Li;given-names:G\", \"name_2\": \"surname:Adar;given-names:SD\", \"name_3\": \"surname:Dirk Keene;given-names:C\", \"name_4\": \"surname:Latimer;given-names:CS\", \"name_5\": \"surname:Crane;given-names:PK\", \"name_6\": \"surname:Larson;given-names:EB\", \"name_7\": \"surname:Kaufman;given-names:JD\", \"name_8\": \"surname:Carone;given-names:M\", \"name_9\": \"surname:Sheppard;given-names:L\", \"pub-id_doi\": \"10.3233/JAD-201005\", \"pub-id_pmid\": \"33459717\", \"section_type\": \"REF\", \"source\": \"J. Alzheimers. Dis\", \"type\": \"ref\", \"volume\": \"79\", \"year\": \"2021\"}, \"text\": \"Fine Particulate Matter and Markers of Alzheimer\\u2019s Disease Neuropathology at Autopsy in a Community-Based Cohort\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36435, \"infons\": {\"name_0\": \"surname:Shah;given-names:NS\", \"name_1\": \"surname:Vidal;given-names:JS\", \"name_2\": \"surname:Masaki;given-names:K\", \"name_3\": \"surname:Petrovitch;given-names:H\", \"name_4\": \"surname:Ross;given-names:GW\", \"name_5\": \"surname:Tilley;given-names:C\", \"name_6\": \"surname:Demattos;given-names:RB\", \"name_7\": \"surname:Tracy;given-names:RP\", \"name_8\": \"surname:White;given-names:LR\", \"name_9\": \"surname:Launer;given-names:LJ\", \"pub-id_doi\": \"10.1161/HYPERTENSIONAHA.111.178962\", \"section_type\": \"REF\", \"source\": \"Hypertension\", \"type\": \"ref\", \"volume\": \"59\", \"year\": \"2012\"}, \"text\": \"Midlife blood pressure, plasma \\u03b2-amyloid, and the risk for alzheimer disease: The honolulu asia aging study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36546, \"infons\": {\"fpage\": \"2716\", \"lpage\": \"2731\", \"name_0\": \"surname:Skillb\\u00e4ck;given-names:T\", \"name_1\": \"surname:Farahmand;given-names:BY\", \"name_10\": \"surname:Blennow;given-names:K\", \"name_11\": \"surname:Eriksdotter;given-names:M\", \"name_12\": \"surname:Zetterberg;given-names:H\", \"name_2\": \"surname:Ro\\u015ben;given-names:C\", \"name_3\": \"surname:Mattsson;given-names:N\", \"name_4\": \"surname:N\\u00e4gga;given-names:K\", \"name_5\": \"surname:Kilander;given-names:L\", \"name_6\": \"surname:Religa;given-names:D\", \"name_7\": \"surname:Wimo;given-names:A\", \"name_8\": \"surname:Winblad;given-names:B\", \"name_9\": \"surname:Schott;given-names:JM\", \"pub-id_doi\": \"10.1093/brain/awv181\", \"pub-id_pmid\": \"26133663\", \"section_type\": \"REF\", \"source\": \"Brain\", \"type\": \"ref\", \"volume\": \"138\", \"year\": \"2015\"}, \"text\": \"Cerebrospinal fluid tau and amyloid-\\u03b21\\u201342 in patients with dementia\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36617, \"infons\": {\"fpage\": \"171\", \"lpage\": \"182\", \"name_0\": \"surname:Snitz;given-names:BE\", \"name_1\": \"surname:Saxton;given-names:J\", \"name_2\": \"surname:Lopez;given-names:OL\", \"name_3\": \"surname:Ives;given-names:DG\", \"name_4\": \"surname:Dunn;given-names:LO\", \"name_5\": \"surname:Rapp;given-names:SR\", \"name_6\": \"surname:Carlson;given-names:MC\", \"name_7\": \"surname:Fitzpatrick;given-names:AL\", \"name_8\": \"surname:Dekosky;given-names:ST\", \"pub-id_doi\": \"10.1080/13607860802380656\", \"pub-id_pmid\": \"19347684\", \"section_type\": \"REF\", \"source\": \"Aging Ment. Health\", \"type\": \"ref\", \"volume\": \"13\", \"year\": \"2009\"}, \"text\": \"Identifying mild cognitive impairment at baseline in the Ginkgo Evaluation of Memory (GEM) study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36714, \"infons\": {\"fpage\": \"365\", \"lpage\": \"375\", \"name_0\": \"surname:Song;given-names:F\", \"name_1\": \"surname:Poljak;given-names:A\", \"name_2\": \"surname:Valenzuela;given-names:M\", \"name_3\": \"surname:Mayeux;given-names:R\", \"name_4\": \"surname:Smythe;given-names:GA\", \"name_5\": \"surname:Sachdev;given-names:PS\", \"pub-id_doi\": \"10.3233/JAD-2011-101977\", \"pub-id_pmid\": \"21709378\", \"section_type\": \"REF\", \"source\": \"J. Alzheimers. Dis\", \"type\": \"ref\", \"volume\": \"26\", \"year\": \"2011\"}, \"text\": \"Meta-analysis of plasma amyloid-\\u03b2 levels in Alzheimer\\u2019s disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36781, \"infons\": {\"fpage\": \"1060\", \"lpage\": \"1061\", \"name_0\": \"surname:Stamatelopoulos;given-names:K\", \"name_1\": \"surname:Pol;given-names:CJ\", \"name_2\": \"surname:Ayers;given-names:C\", \"name_3\": \"surname:Georgiopoulos;given-names:G\", \"name_4\": \"surname:Gatsiou;given-names:A\", \"name_5\": \"surname:Brilakis;given-names:ES\", \"name_6\": \"surname:Khera;given-names:A\", \"name_7\": \"surname:Drosatos;given-names:K\", \"name_8\": \"surname:de Lemos;given-names:JA\", \"name_9\": \"surname:Stellos;given-names:K\", \"pub-id_doi\": \"10.1016/j.jacc.2018.06.027\", \"pub-id_pmid\": \"30139434\", \"section_type\": \"REF\", \"source\": \"J. Am. Coll. Cardiol\", \"type\": \"ref\", \"volume\": \"72\", \"year\": \"2018\"}, \"text\": \"Amyloid-Beta (1\\u201340) Peptide and Subclinical Cardiovascular Disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36850, \"infons\": {\"fpage\": \"2701\", \"lpage\": \"2715\", \"name_0\": \"surname:Toledo;given-names:JB\", \"name_1\": \"surname:Zetterberg;given-names:H\", \"name_10\": \"surname:Osorio;given-names:RS\", \"name_11\": \"surname:Vanderstichele;given-names:H\", \"name_12\": \"surname:Vandijck;given-names:M\", \"name_13\": \"surname:Hampel;given-names:H\", \"name_14\": \"surname:Teipl;given-names:S\", \"name_15\": \"surname:Moghekar;given-names:A\", \"name_16\": \"surname:Albert;given-names:M\", \"name_17\": \"surname:Hu;given-names:WT\", \"name_18\": \"surname:Monge Argil\\u00e9s;given-names:JA\", \"name_19\": \"surname:Gorostidi;given-names:A\", \"name_2\": \"surname:van Harten;given-names:AC\", \"name_20\": \"surname:Teunissen;given-names:CE\", \"name_21\": \"surname:De Deyn;given-names:PP\", \"name_22\": \"surname:Hyman;given-names:BT\", \"name_23\": \"surname:Molinuevo;given-names:JL\", \"name_24\": \"surname:Frisoni;given-names:GB\", \"name_25\": \"surname:Linazasoro;given-names:G\", \"name_26\": \"surname:de Leon;given-names:MJ\", \"name_27\": \"surname:van der Flier;given-names:WM\", \"name_28\": \"surname:Scheltens;given-names:P\", \"name_29\": \"surname:Blennow;given-names:K\", \"name_3\": \"surname:Glodzik;given-names:L\", \"name_30\": \"surname:Shaw;given-names:LM\", \"name_31\": \"surname:Trojanowski;given-names:JQ\", \"name_4\": \"surname:Martinez-Lage;given-names:P\", \"name_5\": \"surname:Bocchio-Chiavetto;given-names:L\", \"name_6\": \"surname:Rami;given-names:L\", \"name_7\": \"surname:Hansson;given-names:O\", \"name_8\": \"surname:Sperling;given-names:R\", \"name_9\": \"surname:Engelborghs;given-names:S\", \"pub-id_doi\": \"10.1093/brain/awv199\", \"pub-id_pmid\": \"26220940\", \"section_type\": \"REF\", \"source\": \"Brain\", \"type\": \"ref\", \"volume\": \"138\", \"year\": \"2015\"}, \"text\": \"Alzheimer\\u2019s disease cerebrospinal fluid biomarker in cognitively normal subjects\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36933, \"infons\": {\"name_0\": \"surname:Wang;given-names:J\", \"name_1\": \"surname:Gu;given-names:BJ\", \"name_2\": \"surname:Masters;given-names:CL\", \"name_3\": \"surname:Wang;given-names:YJ\", \"pub-id_doi\": \"10.1038/nrneurol.2017.111\", \"section_type\": \"REF\", \"source\": \"Nat. Rev. Neurol\", \"type\": \"ref\", \"volume\": \"13\", \"year\": \"2017\"}, \"text\": \"A systemic view of Alzheimer disease - Insights from amyloid-\\u03b2 metabolism beyond the brain\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37027, \"infons\": {\"fpage\": \"819\", \"lpage\": \"832\", \"name_0\": \"surname:Wang;given-names:X\", \"name_1\": \"surname:Sun;given-names:Y\", \"name_2\": \"surname:Li;given-names:T\", \"name_3\": \"surname:Cai;given-names:Y\", \"name_4\": \"surname:Han;given-names:Y\", \"pub-id_doi\": \"10.3233/JAD-190714\", \"pub-id_pmid\": \"31868667\", \"section_type\": \"REF\", \"source\": \"J. Alzheimers. Dis\", \"type\": \"ref\", \"volume\": \"73\", \"year\": \"2020\"}, \"text\": \"Amyloid-\\u03b2 as a Blood Biomarker for Alzheimer\\u2019s Disease: A Review of Recent Literature\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37116, \"infons\": {\"fpage\": \"643\", \"lpage\": \"651\", \"name_0\": \"surname:Washburn;given-names:RA\", \"name_1\": \"surname:McAuley;given-names:E\", \"name_2\": \"surname:Katula;given-names:J\", \"name_3\": \"surname:Mihalko;given-names:SL\", \"name_4\": \"surname:Boileau;given-names:RA\", \"pub-id_doi\": \"10.1016/s0895-4356(99)00049-9\", \"pub-id_pmid\": \"10391658\", \"section_type\": \"REF\", \"source\": \"J. Clin. Epidemiol\", \"type\": \"ref\", \"volume\": \"52\", \"year\": \"1999\"}, \"text\": \"The physical activity scale for the elderly (PASE): evidence for validity\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37190, \"infons\": {\"name_0\": \"surname:Weuve;given-names:J\", \"name_1\": \"surname:Bennett;given-names:EE\", \"name_2\": \"surname:Ranker;given-names:L\", \"name_3\": \"surname:Gianattasio;given-names:KZ\", \"name_4\": \"surname:Pedde;given-names:M\", \"name_5\": \"surname:Adar;given-names:SD\", \"name_6\": \"surname:Yanosky;given-names:JD\", \"name_7\": \"surname:Power;given-names:MC\", \"pub-id_doi\": \"10.1289/EHP8716\", \"section_type\": \"REF\", \"source\": \"Environ. Health Perspect\", \"type\": \"ref\", \"year\": \"2021\"}, \"text\": \"Exposure to air pollution in relation to risk of dementia and related outcomes: An updated systematic review of the epidemiological literature\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37333, \"infons\": {\"fpage\": \"434\", \"lpage\": \"438\", \"name_0\": \"surname:Woolpert;given-names:KM\", \"name_1\": \"surname:Ward;given-names:KC\", \"name_2\": \"surname:England;given-names:CV\", \"name_3\": \"surname:Lash;given-names:TL\", \"pub-id_doi\": \"10.1097/EDE.0000000000001327\", \"pub-id_pmid\": \"33591053\", \"section_type\": \"REF\", \"source\": \"Epidemiology\", \"type\": \"ref\", \"volume\": \"32\", \"year\": \"2021\"}, \"text\": \"Validation of LexisNexis Accurint in the Georgia Cancer Registry\\u2019s Cancer Recurrence and Information Surveillance Program\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37457, \"infons\": {\"fpage\": \"3686\", \"lpage\": \"3694\", \"name_0\": \"surname:Young;given-names:MT\", \"name_1\": \"surname:Bechle;given-names:MJ\", \"name_2\": \"surname:Sampson;given-names:PD\", \"name_3\": \"surname:Szpiro;given-names:AA\", \"name_4\": \"surname:Marshall;given-names:JD\", \"name_5\": \"surname:Sheppard;given-names:L\", \"name_6\": \"surname:Kaufman;given-names:JD\", \"pub-id_doi\": \"10.1021/acs.est.5b05099\", \"pub-id_pmid\": \"26927327\", \"section_type\": \"REF\", \"source\": \"Environ. Sci. Technol\", \"type\": \"ref\", \"volume\": \"50\", \"year\": \"2016\"}, \"text\": \"Satellite-Based NO2 and Model Validation in a National Prediction Model Based on Universal Kriging and Land-Use Regression\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37580, \"infons\": {\"file\": \"nihms-1876059-f0001.jpg\", \"id\": \"F1\", \"section_type\": \"FIG\", \"type\": \"fig_caption\"}, \"text\": \"Histograms of log-transformed and winsorized A\\u03b21\\u201340 (pg/mL), A\\u03b21\\u201342 (pg/mL) and A\\u03b21\\u201342/A\\u03b21\\u201340 ratio values at 2000\\u201302 (A, B and C) and 2007\\u201308 (D, E and F). A\\u03b2 values less than or equal to the first percentile of their distributions at 2000\\u201302 and 2007\\u201308 were removed and set to the minimum value (winsorized) and then log-transformed. The A\\u03b21\\u201342/A\\u03b21\\u201340 ratio was created by taking the log-transformation of both the numerator and denominator before division.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38068, \"infons\": {\"file\": \"nihms-1876059-f0002.jpg\", \"id\": \"F2\", \"section_type\": \"FIG\", \"type\": \"fig_caption\"}, \"text\": \"Distributions of PM2.5, PM10 and NO2 by study site and different exposure periods (1-, 5-, 10- and 20-year averages) prior to 2000\\u201302 (A, B and C) and 2007\\u201308 (D, E and F). Abbreviations: CA, California; MD, Maryland; NC, North Carolina; PA, Pennsylvania. Note: Data were not available for 20-year averages of PM10 and NO2.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38396, \"infons\": {\"file\": \"nihms-1876059-f0003.jpg\", \"id\": \"F3\", \"section_type\": \"FIG\", \"type\": \"fig_caption\"}, \"text\": \"Adjusted percent differences and 95% confidence intervals (CIs) in baseline (A, B and C) and repeat (D, E and F) measures of A\\u03b21\\u201340, A\\u03b21\\u201342 and A\\u03b21\\u201342/A\\u03b21\\u201340 ratio per 1 interquartile range (IQR) unit higher PM2.5 (IQR = 2 \\u03bcg/m3), PM10 (IQR = 3 \\u03bcg/m3) and NO2 (IQR = 6 ppb) by different averaging periods for PM2.5 (10 and 20 years) and PM10 and NO2 (5 and 10 years for both) in Model 3. Model 3 adjusted for age, sex, race, education, study site, treatment assignment, Cystatin C, neighborhood deprivation index, smoking history, alcohol consumption, pack-years smoking, percentage of life exposed to secondhand smoke, physical activity and APOE \\u03b54.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39067, \"infons\": {\"file\": \"T1.xml\", \"id\": \"T1\", \"section_type\": \"TABLE\", \"type\": \"table_caption\"}, \"text\": \"Characteristics at baseline and follow-up of GEMS participants stratified by groups with A\\u03b2 measurements at 2000\\u201302 (N = 3,044) and 2007\\u201308 (N = 1,669).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39225, \"infons\": {\"file\": \"T1.xml\", \"id\": \"T1\", \"section_type\": \"TABLE\", \"type\": \"table\", \"xml\": \"<?xml version=\\\"1.0\\\" encoding=\\\"UTF-8\\\"?>\\n<table frame=\\\"hsides\\\" rules=\\\"none\\\"><colgroup span=\\\"1\\\"><col align=\\\"left\\\" valign=\\\"middle\\\" span=\\\"1\\\"/><col align=\\\"left\\\" valign=\\\"middle\\\" span=\\\"1\\\"/><col align=\\\"left\\\" valign=\\\"middle\\\" span=\\\"1\\\"/></colgroup><thead><tr><th align=\\\"left\\\" valign=\\\"top\\\" style=\\\"border-bottom: solid 1px\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Characteristic</th><th align=\\\"left\\\" valign=\\\"top\\\" style=\\\"border-bottom: solid 1px\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2000\\u201302</th><th align=\\\"left\\\" valign=\\\"top\\\" style=\\\"border-bottom: solid 1px\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2007\\u201308</th></tr><tr><th align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><th align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">N = 3,044</th><th align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">N = 1,669</th></tr></thead><tbody><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Age, years</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">78.6 (3.3)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">84.5 (3.0)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Female sex, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1408 (46)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">727 (44)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">People of color, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">139 (5)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">68 (4)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Placebo assignment, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1511 (50)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">847 (51)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Education, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">High school or less</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">335 (11)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">168 (10)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Some college</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">763 (25)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">415 (25)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">College graduate</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">767 (25)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">400 (24)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Postgraduate</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1179 (39)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">686 (41)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Study site, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Winston-Salem, NC</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">724 (24)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">384 (23)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Sacramento, CA</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">909 (30)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">533 (32)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Hagerstown, MD</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">454 (15)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">252 (15)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Pittsburgh, PA</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">957 (31)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">500 (30)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Alcohol consumption, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1328 (44)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">766 (47)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Smoking history, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Never</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1214 (41)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">684 (42)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Former</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1637 (55)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">887 (54)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Current</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">135 (5)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">66 (4)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Pack-years smoking</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">3.6 (0.0, 27.0)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2.4 (0.0, 24.8)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Percentage of life exposed to SHS</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">24 (1, 46)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">24 (0, 45)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Neighborhood deprivation index</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1 year</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.04 (\\u22122.26, 2.22)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\u22120.08 (\\u22122.28, 1.87)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">5 year</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.08 (\\u22122.18, 2.18)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\u22120.06 (\\u22122.27, 1.90)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">10 year</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.10 (\\u22122.20, 2.22)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.01 (\\u22122.20, 2.02)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">20 year</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.14 (\\u22121.93, 2.25)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.12 (\\u22122.10, 2.05)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Body mass index, kg/m<sup>2</sup></td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">27.1 (4.3)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">26.4 (4.1)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Hypertension, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2114 (69)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1319 (80)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Physical activity score</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">13.4 (4.8)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">14.0 (4.5)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Cystatin C, mg/L</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.83 (0.21)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.97 (0.32)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">APOE \\u03b54 carrier status, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">574 (24)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">299 (22)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Mild cognitive impairment status, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">510 (17)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">469 (28)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Modified Mini-Mental State Exam score</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">93.4 (4.7)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">94.9 (4.9)</td></tr></tbody></table>\\n\"}, \"text\": \"Characteristic\\t2000\\u201302\\t2007\\u201308\\t \\t\\tN = 3,044\\tN = 1,669\\t \\tAge, years\\t78.6 (3.3)\\t84.5 (3.0)\\t \\tFemale sex, n (%)\\t1408 (46)\\t727 (44)\\t \\tPeople of color, n (%)\\t139 (5)\\t68 (4)\\t \\tPlacebo assignment, n (%)\\t1511 (50)\\t847 (51)\\t \\tEducation, n (%)\\t\\t\\t \\tHigh school or less\\t335 (11)\\t168 (10)\\t \\tSome college\\t763 (25)\\t415 (25)\\t \\tCollege graduate\\t767 (25)\\t400 (24)\\t \\tPostgraduate\\t1179 (39)\\t686 (41)\\t \\tStudy site, n (%)\\t\\t\\t \\tWinston-Salem, NC\\t724 (24)\\t384 (23)\\t \\tSacramento, CA\\t909 (30)\\t533 (32)\\t \\tHagerstown, MD\\t454 (15)\\t252 (15)\\t \\tPittsburgh, PA\\t957 (31)\\t500 (30)\\t \\tAlcohol consumption, n (%)\\t1328 (44)\\t766 (47)\\t \\tSmoking history, n (%)\\t\\t\\t \\tNever\\t1214 (41)\\t684 (42)\\t \\tFormer\\t1637 (55)\\t887 (54)\\t \\tCurrent\\t135 (5)\\t66 (4)\\t \\tPack-years smoking\\t3.6 (0.0, 27.0)\\t2.4 (0.0, 24.8)\\t \\tPercentage of life exposed to SHS\\t24 (1, 46)\\t24 (0, 45)\\t \\tNeighborhood deprivation index\\t\\t\\t \\t1 year\\t0.04 (\\u22122.26, 2.22)\\t\\u22120.08 (\\u22122.28, 1.87)\\t \\t5 year\\t0.08 (\\u22122.18, 2.18)\\t\\u22120.06 (\\u22122.27, 1.90)\\t \\t10 year\\t0.10 (\\u22122.20, 2.22)\\t0.01 (\\u22122.20, 2.02)\\t \\t20 year\\t0.14 (\\u22121.93, 2.25)\\t0.12 (\\u22122.10, 2.05)\\t \\tBody mass index, kg/m2\\t27.1 (4.3)\\t26.4 (4.1)\\t \\tHypertension, n (%)\\t2114 (69)\\t1319 (80)\\t \\tPhysical activity score\\t13.4 (4.8)\\t14.0 (4.5)\\t \\tCystatin C, mg/L\\t0.83 (0.21)\\t0.97 (0.32)\\t \\tAPOE \\u03b54 carrier status, n (%)\\t574 (24)\\t299 (22)\\t \\tMild cognitive impairment status, n (%)\\t510 (17)\\t469 (28)\\t \\tModified Mini-Mental State Exam score\\t93.4 (4.7)\\t94.9 (4.9)\\t \\t\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 40643, \"infons\": {\"file\": \"T1.xml\", \"id\": \"T1\", \"section_type\": \"TABLE\", \"type\": \"table_footnote\"}, \"text\": \"Continuous variables are presented as mean (SD) or median (interquartile range), where appropriate, and categorical variables are presented as n (%). Abbreviations: APOE, apolipoprotein E; SHS, secondhand smoke.\", \"sentences\": [], \"annotations\": [], \"relations\": []}], \"annotations\": [], \"relations\": []}]}, {\"bioctype\": \"BioCCollection\", \"source\": \"PMC\", \"date\": \"20240911\", \"key\": \"pmc.key\", \"version\": \"1.0\", \"infons\": {}, \"documents\": [{\"bioctype\": \"BioCDocument\", \"id\": \"PMC9974914\", \"infons\": {\"license\": \"CC BY-NC-ND\"}, \"passages\": [{\"bioctype\": \"BioCPassage\", \"offset\": 0, \"infons\": {\"article-id_doi\": \"10.1016/j.envint.2023.107800\", \"article-id_manuscript\": \"NIHMS1876059\", \"article-id_pmc\": \"PMC9974914\", \"article-id_pmid\": \"36773564\", \"fpage\": \"107800\", \"kwd\": \"Air pollution Alzheimer\\u2019s disease Dementia Biomarkers Amyloid beta Aging\", \"license\": \"This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).\", \"lpage\": \"107800\", \"name_0\": \"surname:Hajat;given-names:Anjum\", \"name_1\": \"surname:Park;given-names:Christina\", \"name_2\": \"surname:Adam;given-names:Claire\", \"name_3\": \"surname:Fitzpatrick;given-names:Annette L.\", \"name_4\": \"surname:Ilango;given-names:Sindana D.\", \"name_5\": \"surname:Leary;given-names:Cindy\", \"name_6\": \"surname:Libby;given-names:Tanya\", \"name_7\": \"surname:Lopez;given-names:Oscar\", \"name_8\": \"surname:Semmens;given-names:Erin O.\", \"name_9\": \"surname:Kaufman;given-names:Joel D.\", \"section_type\": \"TITLE\", \"type\": \"front\", \"volume\": \"172\", \"year\": \"2023\"}, \"text\": \"Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 119, \"infons\": {\"section_type\": \"ABSTRACT\", \"type\": \"abstract\"}, \"text\": \"Air pollution has been linked to Alzheimer\\u2019s disease and related dementias (ADRD), but the mechanisms connecting air pollution to ADRD have not been firmly established. Air pollution may cause oxidative stress and neuroinflammation and contribute to the deposition of amyloid beta (A\\u03b2) in the brain. We examined the association between fine particulate matter<2.5 \\u03bcm in diameter (PM2.5), particulate matter<10 \\u03bcm in diameter (PM10), nitrogen dioxide (NO2), and plasma based measures of A\\u03b21\\u201340, A\\u03b21\\u201342 and A\\u03b21\\u201342/A\\u03b21\\u201340 using data from 3044 dementia-free participants of the Ginkgo Evaluation of Memory Study (GEMS). Air pollution exposures were estimated at residential addresses that incorporated address histories dating back to 1980, resulting in one-, five-, 10- and 20- year exposure averages. A\\u03b2 was measured at baseline (2000\\u20132002) and then again at the end of the study (2007\\u20132008) allowing for linear regression models to assess cross-sectional associations and linear random effects models to evaluate repeated measures. After adjustment for socio-demographic and behavioral covariates, we found small positive associations between each air pollutant and A\\u03b21\\u201340 but no association with A\\u03b21\\u201342 or the ratio measures in cross sectional analysis. In repeat measures analysis, we found larger positive associations between each air pollutant and all three outcomes. We observed a 4.43% (95% CI 3.26%, 5.60%) higher A\\u03b21\\u201340 level, 9.73% (6.20%, 13.38%) higher A\\u03b21\\u201342 and 1.57% (95% CI: 0.94%, 2.20%) higher A\\u03b21\\u201342/A\\u03b21\\u201340 ratio associated with a 2 \\u03bcg/m3 higher 20-year average PM2.5. Associations with other air pollutants were similar. Our study contributes to the broader evidence base on air pollution and ADRD biomarkers by evaluating longer air pollution exposure averaging periods to better mimic disease progression and provides a modifiable target for ADRD prevention.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 2040, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"title_1\"}, \"text\": \"Introduction\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 2053, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"The global population is rapidly aging. Globally, the percentage of people age 65 and older is expected to increase from 8% in 2010 to 16% by 2050. With the aging population, cases of dementia are also anticipated to rise, resulting in an estimated 152.8 million cases, a tripling, by 2050. Treatments for Alzheimer\\u2019s Disease and related dementias (ADRD) remain elusive, but several modifiable risk factors have been identified. In addition to lifestyle factors such as exercise and diet, environmental hazards such as air pollution have also been linked to ADRD.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 2619, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"The mechanism by which air pollution causes dementia has not yet been firmly established. Several animal studies suggest that air pollution through its impacts on the central nervous system (CNS) causes neuroinflammation and oxidative stress, which are critical to the development of ADRD. In addition, by altering the activity of key enzymes, air pollution may increase deposition of amyloid beta (A\\u03b2) in the brain, a hallmark of Alzheimer\\u2019s disease (AD). Animal studies have found that long-term exposure to traffic-related air pollution (TRAP) resulted in more A\\u03b2 plaques in animals exposed to TRAP compared to those exposed to filtered air.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 3270, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"Although the utility of treatments that reduce A\\u03b2 plaques as a means to improve cognitive function have been debated, understanding the mechanism by which air pollution impacts brain health remains an important endeavor. A\\u03b21\\u201340, a peptide with a chain of 40 amino acids, has proinflammatory and atherosclerotic properties and has been associated with cardiovascular disease and diabetes; studying A\\u03b21\\u201340 and air pollution can also shed light on other disease processes. A\\u03b21\\u201342, on the other hand, is a key component of A\\u03b2 plaques found in the brain.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 3835, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"Unlike A\\u03b2 plaques in the brain, the presence of A\\u03b2 in plasma is expected. Plasma A\\u03b2 biomarkers are dynamic over time, can be impacted by various factors and have different trajectories for cognitively intact individuals compared to those that go on to develop dementia. For the cognitively intact, plasma A\\u03b2 levels increase with age while for those who transition from intact to MCI to AD, a decline in plasma A\\u03b2 biomarkers is seen over time. A\\u03b2 from the brain can be transported to the blood via the blood brain barrier (and vice versa). In disease-free individuals, soluble A\\u03b2 found in the brain could clear into the blood resulting in higher plasma levels, while in diseased persons, the soluble A\\u03b2 turns into insoluble A\\u03b2 plaques in the brain, which the body is unable to clear, resulting in lower plasma levels.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 4679, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"Given that higher air pollution has been shown to result in worse outcomes (greater cognitive decline and more dementia), we would expect that higher air pollution levels would be associated with lower plasma A\\u03b2 levels among those who go on to develop dementia but higher among those who remain disease free. Higher plasma A\\u03b2 levels may signify air pollution\\u2019s role in accelerating plasma A\\u03b2 levels that could then result in worse cognitive health.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 5137, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"Only a few studies have explored the association between air pollution and A\\u03b2 in humans, some using positron emission tomography (PET) scans or magnetic resonance imaging (MRI) to identify A\\u03b2, others using cerebrospinal fluid (CSF) or autopsy data. Overall the research finds a positive association between air pollution and A\\u03b2; studies using imaging data show a more consistent association. These approaches, although effective at identifying A\\u03b2, have disadvantages in terms of ease, cost and participant burden relative to blood biomarkers of AD. To our knowledge, no study has examined the effect of air pollution on plasma-based A\\u03b2 biomarkers.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 5800, \"infons\": {\"section_type\": \"INTRO\", \"type\": \"paragraph\"}, \"text\": \"Researchers continue to search for highly sensitive approaches to measuring A\\u03b2 in the blood in hopes of developing a diagnostic test to more easily identify ADRD. Once identified, these approaches will allow for a better understanding of the mechanisms underlying demonstrated associations between air pollution and dementia. In this study we examined the associations between air pollution and plasma based biomarkers of A\\u03b2 both cross-sectionally and in repeated measures in a cohort of dementia-free older adults.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 6322, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_1\"}, \"text\": \"Materials and methods\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 6344, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"This study consisted of 3,069 adults aged 75 years or older who were free of dementia at baseline and enrolled in the Ginkgo Evaluation of Memory Study (GEMS), a randomized double-blind controlled trial originally designed to evaluate the efficacy of Ginkgo biloba on AD and dementia. Participants were recruited from four US study sites (Winston-Salem, North Carolina; Hagerstown, Maryland; Sacramento, California; and Pittsburgh, Pennsylvania) between 2000 and 2002 and followed through 2008. Participants were censored upon death, the development of ADRD or loss to follow-up. This study was approved by the Institutional Review Board at the University of Washington and all institutions affiliated with the trial.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 7062, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_2\"}, \"text\": \"Exposure ascertainment\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 7085, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Primary exposures of interest were long-term residential concentrations of fine particulate matter<2.5 \\u03bcm in diameter (PM2.5), particulate matter<10 \\u03bcm in diameter (PM10) and nitrogen dioxide (NO2) estimated at participant residential addresses. Address histories dating back to 1980 (20 years prior to study entry) were reconstructed using data from LexisNexis (LN), a data analytics corporation that applies a proprietary algorithm to publicly available real estate, driver\\u2019s license, voting and court records to identify residential history. LN has been used by a few previous epidemiologic studies to create residential histories. For individuals missing historical residential address data, we used air pollution estimates from last known residential address. More information on the reconstruction of residential histories can be found in the supplement of.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 7953, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"A previously-described spatiotemporal model was then applied to individual addresses to predict air pollution concentrations at participant\\u2019s address. Briefly, the model uses inputs from EPA monitoring data and over 300 geographic covariates to predict air pollution. External validation statistics show good performance of the air pollution prediction models, with R2 ranging from 0.84 to 0.91 for PM2.5 and 0.78 to 0.88 for NO2. Several exposure metrics reflecting different averaging periods were created to better understand when during the life course exposure to air pollution was most strongly associated with A\\u03b2 and to better reflect the development of ADRD. Exposure to PM2.5 was estimated by averaging one, five, ten, and 20 years of modeled PM2.5 prior to the date of blood draw. Estimates of PM10 and NO2 were based only on one-, five- and ten-year exposure metrics because data were not available to create a 20-year prediction.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 8898, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_2\"}, \"text\": \"Outcome ascertainment\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 8920, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Primary outcomes of interest were levels of plasma A\\u03b21\\u201340, A\\u03b21\\u201342 and A\\u03b21\\u201342/A\\u03b21\\u201340 ratio. The ratio of A\\u03b21\\u201342/A\\u03b21\\u201340, both in plasma and CSF, has been found to improve diagnosis of AD relative to A\\u03b21\\u201342 alone and is used frequently in research. A\\u03b2 levels were measured from stored blood samples collected in 2000\\u20132002 and 2007\\u20132008 using a sandwich ELISA initially developed by Eli Lilly and implemented at the University of Vermont Laboratory for Clinical Biochemistry. Interassay coefficients of variation ranged from 3.1% to 7.9% for A\\u03b21\\u201340 and 12.0% to 20.0% for A\\u03b21\\u201342.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 9528, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_2\"}, \"text\": \"Covariates\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 9539, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Covariates included basic socio-demographic characteristics: continuous age, sex (male or female), race (white or person of color), education (high school or less, some college, college graduate or postgraduate), and study site (Winston-Salem, NC; Sacramento, CA; Hagerstown, MD; and Pittsburgh, PA). Although the GEMS clinical trial was negative, treatment assignment (Ginkgo biloba vs placebo) was included to account for potential differences between the two arms of the original study. Cystatin C (from plasma collected at the same time as A\\u03b2) was an additional covariate given its role in binding to soluble A\\u03b2 and inhibiting A\\u03b2 deposition in the brain.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 10207, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"A neighborhood deprivation index (NDI) was created for all GEMS participants because of the lack of data on individual income and to account for its potential role as a confounder between air pollution and A\\u03b2. Annual NDI values for each participant were based on the census tract of residence and were created from decennial Census data from 1980, 1990, 2000 and American Community Survey (ACS) 2005\\u20132009. Previous research used over 30 Census variables to conduct a principal components analysis (PCA) to identify the variables that most strongly represented the latent construct of neighborhood disadvantage. Seven variables were identified from the PCA (% of adults age 25 or older with at least a high school education; % of adults age 25 or older with at least a Bachelor\\u2019s degree; % of persons age 16 and older with executive, managerial, or professional occupation; median value of owner occupied housing units; median household income; % of households with income of at least $50,000; and % of households with interest, dividend, or net rental income) and weighted according to factor loadings (see supplementary material for more information).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 11365, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Covariates to account for behavioral factors were smoking status (current, former, never), pack-years smoking, percentage of life exposed to secondhand smoke (created by dividing the number of years exposed to secondhand smoke by age at baseline), alcohol consumption (yes/no), and physical activity. We created a physical activity score based on responses to questions from the GEMS questionnaires that are adapted from components of the validated Physical Activity Scale for the Elderly (PASE) questionnaire designed to assess physical activity in adults aged 65 years and older. The total physical activity score was calculated from answers to questions about the frequency of engaging in seven activities: gardening and yard work, walking, volunteering, assisting family or friends, hunting, fishing or camping, babysitting and shopping. Response options were \\u201cnever or less than once a month\\u201d, \\u201conce a month\\u201d, \\u201cfew (2\\u20133) times a month\\u201d, \\u201conce a week\\u201d, \\u201cfew (2\\u20133) times a week\\u201d and \\u201cevery day\\u201d. Responses were assigned a score of 0\\u20135 and then summed to a total score ranging from 0 to 35 (potential maximum total score) with higher scores indicating greater physical activity. Missing values were imputed by taking the average of the non-missing responses within each participant if at least 3 of the questions had complete data. In the present study, we used physical activity data collected one year after baseline (nearest the blood sample collection in 2000\\u20132002) and carried forward to missing measurements at the 2007\\u20132008 visit in participants with non-missing data.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 12977, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Apolipoprotein E (APOE \\u03b54) carrier status (yes/no), hypertension (defined as anti-hypertensive medication use or systolic blood pressure \\u2265 140 mmHg or diastolic blood pressure \\u2265 90 mmHg and recorded one year after baseline) and body mass index (BMI) created from measured height and weight were also included as covariates. Mild cognitive impairment (MCI) was defined using guidelines from the International Working group on mild cognitive impairment and provided for descriptive purposes as was participant\\u2019s average score on the Modified Mini-Mental State Examination (3MSE).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 13563, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"title_2\"}, \"text\": \"Statistical analyses\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 13584, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Descriptive statistics were calculated for all variables. Due to the skewed nature of A\\u03b2, a one percent Winsorization was performed, i.e., values less than or equal to the first percentile of the distribution were set to the minimum value. For A\\u03b21\\u201340 these values corresponded to 56.75 and 28.73 pg/mL in 2000\\u201302 or 2007\\u201308 respectively and for A\\u03b21\\u201342 they were 0.75 and 0.77 pg/mL respectively. Winsorized values were then log transformed (Fig. 1). To create A\\u03b21\\u201342/A\\u03b21\\u201340 ratio, we first log-transformed the numerator and denominator before dividing the values. Given the continuous nature of the outcomes, cross-sectional associations were examined using ordinary least squares regression. Repeated measures analyses were evaluated using linear random effects models with a random intercept for participant. Results were reported as percent differences with their corresponding 95% confidence intervals (CIs).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 14514, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"A staged modeling approach was used to assess the impact of adding increasingly more covariates. Model 1 included basic socio-demographic characteristics (continuous age, sex, race, education, study site, treatment assignment, Cystatin C and NDI). Model 2 included Model 1 covariates plus smoking history, alcohol consumption, pack-years smoking, percentage of life exposed to secondhand smoke and physical activity. Model 3 included Model 2 covariates plus APOE \\u03b54, and Model 4 included Model 3 covariates plus hypertension and BMI. As these variables are potentially on the causal pathway between air pollution and A\\u03b2, they were included at the last stage. We considered model 3 as the primary model of interest. Age, Cystatin C, NDI, BMI and hypertension were treated as time-varying in the random effects models.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 15340, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Data in 2000\\u201302 were carried forward for two individuals missing data on non-time-varying covariates in 2007\\u201308. Most covariates had \\u2264 8% missing data with the exception of APOE \\u03b54 which had about 20% missingness. We implemented multiple imputation using chained equations (MICE) to handle missing continuous and categorical covariates. Separate MICE procedures were implemented for each combination of air pollution metric and A\\u03b2 outcome at baseline and repeat measures. Logistic or multinomial regression models were specified to impute missing categorical variables. Predictive mean matching was used to impute missing continuous variables. All covariates were included as predictors in the imputation models, but we also included time-varying 3MSE scores as they are potentially informative variables. Ten imputed datasets were constructed using 50 iterations per imputation. Final models were evaluated on all ten imputed datasets and parameter estimates and standard errors were pooled according to Rubin\\u2019s rules.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 16370, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"In addition to our main analysis, we conducted a secondary analysis to explore the association between air pollution and A\\u03b2 outcomes among those with and without MCI. This analysis assessed whether or not plasma A\\u03b2 biomarkers show different trajectories for cognitively intact individuals versus those exhibiting some cognitive impairment irrespective of if they go on to develop ADRD. We ran stratified models for both cross-sectional and repeated measures analysis using only Model 3 covariates and the longer-term averaging periods for air pollutants.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 16931, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Two sensitivity analyses are also presented. First, to explore the impact of our approach to handling outliers we constructed models using a) the original distribution of values and b) excluding those that were less than or equal to the first percentile. Second, to account for potential selection bias among participants who remained in the study until the end of follow-up (those with repeated A\\u03b2 measurements), we ran separate OLS models with baseline and follow-up A\\u03b2 as the outcome among only those participants with repeated A\\u03b2 measurements (i.e., we did not include those who only had baseline values of A\\u03b2).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 17559, \"infons\": {\"section_type\": \"METHODS\", \"type\": \"paragraph\"}, \"text\": \"Analyses were performed with SAS version 9.4 (SAS Institute Inc., Cary, NC). MICE was performed using PROC MI/PROC MIANALYZE in SAS, and plots were generated using R version 4.0.4 (R Foundation for Statistical Computing). All statistical tests were two-sided and considered significant at p-value < 0.05.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 17864, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"title_1\"}, \"text\": \"Results\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 17872, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"We excluded 25 individuals who did not have data on at least one baseline A\\u03b2 measurement; 23 of these individuals were also missing address data so did not have air pollution exposure estimates. Our final analytic cohort consisted of 3,044 participants, among whom 1,669 participants had A\\u03b21\\u201340 or A\\u03b21\\u201342 measurements from blood samples drawn between 2007 and 2008. Specifically, 1375 censored participants did not have a blood sample available for testing at follow-up, of these 379 died, 469 developed ADRD, and 527 were lost to follow-up. Exact sample sizes vary depending on the specific outcome (Supplemental Fig. 1). Baseline A\\u03b21\\u201340 ranged from 56.75 pg/mL to 473.95 pg/mL and A\\u03b21\\u201342 from 0.75 pg/mL to 140.23 pg/mL (Fig. 1). At baseline, average age was 78.6 years, participants were mostly non-Hispanic White (95%), were 46% female, and 64% had at least a college degree (Table 1). Seventeen percent were considered to have mild cognitive impairment at baseline and the average score on the 3MSE for all participants was 93.4 out of 100. Distributions of air pollutants showed higher levels of PM2.5 and NO2 at the Pittsburgh site, higher concentrations for longer averaging periods (e.g., 20 year vs one year averages) and declines in air pollution between baseline and follow-up (Fig. 2). Model results are reported per interquartile range (IQR) increase which corresponded to 2 \\u03bcg/m3 for PM2.5, 3 \\u03bcg/ m3 for PM10 and 6 ppb for NO2. IQR for each air pollutant was obtained by taking the mean IQR across all averaging periods at baseline.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 19437, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"Characteristics that are updated at follow-up visit include age, neighborhood deprivation index, body mass index, hypertension, Cystatin C, mild cognitive impairment status and Mini-Mental State Exam Score.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 19644, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"Number and percent missing are presented for the following characteristics that were missing data at baseline and follow-up visits, respectively: alcohol consumption, n = 48 (2%) and n = 26 (2%); smoking history, n = 58 (2%) and n = 32 (2%); pack-years smoking, n = 230 (8%) and n = 132 (8%); percentage of life exposed to SHS, n = 63 (2%) and n = 33 (2%); neighborhood deprivation index, n = 15 (<1%) and n = 10 (<1%); body mass index, n = 13 (<1%) and n = 4 (<1%); hypertension, n = 2 (<1%) and n = 11 (<1%); physical activity score, n = 185 (6%) and n = 21 (1%); Cystatin C, n = 3 (<1%) and n = 2 (<1%); APOE \\u03b54 carrier status, n = 624 (20%) and n = 305 (18%); and Mini-Mental State Exam score, n = 0 (0%) and n = 18 (1%).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 20376, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"In cross-sectional analysis using baseline A\\u03b2 measurements, we observed small positive associations between A\\u03b21\\u201340 and each air pollutant in Model 3, our primary model. A 2 \\u03bcg/m3 higher one-year PM2.5 level was associated with a 1.69% higher A\\u03b21\\u201340 concentration (95% CI: 0.52%,2.87%). The estimates were attenuated and much closer to zero for longer PM2.5 averaging periods. All PM10 averaging periods showed a similar association with A\\u03b21\\u201340, where a 3 \\u03bcg/m3 higher PM10 was associated with 2% (95% CI: 0.82%, 3.19%), 2.19% (95% CI: 0.92%, 3.48%) and 1.89% (95% CI: 0.74%, 3.05%) higher A\\u03b21\\u201340 for the one-, five- and ten-year averages respectively. Associations between the one, five and ten-year NO2 metrics and A\\u03b21\\u201340 were similar in magnitude but had slightly worse precision. For the other two outcomes, A\\u03b21\\u201342 and the ratio measure, Model 3 showed null associations between our three air pollutants at differing averaging periods (Fig. 3a \\u2013 3c and Supplemental Table 1).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 21378, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"The repeated measures analysis showed stronger magnitudes of effect for all pollutant-outcome combinations in Model 3 (Fig. 3d \\u2013 3f and Supplemental Table 2). We observed a 4.43% (95% CI 3.26%, 5.60%), 5.01% (95% CI 3.93%, 6.10%) and 7.20% (95% CI 5.45%, 8.97%) higher A\\u03b21\\u201340 level associated with an IQR higher 20-year average PM2.5, ten-year PM10 and ten-year NO2 respectively. A\\u03b21\\u201342 had even higher magnitudes of association with each of the air pollutants: 20-year PM2.5 was associated with 9.73% (6.20%, 13.38%) higher A\\u03b21\\u201342; ten-year PM10 was associated with 7.34% (95% CI 4.19%, 10.60%) higher A\\u03b21\\u201342; and ten-year NO2 was associated with 13.28% (95% CI: 7.95%, 18.86%) higher A\\u03b21\\u201342. The A\\u03b21\\u201342/A\\u03b21\\u201340 ratio showed the smallest associations with all three pollutants: 1.57% (95% CI: 0.94%, 2.20%) with 20-year PM2.5, 1.13% (95% CI: 0.56%, 1.71%) with ten-year PM10 and 2.09% (95% CI: 1.16%, 3.03%) with ten-year NO2.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 22328, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"Our MCI-stratified models showed little difference between those with and without MCI both in cross-sectional (Supplemental Table 3) and repeated measures analysis (Supplemental Table 4). For example, a 2 \\u03bcg/m3 higher 20-year average PM2.5 was associated with a 3.55% higher A\\u03b21\\u201340 among those with MCI and 4.37% higher A\\u03b21\\u201340 among those without MCI. Slightly larger differences between those with and without MCI were seen in the A\\u03b21\\u201342 results, however, the confidence limits were wide and overlapping.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 22844, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"In sensitivity analyses, we explored alternative methods to ensure normality of the outcome residuals, specifically trimming (i.e., excluding) the extreme outliers and making no change to the distribution. This did not change the results in any substantive way but did result in a slight attenuation of parameter estimates when outliers were excluded specifically in the repeat measures analysis (Supplemental Table 5 for cross sectional analysis and Supplemental Table 6 for repeat measures analysis).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 23347, \"infons\": {\"section_type\": \"RESULTS\", \"type\": \"paragraph\"}, \"text\": \"Furthermore, we investigated the potential impact of selection bias by examining only those participants who contributed samples to both baseline and the 2007 \\u2013 2008 visit (i.e., those who were not censored or lost to follow-up). We found stronger associations for both PM2.5 and NO2 with all outcomes measured at follow-up relative to baseline (Supplemental Table 7). There was little change in PM10 results. This suggests that findings from our repeated measures analysis were driven by participants who remained in the study until the end of follow-up.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 23905, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"title_1\"}, \"text\": \"Discussion\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 23916, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Our study examined the association between air pollutants and biomarkers of A\\u03b2 in plasma samples of dementia-free older adults. Findings suggest strong positive associations in the repeat measures analysis for all pollutant-outcome combinations, confirming our initial hypothesis, but largely null associations (with the exception of A\\u03b21\\u201340) in the cross-sectional ones. Our study contributes to the broader evidence base on air pollution and ADRD biomarkers by evaluating longer air pollution exposure averaging periods relative to many existing studies and improved exposure assessment relative to others. Given that ADRD develops over the course of many years, evaluating air pollution at longer averaging periods more closely mimics disease development.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 24680, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"There are several potential reasons that our repeated measures analysis produced stronger associations compared to the cross-sectional results. First, we have more power to detect an effect in the repeated measures analysis given its larger sample size. In addition, those in our repeated measures analysis may have less misclassification of exposure because we are more certain about residential histories during follow up and the several years prior to GEMS enrollment (e.g., approximately 1998\\u20132008 for the 10 year averaging period) relative to residential histories prior to GEMS enrollment (approximately 1990\\u20132000 for the 10 year averaging period). Furthermore, exposure assessment further back in time relies on historical models which are based on less monitoring data and are thus more prone to measurement error. Both improved power and less exposure measurement error could be producing estimates with larger magnitudes in the repeat measures analysis.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 25648, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"We opted to perform a repeat measures analysis as opposed to one that evaluates change in A\\u03b2 over time because plasma biomarker data fluctuates significantly, with some disease-free participants seeing decreases in A\\u03b2 over the period of follow up. Given the dynamic nature of plasma A\\u03b2 (described above), this is to be expected. Furthermore, given the loss to follow up in our sample the repeat measures approach allows us to have a more generalizable sample with more power.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 26133, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"In terms of our MCI stratified results, we did not observe lower A\\u03b2 levels among those with MCI. It has been well documented that some with MCI revert back to normal cognition over time; one study estimates an over 50% reversion rate from MCI to normal. Alternatively, those with stable MCI may not be far enough along in their disease progression to show declines in A\\u03b2. Furthermore, the number of people with MCI in our study was relatively small and our analysis may have been underpowered to see an effect.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 26650, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Our findings are not directly comparable to existing research as ours was the first to examine plasma A\\u03b2; other studies examined A\\u03b2 via PET scans, CSF and autopsy data. Studies in cognitively normal or mildly impaired populations found five-year average PM10 and annual average NO2 to be associated with higher odds of A\\u03b2 positivity measured via PET scan (i.e., those with indication of A\\u03b2 deposits in their brain). Although these studies were cross-sectional in nature, for these mildly impaired groups the association with air pollution was in the expected direction and corroborates our findings.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 27262, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Another study found that biennial PM2.5 concentrations were associated with higher odds of A\\u03b2 positivity, also measured with PET scans, in a population composed of participants with either MCI or dementia. One might expect to see different associations with air pollution between the two groups; air pollution would be associated with higher odds of A\\u03b2 positivity in the MCI group, but lower A\\u03b2 positivity in those with dementia. To better evaluate the Iaccarino et al. findings, stratification by dementia and MCI would be needed.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 27803, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Limited research has explored the association between air pollution and A\\u03b2 measured in CSF. One recent study found no association between several air pollutants and A\\u03b2 ratio, but others have seen lower concentrations of A\\u03b21\\u201342 among children living in more polluted areas. Substantial research finds that those with AD have lower concentrations of A\\u03b21\\u201342 in CSF compared to those with MCI and normal cognition. Thus future air pollution studies should stratify by disease stage in order to better evaluate the relation between air pollution and CSF A\\u03b2.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 28371, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"It is difficult to compare our results to autopsy studies because the GEMS population at the end of follow-up is likely a mix of those who have ADRD pathology and those who do not and because we do not know who went on to develop ADRD after the GEMS study ended.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 28634, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Many studies of dementia do not find A\\u03b21\\u201340 to be highly predictive of dementia status. In our study the strong associations with A\\u03b21\\u201340, which as noted above has inflammatory and atherosclerotic properties, could reflect the well-established relation between air pollution and cardiovascular disease. These results help validate our findings and suggest that future research on air pollution and dementia should explore A\\u03b21\\u201340 as it may be playing an important role in vascular dementia.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 29132, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"Our study has several strengths. GEMS provides a large sample size of standardized data, thorough adjustment for potential confounders, and state-of-the-art exposure assessment approaches at the individual residential address level. In terms of limitations, we recognize that our study uses an older biomarker assay. In recent years the scientific community has made significant advances in identifying A\\u03b2 in plasma; we hope to utilize new biomarker technology for future air pollution studies. Furthermore, GEMS is a cohort of primarily White participants who were more educated relative to the US population. At the end of GEMS follow up we were left with a healthier and more resilient population. These features limit our ability to generalize to the broader population. Lastly, we did not adjust for multiple comparisons, which could increase the possibility that findings are due to chance alone, because we set out to test a priori hypotheses about the importance of evaluating longer air pollution averaging periods and because the multiple averaging periods (5-, 10- and 20 year) are nested exposures so may not be considered separate exposures.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 30290, \"infons\": {\"section_type\": \"DISCUSS\", \"type\": \"paragraph\"}, \"text\": \"A better understanding of the relationship between air pollution and plasma biomarkers of ADRD will help shed light on the mechanisms by which air pollution may be impacting cognitive health. Air pollution is modifiable through policy and regulation thus providing another realistic target for ADRD prevention.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 30601, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"title_1\"}, \"text\": \"Supplementary Material\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 30624, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"footnote\"}, \"text\": \"CRediT authorship contribution statement\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 30665, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"footnote\"}, \"text\": \"Anjum Hajat: Conceptualization, Funding acquisition, Methodology, Project administration, Supervision, Writing \\u2013 original draft, Writing \\u2013 review & editing. Christina Park: Data curation, Formal analysis, Methodology, Software, Validation, Visualization, Writing \\u2013 original draft, Writing \\u2013 review & editing. Claire Adam: Methodology, Writing \\u2013 review & editing. Annette L. Fitzpatrick: Conceptualization, Funding acquisition, Writing \\u2013 review & editing. Sindana D. Ilango: Writing \\u2013 review & editing. Cindy Leary: Validation, Visualization, Writing \\u2013 review & editing. Tanya Libby: Validation, Visualization, Writing \\u2013 review & editing. Oscar Lopez: Writing \\u2013 review & editing. Erin O. Semmens: Conceptualization, Funding acquisition, Writing \\u2013 review & editing. Joel D. Kaufman: Conceptualization, Funding acquisition, Writing \\u2013 review & editing.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31538, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"footnote\"}, \"text\": \"Declaration of Competing Interest\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31572, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"footnote\"}, \"text\": \"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31743, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"footnote\"}, \"text\": \"Appendix A. Supplementary data\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31774, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"footnote\"}, \"text\": \"Supplementary data to this article can be found online at https://doi.org/10.1016/j.envint.2023.107800.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31878, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"title_1\"}, \"text\": \"Data availability\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31896, \"infons\": {\"section_type\": \"SUPPL\", \"type\": \"paragraph\"}, \"text\": \"The authors do not have permission to share data.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31946, \"infons\": {\"section_type\": \"REF\", \"type\": \"title\"}, \"text\": \"References\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 31957, \"infons\": {\"name_0\": \"surname:Ackley;given-names:SF\", \"name_1\": \"surname:Zimmerman;given-names:SC\", \"name_10\": \"surname:Brickman;given-names:AM\", \"name_11\": \"surname:Glymour;given-names:MM\", \"name_2\": \"surname:Brenowitz;given-names:WD\", \"name_3\": \"surname:Tchetgen Tchetgen;given-names:EJ\", \"name_4\": \"surname:Gold;given-names:AL\", \"name_5\": \"surname:Manly;given-names:JJ\", \"name_6\": \"surname:Mayeda;given-names:ER\", \"name_7\": \"surname:Filshtein;given-names:TJ\", \"name_8\": \"surname:Power;given-names:MC\", \"name_9\": \"surname:Elahi;given-names:FM\", \"pub-id_doi\": \"10.1136/bmj.n156\", \"section_type\": \"REF\", \"source\": \"BMJ\", \"type\": \"ref\", \"volume\": \"372\", \"year\": \"2021\"}, \"text\": \"Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 32074, \"infons\": {\"fpage\": \"106864\", \"name_0\": \"surname:Alemany;given-names:S\", \"name_1\": \"surname:Crous-Bou;given-names:M\", \"name_10\": \"surname:Minguillon;given-names:C\", \"name_11\": \"surname:Fauria;given-names:K\", \"name_12\": \"surname:Kollmorgen;given-names:G\", \"name_13\": \"surname:Domingo Gispert;given-names:J\", \"name_14\": \"surname:Gasc\\u00f3n;given-names:M\", \"name_15\": \"surname:Nieuwenhuijsen;given-names:M\", \"name_16\": \"surname:Zetterberg;given-names:H\", \"name_17\": \"surname:Blennow;given-names:K\", \"name_18\": \"surname:Sunyer;given-names:J\", \"name_19\": \"surname:Luis Molinuevo;given-names:J\", \"name_2\": \"surname:Vilor-Tejedor;given-names:N\", \"name_3\": \"surname:Mila-Alom\\u00e1;given-names:M\", \"name_4\": \"surname:Su\\u00e1rez-Calvet;given-names:M\", \"name_5\": \"surname:Salvad\\u00f3;given-names:G\", \"name_6\": \"surname:Cirach;given-names:M\", \"name_7\": \"surname:Arenaza-Urquijo;given-names:EM\", \"name_8\": \"surname:Sanchez-Benavides;given-names:G\", \"name_9\": \"surname:Grau-Rivera;given-names:O\", \"pub-id_doi\": \"10.1016/j.envint.2021.106864\", \"pub-id_pmid\": \"34537521\", \"section_type\": \"REF\", \"source\": \"Environ. Int\", \"type\": \"ref\", \"volume\": \"157\", \"year\": \"2021\"}, \"text\": \"Associations between air pollution and biomarkers of Alzheimer\\u2019s disease in cognitively unimpaired individuals\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 32187, \"infons\": {\"fpage\": \"795\", \"lpage\": \"804\", \"name_0\": \"surname:Bateman;given-names:RJ\", \"name_1\": \"surname:Xiong;given-names:C\", \"name_10\": \"surname:Holtzman;given-names:DM\", \"name_11\": \"surname:Santacruz;given-names:A\", \"name_12\": \"surname:Buckles;given-names:V\", \"name_13\": \"surname:Oliver;given-names:A\", \"name_14\": \"surname:Moulder;given-names:K\", \"name_15\": \"surname:Aisen;given-names:PS\", \"name_16\": \"surname:Ghetti;given-names:B\", \"name_17\": \"surname:Klunk;given-names:WE\", \"name_18\": \"surname:McDade;given-names:E\", \"name_19\": \"surname:Martins;given-names:RN\", \"name_2\": \"surname:Benzinger;given-names:TLS\", \"name_20\": \"surname:Masters;given-names:CL\", \"name_21\": \"surname:Mayeux;given-names:R\", \"name_22\": \"surname:Ringman;given-names:JM\", \"name_23\": \"surname:Rossor;given-names:MN\", \"name_24\": \"surname:Schofield;given-names:PR\", \"name_25\": \"surname:Sperling;given-names:RA\", \"name_26\": \"surname:Salloway;given-names:S\", \"name_27\": \"surname:Morris;given-names:JC\", \"name_28\": \"surname:Network;given-names:DIA\", \"name_3\": \"surname:Fagan;given-names:AM\", \"name_4\": \"surname:Goate;given-names:A\", \"name_5\": \"surname:Fox;given-names:NC\", \"name_6\": \"surname:Marcus;given-names:DS\", \"name_7\": \"surname:Cairns;given-names:NJ\", \"name_8\": \"surname:Xie;given-names:X\", \"name_9\": \"surname:Blazey;given-names:TM\", \"pub-id_doi\": \"10.1056/NEJMoa1202753\", \"pub-id_pmid\": \"22784036\", \"section_type\": \"REF\", \"source\": \"N. Engl. J. Med\", \"type\": \"ref\", \"volume\": \"367\", \"year\": \"2012\"}, \"text\": \"Clinical and biomarker changes in dominantly inherited Alzheimer\\u2019s disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 32264, \"infons\": {\"name_0\": \"surname:Bhatt;given-names:DP\", \"name_1\": \"surname:Puig;given-names:KL\", \"name_2\": \"surname:Gorr;given-names:MW\", \"name_3\": \"surname:Wold;given-names:LE\", \"name_4\": \"surname:Combs;given-names:CK\", \"pub-id_doi\": \"10.1371/journal.pone.0127102\", \"section_type\": \"REF\", \"source\": \"PLoS One\", \"type\": \"ref\", \"volume\": \"10\", \"year\": \"2015\"}, \"text\": \"A pilot study to assess effects of long-term inhalation of airborne particulate matter on early Alzheimer-like changes in the mouse brain\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 32402, \"infons\": {\"fpage\": \"369\", \"name_0\": \"surname:Bhatti;given-names:GK\", \"name_1\": \"surname:Reddy;given-names:AP\", \"name_2\": \"surname:Reddy;given-names:PH\", \"name_3\": \"surname:Bhatti;given-names:JS\", \"pub-id_doi\": \"10.3389/fnagi.2019.00369\", \"pub-id_pmid\": \"31998117\", \"section_type\": \"REF\", \"source\": \"Front. Aging Neurosci\", \"type\": \"ref\", \"volume\": \"11\", \"year\": \"2019\"}, \"text\": \"Lifestyle Modifications and Nutritional Interventions in Aging-Associated Cognitive Decline and Alzheimer\\u2019s Disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 32520, \"infons\": {\"fpage\": \"2331\", \"lpage\": \"2378\", \"name_0\": \"surname:Brook;given-names:RD\", \"name_1\": \"surname:Rajagopalan;given-names:S\", \"name_10\": \"surname:Peters;given-names:A\", \"name_11\": \"surname:Siscovick;given-names:D\", \"name_12\": \"surname:Smith;given-names:SC\", \"name_13\": \"surname:Whitsel;given-names:L\", \"name_14\": \"surname:Kaufman;given-names:JD\", \"name_2\": \"surname:Pope;given-names:CA\", \"name_3\": \"surname:Brook;given-names:JR\", \"name_4\": \"surname:Bhatnagar;given-names:A\", \"name_5\": \"surname:Diez-Roux;given-names:AV\", \"name_6\": \"surname:Holguin;given-names:F\", \"name_7\": \"surname:Hong;given-names:Y\", \"name_8\": \"surname:Luepker;given-names:RV\", \"name_9\": \"surname:Mittleman;given-names:MA\", \"pub-id_doi\": \"10.1161/CIR.0b013e3181dbece1\", \"pub-id_pmid\": \"20458016\", \"section_type\": \"REF\", \"source\": \"Circulation\", \"type\": \"ref\", \"volume\": \"121\", \"year\": \"2010\"}, \"text\": \"Particulate Matter Air Pollution and Cardiovascular Disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 32580, \"infons\": {\"name_0\": \"surname:Calderon-Garcidueas;given-names:L\", \"name_1\": \"surname:Kavanaugh;given-names:M\", \"name_10\": \"surname:Guo;given-names:R\", \"name_11\": \"surname:Hua;given-names:Z\", \"name_12\": \"surname:Zhu;given-names:H\", \"name_13\": \"surname:Perry;given-names:G\", \"name_14\": \"surname:Diaz;given-names:P\", \"name_2\": \"surname:Block;given-names:M\", \"name_3\": \"surname:D\\u2019Angiulli;given-names:A\", \"name_4\": \"surname:Delgado-Ch\\u00e1vez;given-names:R\", \"name_5\": \"surname:Torres-Jardon;given-names:R\", \"name_6\": \"surname:Gon\\u017aalez-Maciel;given-names:A\", \"name_7\": \"surname:Reynoso-Robles;given-names:R\", \"name_8\": \"surname:Osnaya;given-names:N\", \"name_9\": \"surname:Villarreal-Calderon;given-names:R\", \"pub-id_doi\": \"10.3233/JAD-2011-110722\", \"section_type\": \"REF\", \"source\": \"J. Alzheimer\\u2019s Dis\", \"type\": \"ref\", \"volume\": \"28\", \"year\": \"2012\"}, \"text\": \"Neuroinflammation, hyperphosphorylated tau, diffuse amyloid plaques, and down-regulation of the cellular prion protein in air pollution exposed children and young adults\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 32750, \"infons\": {\"fpage\": \"289\", \"lpage\": \"310\", \"name_0\": \"surname:Calder\\u00f3n-Garcidue\\u00f1as;given-names:L\", \"name_1\": \"surname:Solt;given-names:AC\", \"name_10\": \"surname:Brooks;given-names:DM\", \"name_11\": \"surname:Gonz\\u00e1lez-Maciel;given-names:A\", \"name_12\": \"surname:Reynoso-Robles;given-names:R\", \"name_13\": \"surname:Delgado-Ch\\u00e1vez;given-names:R\", \"name_14\": \"surname:Reed;given-names:W\", \"name_2\": \"surname:Henr\\u00edquez-Rold\\u00e1n;given-names:C\", \"name_3\": \"surname:Torres-Jard\\u00f3n;given-names:R\", \"name_4\": \"surname:Nuse;given-names:B\", \"name_5\": \"surname:Herritt;given-names:L\", \"name_6\": \"surname:Villarreal-Calder\\u00f3n;given-names:R\", \"name_7\": \"surname:Osnaya;given-names:N\", \"name_8\": \"surname:Stone;given-names:I\", \"name_9\": \"surname:Garc\\u00eda;given-names:R\", \"pub-id_doi\": \"10.1177/0192623307313011\", \"pub-id_pmid\": \"18349428\", \"section_type\": \"REF\", \"source\": \"Toxicol. Pathol\", \"type\": \"ref\", \"volume\": \"36\", \"year\": \"2008\"}, \"text\": \"Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid \\u03b2\\u221242 and \\u03b1-synuclein in children and young adults\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33014, \"infons\": {\"fpage\": \"597\", \"lpage\": \"613\", \"name_0\": \"surname:Calder\\u00f3n-Garcidue\\u00f1as;given-names:L\", \"name_1\": \"surname:Avila-Ram\\u00edrez;given-names:J\", \"name_10\": \"surname:Garc\\u00eda-P\\u00e9rez;given-names:MA\", \"name_11\": \"surname:Reis;given-names:J\", \"name_12\": \"surname:Mukherjee;given-names:PS\", \"name_13\": \"surname:Torres-Jard\\u00f3n;given-names:R\", \"name_14\": \"surname:Lachmann;given-names:I\", \"name_2\": \"surname:Calder\\u00e1n-Garcidue\\u00f1as;given-names:A\", \"name_3\": \"surname:Gonz\\u00e1lez-Heredia;given-names:T\", \"name_4\": \"surname:Acu\\u00f1a-Ayala;given-names:H\", \"name_5\": \"surname:Chao;given-names:C-K\", \"name_6\": \"surname:Thompson;given-names:C\", \"name_7\": \"surname:Ruiz-Ramos;given-names:R\", \"name_8\": \"surname:Cort\\u00e9s-Gonz\\u00e1lez;given-names:V\", \"name_9\": \"surname:Mart\\u00ednez-Mart\\u00ednez;given-names:L\", \"pub-id_doi\": \"10.3233/JAD-160472\", \"pub-id_pmid\": \"27567860\", \"section_type\": \"REF\", \"source\": \"J. Alzheimers. Dis\", \"type\": \"ref\", \"volume\": \"54\", \"year\": \"2016\"}, \"text\": \"Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer\\u2019s and Parkinson\\u2019s Diseases in Young Mexico City Residents\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33164, \"infons\": {\"fpage\": \"1437\", \"lpage\": \"1451\", \"name_0\": \"surname:Calder\\u00f3n-Garcidue\\u00f1as;given-names:L\", \"name_1\": \"surname:Mukherjee;given-names:PS\", \"name_10\": \"surname:G\\u00f3nzalez-Maciel;given-names:A\", \"name_11\": \"surname:Lachmann;given-names:I\", \"name_2\": \"surname:Waniek;given-names:K\", \"name_3\": \"surname:Holzer;given-names:M\", \"name_4\": \"surname:Chao;given-names:C-K\", \"name_5\": \"surname:Thompson;given-names:C\", \"name_6\": \"surname:Ruiz-Ramos;given-names:R\", \"name_7\": \"surname:Calder\\u00f3n-Garcidue\\u00f1as;given-names:A\", \"name_8\": \"surname:Franco-Lira;given-names:M\", \"name_9\": \"surname:Reynoso-Robles;given-names:R\", \"pub-id_doi\": \"10.3233/JAD-180853\", \"pub-id_pmid\": \"30412505\", \"section_type\": \"REF\", \"source\": \"J. Alzheimers. Dis\", \"type\": \"ref\", \"volume\": \"66\", \"year\": \"2018\"}, \"text\": \"Non-Phosphorylated Tau in Cerebrospinal Fluid is a Marker of Alzheimer\\u2019s Disease Continuum in Young Urbanites Exposed to Air Pollution\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33301, \"infons\": {\"fpage\": \"943\", \"lpage\": \"948\", \"name_0\": \"surname:Canevelli;given-names:M\", \"name_1\": \"surname:Grande;given-names:G\", \"name_2\": \"surname:Lacorte;given-names:E\", \"name_3\": \"surname:Quarchioni;given-names:E\", \"name_4\": \"surname:Cesari;given-names:M\", \"name_5\": \"surname:Mariani;given-names:C\", \"name_6\": \"surname:Bruno;given-names:G\", \"name_7\": \"surname:Vanacore;given-names:N\", \"pub-id_doi\": \"10.1016/j.jamda.2016.06.020\", \"pub-id_pmid\": \"27502450\", \"section_type\": \"REF\", \"source\": \"J. Am. Med. Dir. Assoc\", \"type\": \"ref\", \"volume\": \"17\", \"year\": \"2016\"}, \"text\": \"Spontaneous Reversion of Mild Cognitive Impairment to Normal Cognition: A Systematic Review of Literature and Meta-Analysis\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33425, \"infons\": {\"name_0\": \"surname:Chen;given-names:GF\", \"name_1\": \"surname:Xu;given-names:TH\", \"name_2\": \"surname:Yan;given-names:Y\", \"name_3\": \"surname:Zhou;given-names:YR\", \"name_4\": \"surname:Jiang;given-names:Y\", \"name_5\": \"surname:Melcher;given-names:K\", \"name_6\": \"surname:Xu;given-names:HE\", \"pub-id_doi\": \"10.1038/aps.2017.28\", \"section_type\": \"REF\", \"source\": \"Acta Pharmacol. Sin\", \"type\": \"ref\", \"volume\": \"38\", \"year\": \"2017\"}, \"text\": \"Amyloid beta: Structure, biology and structure-based therapeutic development\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33502, \"infons\": {\"fpage\": \"1311\", \"lpage\": \"1320\", \"name_0\": \"surname:Christine;given-names:PJ\", \"name_1\": \"surname:Auchincloss;given-names:AH\", \"name_2\": \"surname:Bertoni;given-names:AG\", \"name_3\": \"surname:Carnethon;given-names:MR\", \"name_4\": \"surname:Sanchez;given-names:BN\", \"name_5\": \"surname:Moore;given-names:K\", \"name_6\": \"surname:Adar;given-names:SD\", \"name_7\": \"surname:Horwich;given-names:TB\", \"name_8\": \"surname:Watson;given-names:KE\", \"name_9\": \"surname:Diez Roux;given-names:AV\", \"pub-id_doi\": \"10.1001/jamainternmed.2015.2691\", \"pub-id_pmid\": \"26121402\", \"section_type\": \"REF\", \"source\": \"JAMA Intern Med\", \"type\": \"ref\", \"volume\": \"175\", \"year\": \"2015\"}, \"text\": \"Longitudinal Associations Between Neighborhood Physical and Social Environments and Incident Type 2 Diabetes Mellitus: The Multi-Ethnic Study of Atherosclerosis (MESA)\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33670, \"infons\": {\"fpage\": \"627\", \"lpage\": \"642\", \"name_0\": \"surname:Cosselman;given-names:KE\", \"name_1\": \"surname:Navas-Acien;given-names:A\", \"name_2\": \"surname:Kaufman;given-names:JD\", \"pub-id_doi\": \"10.1038/nrcardio.2015.152\", \"pub-id_pmid\": \"26461967\", \"section_type\": \"REF\", \"source\": \"Nat. Rev. Cardiol\", \"type\": \"ref\", \"volume\": \"12\", \"year\": \"2015\"}, \"text\": \"Environmental factors in cardiovascular disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33718, \"infons\": {\"fpage\": \"238\", \"lpage\": \"253\", \"name_0\": \"surname:DeKosky;given-names:ST\", \"name_1\": \"surname:Fitzpatrick;given-names:A\", \"name_10\": \"surname:Tracy;given-names:R\", \"name_11\": \"surname:Woolard;given-names:N\", \"name_12\": \"surname:Dunn;given-names:L\", \"name_13\": \"surname:Kronmal;given-names:R\", \"name_14\": \"surname:Nahin;given-names:R\", \"name_15\": \"surname:Furberg;given-names:C\", \"name_2\": \"surname:Ives;given-names:DG\", \"name_3\": \"surname:Saxton;given-names:J\", \"name_4\": \"surname:Williamson;given-names:J\", \"name_5\": \"surname:Lopez;given-names:OL\", \"name_6\": \"surname:Burke;given-names:G\", \"name_7\": \"surname:Fried;given-names:L\", \"name_8\": \"surname:Kuller;given-names:LH\", \"name_9\": \"surname:Robbins;given-names:J\", \"pub-id_doi\": \"10.1016/j.cct.2006.02.007\", \"pub-id_pmid\": \"16627007\", \"section_type\": \"REF\", \"source\": \"Contemp. Clin. Trials\", \"type\": \"ref\", \"volume\": \"27\", \"year\": \"2006\"}, \"text\": \"The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33861, \"infons\": {\"fpage\": \"2253\", \"lpage\": \"2262\", \"name_0\": \"surname:DeKosky;given-names:ST\", \"name_1\": \"surname:Williamson;given-names:JD\", \"name_10\": \"surname:Kuller;given-names:LH\", \"name_11\": \"surname:Robbins;given-names:JA\", \"name_12\": \"surname:Tracy;given-names:RP\", \"name_13\": \"surname:Woolard;given-names:NF\", \"name_14\": \"surname:Dunn;given-names:L\", \"name_15\": \"surname:Snitz;given-names:BE\", \"name_16\": \"surname:Nahin;given-names:RL\", \"name_17\": \"surname:Furberg;given-names:CD\", \"name_2\": \"surname:Fitzpatrick;given-names:AL\", \"name_3\": \"surname:Kronmal;given-names:RA\", \"name_4\": \"surname:Ives;given-names:DG\", \"name_5\": \"surname:Saxton;given-names:JA\", \"name_6\": \"surname:Lopez;given-names:OL\", \"name_7\": \"surname:Burke;given-names:G\", \"name_8\": \"surname:Carlson;given-names:MC\", \"name_9\": \"surname:Fried;given-names:LP\", \"pub-id_doi\": \"10.1001/jama.2008.683\", \"pub-id_pmid\": \"19017911\", \"section_type\": \"REF\", \"source\": \"JAMA\", \"type\": \"ref\", \"volume\": \"300\", \"year\": \"2008\"}, \"text\": \"Ginkgo biloba for prevention of dementia: a randomized controlled trial\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 33933, \"infons\": {\"fpage\": \"30\", \"name_0\": \"surname:Dumurgier;given-names:J\", \"name_1\": \"surname:Schraen;given-names:S\", \"name_10\": \"surname:Pasquier;given-names:F\", \"name_11\": \"surname:Touchon;given-names:J\", \"name_12\": \"surname:Hugon;given-names:J\", \"name_13\": \"surname:Paquet;given-names:C\", \"name_14\": \"surname:Lehmann;given-names:S\", \"name_2\": \"surname:Gabelle;given-names:A\", \"name_3\": \"surname:Vercruysse;given-names:O\", \"name_4\": \"surname:Bombois;given-names:S\", \"name_5\": \"surname:Laplanche;given-names:J-L\", \"name_6\": \"surname:Peoc\\u2019h;given-names:K\", \"name_7\": \"surname:Sablonni\\u00e8re;given-names:B\", \"name_8\": \"surname:Kastanenka;given-names:KV\", \"name_9\": \"surname:Delaby;given-names:C\", \"pub-id_doi\": \"10.1186/s13195-015-0114-5\", \"pub-id_pmid\": \"26034513\", \"section_type\": \"REF\", \"source\": \"Alzheimers. Res. Ther\", \"type\": \"ref\", \"volume\": \"7\", \"year\": \"2015\"}, \"text\": \"Cerebrospinal fluid amyloid-\\u03b2 42/40 ratio in clinical setting of memory centers: a multicentric study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34038, \"infons\": {\"fpage\": \"541\", \"lpage\": \"53\", \"name_0\": \"surname:Fitzpatrick;given-names:AL\", \"name_1\": \"surname:Fried;given-names:LP\", \"name_10\": \"surname:Furberg;given-names:CD\", \"name_11\": \"surname:DeKosky;given-names:ST\", \"name_2\": \"surname:Williamson;given-names:J\", \"name_3\": \"surname:Crowley;given-names:P\", \"name_4\": \"surname:Posey;given-names:D\", \"name_5\": \"surname:Kwong;given-names:L\", \"name_6\": \"surname:Bonk;given-names:J\", \"name_7\": \"surname:Moyer;given-names:R\", \"name_8\": \"surname:Chabot;given-names:J\", \"name_9\": \"surname:Kidoguchi;given-names:L\", \"pub-id_doi\": \"10.1016/j.cct.2006.06.007\", \"pub-id_pmid\": \"16949348\", \"section_type\": \"REF\", \"source\": \"Contemp. Clin. Trials\", \"type\": \"ref\", \"volume\": \"27\", \"year\": \"2006\"}, \"text\": \"Recruitment of the elderly into a pharmacologic prevention trial: the Ginkgo Evaluation of Memory Study experience\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34153, \"infons\": {\"name_0\": \"surname:Gouras;given-names:GK\", \"name_1\": \"surname:Olsson;given-names:TT\", \"name_2\": \"surname:Hansson;given-names:O\", \"pub-id_doi\": \"10.1007/s13311-014-0313-y\", \"section_type\": \"REF\", \"source\": \"Neurotherapeutics\", \"type\": \"ref\", \"volume\": \"12\", \"year\": \"2015\"}, \"text\": \"\\u03b2-amyloid Peptides and Amyloid Plaques in Alzheimer\\u2019s Disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34218, \"infons\": {\"fpage\": \"954\", \"lpage\": \"963\", \"name_0\": \"surname:Hansson;given-names:O\", \"pub-id_doi\": \"10.1038/s41591-021-01382-x\", \"pub-id_pmid\": \"34083813\", \"section_type\": \"REF\", \"source\": \"Nat. Med\", \"type\": \"ref\", \"volume\": \"27\", \"year\": \"2021\"}, \"text\": \"Biomarkers for neurodegenerative diseases\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34260, \"infons\": {\"name_0\": \"surname:Hurley;given-names:S\", \"name_1\": \"surname:Hertz;given-names:A\", \"name_2\": \"surname:Nelson;given-names:DO\", \"name_3\": \"surname:Layefsky;given-names:M\", \"name_4\": \"surname:Von Behren;given-names:J\", \"name_5\": \"surname:Bernstein;given-names:L\", \"name_6\": \"surname:Deapen;given-names:D\", \"name_7\": \"surname:Reynolds;given-names:P\", \"pub-id_doi\": \"10.1093/aje/kww108\", \"section_type\": \"REF\", \"source\": \"Am. J. Epidemiol\", \"type\": \"ref\", \"year\": \"2017\"}, \"text\": \"Tracing a Path to the Past: Exploring the Use of Commercial Credit Reporting Data to Construct Residential Histories for Epidemiologic Studies of Environmental Exposures\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34430, \"infons\": {\"fpage\": \"197\", \"lpage\": \"207\", \"name_0\": \"surname:Iaccarino;given-names:L\", \"name_1\": \"surname:La Joie;given-names:R\", \"name_10\": \"surname:Gatsonis;given-names:C\", \"name_11\": \"surname:Rabinovici;given-names:GD\", \"name_2\": \"surname:Lesman-Segev;given-names:OH\", \"name_3\": \"surname:Lee;given-names:E\", \"name_4\": \"surname:Hanna;given-names:L\", \"name_5\": \"surname:Allen;given-names:IE\", \"name_6\": \"surname:Hillner;given-names:BE\", \"name_7\": \"surname:Siegel;given-names:BA\", \"name_8\": \"surname:Whitmer;given-names:RA\", \"name_9\": \"surname:Carrillo;given-names:MC\", \"pub-id_doi\": \"10.1001/jamaneurol.2020.3962\", \"pub-id_pmid\": \"33252608\", \"section_type\": \"REF\", \"source\": \"JAMA Neurol\", \"type\": \"ref\", \"volume\": \"78\", \"year\": \"2021\"}, \"text\": \"Association between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults with Cognitive Impairment\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34566, \"infons\": {\"fpage\": \"207\", \"lpage\": \"216\", \"name_0\": \"surname:Jack;given-names:CR\", \"name_1\": \"surname:Knopman;given-names:DS\", \"name_10\": \"surname:Lesnick;given-names:TG\", \"name_11\": \"surname:Pankratz;given-names:VS\", \"name_12\": \"surname:Donohue;given-names:MC\", \"name_13\": \"surname:Trojanowski;given-names:JQ\", \"name_2\": \"surname:Jagust;given-names:WJ\", \"name_3\": \"surname:Petersen;given-names:RC\", \"name_4\": \"surname:Weiner;given-names:MW\", \"name_5\": \"surname:Aisen;given-names:PS\", \"name_6\": \"surname:Shaw;given-names:LM\", \"name_7\": \"surname:Vemuri;given-names:P\", \"name_8\": \"surname:Wiste;given-names:HJ\", \"name_9\": \"surname:Weigand;given-names:SD\", \"pub-id_doi\": \"10.1016/S1474-4422(12)70291-0\", \"pub-id_pmid\": \"23332364\", \"section_type\": \"REF\", \"source\": \"Lancet. Neurol\", \"type\": \"ref\", \"volume\": \"12\", \"year\": \"2013\"}, \"text\": \"Tracking pathophysiological processes in Alzheimer\\u2019s disease: an updated hypothetical model of dynamic biomarkers\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34682, \"infons\": {\"fpage\": \"1924\", \"lpage\": \"38\", \"name_0\": \"surname:Jansen;given-names:WJ\", \"name_1\": \"surname:Ossenkoppele;given-names:R\", \"name_10\": \"surname:Alexander;given-names:M\", \"name_100\": \"surname:Roe;given-names:CM\", \"name_101\": \"surname:Rot;given-names:U\", \"name_102\": \"surname:Rowe;given-names:CC\", \"name_103\": \"surname:R\\u00fcther;given-names:E\", \"name_104\": \"surname:Sabri;given-names:O\", \"name_105\": \"surname:Sanchez-Juan;given-names:P\", \"name_106\": \"surname:Santana;given-names:I\", \"name_107\": \"surname:Sarazin;given-names:M\", \"name_108\": \"surname:Schr\\u00f6der;given-names:J\", \"name_109\": \"surname:Sch\\u00fctte;given-names:C\", \"name_11\": \"surname:Almdahl;given-names:IS\", \"name_110\": \"surname:Seo;given-names:SW\", \"name_111\": \"surname:Soetewey;given-names:F\", \"name_112\": \"surname:Soininen;given-names:H\", \"name_113\": \"surname:Spiru;given-names:L\", \"name_114\": \"surname:Struyfs;given-names:H\", \"name_115\": \"surname:Teunissen;given-names:CE\", \"name_116\": \"surname:Tsolaki;given-names:M\", \"name_117\": \"surname:Vandenberghe;given-names:R\", \"name_118\": \"surname:Verbeek;given-names:MM\", \"name_119\": \"surname:Villemagne;given-names:VL\", \"name_12\": \"surname:Arnold;given-names:SE\", \"name_120\": \"surname:Vos;given-names:SJB\", \"name_121\": \"surname:van Waalwijk van Doorn;given-names:LJC\", \"name_122\": \"surname:Waldemar;given-names:G\", \"name_123\": \"surname:Wallin;given-names:A\", \"name_124\": \"surname:Wallin;given-names:\\u00c5K\", \"name_125\": \"surname:Wiltfang;given-names:J\", \"name_126\": \"surname:Wolk;given-names:DA\", \"name_127\": \"surname:Zboch;given-names:M\", \"name_128\": \"surname:Zetterberg;given-names:H\", \"name_13\": \"surname:Baldeiras;given-names:I\", \"name_14\": \"surname:Barthel;given-names:H\", \"name_15\": \"surname:van Berckel;given-names:BNM\", \"name_16\": \"surname:Bibeau;given-names:K\", \"name_17\": \"surname:Blennow;given-names:K\", \"name_18\": \"surname:Brooks;given-names:DJ\", \"name_19\": \"surname:van Buchem;given-names:MA\", \"name_2\": \"surname:Knol;given-names:DL\", \"name_20\": \"surname:Camus;given-names:V\", \"name_21\": \"surname:Cavedo;given-names:E\", \"name_22\": \"surname:Chen;given-names:K\", \"name_23\": \"surname:Chetelat;given-names:G\", \"name_24\": \"surname:Cohen;given-names:AD\", \"name_25\": \"surname:Drzezga;given-names:A\", \"name_26\": \"surname:Engelborghs;given-names:S\", \"name_27\": \"surname:Fagan;given-names:AM\", \"name_28\": \"surname:Fladby;given-names:T\", \"name_29\": \"surname:Fleisher;given-names:AS\", \"name_3\": \"surname:Tijms;given-names:BM\", \"name_30\": \"surname:van der Flier;given-names:WM\", \"name_31\": \"surname:Ford;given-names:L\", \"name_32\": \"surname:F\\u00f6rster;given-names:S\", \"name_33\": \"surname:Fortea;given-names:J\", \"name_34\": \"surname:Foskett;given-names:N\", \"name_35\": \"surname:Frederiksen;given-names:KS\", \"name_36\": \"surname:Freund-Levi;given-names:Y\", \"name_37\": \"surname:Frisoni;given-names:GB\", \"name_38\": \"surname:Froelich;given-names:L\", \"name_39\": \"surname:Gabryelewicz;given-names:T\", \"name_4\": \"surname:Scheltens;given-names:P\", \"name_40\": \"surname:Gill;given-names:KD\", \"name_41\": \"surname:Gkatzima;given-names:O\", \"name_42\": \"surname:G\\u00f3mez-Tortosa;given-names:E\", \"name_43\": \"surname:Gordon;given-names:MF\", \"name_44\": \"surname:Grimmer;given-names:T\", \"name_45\": \"surname:Hampel;given-names:H\", \"name_46\": \"surname:Hausner;given-names:L\", \"name_47\": \"surname:Hellwig;given-names:S\", \"name_48\": \"surname:Herukka;given-names:S-K\", \"name_49\": \"surname:Hildebrandt;given-names:H\", \"name_5\": \"surname:Verhey;given-names:FRJ\", \"name_50\": \"surname:Ishihara;given-names:L\", \"name_51\": \"surname:Ivanoiu;given-names:A\", \"name_52\": \"surname:Jagust;given-names:WJ\", \"name_53\": \"surname:Johannsen;given-names:P\", \"name_54\": \"surname:Kandimalla;given-names:R\", \"name_55\": \"surname:Kapaki;given-names:E\", \"name_56\": \"surname:Klimkowicz-Mrowiec;given-names:A\", \"name_57\": \"surname:Klunk;given-names:WE\", \"name_58\": \"surname:K\\u00f6hler;given-names:S\", \"name_59\": \"surname:Koglin;given-names:N\", \"name_6\": \"surname:Visser;given-names:PJ\", \"name_60\": \"surname:Kornhuber;given-names:J\", \"name_61\": \"surname:Kramberger;given-names:MG\", \"name_62\": \"surname:Van Laere;given-names:K\", \"name_63\": \"surname:Landau;given-names:SM\", \"name_64\": \"surname:Lee;given-names:DY\", \"name_65\": \"surname:de Leon;given-names:M\", \"name_66\": \"surname:Lisetti;given-names:V\", \"name_67\": \"surname:Lle\\u00f3;given-names:A\", \"name_68\": \"surname:Madsen;given-names:K\", \"name_69\": \"surname:Maier;given-names:W\", \"name_7\": \"surname:Aalten;given-names:P\", \"name_70\": \"surname:Marcusson;given-names:J\", \"name_71\": \"surname:Mattsson;given-names:N\", \"name_72\": \"surname:de Mendon\\u00e7a;given-names:A\", \"name_73\": \"surname:Meulenbroek;given-names:O\", \"name_74\": \"surname:Meyer;given-names:PT\", \"name_75\": \"surname:Mintun;given-names:MA\", \"name_76\": \"surname:Mok;given-names:V\", \"name_77\": \"surname:Molinuevo;given-names:JL\", \"name_78\": \"surname:M\\u00f8llerg\\u00e5rd;given-names:HM\", \"name_79\": \"surname:Morris;given-names:JC\", \"name_8\": \"surname:Aarsland;given-names:D\", \"name_80\": \"surname:Mroczko;given-names:B\", \"name_81\": \"surname:Van der Mussele;given-names:S\", \"name_82\": \"surname:Na;given-names:DL\", \"name_83\": \"surname:Newberg;given-names:A\", \"name_84\": \"surname:Nordberg;given-names:A\", \"name_85\": \"surname:Nordlund;given-names:A\", \"name_86\": \"surname:Novak;given-names:GP\", \"name_87\": \"surname:Paraskevas;given-names:GP\", \"name_88\": \"surname:Parnetti;given-names:L\", \"name_89\": \"surname:Perera;given-names:G\", \"name_9\": \"surname:Alcolea;given-names:D\", \"name_90\": \"surname:Peters;given-names:O\", \"name_91\": \"surname:Popp;given-names:J\", \"name_92\": \"surname:Prabhakar;given-names:S\", \"name_93\": \"surname:Rabinovici;given-names:GD\", \"name_94\": \"surname:Ramakers;given-names:IHGB\", \"name_95\": \"surname:Rami;given-names:L\", \"name_96\": \"surname:Resende de Oliveira;given-names:C\", \"name_97\": \"surname:Rinne;given-names:JO\", \"name_98\": \"surname:Rodrigue;given-names:KM\", \"name_99\": \"surname:Rodr\\u00edguez-Rodr\\u00edguez;given-names:E\", \"pub-id_doi\": \"10.1001/jama.2015.4668\", \"pub-id_pmid\": \"25988462\", \"section_type\": \"REF\", \"source\": \"JAMA\", \"type\": \"ref\", \"volume\": \"313\", \"year\": \"2015\"}, \"text\": \"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34768, \"infons\": {\"fpage\": \"38\", \"lpage\": \"46\", \"name_0\": \"surname:Kim;given-names:S-Y\", \"name_1\": \"surname:Olives;given-names:C\", \"name_2\": \"surname:Sheppard;given-names:L\", \"name_3\": \"surname:Sampson;given-names:PD\", \"name_4\": \"surname:Larson;given-names:TV\", \"name_5\": \"surname:Keller;given-names:JP\", \"name_6\": \"surname:Kaufman;given-names:JD\", \"pub-id_doi\": \"10.1289/EHP131\", \"pub-id_pmid\": \"27340825\", \"section_type\": \"REF\", \"source\": \"Environ. Health Perspect\", \"type\": \"ref\", \"volume\": \"125\", \"year\": \"2017\"}, \"text\": \"Historical Prediction Modeling Approach for Estimating Long-Term Concentrations of PM2.5 in Cohort Studies before the 1999 Implementation of Widespread Monitoring\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34931, \"infons\": {\"name_0\": \"surname:Kivim\\u00e4ki;given-names:M\", \"name_1\": \"surname:Singh-Manoux;given-names:A\", \"pub-id_doi\": \"10.1016/S0140-6736(18)30578-6\", \"section_type\": \"REF\", \"source\": \"Lancet (London, England)\", \"type\": \"ref\", \"year\": \"2018\"}, \"text\": \"Prevention of dementia by targeting risk factors\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 34980, \"infons\": {\"name_0\": \"surname:Lee;given-names:JH\", \"name_1\": \"surname:Byun;given-names:MS\", \"name_2\": \"surname:Yi;given-names:D\", \"name_3\": \"surname:Ko;given-names:K\", \"name_4\": \"surname:Jeon;given-names:SY\", \"name_5\": \"surname:Sohn;given-names:BK\", \"name_6\": \"surname:Lee;given-names:JY\", \"name_7\": \"surname:Lee;given-names:Y\", \"name_8\": \"surname:Joung;given-names:H\", \"name_9\": \"surname:Lee;given-names:DY\", \"pub-id_doi\": \"10.3233/JAD-200694\", \"section_type\": \"REF\", \"source\": \"J. Alzheimer\\u2019s Dis\", \"type\": \"ref\", \"volume\": \"78\", \"year\": \"2020\"}, \"text\": \"Long-Term Exposure to PM10 and in vivo Alzheimer\\u2019s Disease Pathologies\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35053, \"infons\": {\"fpage\": \"687\", \"lpage\": \"689\", \"name_0\": \"surname:Levy;given-names:E\", \"pub-id_doi\": \"10.1586/14737175.8.5.687\", \"pub-id_pmid\": \"18457524\", \"section_type\": \"REF\", \"source\": \"Expert Rev.Neurother\", \"type\": \"ref\", \"volume\": \"8\", \"year\": \"2008\"}, \"text\": \"Cystatin C: a potential target for Alzheimer\\u2019s treatment\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35112, \"infons\": {\"name_0\": \"surname:Lopez;given-names:OL\", \"name_1\": \"surname:Klunk;given-names:WE\", \"name_2\": \"surname:Mathis;given-names:CA\", \"name_3\": \"surname:Snitz;given-names:BE\", \"name_4\": \"surname:Chang;given-names:Y\", \"name_5\": \"surname:Tracy;given-names:RP\", \"name_6\": \"surname:Kuller;given-names:LH\", \"pub-id_doi\": \"10.1093/braincomms/fcz038\", \"section_type\": \"REF\", \"source\": \"Brain Commun\", \"type\": \"ref\", \"volume\": \"2\", \"year\": \"2020\"}, \"text\": \"Relationship of amyloid-\\u03b21\\u201342 in blood and brain amyloid: Ginkgo Evaluation of Memory Study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35207, \"infons\": {\"name_0\": \"surname:Ma;given-names:Y\", \"name_1\": \"surname:Brettschneider;given-names:J\", \"name_2\": \"surname:Collingwood;given-names:JF\", \"pub-id_doi\": \"10.3390/biomedicines10071713\", \"section_type\": \"REF\", \"source\": \"Biomedicines\", \"type\": \"ref\", \"volume\": \"10\", \"year\": \"2022\"}, \"text\": \"A Systematic Review and Meta-Analysis of Cerebrospinal Fluid Amyloid and Tau Levels Identifies Mild Cognitive Impairment Patients Progressing to Alzheimer\\u2019s Disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35374, \"infons\": {\"name_0\": \"surname:Nakamura;given-names:A\", \"name_1\": \"surname:Kaneko;given-names:N\", \"name_10\": \"surname:Tomita;given-names:T\", \"name_11\": \"surname:Matsuzaki;given-names:K\", \"name_12\": \"surname:Ishii;given-names:K\", \"name_13\": \"surname:Ishii;given-names:K\", \"name_14\": \"surname:Arahata;given-names:Y\", \"name_15\": \"surname:Iwamoto;given-names:S\", \"name_16\": \"surname:Ito;given-names:K\", \"name_17\": \"surname:Tanaka;given-names:K\", \"name_18\": \"surname:Masters;given-names:CL\", \"name_19\": \"surname:Yanagisawa;given-names:K\", \"name_2\": \"surname:Villemagne;given-names:VL\", \"name_3\": \"surname:Kato;given-names:T\", \"name_4\": \"surname:Doecke;given-names:J\", \"name_5\": \"surname:Dor\\u00e9;given-names:V\", \"name_6\": \"surname:Fowler;given-names:C\", \"name_7\": \"surname:Li;given-names:QX\", \"name_8\": \"surname:Martins;given-names:R\", \"name_9\": \"surname:Rowe;given-names:C\", \"pub-id_doi\": \"10.1038/nature25456\", \"section_type\": \"REF\", \"source\": \"Nature\", \"type\": \"ref\", \"volume\": \"554\", \"year\": \"2018\"}, \"text\": \"High performance plasma amyloid-\\u03b2 biomarkers for Alzheimer\\u2019s disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35446, \"infons\": {\"fpage\": \"e105\", \"lpage\": \"e125\", \"name_0\": \"surname:Nichols;given-names:E\", \"name_1\": \"surname:Steinmetz;given-names:JD\", \"name_10\": \"surname:Al Hamad;given-names:H\", \"name_100\": \"surname:Hay;given-names:SI\", \"name_101\": \"surname:Hayat;given-names:K\", \"name_102\": \"surname:Hegazy;given-names:MI\", \"name_103\": \"surname:Heidari;given-names:G\", \"name_104\": \"surname:Heidari-Soureshjani;given-names:R\", \"name_105\": \"surname:Herteliu;given-names:C\", \"name_106\": \"surname:Househ;given-names:M\", \"name_107\": \"surname:Hussain;given-names:R\", \"name_108\": \"surname:Hwang;given-names:B-F\", \"name_109\": \"surname:Iacoviello;given-names:L\", \"name_11\": \"surname:Alahdab;given-names:F\", \"name_110\": \"surname:Iavicoli;given-names:I\", \"name_111\": \"surname:Ilesanmi;given-names:OS\", \"name_112\": \"surname:Ilic;given-names:IM\", \"name_113\": \"surname:Ilic;given-names:MD\", \"name_114\": \"surname:Irvani;given-names:SSN\", \"name_115\": \"surname:Iso;given-names:H\", \"name_116\": \"surname:Iwagami;given-names:M\", \"name_117\": \"surname:Jabbarinejad;given-names:R\", \"name_118\": \"surname:Jacob;given-names:L\", \"name_119\": \"surname:Jain;given-names:V\", \"name_12\": \"surname:Alanezi;given-names:FM\", \"name_120\": \"surname:Jayapal;given-names:SK\", \"name_121\": \"surname:Jayawardena;given-names:R\", \"name_122\": \"surname:Jha;given-names:RP\", \"name_123\": \"surname:Jonas;given-names:JB\", \"name_124\": \"surname:Joseph;given-names:N\", \"name_125\": \"surname:Kalani;given-names:R\", \"name_126\": \"surname:Kandel;given-names:A\", \"name_127\": \"surname:Kandel;given-names:H\", \"name_128\": \"surname:Karch;given-names:A\", \"name_129\": \"surname:Kasa;given-names:AS\", \"name_13\": \"surname:Alipour;given-names:V\", \"name_130\": \"surname:Kassie;given-names:GM\", \"name_131\": \"surname:Keshavarz;given-names:P\", \"name_132\": \"surname:Khan;given-names:MAB\", \"name_133\": \"surname:Khatib;given-names:MN\", \"name_134\": \"surname:Khoja;given-names:TAM\", \"name_135\": \"surname:Khubchandani;given-names:J\", \"name_136\": \"surname:Kim;given-names:MS\", \"name_137\": \"surname:Kim;given-names:YJ\", \"name_138\": \"surname:Kisa;given-names:A\", \"name_139\": \"surname:Kisa;given-names:S\", \"name_14\": \"surname:Almustanyir;given-names:S\", \"name_140\": \"surname:Kivim\\u00e4ki;given-names:M\", \"name_141\": \"surname:Koroshetz;given-names:WJ\", \"name_142\": \"surname:Koyanagi;given-names:A\", \"name_143\": \"surname:Kumar;given-names:GA\", \"name_144\": \"surname:Kumar;given-names:M\", \"name_145\": \"surname:Lak;given-names:HM\", \"name_146\": \"surname:Leonardi;given-names:M\", \"name_147\": \"surname:Li;given-names:B\", \"name_148\": \"surname:Lim;given-names:SS\", \"name_149\": \"surname:Liu;given-names:X\", \"name_15\": \"surname:Amu;given-names:H\", \"name_150\": \"surname:Liu;given-names:Y\", \"name_151\": \"surname:Logroscino;given-names:G\", \"name_152\": \"surname:Lorkowski;given-names:S\", \"name_153\": \"surname:Lucchetti;given-names:G\", \"name_154\": \"surname:Lutzky Saute;given-names:R\", \"name_155\": \"surname:Magnani;given-names:FG\", \"name_156\": \"surname:Malik;given-names:AA\", \"name_157\": \"surname:Massano;given-names:J\", \"name_158\": \"surname:Mehndiratta;given-names:MM\", \"name_159\": \"surname:Menezes;given-names:RG\", \"name_16\": \"surname:Ansari;given-names:I\", \"name_160\": \"surname:Meretoja;given-names:A\", \"name_161\": \"surname:Mohajer;given-names:B\", \"name_162\": \"surname:Mohamed Ibrahim;given-names:N\", \"name_163\": \"surname:Mohammad;given-names:Y\", \"name_164\": \"surname:Mohammed;given-names:A\", \"name_165\": \"surname:Mokdad;given-names:AH\", \"name_166\": \"surname:Mondello;given-names:S\", \"name_167\": \"surname:Moni;given-names:MAA\", \"name_168\": \"surname:Moniruzzaman;given-names:M\", \"name_169\": \"surname:Mossie;given-names:TB\", \"name_17\": \"surname:Arabloo;given-names:J\", \"name_170\": \"surname:Nagel;given-names:G\", \"name_171\": \"surname:Naveed;given-names:M\", \"name_172\": \"surname:Nayak;given-names:VC\", \"name_173\": \"surname:Neupane Kandel;given-names:S\", \"name_174\": \"surname:Nguyen;given-names:TH\", \"name_175\": \"surname:Oancea;given-names:B\", \"name_176\": \"surname:Otstavnov;given-names:N\", \"name_177\": \"surname:Otstavnov;given-names:SS\", \"name_178\": \"surname:Owolabi;given-names:MO\", \"name_179\": \"surname:Panda-Jonas;given-names:S\", \"name_18\": \"surname:Ashraf;given-names:T\", \"name_180\": \"surname:Pashazadeh Kan;given-names:F\", \"name_181\": \"surname:Pasovic;given-names:M\", \"name_182\": \"surname:Patel;given-names:UK\", \"name_183\": \"surname:Pathak;given-names:M\", \"name_184\": \"surname:Peres;given-names:MFP\", \"name_185\": \"surname:Perianayagam;given-names:A\", \"name_186\": \"surname:Peterson;given-names:CB\", \"name_187\": \"surname:Phillips;given-names:MR\", \"name_188\": \"surname:Pinheiro;given-names:M\", \"name_189\": \"surname:Piradov;given-names:MA\", \"name_19\": \"surname:Astell-Burt;given-names:T\", \"name_190\": \"surname:Pond;given-names:CD\", \"name_191\": \"surname:Potashman;given-names:MH\", \"name_192\": \"surname:Pottoo;given-names:FH\", \"name_193\": \"surname:Prada;given-names:SI\", \"name_194\": \"surname:Radfar;given-names:A\", \"name_195\": \"surname:Raggi;given-names:A\", \"name_196\": \"surname:Rahim;given-names:F\", \"name_197\": \"surname:Rahman;given-names:M\", \"name_198\": \"surname:Ram;given-names:P\", \"name_199\": \"surname:Ranasinghe;given-names:P\", \"name_2\": \"surname:Vollset;given-names:SE\", \"name_20\": \"surname:Ayano;given-names:G\", \"name_200\": \"surname:Rawaf;given-names:DL\", \"name_201\": \"surname:Rawaf;given-names:S\", \"name_202\": \"surname:Rezaei;given-names:N\", \"name_203\": \"surname:Rezapour;given-names:A\", \"name_204\": \"surname:Robinson;given-names:SR\", \"name_205\": \"surname:Romoli;given-names:M\", \"name_206\": \"surname:Roshandel;given-names:G\", \"name_207\": \"surname:Sahathevan;given-names:R\", \"name_208\": \"surname:Sahebkar;given-names:A\", \"name_209\": \"surname:Sahraian;given-names:MA\", \"name_21\": \"surname:Ayuso-Mateos;given-names:JL\", \"name_210\": \"surname:Sathian;given-names:B\", \"name_211\": \"surname:Sattin;given-names:D\", \"name_212\": \"surname:Sawhney;given-names:M\", \"name_213\": \"surname:Saylan;given-names:M\", \"name_214\": \"surname:Schiavolin;given-names:S\", \"name_215\": \"surname:Seylani;given-names:A\", \"name_216\": \"surname:Sha;given-names:F\", \"name_217\": \"surname:Shaikh;given-names:MA\", \"name_218\": \"surname:Shaji;given-names:KS\", \"name_219\": \"surname:Shannawaz;given-names:M\", \"name_22\": \"surname:Baig;given-names:AA\", \"name_220\": \"surname:Shetty;given-names:JK\", \"name_221\": \"surname:Shigematsu;given-names:M\", \"name_222\": \"surname:Shin;given-names:JI\", \"name_223\": \"surname:Shiri;given-names:R\", \"name_224\": \"surname:Silva;given-names:DAS\", \"name_225\": \"surname:Silva;given-names:JP\", \"name_226\": \"surname:Silva;given-names:R\", \"name_227\": \"surname:Singh;given-names:JA\", \"name_228\": \"surname:Skryabin;given-names:VY\", \"name_229\": \"surname:Skryabina;given-names:AA\", \"name_23\": \"surname:Barnett;given-names:A\", \"name_230\": \"surname:Smith;given-names:AE\", \"name_231\": \"surname:Soshnikov;given-names:S\", \"name_232\": \"surname:Spurlock;given-names:EE\", \"name_233\": \"surname:Stein;given-names:DJ\", \"name_234\": \"surname:Sun;given-names:J\", \"name_235\": \"surname:Tabar\\u00e9s-Seisdedos;given-names:R\", \"name_236\": \"surname:Thakur;given-names:B\", \"name_237\": \"surname:Timalsina;given-names:B\", \"name_238\": \"surname:Tovani-Palone;given-names:MR\", \"name_239\": \"surname:Tran;given-names:BX\", \"name_24\": \"surname:Barrow;given-names:A\", \"name_240\": \"surname:Tsegaye;given-names:GW\", \"name_241\": \"surname:Valadan Tahbaz;given-names:S\", \"name_242\": \"surname:Valdez;given-names:PR\", \"name_243\": \"surname:Venketasubramanian;given-names:N\", \"name_244\": \"surname:Vlassov;given-names:V\", \"name_245\": \"surname:Vu;given-names:GT\", \"name_246\": \"surname:Vu;given-names:LG\", \"name_247\": \"surname:Wang;given-names:Y-P\", \"name_248\": \"surname:Wimo;given-names:A\", \"name_249\": \"surname:Winkler;given-names:AS\", \"name_25\": \"surname:Baune;given-names:BT\", \"name_250\": \"surname:Yadav;given-names:L\", \"name_251\": \"surname:Yahyazadeh Jabbari;given-names:SH\", \"name_252\": \"surname:Yamagishi;given-names:K\", \"name_253\": \"surname:Yang;given-names:L\", \"name_254\": \"surname:Yano;given-names:Y\", \"name_255\": \"surname:Yonemoto;given-names:N\", \"name_256\": \"surname:Yu;given-names:C\", \"name_257\": \"surname:Yunusa;given-names:I\", \"name_258\": \"surname:Zadey;given-names:S\", \"name_259\": \"surname:Zastrozhin;given-names:MS\", \"name_26\": \"surname:B\\u00e9jot;given-names:Y\", \"name_260\": \"surname:Zastrozhina;given-names:A\", \"name_261\": \"surname:Zhang;given-names:Z-J\", \"name_262\": \"surname:Murray;given-names:CJL\", \"name_263\": \"surname:Vos;given-names:T\", \"name_27\": \"surname:Bezabhe;given-names:WMM\", \"name_28\": \"surname:Bezabih;given-names:YM\", \"name_29\": \"surname:Bhagavathula;given-names:AS\", \"name_3\": \"surname:Fukutaki;given-names:K\", \"name_30\": \"surname:Bhaskar;given-names:S\", \"name_31\": \"surname:Bhattacharyya;given-names:K\", \"name_32\": \"surname:Bijani;given-names:A\", \"name_33\": \"surname:Biswas;given-names:A\", \"name_34\": \"surname:Bolla;given-names:SR\", \"name_35\": \"surname:Boloor;given-names:A\", \"name_36\": \"surname:Brayne;given-names:C\", \"name_37\": \"surname:Brenner;given-names:H\", \"name_38\": \"surname:Burkart;given-names:K\", \"name_39\": \"surname:Burns;given-names:RA\", \"name_4\": \"surname:Chalek;given-names:J\", \"name_40\": \"surname:C\\u00e1mera;given-names:LA\", \"name_41\": \"surname:Cao;given-names:C\", \"name_42\": \"surname:Carvalho;given-names:F\", \"name_43\": \"surname:Castro-de-Araujo;given-names:LFS\", \"name_44\": \"surname:Catal\\u00e1-L\\u00f3pez;given-names:F\", \"name_45\": \"surname:Cerin;given-names:E\", \"name_46\": \"surname:Chavan;given-names:PP\", \"name_47\": \"surname:Cherbuin;given-names:N\", \"name_48\": \"surname:Chu;given-names:D-T\", \"name_49\": \"surname:Costa;given-names:VM\", \"name_5\": \"surname:Abd-Allah;given-names:F\", \"name_50\": \"surname:Couto;given-names:RAS\", \"name_51\": \"surname:Dadras;given-names:O\", \"name_52\": \"surname:Dai;given-names:X\", \"name_53\": \"surname:Dandona;given-names:L\", \"name_54\": \"surname:Dandona;given-names:R\", \"name_55\": \"surname:De la Cruz-G\\u00f3ngora;given-names:V\", \"name_56\": \"surname:Dhamnetiya;given-names:D\", \"name_57\": \"surname:Dias da Silva;given-names:D\", \"name_58\": \"surname:Diaz;given-names:D\", \"name_59\": \"surname:Douiri;given-names:A\", \"name_6\": \"surname:Abdoli;given-names:A\", \"name_60\": \"surname:Edvardsson;given-names:D\", \"name_61\": \"surname:Ekholuenetale;given-names:M\", \"name_62\": \"surname:El Sayed;given-names:I\", \"name_63\": \"surname:El-Jaafary;given-names:SI\", \"name_64\": \"surname:Eskandari;given-names:K\", \"name_65\": \"surname:Eskandarieh;given-names:S\", \"name_66\": \"surname:Esmaeilnejad;given-names:S\", \"name_67\": \"surname:Fares;given-names:J\", \"name_68\": \"surname:Faro;given-names:A\", \"name_69\": \"surname:Farooque;given-names:U\", \"name_7\": \"surname:Abualhasan;given-names:A\", \"name_70\": \"surname:Feigin;given-names:VL\", \"name_71\": \"surname:Feng;given-names:X\", \"name_72\": \"surname:Fereshtehnejad;given-names:S-M\", \"name_73\": \"surname:Fernandes;given-names:E\", \"name_74\": \"surname:Ferrara;given-names:P\", \"name_75\": \"surname:Filip;given-names:I\", \"name_76\": \"surname:Fillit;given-names:H\", \"name_77\": \"surname:Fischer;given-names:F\", \"name_78\": \"surname:Gaidhane;given-names:S\", \"name_79\": \"surname:Galluzzo;given-names:L\", \"name_8\": \"surname:Abu-Gharbieh;given-names:E\", \"name_80\": \"surname:Ghashghaee;given-names:A\", \"name_81\": \"surname:Ghith;given-names:N\", \"name_82\": \"surname:Gialluisi;given-names:A\", \"name_83\": \"surname:Gilani;given-names:SA\", \"name_84\": \"surname:Glavan;given-names:I-R\", \"name_85\": \"surname:Gnedovskaya;given-names:EV\", \"name_86\": \"surname:Golechha;given-names:M\", \"name_87\": \"surname:Gupta;given-names:R\", \"name_88\": \"surname:Gupta;given-names:VB\", \"name_89\": \"surname:Gupta;given-names:VK\", \"name_9\": \"surname:Akram;given-names:TT\", \"name_90\": \"surname:Haider;given-names:MR\", \"name_91\": \"surname:Hall;given-names:BJ\", \"name_92\": \"surname:Hamidi;given-names:S\", \"name_93\": \"surname:Hanif;given-names:A\", \"name_94\": \"surname:Hankey;given-names:GJ\", \"name_95\": \"surname:Haque;given-names:S\", \"name_96\": \"surname:Hartono;given-names:RK\", \"name_97\": \"surname:Hasaballah;given-names:AI\", \"name_98\": \"surname:Hasan;given-names:MT\", \"name_99\": \"surname:Hassan;given-names:A\", \"pub-id_doi\": \"10.1016/S2468-2667(21)00249-8\", \"section_type\": \"REF\", \"source\": \"Lancet Public Heal\", \"type\": \"ref\", \"volume\": \"7\", \"year\": \"2022\"}, \"text\": \"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35593, \"infons\": {\"fpage\": \"1939\", \"lpage\": \"49\", \"name_0\": \"surname:Ossenkoppele;given-names:R\", \"name_1\": \"surname:Jansen;given-names:WJ\", \"name_10\": \"surname:Adriaanse;given-names:SM\", \"name_11\": \"surname:Lammertsma;given-names:AA\", \"name_12\": \"surname:Barkhof;given-names:F\", \"name_13\": \"surname:Jagust;given-names:WJ\", \"name_14\": \"surname:Miller;given-names:BL\", \"name_15\": \"surname:Rosen;given-names:HJ\", \"name_16\": \"surname:Landau;given-names:SM\", \"name_17\": \"surname:Villemagne;given-names:VL\", \"name_18\": \"surname:Rowe;given-names:CC\", \"name_19\": \"surname:Lee;given-names:DY\", \"name_2\": \"surname:Rabinovici;given-names:GD\", \"name_20\": \"surname:Na;given-names:DL\", \"name_21\": \"surname:Seo;given-names:SW\", \"name_22\": \"surname:Sarazin;given-names:M\", \"name_23\": \"surname:Roe;given-names:CM\", \"name_24\": \"surname:Sabri;given-names:O\", \"name_25\": \"surname:Barthel;given-names:H\", \"name_26\": \"surname:Koglin;given-names:N\", \"name_27\": \"surname:Hodges;given-names:J\", \"name_28\": \"surname:Leyton;given-names:CE\", \"name_29\": \"surname:Vandenberghe;given-names:R\", \"name_3\": \"surname:Knol;given-names:DL\", \"name_30\": \"surname:van Laere;given-names:K\", \"name_31\": \"surname:Drzezga;given-names:A\", \"name_32\": \"surname:Forster;given-names:S\", \"name_33\": \"surname:Grimmer;given-names:T\", \"name_34\": \"surname:S\\u00e1nchez-Juan;given-names:P\", \"name_35\": \"surname:Carril;given-names:JM\", \"name_36\": \"surname:Mok;given-names:V\", \"name_37\": \"surname:Camus;given-names:V\", \"name_38\": \"surname:Klunk;given-names:WE\", \"name_39\": \"surname:Cohen;given-names:AD\", \"name_4\": \"surname:van der Flier;given-names:WM\", \"name_40\": \"surname:Meyer;given-names:PT\", \"name_41\": \"surname:Hellwig;given-names:S\", \"name_42\": \"surname:Newberg;given-names:A\", \"name_43\": \"surname:Frederiksen;given-names:KS\", \"name_44\": \"surname:Fleisher;given-names:AS\", \"name_45\": \"surname:Mintun;given-names:MA\", \"name_46\": \"surname:Wolk;given-names:DA\", \"name_47\": \"surname:Nordberg;given-names:A\", \"name_48\": \"surname:Rinne;given-names:JO\", \"name_49\": \"surname:Ch\\u00e9telat;given-names:G\", \"name_5\": \"surname:van Berckel;given-names:BNM\", \"name_50\": \"surname:Lleo;given-names:A\", \"name_51\": \"surname:Blesa;given-names:R\", \"name_52\": \"surname:Fortea;given-names:J\", \"name_53\": \"surname:Madsen;given-names:K\", \"name_54\": \"surname:Rodrigue;given-names:KM\", \"name_55\": \"surname:Brooks;given-names:DJ\", \"name_6\": \"surname:Scheltens;given-names:P\", \"name_7\": \"surname:Visser;given-names:PJ\", \"name_8\": \"surname:Verfaillie;given-names:SCJ\", \"name_9\": \"surname:Zwan;given-names:MD\", \"pub-id_doi\": \"10.1001/jama.2015.4669\", \"pub-id_pmid\": \"25988463\", \"section_type\": \"REF\", \"source\": \"JAMA\", \"type\": \"ref\", \"volume\": \"313\", \"year\": \"2015\"}, \"text\": \"Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35669, \"infons\": {\"fpage\": \"317\", \"lpage\": \"329\", \"name_0\": \"surname:Overton;given-names:M\", \"name_1\": \"surname:Pihlsg\\u00e5rd;given-names:M\", \"name_2\": \"surname:Elmst\\u00e5hl;given-names:S\", \"pub-id_doi\": \"10.1159/000506255\", \"pub-id_pmid\": \"32224608\", \"section_type\": \"REF\", \"source\": \"Dement. Geriatr. Cogn. Disord\", \"type\": \"ref\", \"volume\": \"48\", \"year\": \"2019\"}, \"text\": \"Diagnostic Stability of Mild Cognitive Impairment, and Predictors of Reversion to Normal Cognitive Functioning\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35780, \"infons\": {\"name_0\": \"surname:Patten;given-names:KT\", \"name_1\": \"surname:Valenzuela;given-names:AE\", \"name_2\": \"surname:Wallis;given-names:C\", \"name_3\": \"surname:Berg;given-names:EL\", \"name_4\": \"surname:Silverman;given-names:JL\", \"name_5\": \"surname:Bein;given-names:KJ\", \"name_6\": \"surname:Wexler;given-names:AS\", \"name_7\": \"surname:Lein;given-names:PJ\", \"pub-id_doi\": \"10.1289/EHP8905\", \"section_type\": \"REF\", \"source\": \"Environ. Health Perspect\", \"type\": \"ref\", \"volume\": \"129\", \"year\": \"2021\"}, \"text\": \"The effects of chronic exposure to ambient traffic-related air pollution on alzheimer\\u2019s disease phenotypes in wildtype and genetically predisposed male and female rats\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 35950, \"infons\": {\"fpage\": \"1127\", \"lpage\": \"1133\", \"name_0\": \"surname:Peters;given-names:KE\", \"name_1\": \"surname:Davis;given-names:WA\", \"name_2\": \"surname:Taddei;given-names:K\", \"name_3\": \"surname:Martins;given-names:RN\", \"name_4\": \"surname:Masters;given-names:CL\", \"name_5\": \"surname:Davis;given-names:TME\", \"name_6\": \"surname:Bruce;given-names:DG\", \"pub-id_doi\": \"10.3233/JAD-161050\", \"pub-id_pmid\": \"28106562\", \"section_type\": \"REF\", \"source\": \"J. Alzheimer\\u2019s Dis\", \"type\": \"ref\", \"volume\": \"56\", \"year\": \"2017\"}, \"text\": \"Plasma Amyloid-\\u03b2 Peptides in Type 2 Diabetes: A Matched Case-Control Study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36028, \"infons\": {\"fpage\": \"161\", \"lpage\": \"169\", \"name_0\": \"surname:Roeben;given-names:B\", \"name_1\": \"surname:Maetzler;given-names:W\", \"name_10\": \"surname:Gaenslen;given-names:A\", \"name_11\": \"surname:Gr\\u00fcner;given-names:E\", \"name_12\": \"surname:Niebler;given-names:R\", \"name_13\": \"surname:Eschweiler;given-names:GW\", \"name_14\": \"surname:Berg;given-names:D\", \"name_2\": \"surname:Vanmechelen;given-names:E\", \"name_3\": \"surname:Schulte;given-names:C\", \"name_4\": \"surname:Heinzel;given-names:S\", \"name_5\": \"surname:Stellos;given-names:K\", \"name_6\": \"surname:Godau;given-names:J\", \"name_7\": \"surname:Huber;given-names:H\", \"name_8\": \"surname:Brockmann;given-names:K\", \"name_9\": \"surname:Wurster;given-names:I\", \"pub-id_doi\": \"10.3233/JAD-150575\", \"pub-id_pmid\": \"27003209\", \"section_type\": \"REF\", \"source\": \"J. Alzheimer\\u2019s Dis\", \"type\": \"ref\", \"volume\": \"52\", \"year\": \"2016\"}, \"text\": \"Association of Plasma A\\u03b240 Peptides, but Not A\\u03b242, with Coronary Artery Disease and Diabetes Mellitus\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36136, \"infons\": {\"name_0\": \"surname:Rubin;given-names:DB\", \"section_type\": \"REF\", \"source\": \"Multiple imputation for nonresponse in surveys\", \"type\": \"ref\", \"year\": \"2004\"}, \"text\": \"\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36137, \"infons\": {\"name_0\": \"surname:Sahu;given-names:B\", \"name_1\": \"surname:Mackos;given-names:AR\", \"name_2\": \"surname:Floden;given-names:AM\", \"name_3\": \"surname:Wold;given-names:LE\", \"name_4\": \"surname:Combs;given-names:CK\", \"pub-id_doi\": \"10.3233/JAD-200919\", \"section_type\": \"REF\", \"source\": \"J. Alzheimer\\u2019s Dis\", \"type\": \"ref\", \"volume\": \"80\", \"year\": \"2021\"}, \"text\": \"Particulate Matter Exposure Exacerbates Amyloid-\\u03b2 Plaque Deposition and Gliosis in APP/PS1 Mice\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36236, \"infons\": {\"name_0\": \"surname:Semmens;given-names:EO\", \"name_1\": \"surname:Leary;given-names:CS\", \"name_2\": \"surname:Fitzpatrick;given-names:AL\", \"name_3\": \"surname:Ilango;given-names:SD\", \"name_4\": \"surname:Park;given-names:C\", \"name_5\": \"surname:Adam;given-names:CE\", \"name_6\": \"surname:DeKosky;given-names:ST\", \"name_7\": \"surname:Lopez;given-names:O\", \"name_8\": \"surname:Hajat;given-names:A\", \"name_9\": \"surname:Kaufman;given-names:JD\", \"pub-id_doi\": \"10.1002/alz.12654\", \"section_type\": \"REF\", \"source\": \"Alzheimers. Dement\", \"type\": \"ref\", \"year\": \"2022\"}, \"text\": \"Air pollution and dementia in older adults in the Ginkgo Evaluation of Memory Study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36320, \"infons\": {\"fpage\": \"1761\", \"lpage\": \"1773\", \"name_0\": \"surname:Shaffer;given-names:RM\", \"name_1\": \"surname:Li;given-names:G\", \"name_2\": \"surname:Adar;given-names:SD\", \"name_3\": \"surname:Dirk Keene;given-names:C\", \"name_4\": \"surname:Latimer;given-names:CS\", \"name_5\": \"surname:Crane;given-names:PK\", \"name_6\": \"surname:Larson;given-names:EB\", \"name_7\": \"surname:Kaufman;given-names:JD\", \"name_8\": \"surname:Carone;given-names:M\", \"name_9\": \"surname:Sheppard;given-names:L\", \"pub-id_doi\": \"10.3233/JAD-201005\", \"pub-id_pmid\": \"33459717\", \"section_type\": \"REF\", \"source\": \"J. Alzheimers. Dis\", \"type\": \"ref\", \"volume\": \"79\", \"year\": \"2021\"}, \"text\": \"Fine Particulate Matter and Markers of Alzheimer\\u2019s Disease Neuropathology at Autopsy in a Community-Based Cohort\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36435, \"infons\": {\"name_0\": \"surname:Shah;given-names:NS\", \"name_1\": \"surname:Vidal;given-names:JS\", \"name_2\": \"surname:Masaki;given-names:K\", \"name_3\": \"surname:Petrovitch;given-names:H\", \"name_4\": \"surname:Ross;given-names:GW\", \"name_5\": \"surname:Tilley;given-names:C\", \"name_6\": \"surname:Demattos;given-names:RB\", \"name_7\": \"surname:Tracy;given-names:RP\", \"name_8\": \"surname:White;given-names:LR\", \"name_9\": \"surname:Launer;given-names:LJ\", \"pub-id_doi\": \"10.1161/HYPERTENSIONAHA.111.178962\", \"section_type\": \"REF\", \"source\": \"Hypertension\", \"type\": \"ref\", \"volume\": \"59\", \"year\": \"2012\"}, \"text\": \"Midlife blood pressure, plasma \\u03b2-amyloid, and the risk for alzheimer disease: The honolulu asia aging study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36546, \"infons\": {\"fpage\": \"2716\", \"lpage\": \"2731\", \"name_0\": \"surname:Skillb\\u00e4ck;given-names:T\", \"name_1\": \"surname:Farahmand;given-names:BY\", \"name_10\": \"surname:Blennow;given-names:K\", \"name_11\": \"surname:Eriksdotter;given-names:M\", \"name_12\": \"surname:Zetterberg;given-names:H\", \"name_2\": \"surname:Ro\\u015ben;given-names:C\", \"name_3\": \"surname:Mattsson;given-names:N\", \"name_4\": \"surname:N\\u00e4gga;given-names:K\", \"name_5\": \"surname:Kilander;given-names:L\", \"name_6\": \"surname:Religa;given-names:D\", \"name_7\": \"surname:Wimo;given-names:A\", \"name_8\": \"surname:Winblad;given-names:B\", \"name_9\": \"surname:Schott;given-names:JM\", \"pub-id_doi\": \"10.1093/brain/awv181\", \"pub-id_pmid\": \"26133663\", \"section_type\": \"REF\", \"source\": \"Brain\", \"type\": \"ref\", \"volume\": \"138\", \"year\": \"2015\"}, \"text\": \"Cerebrospinal fluid tau and amyloid-\\u03b21\\u201342 in patients with dementia\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36617, \"infons\": {\"fpage\": \"171\", \"lpage\": \"182\", \"name_0\": \"surname:Snitz;given-names:BE\", \"name_1\": \"surname:Saxton;given-names:J\", \"name_2\": \"surname:Lopez;given-names:OL\", \"name_3\": \"surname:Ives;given-names:DG\", \"name_4\": \"surname:Dunn;given-names:LO\", \"name_5\": \"surname:Rapp;given-names:SR\", \"name_6\": \"surname:Carlson;given-names:MC\", \"name_7\": \"surname:Fitzpatrick;given-names:AL\", \"name_8\": \"surname:Dekosky;given-names:ST\", \"pub-id_doi\": \"10.1080/13607860802380656\", \"pub-id_pmid\": \"19347684\", \"section_type\": \"REF\", \"source\": \"Aging Ment. Health\", \"type\": \"ref\", \"volume\": \"13\", \"year\": \"2009\"}, \"text\": \"Identifying mild cognitive impairment at baseline in the Ginkgo Evaluation of Memory (GEM) study\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36714, \"infons\": {\"fpage\": \"365\", \"lpage\": \"375\", \"name_0\": \"surname:Song;given-names:F\", \"name_1\": \"surname:Poljak;given-names:A\", \"name_2\": \"surname:Valenzuela;given-names:M\", \"name_3\": \"surname:Mayeux;given-names:R\", \"name_4\": \"surname:Smythe;given-names:GA\", \"name_5\": \"surname:Sachdev;given-names:PS\", \"pub-id_doi\": \"10.3233/JAD-2011-101977\", \"pub-id_pmid\": \"21709378\", \"section_type\": \"REF\", \"source\": \"J. Alzheimers. Dis\", \"type\": \"ref\", \"volume\": \"26\", \"year\": \"2011\"}, \"text\": \"Meta-analysis of plasma amyloid-\\u03b2 levels in Alzheimer\\u2019s disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36781, \"infons\": {\"fpage\": \"1060\", \"lpage\": \"1061\", \"name_0\": \"surname:Stamatelopoulos;given-names:K\", \"name_1\": \"surname:Pol;given-names:CJ\", \"name_2\": \"surname:Ayers;given-names:C\", \"name_3\": \"surname:Georgiopoulos;given-names:G\", \"name_4\": \"surname:Gatsiou;given-names:A\", \"name_5\": \"surname:Brilakis;given-names:ES\", \"name_6\": \"surname:Khera;given-names:A\", \"name_7\": \"surname:Drosatos;given-names:K\", \"name_8\": \"surname:de Lemos;given-names:JA\", \"name_9\": \"surname:Stellos;given-names:K\", \"pub-id_doi\": \"10.1016/j.jacc.2018.06.027\", \"pub-id_pmid\": \"30139434\", \"section_type\": \"REF\", \"source\": \"J. Am. Coll. Cardiol\", \"type\": \"ref\", \"volume\": \"72\", \"year\": \"2018\"}, \"text\": \"Amyloid-Beta (1\\u201340) Peptide and Subclinical Cardiovascular Disease\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36850, \"infons\": {\"fpage\": \"2701\", \"lpage\": \"2715\", \"name_0\": \"surname:Toledo;given-names:JB\", \"name_1\": \"surname:Zetterberg;given-names:H\", \"name_10\": \"surname:Osorio;given-names:RS\", \"name_11\": \"surname:Vanderstichele;given-names:H\", \"name_12\": \"surname:Vandijck;given-names:M\", \"name_13\": \"surname:Hampel;given-names:H\", \"name_14\": \"surname:Teipl;given-names:S\", \"name_15\": \"surname:Moghekar;given-names:A\", \"name_16\": \"surname:Albert;given-names:M\", \"name_17\": \"surname:Hu;given-names:WT\", \"name_18\": \"surname:Monge Argil\\u00e9s;given-names:JA\", \"name_19\": \"surname:Gorostidi;given-names:A\", \"name_2\": \"surname:van Harten;given-names:AC\", \"name_20\": \"surname:Teunissen;given-names:CE\", \"name_21\": \"surname:De Deyn;given-names:PP\", \"name_22\": \"surname:Hyman;given-names:BT\", \"name_23\": \"surname:Molinuevo;given-names:JL\", \"name_24\": \"surname:Frisoni;given-names:GB\", \"name_25\": \"surname:Linazasoro;given-names:G\", \"name_26\": \"surname:de Leon;given-names:MJ\", \"name_27\": \"surname:van der Flier;given-names:WM\", \"name_28\": \"surname:Scheltens;given-names:P\", \"name_29\": \"surname:Blennow;given-names:K\", \"name_3\": \"surname:Glodzik;given-names:L\", \"name_30\": \"surname:Shaw;given-names:LM\", \"name_31\": \"surname:Trojanowski;given-names:JQ\", \"name_4\": \"surname:Martinez-Lage;given-names:P\", \"name_5\": \"surname:Bocchio-Chiavetto;given-names:L\", \"name_6\": \"surname:Rami;given-names:L\", \"name_7\": \"surname:Hansson;given-names:O\", \"name_8\": \"surname:Sperling;given-names:R\", \"name_9\": \"surname:Engelborghs;given-names:S\", \"pub-id_doi\": \"10.1093/brain/awv199\", \"pub-id_pmid\": \"26220940\", \"section_type\": \"REF\", \"source\": \"Brain\", \"type\": \"ref\", \"volume\": \"138\", \"year\": \"2015\"}, \"text\": \"Alzheimer\\u2019s disease cerebrospinal fluid biomarker in cognitively normal subjects\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 36933, \"infons\": {\"name_0\": \"surname:Wang;given-names:J\", \"name_1\": \"surname:Gu;given-names:BJ\", \"name_2\": \"surname:Masters;given-names:CL\", \"name_3\": \"surname:Wang;given-names:YJ\", \"pub-id_doi\": \"10.1038/nrneurol.2017.111\", \"section_type\": \"REF\", \"source\": \"Nat. Rev. Neurol\", \"type\": \"ref\", \"volume\": \"13\", \"year\": \"2017\"}, \"text\": \"A systemic view of Alzheimer disease - Insights from amyloid-\\u03b2 metabolism beyond the brain\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37027, \"infons\": {\"fpage\": \"819\", \"lpage\": \"832\", \"name_0\": \"surname:Wang;given-names:X\", \"name_1\": \"surname:Sun;given-names:Y\", \"name_2\": \"surname:Li;given-names:T\", \"name_3\": \"surname:Cai;given-names:Y\", \"name_4\": \"surname:Han;given-names:Y\", \"pub-id_doi\": \"10.3233/JAD-190714\", \"pub-id_pmid\": \"31868667\", \"section_type\": \"REF\", \"source\": \"J. Alzheimers. Dis\", \"type\": \"ref\", \"volume\": \"73\", \"year\": \"2020\"}, \"text\": \"Amyloid-\\u03b2 as a Blood Biomarker for Alzheimer\\u2019s Disease: A Review of Recent Literature\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37116, \"infons\": {\"fpage\": \"643\", \"lpage\": \"651\", \"name_0\": \"surname:Washburn;given-names:RA\", \"name_1\": \"surname:McAuley;given-names:E\", \"name_2\": \"surname:Katula;given-names:J\", \"name_3\": \"surname:Mihalko;given-names:SL\", \"name_4\": \"surname:Boileau;given-names:RA\", \"pub-id_doi\": \"10.1016/s0895-4356(99)00049-9\", \"pub-id_pmid\": \"10391658\", \"section_type\": \"REF\", \"source\": \"J. Clin. Epidemiol\", \"type\": \"ref\", \"volume\": \"52\", \"year\": \"1999\"}, \"text\": \"The physical activity scale for the elderly (PASE): evidence for validity\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37190, \"infons\": {\"name_0\": \"surname:Weuve;given-names:J\", \"name_1\": \"surname:Bennett;given-names:EE\", \"name_2\": \"surname:Ranker;given-names:L\", \"name_3\": \"surname:Gianattasio;given-names:KZ\", \"name_4\": \"surname:Pedde;given-names:M\", \"name_5\": \"surname:Adar;given-names:SD\", \"name_6\": \"surname:Yanosky;given-names:JD\", \"name_7\": \"surname:Power;given-names:MC\", \"pub-id_doi\": \"10.1289/EHP8716\", \"section_type\": \"REF\", \"source\": \"Environ. Health Perspect\", \"type\": \"ref\", \"year\": \"2021\"}, \"text\": \"Exposure to air pollution in relation to risk of dementia and related outcomes: An updated systematic review of the epidemiological literature\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37333, \"infons\": {\"fpage\": \"434\", \"lpage\": \"438\", \"name_0\": \"surname:Woolpert;given-names:KM\", \"name_1\": \"surname:Ward;given-names:KC\", \"name_2\": \"surname:England;given-names:CV\", \"name_3\": \"surname:Lash;given-names:TL\", \"pub-id_doi\": \"10.1097/EDE.0000000000001327\", \"pub-id_pmid\": \"33591053\", \"section_type\": \"REF\", \"source\": \"Epidemiology\", \"type\": \"ref\", \"volume\": \"32\", \"year\": \"2021\"}, \"text\": \"Validation of LexisNexis Accurint in the Georgia Cancer Registry\\u2019s Cancer Recurrence and Information Surveillance Program\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37457, \"infons\": {\"fpage\": \"3686\", \"lpage\": \"3694\", \"name_0\": \"surname:Young;given-names:MT\", \"name_1\": \"surname:Bechle;given-names:MJ\", \"name_2\": \"surname:Sampson;given-names:PD\", \"name_3\": \"surname:Szpiro;given-names:AA\", \"name_4\": \"surname:Marshall;given-names:JD\", \"name_5\": \"surname:Sheppard;given-names:L\", \"name_6\": \"surname:Kaufman;given-names:JD\", \"pub-id_doi\": \"10.1021/acs.est.5b05099\", \"pub-id_pmid\": \"26927327\", \"section_type\": \"REF\", \"source\": \"Environ. Sci. Technol\", \"type\": \"ref\", \"volume\": \"50\", \"year\": \"2016\"}, \"text\": \"Satellite-Based NO2 and Model Validation in a National Prediction Model Based on Universal Kriging and Land-Use Regression\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 37580, \"infons\": {\"file\": \"nihms-1876059-f0001.jpg\", \"id\": \"F1\", \"section_type\": \"FIG\", \"type\": \"fig_caption\"}, \"text\": \"Histograms of log-transformed and winsorized A\\u03b21\\u201340 (pg/mL), A\\u03b21\\u201342 (pg/mL) and A\\u03b21\\u201342/A\\u03b21\\u201340 ratio values at 2000\\u201302 (A, B and C) and 2007\\u201308 (D, E and F). A\\u03b2 values less than or equal to the first percentile of their distributions at 2000\\u201302 and 2007\\u201308 were removed and set to the minimum value (winsorized) and then log-transformed. The A\\u03b21\\u201342/A\\u03b21\\u201340 ratio was created by taking the log-transformation of both the numerator and denominator before division.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38068, \"infons\": {\"file\": \"nihms-1876059-f0002.jpg\", \"id\": \"F2\", \"section_type\": \"FIG\", \"type\": \"fig_caption\"}, \"text\": \"Distributions of PM2.5, PM10 and NO2 by study site and different exposure periods (1-, 5-, 10- and 20-year averages) prior to 2000\\u201302 (A, B and C) and 2007\\u201308 (D, E and F). Abbreviations: CA, California; MD, Maryland; NC, North Carolina; PA, Pennsylvania. Note: Data were not available for 20-year averages of PM10 and NO2.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 38396, \"infons\": {\"file\": \"nihms-1876059-f0003.jpg\", \"id\": \"F3\", \"section_type\": \"FIG\", \"type\": \"fig_caption\"}, \"text\": \"Adjusted percent differences and 95% confidence intervals (CIs) in baseline (A, B and C) and repeat (D, E and F) measures of A\\u03b21\\u201340, A\\u03b21\\u201342 and A\\u03b21\\u201342/A\\u03b21\\u201340 ratio per 1 interquartile range (IQR) unit higher PM2.5 (IQR = 2 \\u03bcg/m3), PM10 (IQR = 3 \\u03bcg/m3) and NO2 (IQR = 6 ppb) by different averaging periods for PM2.5 (10 and 20 years) and PM10 and NO2 (5 and 10 years for both) in Model 3. Model 3 adjusted for age, sex, race, education, study site, treatment assignment, Cystatin C, neighborhood deprivation index, smoking history, alcohol consumption, pack-years smoking, percentage of life exposed to secondhand smoke, physical activity and APOE \\u03b54.\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39067, \"infons\": {\"file\": \"T1.xml\", \"id\": \"T1\", \"section_type\": \"TABLE\", \"type\": \"table_caption\"}, \"text\": \"Characteristics at baseline and follow-up of GEMS participants stratified by groups with A\\u03b2 measurements at 2000\\u201302 (N = 3,044) and 2007\\u201308 (N = 1,669).\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 39225, \"infons\": {\"file\": \"T1.xml\", \"id\": \"T1\", \"section_type\": \"TABLE\", \"type\": \"table\", \"xml\": \"<?xml version=\\\"1.0\\\" encoding=\\\"UTF-8\\\"?>\\n<table frame=\\\"hsides\\\" rules=\\\"none\\\"><colgroup span=\\\"1\\\"><col align=\\\"left\\\" valign=\\\"middle\\\" span=\\\"1\\\"/><col align=\\\"left\\\" valign=\\\"middle\\\" span=\\\"1\\\"/><col align=\\\"left\\\" valign=\\\"middle\\\" span=\\\"1\\\"/></colgroup><thead><tr><th align=\\\"left\\\" valign=\\\"top\\\" style=\\\"border-bottom: solid 1px\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Characteristic</th><th align=\\\"left\\\" valign=\\\"top\\\" style=\\\"border-bottom: solid 1px\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2000\\u201302</th><th align=\\\"left\\\" valign=\\\"top\\\" style=\\\"border-bottom: solid 1px\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2007\\u201308</th></tr><tr><th align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><th align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">N = 3,044</th><th align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">N = 1,669</th></tr></thead><tbody><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Age, years</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">78.6 (3.3)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">84.5 (3.0)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Female sex, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1408 (46)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">727 (44)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">People of color, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">139 (5)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">68 (4)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Placebo assignment, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1511 (50)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">847 (51)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Education, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">High school or less</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">335 (11)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">168 (10)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Some college</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">763 (25)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">415 (25)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">College graduate</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">767 (25)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">400 (24)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Postgraduate</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1179 (39)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">686 (41)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Study site, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Winston-Salem, NC</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">724 (24)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">384 (23)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Sacramento, CA</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">909 (30)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">533 (32)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Hagerstown, MD</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">454 (15)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">252 (15)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Pittsburgh, PA</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">957 (31)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">500 (30)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Alcohol consumption, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1328 (44)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">766 (47)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Smoking history, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Never</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1214 (41)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">684 (42)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Former</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1637 (55)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">887 (54)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Current</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">135 (5)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">66 (4)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Pack-years smoking</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">3.6 (0.0, 27.0)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2.4 (0.0, 24.8)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Percentage of life exposed to SHS</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">24 (1, 46)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">24 (0, 45)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Neighborhood deprivation index</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\"/></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1 year</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.04 (\\u22122.26, 2.22)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\u22120.08 (\\u22122.28, 1.87)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">5 year</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.08 (\\u22122.18, 2.18)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">\\u22120.06 (\\u22122.27, 1.90)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">10 year</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.10 (\\u22122.20, 2.22)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.01 (\\u22122.20, 2.02)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">20 year</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.14 (\\u22121.93, 2.25)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.12 (\\u22122.10, 2.05)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Body mass index, kg/m<sup>2</sup></td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">27.1 (4.3)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">26.4 (4.1)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Hypertension, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">2114 (69)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">1319 (80)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Physical activity score</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">13.4 (4.8)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">14.0 (4.5)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Cystatin C, mg/L</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.83 (0.21)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">0.97 (0.32)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">APOE \\u03b54 carrier status, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">574 (24)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">299 (22)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Mild cognitive impairment status, n (%)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">510 (17)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">469 (28)</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">Modified Mini-Mental State Exam score</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">93.4 (4.7)</td><td align=\\\"left\\\" valign=\\\"top\\\" rowspan=\\\"1\\\" colspan=\\\"1\\\">94.9 (4.9)</td></tr></tbody></table>\\n\"}, \"text\": \"Characteristic\\t2000\\u201302\\t2007\\u201308\\t \\t\\tN = 3,044\\tN = 1,669\\t \\tAge, years\\t78.6 (3.3)\\t84.5 (3.0)\\t \\tFemale sex, n (%)\\t1408 (46)\\t727 (44)\\t \\tPeople of color, n (%)\\t139 (5)\\t68 (4)\\t \\tPlacebo assignment, n (%)\\t1511 (50)\\t847 (51)\\t \\tEducation, n (%)\\t\\t\\t \\tHigh school or less\\t335 (11)\\t168 (10)\\t \\tSome college\\t763 (25)\\t415 (25)\\t \\tCollege graduate\\t767 (25)\\t400 (24)\\t \\tPostgraduate\\t1179 (39)\\t686 (41)\\t \\tStudy site, n (%)\\t\\t\\t \\tWinston-Salem, NC\\t724 (24)\\t384 (23)\\t \\tSacramento, CA\\t909 (30)\\t533 (32)\\t \\tHagerstown, MD\\t454 (15)\\t252 (15)\\t \\tPittsburgh, PA\\t957 (31)\\t500 (30)\\t \\tAlcohol consumption, n (%)\\t1328 (44)\\t766 (47)\\t \\tSmoking history, n (%)\\t\\t\\t \\tNever\\t1214 (41)\\t684 (42)\\t \\tFormer\\t1637 (55)\\t887 (54)\\t \\tCurrent\\t135 (5)\\t66 (4)\\t \\tPack-years smoking\\t3.6 (0.0, 27.0)\\t2.4 (0.0, 24.8)\\t \\tPercentage of life exposed to SHS\\t24 (1, 46)\\t24 (0, 45)\\t \\tNeighborhood deprivation index\\t\\t\\t \\t1 year\\t0.04 (\\u22122.26, 2.22)\\t\\u22120.08 (\\u22122.28, 1.87)\\t \\t5 year\\t0.08 (\\u22122.18, 2.18)\\t\\u22120.06 (\\u22122.27, 1.90)\\t \\t10 year\\t0.10 (\\u22122.20, 2.22)\\t0.01 (\\u22122.20, 2.02)\\t \\t20 year\\t0.14 (\\u22121.93, 2.25)\\t0.12 (\\u22122.10, 2.05)\\t \\tBody mass index, kg/m2\\t27.1 (4.3)\\t26.4 (4.1)\\t \\tHypertension, n (%)\\t2114 (69)\\t1319 (80)\\t \\tPhysical activity score\\t13.4 (4.8)\\t14.0 (4.5)\\t \\tCystatin C, mg/L\\t0.83 (0.21)\\t0.97 (0.32)\\t \\tAPOE \\u03b54 carrier status, n (%)\\t574 (24)\\t299 (22)\\t \\tMild cognitive impairment status, n (%)\\t510 (17)\\t469 (28)\\t \\tModified Mini-Mental State Exam score\\t93.4 (4.7)\\t94.9 (4.9)\\t \\t\", \"sentences\": [], \"annotations\": [], \"relations\": []}, {\"bioctype\": \"BioCPassage\", \"offset\": 40643, \"infons\": {\"file\": \"T1.xml\", \"id\": \"T1\", \"section_type\": \"TABLE\", \"type\": \"table_footnote\"}, \"text\": \"Continuous variables are presented as mean (SD) or median (interquartile range), where appropriate, and categorical variables are presented as n (%). Abbreviations: APOE, apolipoprotein E; SHS, secondhand smoke.\", \"sentences\": [], \"annotations\": [], \"relations\": []}], \"annotations\": [], \"relations\": []}]}]\n"
     ]
    },
    {
     "ename": "TypeError",
     "evalue": "'str' object does not support item assignment",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[5], line 2\u001b[0m\n\u001b[1;32m      1\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m \u001b[38;5;28mid\u001b[39m \u001b[38;5;129;01min\u001b[39;00m valid_ids:\n\u001b[0;32m----> 2\u001b[0m     \u001b[43marticle_info\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;28;43mid\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[38;5;124;43msummary\u001b[39;49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[43m]\u001b[49m \u001b[38;5;241m=\u001b[39m fetch_full_text(\u001b[38;5;28mid\u001b[39m)\n\u001b[1;32m      4\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m \u001b[38;5;28mid\u001b[39m \u001b[38;5;129;01min\u001b[39;00m invalid_ids:\n\u001b[1;32m      5\u001b[0m     article_info[\u001b[38;5;28mid\u001b[39m][\u001b[38;5;124m'\u001b[39m\u001b[38;5;124msummary\u001b[39m\u001b[38;5;124m'\u001b[39m] \u001b[38;5;241m=\u001b[39m fetch_full_text(\u001b[38;5;28mid\u001b[39m)\n",
      "\u001b[0;31mTypeError\u001b[0m: 'str' object does not support item assignment"
     ]
    }
   ],
   "source": [
    "for id in valid_ids:\n",
    "    article_info[id]['summary'] = fetch_full_text(id)\n",
    "    \n",
    "for id in invalid_ids:\n",
    "    article_info[id]['summary'] = fetch_full_text(id)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 148,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "defaultdict(<class 'str'>, {'PMC7649343': {'class': 1, 'title': 'Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimerâs disease', 'summary': {'Abstract': ['Cerebrospinal fluid (CSF) neurofilament light (NfL) concentration has reproducibly been shown to reflect neurodegeneration in brain disorders, including Alzheimerâs disease (AD). NfL concentration in blood correlates with the corresponding CSF levels, but few studies have directly compared the reliability of these 2 markers in sporadic AD. Herein, we measured plasma and CSF concentrations of NfL in 478 cognitively unimpaired (CU) subjects, 227 patients with mild cognitive impairment, and 113 patients with AD dementia. We found that the concentration of NfL in CSF, but not in plasma, was increased in response to AÎ² pathology in CU subjects. Both CSF and plasma NfL concentrations were increased in patients with mild cognitive impairment and AD dementia. Furthermore, only NfL in CSF was associated with reduced white matter microstructure in CU subjects. Finally, in a transgenic mouse model of AD, CSF NfL increased before serum NfL in response to the development of AÎ² pathology. In conclusion, NfL in CSF may be a more reliable biomarker of neurodegeneration than NfL in blood in preclinical sporadic AD.', 'Highlights', 'CSF NfL is increased and associated with amyloid pathology in preclinical AD.', 'Plasma NfL is increased in symptomatic AD.', 'CSF NfL is associated with reduced white matter microstructure in preclinical AD.', 'Plasma NfL is associated with reduced white matter microstructure in symptomatic AD.', 'In 5xFAD mice, NfL in CSF is increased at an earlier time point than in serum.'], 'Method': ['Materials and methods', 'BioFINDER study population', 'The study was approved by the Regional Ethics Committee in Lund, Sweden, and the participants or their relatives gave written informed consent.', 'The study population originated from the prospective and longitudinal Swedish BioFINDER study and consisted of 298 cognitively healthy elderly participants, 407 patients with mild cognitive symptoms, and 113 patients with AD dementia from which baseline CSF and plasma NFL samples were available.', 'Cognitively healthy elderly participants were recruited from the longitudinal population-based MalmÃ¶ Diet and Cancer Study between 2010 and 2014 according to the following inclusion criteria: â¥60\\xa0years of age, absence of cognitive symptoms as assessed by a physician, Mini-Mental State Examination score of 28â30 at screening visit, not fulfilling the criteria for MCI or any dementia, and fluency in Swedish. Exclusion criteria were significant neurological or psychiatric illness, significant alcohol or substance abuse, and refusing lumbar puncture or magnetic resonance imaging (MRI).', 'Patients with mild cognitive symptoms were consecutively enrolled from the Memory Clinic at SkÃ¥ne University Hospital and Ãngelholm Hospital in Sweden between 2010 and 2014. Included individuals had an age between 60 and 80\\xa0years, were referred to any of the 2 memory clinics due to cognitive symptoms, had an Mini-Mental State Examination score of 24â30 at baseline visit, did not fulfill the criteria for any dementia, and were fluent in Swedish. The exclusion criteria were cognitive impairment that with certainty could be explained by another condition or disease, significant alcohol or substance abuse, and refusing lumbar puncture or neuropsychological assessment. Following neuropsychological assessment including a test battery evaluating verbal ability, episodic memory function, visuospatial construction ability, and attention and executive functions, 180 patients were classified as subjective cognitive decline and 227 patients were classified as MCI. In accordance with the guidelines from the US National Institute on Aging-Alzheimerâs Association, cognitively healthy elderly participants and patients with subjective cognitive decline were included in the CU group.', 'Patients with AD dementia were included after thorough clinical assessment at the Memory Clinic at SkÃ¥ne University Hospital in Sweden. All study participants met the criteria for probable AD dementia as defined by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimerâs Disease and Related Disorders Association. Individuals with significant alcohol or substance abuse were excluded.', 'Study participants who were CU or diagnosed with MCI were categorized into groups with normal (Aâ) or pathologic (A+) CSF AÎ² using the AÎ²42/AÎ²40 ratio with the cutoff <0.091. This cutoff was established using Gaussian mixture modeling. In addition, these individuals were further categorized based on normal (Nâ) and abnormal (N+) cortical thickness in AD-susceptible temporal regions as determined by MRI (see Section 2.3 below) with the cutoff <2.25. As cortical thickness was not bimodally distributed, Gaussian mixture modeling for cutoff determination could not be applied. Instead, the cutoff was defined as mean\\xa0â1.5 standard deviation of Aâ CU cases, which has been commonly used in other studies. Participants with AD dementia were all A+, however, no information on cortical thickness was available for this group.', 'CSF and blood collection in the BioFINDER study population', 'Collection of lumbar CSF and blood samples from each study participant was performed on the same day, where blood was obtained within 15\\xa0minutes of CSF sampling. Lumbar CSF samples were collected according to a standardized protocol, centrifuged for 10\\xa0minutes at 2000Ãg at 4 Â°C, and aliquoted into polypropylene tubes. Blood was drawn into EDTA-containing tubes and centrifuged for 10\\xa0minutes at 2000Ãg at 4 Â°C. Following centrifugation, plasma was collected and aliquoted into polypropylene tubes. The obtained CSF and plasma samples were stored at\\xa0â80 Â°C until biochemically analyzed.', 'Magnetic resonance imaging', 'MRI was completed in 478 CU subjects and 227 MCI patients, and the average time interval between MRI acquisition and fluid collection was 17\\xa0days. High-resolution T1-weighted MP-RAGE (TR\\xa0= 1950\\xa0ms, TE\\xa0= 3.4\\xa0ms, in-plane resolution\\xa0= 1\\xa0Ã\\xa01 mm2, slice thickness\\xa0= 1.2\\xa0mm, 176 slices) and transversal T2-weighted FLAIR (TR\\xa0= 9000\\xa0ms, TE\\xa0= 89\\xa0ms, TI\\xa0= 2500\\xa0ms, voxel size 0.7\\xa0Ã\\xa00.7\\xa0Ã\\xa04 mm3, distance factor 25%, 27 slices) imaging was performed on a 3T MR scanner (Siemens Tim Trio 3T; Siemens Medical Solutions, Erlangen, Germany).', 'Cortical reconstruction and volumetric segmentation were performed with the FreeSurfer image analysis pipeline v5.3 (http://surfer.nmr.mgh.harvard.edu/). Briefly, the T1-weighted images underwent correction for intensity homogeneity, removal of non-brain tissue, and segmentation into gray matter and white matter with intensity gradient and connectivity among voxels. Cortical modeling allowed parcellation of the cerebral cortex into units with respect to gyral and sulcal structure. Cortical thickness was measured as the distance from the gray/white matter boundary to the corresponding pial surface. Reconstructed data sets were visually inspected for accuracy, and segmentation errors were corrected. To determine AD-related brain atrophy we used the average cortical thickness in a predefined temporal lobe meta-region (composed of entorhinal, inferior temporal, middle temporal, and fusiform cortex).', 'Global white matter lesion volume was determined by the use of an automated segmentation method, using the lesion prediction algorithm in the LST toolbox implemented in SPM8.', 'For diffusion MRI, a single-shot EPI sequence was used to obtain 66 contiguous axial slices with a spatial resolution of 2\\xa0Ã\\xa02\\xa0Ã\\xa02\\xa0mm3\\xa0(TR/TE\\xa0= 86/8200\\xa0ms). The diffusion encoding was performed in 64 directions with b\\xa0= 1000\\xa0s/mm2, and one additional volume was obtained for b\\xa0= 0\\xa0s/mm2. To correct for motion and eddy-current induced distortions, all data were registered to the b\\xa0= 0\\xa0s/mm2 volume using an affine transform implemented in Elastix. DTI analysis was performed using linear least squares with heteroscedasticity correction with software developed in-house in MATLAB (The MathWorks Inc, Natick, MA). Parameter maps for mean diffusivity (MD) and fractional anisotropy (FA) were calculated from the diffusion tensor.', 'The DTI data were analyzed using tract-based spatial statistics (TBSS) (v 1.03) from the FMRIB Software Library. In this process, FA volumes were first masked with the FSL Brain Extraction Tool and then non-linearly registered to the 1\\xa0mm3 FMRIB58 FA template in MNI152 standard space, using FLIRT and FNIRT. The resulting subject-specific non-linear transform was then applied to the MD map. The maps in template space were then skeletonized by computing of the projection of the FA map onto the FMRIB58 template skeleton. Statistical processing was performed using a significance threshold of 0.05 in Threshold-Free Cluster Enhancement and FSL Randomize (v 2.9), with 7500 permutations for generation of the null distribution. When generating the p-maps, multiple comparison-correction was accounted for by controlling the family-wise error rate. Hypothesis tests were performed using the null hypothesis that the regression coefficient for CSF NfL, or for plasma NfL, was zero, using age and sex as additional covariates. The tests were performed separately for CSF NfL and for plasma NfL for each of the 3 groups comprising all subjects, those in the CU group, or those in the MCI group. Due to incomplete data or failure of normalization, 11 CU subjects and 5 MCI subjects were excluded from the TBSS analysis.', '18F-flutemetamol PET imaging', '18F-flutemetomol PET scans for visualization of cerebral AÎ² depositions were completed for 382 individuals, including 244 CU subjects and 138 MCI patients. Production of 18F-flutemetamol was performed at the radiopharmaceutical production site in RisÃ¸, Denmark, using a FASTlab synthesizer module (GE Healthcare, Cleveland, OH). PET/CT scans of the brain were obtained from 2 different sites using the same type of scanner (Germini; Philips Healthcare, Best, Netherlands). 18F-flutemetamol summation images for the period 90â110\\xa0minutes post injection a single dose of 18F-flutemetamol was analyzed using the NeuroMarQ software (GE Healthcare). A volume of interest (VOI) template was applied to define a global neocortical composite region, encompassing prefrontal, parietal, temporal lateral, anterior cingulate, posterior cingulate, and precuneus VOIs. The standardized uptake value ratio was defined as the uptake in a VOI normalized to a composite reference region (whole cerebellum, the pons/brainstem, and eroded cortical white matter).', 'Animals', 'Two- to 12-month-old male and female heterozygous 5ÃFAD tg mice (n\\xa0= 40), originally obtained from Jackson Laboratory, and age-matched non-tg littermates (n\\xa0= 41) were used for the experiments. Animals were housed in groups of 2â6 mice per cage under a 12:12\\xa0hour light/dark cycle with free access to food and water. Under the control of the mouse Thy1 promotor element, 5ÃFAD mice overexpress human APP(695) with the K670N/M671L (Swedish), 1716V (Florida), and V7171 (London) mutations together with human PS1 harboring the M146L and L286V mutations. Intraneuronal AÎ² appears at 1.5\\xa0months in the deep cortical layers and subiculum, and extracellular amyloid plaques start to accumulate in the same regions around 2\\xa0months of age, spreading to other brain areas as the animal ages. In addition, a reduction in pre- and postsynaptic markers as well as neuronal loss has been reported in 9-month-old mice.', 'The experimental procedures were carried out in accordance with the Swedish animal research regulations and were approved by the committee of animal research at Lund University (ethical permit number: 7482/2017).', 'CSF, blood, and brain tissue collection in mice', 'CSF was collected from cisterna magna in accordance with a method previously described. All sample collection was performed between 9 AM and 13 PM. Under isoflurane anesthesia, mice were placed on a stereotaxic instrument and an incision of the skin inferior to the occiput was made. Using a dissecting microscope, the underlying neck muscles were then separated to expose the dura mater of the cisterna magna. A glass capillary tube with a tapered tip was used to penetrate the dura mater and collect CSF. Samples were immediately transferred to protein LoBind tubes (Eppendorf, Hamburg, Germany), snap frozen on dry ice, and stored at\\xa0â80 Â°C until analysis.', 'Following CSF sampling, blood was collected from the left heart ventricle using a 23G needle and immediately transferred to protein LoBind Tubes (Eppendorf). The blood samples were allowed to clot for 2\\xa0hours at room temperature before they were centrifuged at 2000Ãg for 20\\xa0minutes. Serum was then collected, aliquoted into protein LoBind tubes (Eppendorf), and stored at\\xa0â80 Â°C until analysis.', 'For brain tissue collections, mice were transcardially perfused with ice-cold 0.1\\xa0M phosphate buffer (PB). The brain was removed and the left hemisphere was fixed in 4% paraformaldehyde in 0.1\\xa0M PB, pH 7.4, for 48\\xa0hours at 4 Â°C and then immersed in 30% sucrose solution for 48\\xa0hours at 4 Â°C. Brains were serially cut into 30\\xa0Î¼m sagittal sections using a sliding microtome (Leica Biosystems, Wetzlar, Germany) and collected in antifreeze solution (30% sucrose and 30% ethylene glycol in PB) for storage at\\xa0â20 Â°C.', 'Thioflavin S staining and analysis of mouse brain sections', 'Free-floating sagittal brain sections (30\\xa0Î¼m) were washed 3\\xa0Ã\\xa010\\xa0minutes in Tris-buffered saline and then stained with 0.01% Thioflavin S (ThioS) in 50% ethanol for 10\\xa0minutes. Sections were washed 2\\xa0Ã\\xa01 minute in 50% ethanol, 3\\xa0Ã\\xa01 minute in ddH2O, and finally 10\\xa0minutes in Tris-buffered saline. The stained specimens were mounted on glass slides and coverslipped with SlowFade Gold Antifade Mountant (Life Technologies, Carlsbad, CA) according to the manufacturerâs recommendations. Images of cortex and subiculum from 3 sections per animal were captured using a 10Ã objective lens on an Olympus IX70 fluorescence microscope equipped with a Hamamatsu ORCA-Flash4.0 LT+ digital COMOS camera. The area (%) covered by ThioS-positive amyloid plaques in the regions of interest was quantified using the Fiji software by applying an automated threshold that was maintained for all images analyzed.', 'Biochemical analysis of CSF and blood from the BioFINDER study population and mice', 'CSF NfL concentration in the BioFINDER study population was measured using a sensitive sandwich ELISA method (NF-light ELISA kit; UmanDiagnostics AB, UmeÃ¥, Sweden). Intra-assay coefficient of variance (CV) ranged between 7% and 10% and inter-assay CV was 13%. An in-house Simoa NfL assay, in which the monoclonal antibodies and calibrators from the NF-light ELISA kit (UmanDiagnostics AB) were transferred onto the Simoa platform using a homebrew kit (Quanterix, Lexington, MA), was used to measure plasma NfL concentration in the BioFINDER study population, as well as CSF and serum NfL concentrations in mice. The core domain of NfL, against which the antibodies are directed, is fully conserved between humans and mice. For measurement of plasma samples from the BioFINDER study population, the intra-assay CV was 5.5% and the inter-assay CV was 8.2% for the low-concentration quality control sample (11.1 pg/mL). For the high-concentration quality control sample (107.0 pg/mL), the corresponding CVs were 9.3% and 9.4%, respectively. Intra-assay CV for measurement of mouse CSF samples ranged between 2.9% and 11.1%, and intra- and inter-assay CV for measurement of mouse serum samples ranged between 3.2% and 8.7% and 6.5% and 13.8%, respectively. The concentration of AÎ²40, AÎ²42, and phosphorylated tau in CSF in the BioFINDER study population was measured by Euroimmun immunoassay. All measurements were performed in one round of experiments using one batch of reagents by board-certified laboratory technicians who were blinded to clinical and genotype information.', 'Statistical analysis', 'For the BioFINDER study population, demographic factors and clinical characteristics were compared between different diagnostic groups using the Mann-Whitney U-test for continuous variables and the Ï2 test for categorical variables. Group comparisons of CSF and plasma biomarkers were performed on log-transformed data using univariate general linear models adjusted for the confounding effects of age and sex. p-values were corrected for multiple comparisons using the Bonferroni method. Spearmanâs rank-ordered correlation coefficient and linear regression models adjusted for age and sex were used to examine associations between 2 continuous variables. The diagnostic accuracy of NfL in CSF and plasma was evaluated using receiver operating characteristic curve analysis by calculating the area under the curve (AUC). Associations between NfL concentrations and 18F-flutemetamol standardized uptake value ratio were analyzed voxel-wise using SPM12 multilinear regression models, including age, sex, and the time interval between fluid collection and 18F-flutemetamol PET acquisition as covariates. Parametric maps were adjusted for multiple comparisons using family wise error correction.', 'Nonparametric statistical methods were used for analysis of data derived from animal experiments due to the relatively small sample size. Three extreme outliers with CSF or plasma NfL concentrations above 3 interquartile ranges of the third quartile were excluded from the analysis. The Jonckheere-Terpstra trend test was performed to study if CSF and serum NfL concentrations increased with age in 5ÃFAD mice and non-tg littermates. This test was also used to study if amyloid plaque load in cortex and subiculum of 5ÃFAD mice increased with age. If a statistically significant trend was found, post hoc analysis for group comparisons between the youngest group an all other groups were performed using the Mann-Whitney U-test. p-values were corrected for multiple comparisons using the Bonferroni method. In addition, the Mann-Whitney U-test was performed to compare the concentrations of NfL in CSF and serum between 5ÃFAD mice and age-matched non-tg littermates. Correlation analysis was done using Spearmanâs rank-ordered correlation coefficient. For comparisons between correlation coefficients, Mengâs Z-test for correlated correlations was performed. Statistical analysis was performed using IBM SPSS Statistics 25 and corresponding graphs were produced in GraphPad Prism\\xa08.']}}, 'PMC10612408': {'class': 1, 'title': 'A blunted TH17 cytokine signature in women with mild cognitive impairment: Insights from inflammatory profiling of a community-based cohort of older adults', 'summary': {'Abstract': ['Abstract', 'People with dementia have an increase in brain inflammation, caused in part by innate and adaptive immune cells. However, it remains unknown whether dementia-associated diseases alter neuro-immune reflex arcs to impact the systemic immune system. We examined peripheral immune cells from a community-based cohort of older adults to test if systemic inflammatory cytokine signatures associated with early stages of cognitive impairment. Human peripheral blood mononuclear cells were cultured with monocyte or T-cell-targeted stimuli, and multiplex assays quantitated cytokines in the conditioned media. Following T-cell-targeted stimulation, cells from women with cognitive impairment produced lower amounts of TH17 cytokines compared with cells from cognitively healthy women, while myeloid-targeted stimuli elicited similar amounts of cytokines from cells of both groups. This TH17 signature correlated with the proportion of circulating CD4+ and CD8+ T cells and plasma glial fibrillary acidic protein and neurofilament light concentrations. These results suggest that decreases in TH17 cytokines could be an early systemic change in women at risk for developing dementia. Amelioration of TH17s cytokines in early cognitive impairment could, in part, explain the compromised ability of older adults to respond to vaccines or defend against infection.', 'Bachstetter et al. found diminished TH17 cytokines produced by activated T cells from women with early cognitive decline, indicating a dementia-linked systemic immunological shift associated with the proportion of circulating CD4+ and CD8+ T cells and plasma glial fibrillary acidic protein and neurofilament light concentrations.', 'Graphical Abstract'], 'Method': ['Materials and methods', 'Human subjects', 'Study participants were selected from a larger University of Kentucky Alzheimer Disease Research Center (UK-ADRC) community-based cohort study of ageing and dementia. Informed consent was obtained following University of Kentucky Institutional Review Board-approved protocols. As previously described, the UK-ADRC study recruits older adult participants from the central Kentucky region of the USA, and includes â¼500 active participants that have annual follow-up visits. These visits include physical examination, neurological examination, medical history, and cognitive testing, among other measures. Clinical evaluations and cognitive testing were completed as previously described and followed the National Alzheimerâs Coordinating Center uniform data set used by Alzheimerâs disease centres. From the UK-ADRC cohort, we assayed peripheral blood from n = 44 cognitively healthy [Clinical Dementia Rating score (CDR) = 0], and n = 40 cognitively impaired (CDR = 0.5â1) individuals, with groups statistically similar for gender, and cardiovascular disease (CVD) risk factors (hypertension, hyperlipidaemia, or obesity), and age as indicated by their previous year study visit data. Exclusion criteria included Type 2 diabetes, autoimmune disease, and current cancers. Blood samples were collected from August 2020 until June 2021. The study coordinator (B.J.M.) provided the de-identified samples to the experimentalists (A.D.B., J.L., and B.S.N.), who were blinded to the participant group identity until all the data had been generated.', 'Peripheral blood mononuclear cell isolation', 'Five to 10\\u2005mL of peripheral blood was collected into acid/citrate/dextrose-containing tubes by venous puncture. The peripheral blood mononuclear cells (PBMCs) were purified by density centrifugation in Ficoll histopaque 1077 using SepMate PBMC isolation tube (StemCell Technologies, Cat#: 85415) according to the manufacturerâs protocol. The cells were then washed in buffer [0.1 BSA, 2\\u2005mM EDTA (ethylenediaminetetraacetic acid), 1Ã PBS]. Residual red blood cells were removed using red blood cells lysis buffer (eBioScience, Cat#: 00-4300-54), and the resulting PBMCs were aliquoted at a density of 1 Ã 106/mL, in freezing media containing 90% heat-inactivated FBS, plus 10% DMSO. The cells were then frozen at â80Â°C in a Mr Frosty apparatus (Nalgene) for 24\\u2005h, before storing the cells in liquid N2, until use.', 'Cell culture', 'After thawing rapidly in a 37Â°C water bath, the PBMCs were plated at a density of 106\\u2005cells/mL/well in a 12-well plate (VWR, Cat#: 10062-894), in glucose-free RPMI media, containing L-glutamine and 25\\u2005mM hepes (Gibco, Cat#: 11879020) supplemented with 10% FBS heat-inactivated (Gibco, Cat#: 10438026), 1% pen/strep (Gibco, Cat#: 15140122), and 1% sodium pyruvate (Corning, Cat#: 25-000-CI). The cells were stimulated in multiple batches, and each batch included a random sampling of approximately six participants. The PBMCs were stimulated with Escherichia coli O111:B4 lipopolysaccharides (LPS) (25\\u2005ng/mL, Millipore Sigma; 20\\u2005h) or Î±CD3/Î±CD28 Dynabeads (1 bead/cell; Gibco, Cat#: 11131D; 40\\u2005h) in a CO2 incubator at 37Â°C prior to conditioned media collection. The unstimulated cells were incubated 40\\u2005h prior to conditioned media collection. The conditioned media was aliquoted and stored at â80Â°C for cytokine assays. The 20 and 40\\u2005h post-stimulation timepoints were determined based on prior studies.', 'Multiplex measurement of cytokine concentrations from stimulated PBMCs', 'Supernatant samples were thawed then centrifuged for 10\\u2005min at 1200\\u2005rpm to remove debris before being added to a 384-well plate for analysis by bioplex using the Milliplex human TH17 25-plex kit (Millipore) or 96-well Meso Scale Discovery (MSD) proinflammatory or TH17 multiplex kit, following the manufacturerâs protocols (Supplemental Tables 1 and 2). Samples were diluted in an assay buffer to ensure that the cytokines were in the linear range of the standard curve. The unstimulated cells were run undiluted. The MSD assay was used for cytokines that outside the linear range for the Milliplex kits.', 'Plasma biomarker analysis', 'Plasma collected from the same blood draw providing PBMCs was analysed on the Quanterix Simoa HD-X as previously described or on the MSD Quickplex SQ 120 using the V-Plex TH17 panel 1 (MSD, Cat#: K15085D), following the manufacturerâs instructions.', 'Flow cytometry', 'PBMCs were unthawed and washed with warm RPMI then washed with PBS. Cells were then stained with live/dead marker Ghost Dye-Alexa Fluor 700 (Tonbo Biosciences) for 30\\u2005min at 4Â°C according to the manufacturerâs instructions, then washed with FACS buffer. Human FcR blocking reagent, human (Miltenyi Biotec) was used to block unwanted binding of antibodies to FC receptors for 10\\u2005min at 4Â°C. Cells were then stained for immune cell markers CD3-FITC (BD Biosciences, Cat#: 555332), CD8-PE (BD Biosciences, Cat#: 555635), CD4-APC (BD Biosciences, Cat#: 555349) for 30\\u2005min at 4Â°C. Stained cells were fixed with cytofix (BD Biosciences) for 30\\u2005min at 4Â°C, then washed and suspended in FACS buffer (PBS with 1% BSA and 0.1% sodium azide). BD Symphony A3 was used to acquire cell populations. Analysis was conducted with Flow v10.8 software. Fluorescence-minus one controls were used to identify cell populations, and each experiment had single-stained and no-stain controls.', 'Statistics', 'Characteristics of participants were assessed with ANOVA, or Ï2 tests. All cytokine and fluid biomarker data were log2 transformed. For categorical comparisons, an unadjusted t-test or one-way ANOVA were used for the combined data, or for data stratified by sex. Multiple linear regression models were used to adjust mean responses for covariates as listed in the figure and Supplemental tables. False discovery rate (FDR) values for multiple comparisons were applied based on the BenjaminiâHochberg adjustment. Pairwise effect sizes were calculated using Cohenâs d. The effect size for linear regressions was calculated as R2 or Î©2. Z-scores were created using the sample means and standard deviations of the log2 transformed data. For the box-and-whiskers plots, the box shows the median and 25th and 75th percentile, and the whiskers show the minimum and maximum values. All data analysis was completed in JMP Pro v16 between January 2022 and September 2022. Data visualizations were created in JMP Pro v16 or GraphPad Prism v9.4.']}}, 'PMC11193202': {'class': 1, 'title': 'Age, sex, and Alzheimerâs disease: A longitudinal study of 3xTg-AD mice reveals sex-specific disease trajectories and inflammatory responses mirrored in postmortem brains from Alzheimerâs patients', 'summary': {'Abstract': ['Background', 'Aging and sex are major risk factors for developing late-onset Alzheimerâs disease. Compared to men, women experience worse neuropathological burden and cognitive decline despite living longer with the disease. Similarly, male 3xTg-AD mice, developed to model Alzheimerâs disease, no longer consistently exhibit standard Alzheimerâs neuropathology yet experience higher rates of mortality - providing a unique opportunity to further elucidate this dichotomy. We hypothesized that sex differences in the biological aging process yield distinct pathological and molecular Alzheimerâs disease signatures in males and females, which could be harnessed for therapeutic and biomarker development.', 'Methods', 'We aged male and female, 3xTg-AD and B6129 control mice across their respective lifespans (n\\u2009=\\u20093â8 mice per sex, strain, and age group) and longitudinally assessed neuropathological hallmarks of Alzheimerâs disease, markers of hepatic inflammation, splenic mass and morphology, as well as plasma cytokine levels. We conducted RNA sequencing analysis on bulk brain tissue and examined differentially expressed genes (DEGs) between 3xTg-AD and B6129 samples and across ages in each sex. We also examined DEGs between clinical Alzheimerâs and control parahippocampal gyrus brain tissue samples from the Mount Sinai Brain Bank study in each sex.', 'Results', '3xTg-AD females significantly outlived 3xTg-AD males and exhibited progressive Alzheimerâs neuropathology, while 3xTg-AD males demonstrated progressive hepatic inflammation, splenomegaly, circulating inflammatory proteins, and minimal Alzheimerâs neuropathological hallmarks. Instead, 3xTg-AD males experienced an accelerated upregulation of immune-related gene expression in the brain relative to females. Our clinical investigations revealed that individuals with Alzheimerâs disease develop similar sex-specific alterations in neuronal and immune function. In diseased males of both species, we observed greater upregulation of complement-related gene expression, and lipopolysaccharide was predicted as the top upstream regulator of DEGs.', 'Conclusions', 'Our data demonstrate that chronic inflammation and complement activation are associated with increased mortality, indicating that age-related changes in immune response contribute to sex differences in Alzheimerâs disease trajectories. We provide evidence that aging and transgene-driven disease progression trigger a widespread inflammatory response in 3xTg-AD males, which mimics the impact of lipopolysaccharide stimulation despite the absence of infection.', 'Supplementary Information', 'The online version contains supplementary material available at 10.1186/s13195-024-01492-x.'], 'Method': ['Methods', 'Animals', 'Colony Maintenance: The 3xTg-AD mice utilized were previously described and were obtained from The Jackson Laboratory (B6;129-Tg(APPSwe,tauP301L)1Lfa Psen1tm1Mpm/Mmjax; MMRRC Strain #034830-JAX). Homozygous expression for the mutations in the PSEN1, APP, and MAPT genes were confirmed with TaqMan Real-Time PCR assays and the colony was maintained using 3xTg-AD mice breeding pairs. Wildtype controls were bred in-house - C57BL/6J (B6; Strain #000664) females and 129S1/SvImJ males (129S; Strain #002448) were crossed to produce B6129SF1/J mice. Mice were housed 3â5 per cage, kept on a 12-h light/dark cycle, and allowed ad libitum access to food and water. All animal procedures were approved by Dartmouth Collegeâs Institutional Animal Care and Use Committee (IACUC). Blood samples obtained from sentinel mice underwent quarterly and yearly serology testing with the Multiplexed Fluorometric ImmunoAssay at Charles River Research Animal Diagnostic Services to confirm the absence of pathogens (see Supplementary Table\\xa01, Additional file 1 for list of tested agents).', 'Histology', 'Antibodies: We obtained beta-amyloid recombinant rabbit monoclonal antibody (H31L21, catalog #700254), phospho-tau (Ser202, Thr205) mouse monoclonal antibody (AT8, catalog #MN1020), and tau mouse monoclonal antibody (HT7, catalog #MN1000) from Thermo Fisher Scientific. We obtained CD45 rabbit monoclonal antibody (D3F8Q, catalog #70257) and F4/80 XP rabbit monoclonal antibody (D2S9R, catalog #70076 from Cell Signaling Technology. Staining: Hemibrains, spleen, and liver tissue samples were collected from animals euthanized via carbon dioxide inhalation, followed by cervical dislocation. Transcardiac perfusion with PBS and heparin was subsequently performed. Samples were fixed in formalin for 24\\xa0h and then transferred to 70% ethanol. Tissues were stored in hinged biopsy cassettes and embedded in paraffin. Immunohistochemistry slides were cut at 4um and air dried at room temperature before baking at 60ÂºC for 30\\xa0min. Automated protocol performed on the Leica Bond Rx included paraffin dewax, antigen retrieval and staining. Heat-induced epitope retrieval using Bond Epitope Retrieval 2, pH9 (Leica Biosystems AR9961) was incubated at 100ÂºC for 30\\xa0min. Primary antibody was applied and incubated for 15\\xa0min at room temperature. Primary antibody binding was detected and visualized using the Leica Bond Polymer Refine Detection Kit (Leica Biosystems DS9800) with DAB chromogen and hematoxylin counterstain. Quantification: Slides were imaged with a 40\\u2009Ã\\u2009slide scanner and converted to digital files. QuPath software was utilized to quantify antibody staining. For AÎ² staining, plaques were outlined with the QuPath wand tool, and plaque surface areas were measured and summated across the sagittal brain section. Total brain surface area, excluding the olfactory bulb and cerebellum due to variation in tissue integrity across samples, was measured. Total plaque surface area out of total brain surface area produced normalized AÎ² plaque surface area values for each sample. For all other staining, QuPath automated positive cell detection analyzed the designated region of interest, generating a number of positive detections per mm2 of annotation area. For phospho-tau staining, the subiculum and CA1 comprised the annotated region. For total tau staining, the hippocampal formation and its immediate surroundings comprised the annotated region. For CD45 and F4/80 staining, a representative portion of the liver comprised the annotated region, given the lack of anatomical differentiation. While regions of interest ranged across markers, only a single annotated region from a single brain section was quantified for each stain per individual mouse. For each batch of samples, negative controls that underwent all histology protocol steps except for primary antibody application were quantified using the same methods, and resulting values were subtracted from stained samples to normalize for background staining and technical variation.', 'Cytokine profiling', 'Plasma collection: Blood was collected retro-orbitally in living animals or through the inferior vena cava immediately following euthanasia via carbon dioxide inhalation with confirmatory cervical dislocation. This euthanasia method limited stress induced cytokine expression at the end of life and minimized differences between terminal and retro-orbital (RO) bleeds. Of the 80 total plasma samples analyzed, 25 (10 terminally bled, 15 retro-orbitally bled) came from 3xTg-AD females, 15 (7 terminal, 8 RO) came from 3xTg-AD males, 20 (9 terminal, 11 RO) came from WT females, and 20 (10 terminal, 10 RO) came from WT males. Overall, 71 individual mice were represented, with repeated blood draws only included from 9 mice. Animals were anesthetized with isoflurane during retro-orbital bleeds. Blood samples were transferred into 1.5\\xa0mL Eppendorf tubes with edetic acid (EDTA) for anti-coagulation (4uL EDTA/\\u2009~\\u2009200 uL blood). Tubes were immediately placed on ice and then centrifuged at 4ÂºC for 10\\xa0min at 1000 rcf. The supernatant was transferred to a new tube and centrifuged at 4ÂºC for 3\\xa0min at 14,000\\xa0rpm. Plasma was transferred to a new tube and stored at -80ÂºC until use. Assay: Inflammatory proteins were measured using the MILLIPLEX Mouse Cytokine/Chemokine Magnetic Bead Panel â Premixed 32 Plex â Immunology Multiplex Assay (EMD Millipore. Corporation, Billerica, MA). Calibration curves from recombinant cytokine standards were prepared with threefold dilution steps in the same matrix as the samples. High and low spikes (supernatants from stimulated PBMCs and dendritic cells) were included to determine cytokine recovery. Standards and spikes were measured in triplicate, samples were measured once, and blank values were subtracted from all readings. All assays were carried out directly in a 96-well filtration plate (Millipore, Billerica, MA) at room temperature and protected from light. Briefly, wells were pre-wet with 100 uL PBS containing 1% BSA, then beads together with a standard, sample, spikes, or blank were added in a final volume of 100 uL and incubated together at room temperature for 30\\xa0min with continuous shaking. Beads were washed three times with 100 uL PBS containing 1% BSA and 0.05% Tween 20. A cocktail of biotinylated antibodies (50 uL/well) was added to beads for a further 30-min incubation with continuous shaking. Beads were washed three times, then streptavidin-PE was added for 10\\xa0min. Beads were again washed three times and resuspended in 125 uL of PBS containing 1% BSA and 0.05% Tween 20. The fluorescence intensity of the beads was measured using the Bio-Plex array reader. Bio-Plex Manager software with five-parametric-curve fitting was used for data analysis. Intra-assay precision quality controls indicated 2.9% coefficient of variation. Data points considered out of range below (OOR\\u2009<) were substituted with a 0, the minimum detectable value.', 'RNA isolation and sequencing', 'Isolation: Brain tissue was dissected from animals euthanized via carbon dioxide inhalation with confirmatory cervical dislocation, followed by perfusion with PBS and heparin. Samples were flash-frozen in liquid nitrogen and stored at -80ÂºC. Samples were later placed in a deep-well 96-well plate with stainless steel RNase-free homogenization beads and QIAzol lysis buffer. Plates were inserted into the SPEX SamplePrep 1600 MiniG tissue homogenizer and run at maximum speed for 5\\xa0min. Following homogenization, the tissue solution was added to QIAzol lysis buffer and stored at -80ÂºC. Lysed tissue solution was subsequently added to the QIAGEN miRNeasy Micro Kit for purification of total RNA. Sequencing: RNA for RNA sequencing (RNA-seq) was quantified by qubit, and integrity was measured on a fragment analyzer (Agilent). 200\\xa0ng RNA was hybridized to FastSelect probes (QIAGEN) for ribodepletion, followed by library preparation using the Kapa RNA HyperPrep kit (Roche) following the manufacturerâs instructions. Libraries were pooled for sequencing on a NextSeq500 instrument (Illumina) targeting 30\\xa0M, paired-end 50\\xa0bp reads per sample. A fastqc report was generated for visual inspection of the data. Raw data were pre-processed by removing adapter sequences using Cutadapt (v3.4), aligning to the mm10 reference genome using HISAT2 (v2.1.0) and quantifying read counts using the Featurecounts function (v2.0.1) from the subreads package to generate a gene expression matrix for downstream processing. Reads mapping to rRNAs were not used for analysis and were filtered from the dataset. Pseudogenes and genes without canonical names were filtered from the matrix prior to further analysis.', 'RNA-Seq analysis', 'Batch Adjustment: To adjust for sequencing batch effects within our total sample population, ComBat-seq was applied as previously described. Differential Expression Analysis: DESeq2 was utilized as previously described to identify differentially expressed mRNAs (DEGs) between 3xTg-AD and WT controls at various ages using R (v4.3.0) and RStudio (v2023.12.0\\u2009+\\u2009369). A negative binomial generalized linear model was applied. Differential expression p-values were adjusted for multiple comparisons with the Benjamini-Hochberg method. Clinical data access: Clinical data were obtained from the Mount Sinai Brain Bank (MSBB) study through the AD Knowledge Portal. Parahippocampal gyrus brain tissue samples from females with AD (n\\u2009=\\u2009103), female controls (n\\u2009=\\u200939), males with AD (n\\u2009=\\u200952), and male controls (n\\u2009=\\u200932) were sequenced and analyzed. Diagnoses of AD or control (CT) were determined based on the clinical dementia rating scale, Mini Mental State Exam, and Braak staging. Age: In the female AD sample group, 1% were in their sixties, 8% were in their seventies, 34% were in their eighties, and 57% were in their nineties or older. In the female control group, 5% were in their sixties, 20% were in their seventies, 54% were in their eighties, and 20% were in their nineties or older. In the male AD sample group, 12% were in their sixties, 38% were in their seventies, 38% were in their eighties, and 12% were in their nineties or older. In the male control group, 25% were in their sixties, 44% were in their seventies, 13% were in their eighties, and 19% were in their nineties or older. Race: The majority of individuals identified as white (91% in AD females, 80% in CT females, 88% in AD males, and 66% in CT males). The remainder were Hispanic or Black, in addition to one Asian control male. APOE genotype: The majority of individuals possessed no APOE4 alleles (58% in AD females, 77% in CT females, 63% in AD males, and 81% in CT males), followed by APOE4 heterozygotes (37% in AD females, 23% in CT females, 23% in AD males, and 19% in CT males), and APOE4 homozygotes (5% in AD females, 0% in CT females, 13% in AD males, and 0% in CT males). Pathway Analysis: Statistically significant, differentially expressed genes (p\\u2009<\\u20090.05) were categorized into canonical pathways using QIAGEN Ingenuity Pathway Analysis (IPA) Core Analysis and Enrichr. Predicted upstream regulators of DEGs were identified using IPA Upstream Analysis. Over-Representation Analysis: Statistically significant, differentially expressed genes (p\\u2009<\\u20090.05) underwent Over-Representation Analysis (ORA) to determine if specific gene ontology biological processes were likely present more than by chance. WebGestalt was utilized to perform ORA with the Illumina mouseref 8 reference set. Affinity propagation was applied for redundancy reduction of enrichment categories. Differential expression p-values were adjusted for multiple comparisons by the Benjamini-Hochberg method.', 'Statistical analysis', 'Splenic weight, IHC markers, and cytokine concentrations were analyzed using a linear regression model with R (v4.3.0) and RStudio (v2023.12.0\\u2009+\\u2009369). We tested the overall effects of relevant independent variables (i.e. sex, strain, age) across samples in each analysis. Independent variables were only incorporated into a model if they were matched across all conditions (i.e. age-matched samples of each condition in splenic weight analyses). We also performed secondary linear regression analyses in which samples were organized into experimental groups (i.e. 6-month-old 3xTg-AD females). Experimental groups were then contrasted against respective control/reference groups (i.e. 6-month-old 3xTg-AD females vs. 6-month-old 3xTg-AD males). P-values less than 0.05 were considered statistically significant. R-squared values determined the effect size of each regression model. Effect sizes, f-statistics, and complete linear regression results can be found in Supplementary Table\\xa03, Additional file 3. Animal survival probabilities were compared between sexes and strains using the likelihood ratio test, Wald test, and log-rank test for Kaplan-Meier analyses. A Cox proportional hazards model was used to examine the association of sex and strain with mortality risk.', 'Availability of data and materials', 'The RNA-seq dataset generated during the current study is deposited in NCBIâs Gene Expression Omnibus and is accessible through GEO Series Accession Number GSE254970 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE254970). The results published here are in part based on data obtained from the AD Knowledge Portal (https://adknowledgeportal.org). Controlled data is accessible upon the submission and acceptance of a Data Use Certificate.', 'Declarations', 'Ethics approval and consent to participate', 'All applicable national and institutional guidelines for the care and use of animals were followed.', 'Consent for publication', 'Not applicable.']}}, 'PMC10794000': {'class': 1, 'title': 'Two Phase 3 trials of Gantenerumab in early Alzheimerâs disease', 'summary': {'Abstract': [], 'Method': []}}, 'PMC11485411': {'class': 1, 'title': 'Association of caffeine consumption with cerebrospinal fluid biomarkers in mild cognitive impairment and Alzheimerâs disease: A BALTAZAR cohort study', 'summary': {'Abstract': [], 'Method': []}}, 'PMC11032534': {'class': 1, 'title': 'Nanoscale imaging of pT217-tau in aged rhesus macaque entorhinal and dorsolateral prefrontal cortex: Evidence of interneuronal trafficking and early-stage neurodegeneration', 'summary': {'Abstract': ['Abstract', 'INTRODUCTION', \"Tau phosphorylated at threonineâ217 (pT217âtau) is a novel fluidâbased biomarker that predicts onset of Alzheimer's disease (AD) symptoms, but little is known about how pT217âtau arises in the brain, as soluble pT217âtau is dephosphorylated post mortem in humans.\", 'METHODS', 'We used multilabel immunofluorescence and immunoelectron microscopy to examine the subcellular localization of earlyâstage pT217âtau in entorhinal and prefrontal cortices of aged macaques with naturally occurring tau pathology and assayed pT217âtau levels in plasma.', 'RESULTS', 'pT217âtau was aggregated on microtubules within dendrites exhibiting early signs of degeneration, including autophagic vacuoles. It was also seen trafficking between excitatory neurons within synapses on spines, where it was exposed to the extracellular space, and thus accessible to cerebrospinal fluid (CSF)/blood. Plasma pT217âtau levels increased across the age span and thus can serve as a biomarker in macaques.', 'DISCUSSION', 'These data help to explain why pT217âtau predicts degeneration in AD and how it gains access to CSF and plasma to serve as a fluid biomarker.'], 'Method': ['METHODS', 'Electron microscopy', 'Animals and tissue processing', \"Three âearlyâ aged (18â24 years) and five âlateâ aged (26â31 years) rhesus monkeys (Macaca mulatta) were used in this study and were maintained and euthanized in accordance with the guidelines of the US Department of Agriculture, the Yale University Institutional Animal Care and Use Committee (IACUC), and in accordance with the Weatherall report. As described previously, primates were deeply anesthetized prior to transcardial perfusion of 100\\xa0mM phosphateâbuffered saline, followed by 4% paraformaldehyde/0.05% glutaraldehyde in 100\\xa0mM phosphateâbuffered saline. After perfusion, a craniotomy was performed, and the entire brain was removed and blocked. The brains were sectioned coronally at 60\\xa0Î¼m on a vibratome (Leica) across the entire rostrocaudal extent of the ERC and dlPFC (Walker's area 46). The sections were cryoprotected through increasing concentrations of sucrose solution (10%, 20%, and 30% each for overnight), cooled rapidly using liquid nitrogen, and stored at â80Â°C. Sections of ERC and dlPFC were processed for immunocytochemistry. To enable penetration of immunoreagents, all sections went through three freezeâthaw cycles in liquid nitrogen. Nonâspecific reactivity was suppressed with 10% normal goat serum (NGS) and 5% bovine serum albumin (BSA), and antibody penetration was enhanced with 0.3% Triton Xâ100 in 50\\xa0mM Trisâbuffered saline (TBS).\", 'Histology and immunoreagents', 'Previously characterized primary antibodies for pT217âtau raised in rabbits were used, and complexed with speciesâspecific goat secondary antibodies. The following primary antibodies were used: (1) rabbit antiâpT217âtau at 1:200 (cat# ASâ54968, Anaspec). The immunogen used keyhole limpet hemocyanin conjugated with synthetic peptides corresponding to human tau at phosphorylated threonine 217; (2) rabbit antiâpT217âtau at 1:200 (cat # 44â744, Thermo Fisher). The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of human tau that contains threonine 217. Both primary antibodies for pT217âtau produced comparable results; (3) mouse antiâEEA1 at 1:250 (cat# 610456, BD Biosciences); (4) mouse antiâAmyloidâÎ²1â42 IgG2b (clone MOABâ2) at 1:300 (cat# NBP213075, Novus). This antibody recognizes unaggregated, oligomeric, and fibrillary forms of AÎ²42 and unaggregated AÎ²40, and has been previously used in aged macaque tissue to characterize Braak stage III/IV ADâlike pathology; (5) mouse antiphosphoSer202/Thr205âtau IgG1k (clone AT8) at 1:300 (cat# MN1020; Thermo Fisher Scientific); (6) mouse monoclonal casein kinase IÎ´ Antibody (cat #scâ55553, Santa Cruz Biotechnology); (7) goat polyclonal casein kinase IÎ´ Antibody (cat #NB100â2919; Novus Biologicals). The specificity and selectivity of the primary antibodies have been characterized using immunoblot, immunohistochemistry, immunofluorescence, and enzymeâlinked immunosorbent assay approaches in various tissue types in multiple species. Normal sera and immunoglobulin G (IgG)âfree BSA were purchased from Jackson ImmunoResearch. All chemicals and supplies for electron microscopy were purchased from Sigma Aldrich and Electron Microscopy Sciences, respectively.', 'Single preâembedding peroxidase immunocytochemistry', 'As described previously, the sections were incubated for 72\\xa0hours at 4Â°C with primary antibodies in TBS, and transferred for 2\\xa0hours at room temperature to speciesâspecific biotinylated Fabâ or F(abâ)2 fragments in TBS. To reveal immunoperoxidase labeling, sections were incubated with the avidinâbiotin peroxidase complex (ABC; 1:300; Vector Laboratories) and then visualized in 0.025% Niâintensified 3,3âdiaminobenzidine tetrahydrochloride (DAB; Sigma Aldrich) as a chromogen in 100\\xa0mM phosphate buffer (PB) with the addition of 0.005% hydrogen peroxide for 8 minutes. After the DAB reaction, sections were exposed to osmification (concentration 1%), dehydration through a series of increasing ethanol concentrations (70%â100%), and infiltrated with propylene oxide. Tissue sections were counterstained with 1% uranyl acetate in 70% ethanol. Standard epoxy resin embedding followed typical immunoEM procedures followed by polymerization at 60Â°C for 60\\xa0hours. Omission of primary antibodies or substitution with nonâimmune serum resulted in complete lack of immunoperoxidase labeling. Similarly, labeling was nullified when blocking the biotinylated probes with avidin/biotin.', 'Doubleâlabel preâembedding gold and peroxidase immunohistochemistry', 'Doubleâlabel immunoEM was accomplished by pairing gold (for AÎ²) and DAB (for pT217âtau) in dlPFC of two âlateâagedâ female macaques, aged 24 and 26 years. Sections underwent a 50\\xa0mM glycine in 0.1\\xa0M PBS incubation for 1\\xa0hour (Sigma, cat# Gâ7126), a 30 minute 0.3% hydrogen peroxide incubation at 4Â°C, and avidinâbiotin blocking (Vector cat# SPâ2001) to prevent nonâspecific labeling from free aldehydes, and the immunoperoxidase product, respectively. Sections were blocked for 1 hour at room temperature (RT; 5% BSA, 10% NGS, 0.4% Triton Xâ100, and 0.1% Aurion acetylated BSA, or BSAâc, Electron Microscopy Sciences, cat# 25557, in 0.1\\xa0M PB), and incubated in Anaspec rabbit antiâpT217âtau at 1:200 for 72\\xa0hours at 4Â°C. After removal from the primary antibody incubation, sections were incubated in biotinylated F(abâ)2 fragment goat antiârabbit at 1:200 (Jackson ImmunoResearch cat# 111â066â144) for 3\\xa0hours at RT, and then underwent avidinâbiotin amplification using ABC, as above, and were visualized using a DAB kit (Vector SKâ4100) with no nickel intensification for 3 minutes. Then, sections were incubated in the mouse antiâAmyloidâÎ²1â42 at 1:300 for 72\\xa0hours at 4Â°C. After removal from the primary antibody, sections were incubated in Aurion F(ab) fragment of goat antiâmouse ultrasmall at 1:50 (Electron Microscopy Sciences, cat#25415) for 3\\xa0hours at RT. Subsequently, sections underwent a 4% paraformaldehyde (in PBS) postfix for 5 minutes, followed by a 10 minute 50\\xa0mM glycine incubation to quench free aldehydes, and a few quick distilled water washes. Silver enhancement was performed with the Nanoprobes HQ Silver kit (cat# 2012â45ML) in the dark for 20 to 30 minutes, and produced variableâsized particles.', 'Sections were first postâfixed in 4% paraformaldehyde in 0,1\\xa0M PBS for 20 minutes, then were submerged in 1% osmium tetroxide in PB, followed by immediate dilution by half (to 0.5%), and the sections incubated in the dark for 30 minutes at 4Â°C. Sections then proceeded with the remainder of EM processing steps as described in the preceding section.', 'Electron microscopy and data analysis', 'For singleâlabel immunoperoxidase immunohistochemistry, sections were mounted on microscope slides and ERC layer II and dlPFC layer III were photographed under an Olympus BX51 microscope equipped with a Zeiss AxioCam chargeâcoupled device camera. Zeiss AxioVision imaging software was used for imaging and data acquisition. All sections were processed as previously described and immunoEM imaging was conducted in ERC layer II and dlPFC layer III. Briefly, blocks containing ERC layer II and dlPFC layer III were sampled and mounted on resin blocks. The specimens were cut into 50\\xa0nm sections using an ultramicrotome (Leica) and analyzed under a Talos L120C transmission electron microscope (Thermo Fisher Scientific). Several plastic blocks of each brain were examined using the 4th to 12th surfaceâmost sections of each block (i.e., 200â600\\xa0nm), to sample the superficial component of sections, avoiding penetration artifacts. Structures were digitally captured at Ã25,000 to Ã100,000 magnification with a Ceta complementary metal oxide semiconductor (CMOS) camera and individual panels were adjusted for brightness and contrast using Adobe Photoshop and Illustrator CC.2020.01 image editing software (Adobe Systems Inc.). Approximately 5000 micrographs of selected areas of neuropil with immunopositive profiles were used for analyses with wellâdefined criteria.', 'For profile identification, we adopted the criteria summarized in Peters et\\xa0al. Dendritic spines in the prefrontal cortex are typically long and thin, devoid of mitochondria, with the presence of a noticeable postsynaptic density (PSD) at asymmetric synapses, and often containing an elaborated spine apparatus, the extension of the smooth endoplasmic reticulum into the spine. Dendritic shafts were typically round in perpendicular planes or irregular shaped when assessed in horizontal planes, usually containing mitochondria and numerous tubular and pleomorphic cellular organelles. Depending on the proximity to axon terminals, various dendritic shafts received synaptic inputs. Axon terminals contained accumulations of synaptic vesicles and the axoplasm of these terminals usually contained neurofilaments and mitochondria. The synaptic innervations made by these axon terminals were either asymmetric, containing spherical vesicles, or symmetric, containing pleomorphic vesicles, with typical differences in PSD, respectively. Unmyelinated axons were small, round processes with a predominantly even and regular shape, traversing the neuropil in a straight orientation, often forming bundles in perpendicular planes. Astrocytic processes were typically of irregular morphology, forming contours that filled the empty space around neuronal elements.', 'To evaluate whether there was concordance between dendrites immunopositive for pT217âtau and signatures of autophagic degeneration, quantitative assessments were performed on a series of low and high magnification 2D micrographs of ERC layer II and supragranular dlPFC layer III. Each field covered an area of 15 to 30 Î¼m2 captured from the thin sections in earlyâaged ERC and lateâaged dlPFC in rhesus macaques for analyses. Approximately 200 micrographs of selected areas of neuropil with immunopositive profiles were used for quantitative analyses. Autophagic vacuoles were identified based on multilamellar bodies, containing partially degraded cytoplasmic materials. The frequency of pT217âtau positive elements was highly consistent across all animals and pooled across animals within an age group.', 'Immunofluorescence with confocal microscopy', 'Immunofluorescence staining was carried out on freeâfloating sections as described previously. Three adult (8â10 years), two âearlyâ aged (18â19 years), and four âlateâ aged (28â34 years) rhesus monkeys (Macaca mulatta) were used in this study. Antigen retrieval was performed with 10\\xa0mM solution citrate buffer in a hot water bath for 25\\xa0minutes at high temperature. The freeâfloating sections were left to cool for 30\\xa0minutes at RT. The sections were transferred to 1X TBS for 10\\xa0minutes. Sections were then incubated in 0.5% sodium borohydride in 0.01\\xa0M TBS. Sections were blocked for 1\\xa0hour at RT in 1X TBS containing 5% BSA, 2% Triton Xâ100, and 10% normal goat serum. Sections were incubated for 72\\xa0hours at 4Â°C with pT217âtau primary antibody (dilution 1:100; see supplier information above), MAP2 (dilution 1:1000; ab5392, Abcam), mouse antiphosphoSer202/Thr205âtau IgG1k (clone AT8; dilution 1:300; cat# MN1020; Thermo Fisher Scientific), casein kinase IÎ´ antibody (dilution 1:100; cat #scâ55553, Santa Cruz Biotechnology), goat polyclonal casein kinase IÎ´ antibody (dilution 1:100; cat #NB100â2919; Novus Biologicals) ,followed by incubation overnight at 4Â°C with secondary antibodies (1:1000, AlexaâFluor conjugated, Invitrogen). After incubation in secondary antibodies, they were incubated in 70% ethanol with 0.3% Sudan Black B (MP Biomedicals, cat# 4197â25â5), to decrease autofluorescence from lipofuscin, and counterstained with Hoechst (1:10,000, Thermo Fisher, cat# H3570). The sections were mounted in ProLong Gold Antifade Mountant (Invitrogen, cat# P36930). Confocal images from ERC layer II and dlPFC layer III were acquired using a Zeiss LSM 880 Airyscan Confocal Microscope, with the CâApochromat 40x/1.2\\xa0W Korr FCS M27 (Zeiss) water objective. Emission filter bandwidths and sequential scanning acquisition were set up to avoid possible spectral overlaps between fluorophores. Images were merged using Fiji software.', 'Measurement of pT217âtau in blood plasma by nanoneedles', 'Fifteen young (1â17 years) and twentyâone aged (18â34 years) rhesus monkeys (Macaca mulatta) were used in the plasma pT217âtau study (total cohort N\\xa0=\\xa036). Blood plasma was collected during routine tuberculosis testing for rhesus macaques. We developed inâhouse phosphorylated tau assays using the nanoneedle technology to measure plasma concentrations of pT217âtau. More than 20,000 nanoneedles are integrated on a silicon substrate assigned to detect one analyte. Each nanoneedle is a singleâmolecule biosensor functionalized with antibodies. Because phosphorylated tau in blood samples is present at low abundance, the binding events of phosphorylated tau on the nanoneedle sensor array follow Poisson statistics, that is, one or no molecule is captured on each nanoneedle. This allows precise quantitation of analytes by digitally counting the number of nanoneedles that have a positive signal. In the present study, we developed sandwichâtype pT217âtau assays to measure the ultraâlow concentration of protein levels in patient blood samples. The nanoneedle chip was provided by NanoMosaic. Nanoneedles are fabricated in an array format with a spacing of 1.8\\xa0Î¼m. Each nanoneedle has a diameter of < 100\\xa0nm. The nanoneedle surfaces were modified with 0.5% 3âaminopropyltrimethoxysilane (APTMS) and activated with 2% glutaraldehyde. This enables antibodies to covalently bind on the surface of the nanoneedles. We used 5\\xa0Î¼g/ml capture antibody concentration and incubated with chip overnight. We then washed the chip in PBS and incubated it with blocking solution for 1\\xa0hour. Five\\xa0Î¼l of plasma samples were thawed and diluted 2 X into the dilution buffer provided by NanoMosaic. The diluted sample was incubated on the chip for 2\\xa0hours. After washing, a biotinylated detection antibody at 0.5\\xa0Î¼g/ml was incubated on the chip. Next, 0.5\\xa0Î¼g/ml streptavidinâhorseradish peroxidase (HRP) conjugate was incubated for 30 minutes, and 3,3â²,5,5â²âtetramethylbenzidine (TMB) provided by NanoMosaic was applied on the chip for 15 minutes to illuminate the HRP. The enzymatic reaction produced a nonâsoluble precipitate on the nanoneedles when the sandwich complex was present. The precipitate changes the local refractive index of the nanoneedle and induces a color shift intrinsic to the nanoneedle property. The nanoneedles are imaged under a darkâfield configuration with a CMOS color camera before and after the assay using the Tessieâ¢ instrument from NanoMosaic. Software provided by NanoMosaic analyzed the colors of all nanoneedles and reported the percentage of the colorâshifted number of nanoneedles. We used phosphoâspecific antibodies to pT217âtau (Thermo Fisher 44â744) as the detection antibodies for pT217âtau measurement. The specificity of the phosphoâspecific antibodies to pT217âtau was validated with peptide array, described in the following section.', 'The protein levels are reported in relative units specific to the nanoneedle technology (i.e., Nano Unit) as described in previous studies because pT217âtau recombinant protein standards are not available at present. All measurement results were above the lower limit of detection of the nanoneedle assay. Assay specificity was validated with dot blot measurement of the phosphoâspecific antibodies against an array of synthesized peptides phosphorylated at different residues along the fullâlength tau protein as described in a previous study. ', 'Statistical analysis of rhesus macaque blood plasma pT217âtau data', \"To assess ageârelated alterations in pT217âtau expression in blood plasma during age span, a Pearson's correlation regression analysis was computed. For group analysis, a Welch t test was performed because the pT217âtau expression in blood plasma was normally distributed. Fits were modelled as linear and exponential growth equations.\"]}}, 'PMC9974914 ': {'class': 1, 'title': 'Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study'}, 'PMC11035722': {'class': 1, 'title': 'Plasma GFAP, NfL, and pTau181 detect preclinical stages of dementia'}, 'PMC11247680': {'class': 1, 'title': 'Potential role of blood pressure variability and plasma neurofilament light in the mechanism of comorbidity between Alzheimerâs disease and cerebral small vessel disease'}, 'PMC10729487': {'class': 1, 'title': 'Advanced structural brain aging in preclinical autosomal dominant Alzheimerâs disease'}, 'PMC10019964': {'class': 1, 'title': 'A comprehensive investigation of the potential role of lipoproteins and metabolite profiles as biomarkers of Alzheimerâs disease compared to the known CSF biomarkers'}, 'PMC10472051': {'class': 1, 'title': 'A leaky gut contributes to postural dysfunction in patients with Alzheimerâs disease'}, 'PMC11436400': {'class': 1, 'title': 'Japanese subgroup analyses from EMERGE and ENGAGE Phase 3 clinical trials of Aducanumab in patients with early Alzheimerâs disease'}, 'PMC10527358': {'class': 1, 'title': 'Sex differences in blood biomarkers and cognitive performance in individuals with autosomal dominant Alzheimerâs disease'}, 'PMC1101566': {'class': 1, 'title': 'Synaptic vesicle glycoprotein 2A in serum is an ideal biomarker for early diagnosis of Alzheimerâs diseas'}, '---': {'class': 0, 'title': 'A Study of Once-a-Week Donepezil TransdermalSystemâs Bioequivalence to Oral Donepezil inHealthy Volunteers: A Plain Language Summary'}, 'PMC10047620': {'class': 0, 'title': 'Implementing a home-based virtual hypertensionprogrammeâa pilot feasibility study'}, 'PMC10026083': {'class': 0, 'title': 'ARIA in patients treated with lecanemab (BAN2401) in a phase2 study in early Alzheimerâs disease'}, 'PMC10366339 ': {'class': 0, 'title': 'Acute sleep loss decreases CSF-to-blood clearance ofAlzheimerâs disease biomarkers'}, 'PMC10612412': {'class': 0, 'title': 'Unbiased insights into the multiplicity of the CYP46A1 braineffects in 5XFAD mice treated with low dose-efaviren'}, 'PMC11233274 ': {'class': 0, 'title': 'zRelationships between plasma biomarkers, tau PET, FDG PET,and volumetric MRI in mild to moderate Alzheimerâs diseasepatients'}, 'PMC11065015': {'class': 0, 'title': 'Brain and Blood Transcriptome-Wide Association Studies Identify Five NovelGenes Associated with Alzheimerâs Disease'}, 'PMC10551138 ': {'class': 0, 'title': 'A five-year observationalprospective mono-center study ofthe efficacy of alemtuzumab in areal-world cohort of patients withmultiple sclerosis'}, 'PMC10612416': {'class': 0, 'title': 'Plasma extracellular vesicle tau and TDP-43as diagnostic biomarkers in FTD and ALS'}, 'PMC10612417': {'class': 0, 'title': 'Aerobic Training and Circulating Neurotrophins inAlzheimerâs Disease Patients: A Controlled Trial'}, 'PMC11230216': {'class': 0, 'title': 'Mapping the impact of age and APOE risk factors for late onsetAlzheimerâs disease on long range brain connections throughmultiscale bundle analysis'}, 'PMC10452707 ': {'class': 0, 'title': 'Acute Myocardial Infarction and Risk of Cognitive Impairmentand Dementia: A Review'}, 'PMC9856280 ': {'class': 0, 'title': 'A Multi-Trait Association Analysis of Brain Disorders andPlatelet Traits Identifies Novel Susceptibility Loci for MajorDepression, Alzheimerâs and Parkinsonâs Disease'}, 'PMC10612421': {'class': 0, 'title': 'Bacteroidota inhibit microglia clearance ofamyloid-beta and promote plaquedeposition in Alzheimerâs diseasemouse models'}, 'PMC10630899': {'class': 0, 'title': 'Algorithmic Fairness of Machine Learning Models for Alzheimer Disease Progression'}, 'PMC10630899 ': '', 'PMC9974914': ''})\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[148], line 2\u001b[0m\n\u001b[1;32m      1\u001b[0m \u001b[38;5;28mprint\u001b[39m(article_info)\n\u001b[0;32m----> 2\u001b[0m \u001b[38;5;28;43mprint\u001b[39;49m(\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mhey\u001b[39m\u001b[38;5;124m'\u001b[39m)\n",
      "Cell \u001b[0;32mIn[148], line 2\u001b[0m\n\u001b[1;32m      1\u001b[0m \u001b[38;5;28mprint\u001b[39m(article_info)\n\u001b[0;32m----> 2\u001b[0m \u001b[38;5;28;43mprint\u001b[39;49m(\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mhey\u001b[39m\u001b[38;5;124m'\u001b[39m)\n",
      "File \u001b[0;32m_pydevd_bundle\\\\pydevd_cython.pyx:1698\u001b[0m, in \u001b[0;36m_pydevd_bundle.pydevd_cython.SafeCallWrapper.__call__\u001b[0;34m()\u001b[0m\n",
      "File \u001b[0;32m_pydevd_bundle\\\\pydevd_cython.pyx:636\u001b[0m, in \u001b[0;36m_pydevd_bundle.pydevd_cython.PyDBFrame.trace_dispatch\u001b[0;34m()\u001b[0m\n",
      "File \u001b[0;32m_pydevd_bundle\\\\pydevd_cython.pyx:1113\u001b[0m, in \u001b[0;36m_pydevd_bundle.pydevd_cython.PyDBFrame.trace_dispatch\u001b[0;34m()\u001b[0m\n",
      "File \u001b[0;32m_pydevd_bundle\\\\pydevd_cython.pyx:1091\u001b[0m, in \u001b[0;36m_pydevd_bundle.pydevd_cython.PyDBFrame.trace_dispatch\u001b[0;34m()\u001b[0m\n",
      "File \u001b[0;32m_pydevd_bundle\\\\pydevd_cython.pyx:496\u001b[0m, in \u001b[0;36m_pydevd_bundle.pydevd_cython.PyDBFrame.do_wait_suspend\u001b[0;34m()\u001b[0m\n",
      "File \u001b[0;32m~/Desktop/College/Research/ADBMO-UNLV/adbmo_venv/lib/python3.10/site-packages/debugpy/_vendored/pydevd/pydevd.py:2181\u001b[0m, in \u001b[0;36mPyDB.do_wait_suspend\u001b[0;34m(self, thread, frame, event, arg, exception_type)\u001b[0m\n\u001b[1;32m   2178\u001b[0m             from_this_thread\u001b[38;5;241m.\u001b[39mappend(frame_custom_thread_id)\n\u001b[1;32m   2180\u001b[0m     \u001b[38;5;28;01mwith\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_threads_suspended_single_notification\u001b[38;5;241m.\u001b[39mnotify_thread_suspended(thread_id, thread, stop_reason):\n\u001b[0;32m-> 2181\u001b[0m         keep_suspended \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_do_wait_suspend\u001b[49m\u001b[43m(\u001b[49m\u001b[43mthread\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mframe\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mevent\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43marg\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtrace_suspend_type\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mfrom_this_thread\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mframes_tracker\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   2183\u001b[0m frames_list \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[1;32m   2185\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m keep_suspended:\n\u001b[1;32m   2186\u001b[0m     \u001b[38;5;66;03m# This means that we should pause again after a set next statement.\u001b[39;00m\n",
      "File \u001b[0;32m~/Desktop/College/Research/ADBMO-UNLV/adbmo_venv/lib/python3.10/site-packages/debugpy/_vendored/pydevd/pydevd.py:2250\u001b[0m, in \u001b[0;36mPyDB._do_wait_suspend\u001b[0;34m(self, thread, frame, event, arg, trace_suspend_type, from_this_thread, frames_tracker)\u001b[0m\n\u001b[1;32m   2247\u001b[0m                 queue\u001b[38;5;241m.\u001b[39mput(internal_cmd)\n\u001b[1;32m   2248\u001b[0m                 wait_timeout \u001b[38;5;241m=\u001b[39m TIMEOUT_FAST\n\u001b[0;32m-> 2250\u001b[0m         \u001b[43mnotify_event\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mwait\u001b[49m\u001b[43m(\u001b[49m\u001b[43mwait_timeout\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   2251\u001b[0m         notify_event\u001b[38;5;241m.\u001b[39mclear()\n\u001b[1;32m   2253\u001b[0m \u001b[38;5;28;01mfinally\u001b[39;00m:\n",
      "File \u001b[0;32m/usr/lib/python3.10/threading.py:607\u001b[0m, in \u001b[0;36mEvent.wait\u001b[0;34m(self, timeout)\u001b[0m\n\u001b[1;32m    605\u001b[0m signaled \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_flag\n\u001b[1;32m    606\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m signaled:\n\u001b[0;32m--> 607\u001b[0m     signaled \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_cond\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mwait\u001b[49m\u001b[43m(\u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    608\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m signaled\n",
      "File \u001b[0;32m/usr/lib/python3.10/threading.py:324\u001b[0m, in \u001b[0;36mCondition.wait\u001b[0;34m(self, timeout)\u001b[0m\n\u001b[1;32m    322\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m    323\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m timeout \u001b[38;5;241m>\u001b[39m \u001b[38;5;241m0\u001b[39m:\n\u001b[0;32m--> 324\u001b[0m         gotit \u001b[38;5;241m=\u001b[39m \u001b[43mwaiter\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43macquire\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43;01mTrue\u001b[39;49;00m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    325\u001b[0m     \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m    326\u001b[0m         gotit \u001b[38;5;241m=\u001b[39m waiter\u001b[38;5;241m.\u001b[39macquire(\u001b[38;5;28;01mFalse\u001b[39;00m)\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "print(article_info)\n",
    "print('hey')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "background_save": true
    },
    "id": "hN8JEQd4-h87"
   },
   "outputs": [],
   "source": [
    "not_found_counter = 0\n",
    "full_texts = []\n",
    "over_context_window = 0\n",
    "for id in pmc_id_list:\n",
    "        response = requests.get(f\"https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_json/PMC{id}/unicode\")\n",
    "        # print(response, id)\n",
    "        if response.text == f'No record can be found for the input: pmc{id}':\n",
    "            not_found_counter += 1\n",
    "            print(f\"No record found for article {id}.\\Didn't find {not_found_counter} articles\")\n",
    "            continue\n",
    "        else:\n",
    "            try:\n",
    "                data = json.loads(response.text[1:-1].strip())\n",
    "                # print(data['documents'][0]['passages'][1:][1]['infons']['section_type'])\n",
    "                total_len = 0\n",
    "                total_len_tokenized = 0\n",
    "                for text in data['documents'][0]['passages'][:]:\n",
    "                    if text != None:\n",
    "                        # print(text['text'])\n",
    "                        total_len += len(text['text'])\n",
    "                        # total_len_tokenized += len(tokenizer.encode(text['text']))\n",
    "                        # print(tokenizer.encode(text['text']))\n",
    "                # if data['documents'][0]['passages'][1:][1]['infons']['section_type'] == 'ABSTRACT' or data['documents'][0]['passages'][1:][1]['infons']['section_type'] == 'METHOD':\n",
    "                print(total_len)\n",
    "                # break\n",
    "                # print(total_len_tokenized)\n",
    "                if total_len_tokenized > 120000:\n",
    "                     over_context_window += 1\n",
    "                     print(total_len_tokenized, ' ', id, ' --- ', over_context_window)\n",
    "                # break\n",
    "            except json.JSONDecodeError as e:\n",
    "                 print(\"Json error for string: \", response.text)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 669
    },
    "executionInfo": {
     "elapsed": 167,
     "status": "error",
     "timestamp": 1731565457827,
     "user": {
      "displayName": "Abreham Tadesse",
      "userId": "00073469144777826962"
     },
     "user_tz": 480
    },
    "id": "IrAV1eH4J5r6",
    "outputId": "442b75e2-b57d-4f6f-d125-2ef3b76c3517"
   },
   "outputs": [],
   "source": [
    "list_models_path = \"http://oceanus.cs.unlv.edu:11434/api/tags\"\n",
    "res = requests.get(path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "executionInfo": {
     "elapsed": 181,
     "status": "ok",
     "timestamp": 1731565536708,
     "user": {
      "displayName": "Abreham Tadesse",
      "userId": "00073469144777826962"
     },
     "user_tz": 480
    },
    "id": "XLAfRoXyGVut"
   },
   "outputs": [],
   "source": [
    "import requests\n",
    "\n",
    "path = \"\"\n",
    "\n",
    "params = {\n",
    "    \"model\": \"llama3.2:1b\",\n",
    "    \"prompt\": \"What's the definition of a random variable?\",\n",
    "    # \"stream\": \"false\",\n",
    "    \"format\": \"json\"\n",
    "}\n",
    "\n",
    "res = requests.post(path, json=params)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 408
    },
    "executionInfo": {
     "elapsed": 203,
     "status": "error",
     "timestamp": 1731565669094,
     "user": {
      "displayName": "Abreham Tadesse",
      "userId": "00073469144777826962"
     },
     "user_tz": 480
    },
    "id": "kGYUSRdAWxoD",
    "outputId": "b5af852d-43e2-4e52-a063-24bcd09ed694"
   },
   "outputs": [],
   "source": [
    "response = client.chat(model=\"llama3.2:1b\", messages=[{'role':'user', 'content': 'What is the definition of a random variable?',},])"
   ]
  }
 ],
 "metadata": {
  "colab": {
   "authorship_tag": "ABX9TyNqPiESVqxtTdm9T0WVpQQP",
   "provenance": []
  },
  "kernelspec": {
   "display_name": "adbmo_venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}
